



(12) **DEMANDE DE BREVET CANADIEN**  
**CANADIAN PATENT APPLICATION**  
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/12/22  
(87) Date publication PCT/PCT Publication Date: 2018/07/05  
(85) Entrée phase nationale/National Entry: 2019/09/03  
(86) N° demande PCT/PCT Application No.: US 2017/068190  
(87) N° publication PCT/PCT Publication No.: 2018/125800  
(30) Priorité/Priority: 2016/12/29 (US62/440,181)

(51) Cl.Int./Int.Cl. *A61K 31/501* (2006.01),  
*A61K 31/437* (2006.01)  
(71) Demandeur/Applicant:  
SELENITY THERAPEUTICS (BERMUDA), LTD., BM  
(72) Inventeurs/Inventors:  
SPARKS, STEVEN, US;  
YATES, CHRISTOPHER M., US;  
SHAVER, SAMMY R., US;  
HOEKSTRA, WILLIAM J., US  
(74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : COMPOSES INHIBITEURS DES METALLOENZYMES  
(54) Title: METALLOENZYME INHIBITOR COMPOUNDS

(57) Abrégé/Abstract:

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
05 July 2018 (05.07.2018)



(10) International Publication Number  
**WO 2018/125800 A3**

(51) International Patent Classification:

A61K 31/501 (2006.01) A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2017/068190

(22) International Filing Date:

22 December 2017 (22.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/440,181 29 December 2016 (29.12.2016) US

(71) Applicant: VIAMET PHARMACEUTICALS  
(BERMUDA), LTD.; Clarendon House, 2 Church Street,  
Hamilton, HM 11 (BM).

(72) Inventor; and

(71) Applicant: SPARKS, Steven [US/US]; 1451 Big Leaf  
Loop, Apex, NC 27502 (US).

(72) Inventors: YATES, Christopher, M.; 6201 Therfield Drive,  
Raleigh, NC 27614 (US). SHAVER, Sammy, R.;  
30167 Pharr, Chapel Hill, NC 27517 (US). HOEKSTRA,  
William, J.; 7 Treviso Place, Durham, NC 27707 (US).

(74) Agent: HSI, Jeffrey, D.; Wolf, Greenfield & Sacks, P.C.,  
600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

16 August 2018 (16.08.2018)

(54) Title: METALLOENZYME INHIBITOR COMPOUNDS

(57) Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or  
symptoms thereof mediated by such metalloenzymes.

WO 2018/125800 A3

## Metalloenzyme Inhibitor Compounds

### CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional  
5 Patent Application Serial No. 62/440,181, filed December 29, 2016. The entirety of which is  
incorporated herein by reference.

### BACKGROUND

Aldosterone is a steroid hormone secreted from the adrenal gland which binds and  
10 activates the mineralocorticoid receptor (MR). In the primary cells of the distal tubules and  
collecting ducts of the kidney MR activation leads to sodium and water retention with  
excretion of potassium, resulting in plasma volume expansion leading to increased blood  
pressure (BP). Excess aldosterone measured in circulation is termed primary aldosteronism  
(PA) and occurs when aldosterone production is dysregulated by the renin-angiotensin-  
15 aldosterone system (RAAS). PA was initially identified in patients with adrenal adenomas,  
with recent evidence suggesting an increase in prevalence associated with obesity. PA is a  
common cause of secondary hypertension with the prevalence of PA ranging from 14-21% in  
patients with resistant hypertension (RHTN), a condition defined as BP remaining above goal  
despite the concurrent use of 3 antihypertensive agents of different classes, including a  
20 diuretic agent. Recent studies have shown an association between excess aldosterone, RHTN,  
and obstructive sleep apnea (OSA) which is worsened by aldosterone-mediated fluid retention.

Local overproduction of aldosterone has been noted in several severe disease states  
even when no significant plasma elevation is observed. In patients with chronic congestive  
heart failure (CHF), aldosterone levels in failing heart tissue is higher than in peripheral  
25 plasma. In animal models of kidney disease, local production of aldosterone in the renal  
cortex is postulated to contribute to disease progression. In both these states, local elevated  
aldosterone levels contribute to harmful effects via both MR-dependent and MR-independent  
mechanisms including the generation of reactive oxygen species and endothelial dysfunction  
leading to inflammation and stimulation of cell growth and proliferation, with upregulated  
30 collagen deposition leading to fibrosis.

Antagonists of MR, including spironolactone and eplerenone, have been extensively  
used to block the effects of aldosterone binding to MR. Significant reductions in morbidity  
and mortality in patients with heart failure or myocardial infarction have been demonstrated

with these agents in combination with angiotensin-converting enzyme (ACE) inhibitors and diuretics (RALES & EPHESUS trials). Side effects including hyperkalemia are seen with both agents with the nonselective spironolactone also eliciting gynaecomastia via nonselective modulation of the progesterone and androgen receptors. Additionally, elevations of renin and aldosterone result from MR antagonism and thus the MR-independent (non-genomic) effects of aldosterone are exacerbated.

In contrast to MR antagonists, inhibition of CYP11B2 (aldosterone synthase), the key enzyme in aldosterone biosynthesis, should afford the beneficial effects of MR antagonism without the deleterious buildup of aldosterone leading to activation of MR-independent inflammatory and fibrotic states. CYP11B2 is a mitochondrial cytochrome P450 enzyme which converts 11-deoxycorticosterone to aldosterone. Selective inhibition of CYP11B2 represents a promising treatment for aldosterone related diseases.

The highly homologous metalloenzyme CYP11B1 (11- $\beta$ -steroid-hydroxylase) catalyzes the formation of the primary glucocorticoid cortisol from 11-deoxycortisol. Given the high degree of homology between CYP11B2 and CYP11B1 (93%), the development of selective CYP11B2 inhibitors has been a significant challenge. The inhibitor Osilodrostat (LCI-699) was developed as a CYP11B2 inhibitor for the treatment of hypertension but was abandoned due to its potent inhibition of CYP11B1. Selective compounds which block the production of aldosterone via CYP11B2 without inhibition of cortisol production via CYP11B1 are described herein.

Living organisms have developed tightly regulated processes that specifically import metals, transport them to intracellular storage sites and ultimately transport them to sites of use. One of the most useful functions of metals such as zinc and iron in biological systems is to enable the activity of metalloenzymes. Metalloenzymes are enzymes that incorporate metal ions into the enzyme active site and utilize the metal as a part of the catalytic process. More than one-third of all characterized enzymes are metalloenzymes.

The function of metalloenzymes is highly dependent on the presence of the metal ion in the active site of the enzyme. It is well recognized that agents which bind to and inactivate the active site metal ion dramatically decrease the activity of the enzyme. Nature employs this same strategy to decrease the activity of certain metalloenzymes during periods in which the enzymatic activity is undesirable. For example, the protein TIMP (tissue inhibitor of metalloproteases) binds to the zinc ion in the active site of various matrix metalloprotease

enzymes and thereby arrests the enzymatic activity. The pharmaceutical industry has used the same strategy in the design of therapeutic agents. For example, the azole antifungal agents fluconazole and voriconazole contain a 1-(1,2,4-triazole) group that binds to the heme iron present in the active site of the target enzyme lanosterol demethylase and thereby inactivates the enzyme. Another example includes the zinc-binding hydroxamic acid group that has been incorporated into most published inhibitors of matrix metalloproteinases and histone deacetylases. Another example is the zinc-binding carboxylic acid group that has been incorporated into most published angiotensin-converting enzyme inhibitors.

In the design of clinically safe and effective metalloenzyme inhibitors, use of appropriate metal-binding groups for any particular target and clinical indication is desirable. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available azole antifungal agents such as fluconazole and voriconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-(1,2,4-triazole) to iron in the active site of CYP2C9, CYP2C19 and CYP3A4. Another example of this is the joint pain that has been observed in many clinical trials of matrix metalloproteinase inhibitors. This toxicity is considered to be related to inhibition of off-target metalloenzymes due to indiscriminate binding of the hydroxamic acid group to zinc in the off-target active sites.


Therefore, the search for metal-binding groups that can achieve a better balance of potency and selectivity remains an important goal and would be significant in the realization of therapeutic agents and methods to address currently unmet needs in treating and preventing diseases, disorders and symptoms thereof.

## BRIEF SUMMARY OF THE INVENTION

The invention is directed towards compounds (e.g., any of those delineated herein; any of the formulae delineated herein), methods of modulating activity of metalloenzymes, and methods of treating diseases, disorders or symptoms thereof. The methods can comprise the compounds herein.

It is understood that the embodiments of the invention discussed below with respect to the preferred variable selections can be taken alone or in combination with one or more embodiments, or preferred variable selections, of the invention, as if each combination were explicitly listed herein.

5 In one aspect, provided are compounds of Formula **I**:



**I**,

or pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically enriched derivatives, or prodrugs thereof, wherein:

10 A is N or CR<sup>5</sup>;

W is N or CR<sup>6</sup>;

X is N or CR<sup>6</sup>;

Y is N or CR<sup>6</sup>;

Z is N or CR<sup>6</sup>;

15 provided that no more than two of W, X, Y, and Z are N;

R<sup>1</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NHSO<sub>2</sub>R<sup>d</sup>, CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, S(O)R<sup>d</sup>, S(O)<sub>2</sub>R<sup>d</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH, wherein any R<sup>1</sup> can be optionally substituted with 1-3 independent substituents R<sup>7</sup>;

R<sup>2</sup> is hydrogen, halogen, cyano, alkyl, or haloalkyl;

or R<sup>1</sup> and R<sup>2</sup> together with the atoms to which they are attached form an aryl, heterocycloalkyl, or cycloalkyl ring;

25 R<sup>3</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NHSO<sub>2</sub>R<sup>d</sup>, CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH;

R<sup>4</sup> is alkyl, cycloalkyl, haloalkyl, or heteroalkyl;

R<sup>5</sup> is hydrogen, alkyl, haloalkyl, heteroalkyl, or cycloalkyl;

each occurrence of  $R^6$  is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, alkoxy, haloalkyl, or carboxyl;

each occurrence of  $R^7$  is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl, aryl, aryl substituted with 1-3 independent halogen,  $-(CH_2)_nC(O)NR^gR^h$ ,  $-S(O)_2R^i$ ,  $-CO_2R^j$ , or  $NR^gR^h$ ;

each  $n$  is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

each occurrence of  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$ , and  $R^f$  is, independently, hydrogen, acyl, alkoxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $C(O)OC_{1-6}$  alkyl,  $C(O)C_{1-6}$  alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or  $R^a$  and  $R^b$  together with the atoms to which they are attached form a heterocycloalkyl ring; or  $R^e$  and  $R^f$  together with the atoms to which they are attached form a cycloalkyl ring; and

each occurrence of  $R^g$ ,  $R^h$ ,  $R^i$ , and  $R^j$  is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $C(O)OC_{1-6}$  alkyl,  $C(O)C_{1-6}$  alkyl, or  $R^g$  and  $R^h$  together with the atoms to which they are attached form a heterocycloalkyl ring.

In certain embodiments,  $R^1$  is aryl, heteroaryl, or heterocycloalkyl, wherein any  $R^1$  can be optionally substituted with 1-3 independent substituents  $R^7$ .

In certain embodiments,  $R^1$  is aryl, heteroaryl, or heterocycloalkyl, wherein any  $R^1$  can be optionally substituted with 1-3 independent substituents  $R^7$ , and each  $R^7$  is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl,  $-(CH_2)_nC(O)NR^gR^h$ ,  $-S(O)_2R^i$ ,  $-CO_2R^j$ , or  $NR^gR^h$ , and each  $R^g$  and  $R^h$  is, independently, hydrogen, alkyl,  $C(O)C_{1-6}$  alkyl, or  $R^g$  and  $R^h$  together with the atoms to which they are attached form a heterocycloalkyl ring.

In certain embodiments,  $R^1$  is hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $COR^f$ , or  $CR^eR^fOH$ ; or  $R^1$  and  $R^2$  together with the atoms to which they are attached form an aryl ring.

In certain embodiments,  $R^1$  is hydrogen, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, cycloalkoxy, aryl,  $NR^aR^b$ ,  $CH_2NHSO_2R^d$ , or  $CR^eR^fOH$ ; or  $R^1$  and  $R^2$  together with the atoms to which they are attached form an aryl ring.

In certain embodiments,  $R^1$  is hydrogen, halogen, alkyl, haloalkyl,  $CH_2NHSO_2R^d$ , or  $NR^aR^b$ ; and  $R^a$ ,  $R^b$ , and  $R^d$  are, independently, hydrogen, alkyl, or haloalkyl.

In certain embodiments,  $R^1$  is alkyl or haloalkyl.

In certain embodiments,  $R^1$  is  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl.

In certain embodiments,  $R^1$  is haloalkyl.

In certain embodiments,  $R^1$  is  $C_{1-6}$  haloalkyl.

5 In certain embodiments,  $R^1$  is fluoroalkyl. In certain embodiments,  $R^1$  is  $C_{1-6}$  fluoroalkyl. In certain embodiments,  $R^1$  is  $C_{1-3}$  fluoroalkyl. In certain embodiments,  $R^1$  is difluoromethyl or trifluoromethyl. In certain embodiments,  $R^1$  is difluoromethyl. In certain embodiments,  $R^1$  is trifluoromethyl.

In certain embodiments,  $R^2$  is hydrogen or alkyl.

10 In certain embodiments,  $R^2$  is hydrogen or  $C_{1-6}$  alkyl.

In certain embodiments,  $R^2$  is hydrogen or  $C_{1-3}$  alkyl.

In certain embodiments,  $R^2$  is alkyl. In certain embodiments,  $R^2$  is  $C_{1-6}$  alkyl. In certain embodiments,  $R^2$  is  $C_{1-3}$  alkyl. In certain embodiments,  $R^2$  is hydrogen.

15 In certain embodiments,  $R^1$  is hydrogen and  $R^2$  is alkyl. In certain embodiments,  $R^1$  is hydrogen and  $R^2$  is  $C_{1-6}$  alkyl. In certain embodiments,  $R^1$  is hydrogen and  $R^2$  is  $C_{1-3}$  alkyl.

In certain embodiments,  $R^4$  is alkyl or cycloalkyl.

In certain embodiments,  $R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl.

In certain embodiments,  $R^4$  is  $C_{1-4}$  alkyl. In certain embodiments,  $R^4$  is  $C_{3-5}$  cycloalkyl.

20 In certain embodiments,  $R^4$  is cyclopentyl. In certain embodiments,  $R^4$  is cyclobutyl. In certain embodiments,  $R^4$  is cyclopropyl.

In certain embodiments, each  $R^6$  is, independently, hydrogen, halogen, cyano, alkoxy, haloalkyl, or carboxyl.

In certain embodiments, each  $R^6$  is, independently, hydrogen, halogen, or cyano.

In certain embodiments, each  $R^6$  is, independently, hydrogen, chloro, fluoro, or cyano.

25 In certain embodiments, each  $R^6$  is, independently, hydrogen, fluoro, or cyano.

In certain embodiments, each  $R^6$  is, independently, hydrogen, or halogen.

In certain embodiments, each  $R^6$  is, independently, hydrogen, chloro, or fluoro.

In certain embodiments, each  $R^6$  is, independently, hydrogen or fluoro.

In certain embodiments, each  $R^6$  is, independently, hydrogen or cyano.

30 In certain embodiments, each  $R^6$  is halogen. In certain embodiments, each  $R^6$  is chloro or fluoro. In certain embodiments, each  $R^6$  is fluoro. In certain embodiments, each  $R^6$  is cyano.

In certain embodiments, A is CR<sup>5</sup> and R<sup>5</sup> is hydrogen, C<sub>1-4</sub> alkyl, or C<sub>3-5</sub> cycloalkyl.


In certain embodiments, A is N.

In certain embodiments, no more than one of W, X, Y, and Z is N.

In certain embodiments, W, X, Y, and Z are each CR<sup>6</sup>.

5 In certain embodiments, Z is N.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-a**:



**I-a,**

10 or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>6</sup>, A, X, and Z are as defined herein.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-b**:



**I-b,**

15 or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, W, X, Y, and Z are as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-c**:




**I-c,**

20


or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>6</sup>, and Z are as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-d**:

**I-d,**


or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^6$ , and Z are as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-e**:

**I-e,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ ,  $R^6$ , and Z are as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-f**:

**I-f,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ , and  $R^6$  are as defined herein.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; and  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; and  $R^6$  is halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl;  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-f** are those  
5 wherein:

$R^4$  is alkyl or cycloalkyl;  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.


In certain embodiments, the aforementioned compounds of formula **I-f** are those  
10 wherein:

$R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those  
wherein:

15  $R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and  $R^6$  is halo.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-g**:



**I-g,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate,  
20 polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ , and  $R^6$  are as defined herein.

In certain embodiments, the aforementioned compounds of formula **I-g** are those  
wherein:

$R^4$  is alkyl or cycloalkyl; and  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo.

25 In certain embodiments, the aforementioned compounds of formula **I-g** are those  
wherein:

$R^4$  is alkyl or cycloalkyl; and  $R^6$  is halo.


In certain embodiments, the aforementioned compounds of formula **I-g** are those  
wherein:

$R^4$  is alkyl or cycloalkyl;  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-g** are those  
5 wherein:

$R^4$  is alkyl or cycloalkyl;  $R^6$  is hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

In another aspect, provided are compounds of Formula **I**:



**I,**

or pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically enriched derivatives, or prodrugs thereof, wherein:

A is N or  $CR^5$ ;

W is N or  $CR^6$ ;

X is N or  $CR^6$ ;

Y is N or  $CR^6$ ;

Z is N or  $CR^6$ ;

provided that no more than two of W, X, Y, and Z are N;

$R^1$  is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CR^eR^fNHSO_2R^d$ ,  $OR^f$ ,  $SR^f$ ,  $CO_2R^e$ ,  $COR^f$ ,  $S(O)R^d$ ,  $S(O)_2R^d$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ , wherein any  $R^1$  can be optionally substituted with 1-3 independent substituents  $R^7$ ;

$R^2$  is hydrogen, halogen, cyano, alkyl, or haloalkyl;

or  $R^1$  and  $R^2$  together with the atoms to which they are attached form an aryl, heterocycloalkyl, or cycloalkyl ring;

$R^3$  is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl,

heterocycloalkyl, heterocycloalkylalkyl,  $\text{NR}^a\text{R}^b$ ,  $\text{NHSO}_2\text{R}^c$ ,  $\text{CH}_2\text{NR}^a\text{R}^b$ ,  $\text{CH}_2\text{NHSO}_2\text{R}^d$ ,  $\text{CO}_2\text{R}^e$ ,  $\text{COR}^f$ ,  $\text{CH}_2\text{OR}^f$ , or  $\text{CR}^e\text{R}^f\text{OH}$ ;

$\text{R}^4$  is alkyl, cycloalkyl, haloalkyl, or heteroalkyl;

$\text{R}^5$  is hydrogen, cyano, alkyl, haloalkyl, heteroalkyl, or cycloalkyl;

5 each occurrence of  $\text{R}^6$  is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, alkoxy, haloalkyl,  $\text{OR}^f$ , or carboxyl;

each occurrence of  $\text{R}^7$  is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl, cycloalkyl, aryl, aryl substituted with 1-3 independent halogen,  $-(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^g\text{R}^h$ ,  $-\text{S}(\text{O})_2\text{R}^i$ ,  $-\text{CO}_2\text{R}^j$ , or  $\text{NR}^g\text{R}^h$ ;

10 each  $n$  is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

each occurrence of  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^c$ ,  $\text{R}^d$ ,  $\text{R}^e$ , and  $\text{R}^f$  is, independently, hydrogen, acyl, alkoxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $\text{C}(\text{O})\text{OC}_{1-6}$  alkyl,  $\text{C}(\text{O})\text{C}_{1-6}$  alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or  $\text{R}^a$  and  $\text{R}^b$  together with the atoms to which they are attached form a heterocycloalkyl ring; or  $\text{R}^e$  and  $\text{R}^f$  together with the atoms to which they are attached form a cycloalkyl ring; and

each occurrence of  $\text{R}^g$ ,  $\text{R}^h$ ,  $\text{R}^i$ , and  $\text{R}^j$  is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $\text{C}(\text{O})\text{OC}_{1-6}$  alkyl,  $\text{C}(\text{O})\text{C}_{1-6}$  alkyl, or  $\text{R}^g$  and  $\text{R}^h$  together with the atoms to which they are attached form a heterocycloalkyl ring.

In certain embodiments,  $\text{R}^1$  is aryl, heteroaryl, or heterocycloalkyl, wherein any  $\text{R}^1$  can be optionally substituted with 1-3 independent substituents  $\text{R}^7$ .

In certain embodiments,  $\text{R}^1$  is aryl, heteroaryl, or heterocycloalkyl, wherein any  $\text{R}^1$  can be optionally substituted with 1-3 independent substituents  $\text{R}^7$ , and each  $\text{R}^7$  is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl,  $-(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^g\text{R}^h$ ,  $-\text{S}(\text{O})_2\text{R}^i$ ,  $-\text{CO}_2\text{R}^j$ , or  $\text{NR}^g\text{R}^h$ , and each  $\text{R}^g$  and  $\text{R}^h$  is, independently, hydrogen, alkyl,  $\text{C}(\text{O})\text{C}_{1-6}$  alkyl, or  $\text{R}^g$  and  $\text{R}^h$  together with the atoms to which they are attached form a heterocycloalkyl ring.

In certain embodiments,  $\text{R}^1$  is hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl,  $\text{NR}^a\text{R}^b$ ,  $\text{NHSO}_2\text{R}^c$ ,  $\text{CH}_2\text{NR}^a\text{R}^b$ ,  $\text{CR}^e\text{R}^f\text{NHSO}_2\text{R}^d$ ,  $\text{SR}^f$ ,  $\text{COR}^f$ , or  $\text{CR}^e\text{R}^f\text{OH}$ ; or  $\text{R}^1$  and  $\text{R}^2$  together with the atoms to which they are attached form an aryl or cycloalkyl ring.

In certain embodiments,  $\text{R}^1$  is hydrogen, halogen, alkyl, alkenyl, haloalkyl, alkoxy,

haloalkoxy, cycloalkoxy, aryl,  $\text{NR}^a\text{R}^b$ ,  $\text{CR}^e\text{R}^f\text{NHSO}_2\text{R}^d$ ,  $\text{SR}^f$ , or  $\text{CR}^e\text{R}^f\text{OH}$ ; or  $\text{R}^1$  and  $\text{R}^2$  together with the atoms to which they are attached form an aryl or cycloalkyl ring.

In certain embodiments,  $\text{R}^1$  is hydrogen, halogen, alkyl, haloalkyl,  $\text{CR}^e\text{R}^f\text{NHSO}_2\text{R}^d$ ,  $\text{SR}^f$ , or  $\text{NR}^a\text{R}^b$ ; and  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^d$ ,  $\text{R}^e$ , and  $\text{R}^f$  are, independently, hydrogen, alkyl, or haloalkyl.

5 In certain embodiments,  $\text{R}^1$  is  $\text{SR}^f$ . In certain embodiments,  $\text{R}^1$  is  $\text{SR}^f$ ; and  $\text{R}^f$  is hydrogen, alkyl, or haloalkyl.

In certain embodiments,  $\text{R}^1$  is alkyl or haloalkyl.

In certain embodiments,  $\text{R}^1$  is  $\text{C}_{1-6}$  alkyl or  $\text{C}_{1-6}$  haloalkyl.

In certain embodiments,  $\text{R}^1$  is haloalkyl.

10 In certain embodiments,  $\text{R}^1$  is  $\text{C}_{1-6}$  haloalkyl.

In certain embodiments,  $\text{R}^1$  is fluoroalkyl. In certain embodiments,  $\text{R}^1$  is  $\text{C}_{1-6}$  fluoroalkyl. In certain embodiments,  $\text{R}^1$  is difluoromethyl or trifluoromethyl. In certain embodiments,  $\text{R}^1$  is difluoromethyl. In certain embodiments,  $\text{R}^1$  is trifluoromethyl.

15 In certain embodiments,  $\text{R}^2$  is hydrogen or alkyl.

In certain embodiments,  $\text{R}^2$  is hydrogen or  $\text{C}_{1-6}$  alkyl.

In certain embodiments,  $\text{R}^2$  is hydrogen or  $\text{C}_{1-3}$  alkyl.

In certain embodiments,  $\text{R}^2$  is alkyl. In certain embodiments,  $\text{R}^2$  is  $\text{C}_{1-6}$  alkyl. In certain embodiments,  $\text{R}^2$  is  $\text{C}_{1-3}$  alkyl. In certain embodiments,  $\text{R}^2$  is hydrogen.

20 In certain embodiments,  $\text{R}^1$  is hydrogen and  $\text{R}^2$  is alkyl. In certain embodiments,  $\text{R}^1$  is hydrogen and  $\text{R}^2$  is  $\text{C}_{1-6}$  alkyl. In certain embodiments,  $\text{R}^1$  is hydrogen and  $\text{R}^2$  is  $\text{C}_{1-3}$  alkyl.

In certain embodiments,  $\text{R}^1$  and  $\text{R}^2$  together with the atoms to which they are attached form an aryl or cycloalkyl ring. In certain embodiments,  $\text{R}^1$  and  $\text{R}^2$  together with the atoms to which they are attached form an aryl ring. In certain embodiments,  $\text{R}^1$  and  $\text{R}^2$  together with the atoms to which they are attached form cycloalkyl ring.

25 In certain embodiments,  $\text{R}^4$  is alkyl or cycloalkyl.

In certain embodiments,  $\text{R}^4$  is  $\text{C}_{1-4}$  alkyl or  $\text{C}_{3-5}$  cycloalkyl.

In certain embodiments,  $\text{R}^4$  is  $\text{C}_{1-4}$  alkyl. In certain embodiments,  $\text{R}^4$  is  $\text{C}_{3-5}$  cycloalkyl. In certain embodiments,  $\text{R}^4$  is cyclopentyl. In certain embodiments,  $\text{R}^4$  is cyclobutyl. In certain  
30 embodiments,  $\text{R}^4$  is cyclopropyl.

In certain embodiments, each  $\text{R}^6$  is, independently, hydrogen, halogen, cyano, alkoxy, haloalkyl, or carboxyl.

In certain embodiments, each  $R^6$  is, independently, hydrogen, halogen, or cyano.

In certain embodiments, each  $R^6$  is, independently, hydrogen, chloro, fluoro, or cyano.

In certain embodiments, each  $R^6$  is, independently, hydrogen, fluoro, or cyano.

In certain embodiments, each  $R^6$  is, independently, hydrogen, or halogen.

5 In certain embodiments, each  $R^6$  is, independently, hydrogen, chloro, or fluoro.

In certain embodiments, each  $R^6$  is, independently, hydrogen or fluoro.

In certain embodiments, each  $R^6$  is, independently, hydrogen or cyano.

In certain embodiments, each  $R^6$  is halogen. In certain embodiments, each  $R^6$  is chloro or fluoro. In certain embodiments, each  $R^6$  is fluoro. In certain embodiments, each  $R^6$  is  
10 cyano.

In certain embodiments, A is  $CR^5$  and  $R^5$  is hydrogen, cyano,  $C_{1-4}$  alkyl, or  $C_{3-5}$  cycloalkyl.


In certain embodiments, A is N.

In certain embodiments, no more than one of W, X, Y, and Z is N.

15 In certain embodiments, W, X, Y, and Z are each independently  $CR^6$ .

In certain embodiments, Z is N.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-a**:



**I-a,**

20 or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^6$ , A, X, and Z are each independently as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-b**:




**I-b,**

25

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^2$ ,  $R^4$ , W, X, Y, and Z are each independently as defined herein.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-c**:



**I-c,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^6$ , and Z are each independently as defined herein.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-d**:



**I-d,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^6$ , and Z are each independently as defined herein.


In certain embodiments, the compound of Formula **I** is a compound of Formula **I-e**:



**I-e,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ ,  $R^6$ , and Z are each independently as defined herein.

In certain embodiments, the compound of Formula **I** is a compound of Formula **I-f**:

**I-f,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ , and  $R^6$  are  
 5 each independently as defined herein.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo.

10 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

15  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:  $R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

20 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

25 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

30  $R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen, cyano, or halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  
5  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  
10  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is optionally substituted cycloalkyl, optionally substituted aryl,  
15 optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo.

20 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

25  $R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

30  $R^1$  is haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

5  $R^1$  is haloalkyl;  $R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.


10 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently halo.

15 In certain embodiments, the compound of Formula **I** is a compound of Formula **I-g**:



**I-g,**

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof, wherein  $R^1$ ,  $R^4$ , and  $R^6$  are  
20 each independently as defined herein.

In certain embodiments, the aforementioned compounds of formula **I-g** are those wherein:

$R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo.

25 In certain embodiments, the aforementioned compounds of formula **I-g** are those wherein:

$R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

30  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently halo.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen, cyano, or halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-g** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is hydrogen, halogen, cyano, acyl, alkyl, haloalkyl, alkoxy, haloalkoxy,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $CO_2R^e$ ,  $COR^f$ ,  $CH_2OR^f$ , or  $CR^eR^fOH$ .

In certain embodiments, the aforementioned compounds of formula **I-g** are those wherein:

$R^4$  is alkyl or cycloalkyl; each  $R^6$  is independently hydrogen or halo, wherein at least one  $R^6$  is halo; and  $R^1$  is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is alkyl or haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is alkyl or haloalkyl;  $R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is alkyl or cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is  $C_{1-4}$  alkyl or  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is  $C_{3-5}$  cycloalkyl; and each  $R^6$  is independently hydrogen, halo, or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

$R^1$  is haloalkyl;  $R^4$  is cycloalkyl; and each  $R^6$  is independently hydrogen or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

R<sup>1</sup> is haloalkyl; R<sup>4</sup> is C<sub>3-5</sub> cycloalkyl; and each R<sup>6</sup> is independently hydrogen or cyano.

In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

R<sup>1</sup> is haloalkyl; R<sup>4</sup> is cycloalkyl; and each R<sup>6</sup> is independently halo.

5 In certain embodiments, the aforementioned compounds of formula **I-f** are those wherein:

R<sup>1</sup> is haloalkyl; R<sup>4</sup> is C<sub>3-5</sub> cycloalkyl; and each R<sup>6</sup> is independently halo.

In certain embodiments, the compound of Formula **I** is a compound selected from the group consisting of:

- 10 1-cyclopropyl-6-fluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (1);
- 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbonitrile (2);
- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole (3);
- 1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (4);
- 15 methyl 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (5);
- 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole (6);
- 1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (7);
- 20 *N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propionamide (8);
- ethyl ((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)carbamate (9);
- 4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)morpholine (10);
- 25 1-cyclopropyl-6-fluoro-2-(6-(4-(4-fluorophenyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (11);
- 2-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)propan-2-ol (12);
- 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridazin-3-amine (13);
- 30 4-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)cinnoline (14);
- 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (15);

- N*-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethanesulfonamide (16);
- 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (17);
- 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-*N*-isopropylacetamide (18);
- 1-cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (19);
- 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (20);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-methylpyridazin-3-amine (21);
- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (22);
- 1-cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole (23);
- 1-cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole (24);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N,N*-dimethylpyridazin-3-amine (25);
- 1-ethyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (26);
- 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (27);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2-methoxyethyl)pyridazin-3-amine (28);
- 1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (29);
- 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (30);
- N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (31);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2,2,2-trifluoroethyl)pyridazin-3-amine (32);
- 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (33);
- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (34);
- 1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (35);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-methylpiperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (36);

- 1-(4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)ethan-1-one (37);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (38);
- 5 tert-butyl 4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazine-1-carboxylate (39);
- 1-ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (40);
- 1-ethyl-2-(6-ethylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (41);
- 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-
- 10 benzo[*d*]imidazole (42);
- 2-(6-cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (43);
- 1-cyclopropyl-2-(6-(4,4-difluoropiperidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (44);
- 15 5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (45);
- 1-cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (46);
- 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (47);
- 20 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N,N*-dimethylpyrrolidin-3-amine (48);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (49);
- 1-cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl)ethynyl)pyridazin-4-yl)-1*H*-
- 25 benzo[*d*]imidazole (50);
- 1-cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (51);
- N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (52);
- 1-cyclopropyl-5,6-difluoro-2-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyridazin-4-yl)-1*H*-
- 30 benzo[*d*]imidazole (53);
- 3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (54);

- 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (55);  
 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-4-(trifluoromethyl)-1*H*-  
 benzo[*d*]imidazole (56);  
 1-cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 5 benzo[*d*]imidazole (57);  
 1-cyclopropyl-5,6-difluoro-2-(5-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (58);  
 1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole  
 (59);  
 2-(6-chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridine (60);  
 10 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (61);  
 1-cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (62);  
 1-cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 15 benzo[*d*]imidazole (63);  
 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-  
 one (64);  
 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (65);  
 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-  
 20 carbonitrile (66);  
 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (67);  
 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (68);  
 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile  
 (69);  
 25 1-cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (70);  
 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (71);  
 2-(6-Cyclopropylpyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (72);  
 30 5-Chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-  
*b*]pyridine (73);  
 1-Cyclopropyl-5,6-difluoro-2-(5-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (74);

- 1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (75);
- 3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (76);
- 5 *N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)methane sulfonamide (77);
- N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)-*N*-methylmethanesulfonamide (78);
- 10 *N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-2-sulfonamide (79);
- 1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (80);
- 1-Cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (81);
- 15 1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (82);
- 1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (83);
- 5-Chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (84);
- 20 1-Cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (85);
- 1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (86);
- 25 3-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (87);
- 2-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)isothiazolidine 1,1-dioxide (88);
- 3-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (89);
- 30 1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (90);

- N*-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl) methanesulfonamide (91);
- 1-Cyclopropyl-5,6-difluoro-2-(6-(fluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (92);
- 5 1-Cyclopropyl-2-(5,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (93);
- (5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanol (94);
- 5-Chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (95);
- 10 *N*-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl) ethanesulfonamide (96);
- 2-(6-Butylpyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (97);
- 1-Cyclopropyl-6-methyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (98);
- 15 1-Cyclopropyl-5,6-difluoro-2-(3-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (99);
- 1-Cyclopropyl-2-(3,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (100);
- 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6,7-difluoro-1*H*-benzo[*d*]imidazole (101);
- 20 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-thiol (102);
- 2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-methyl-1*H*-benzo[*d*]imidazole (104);
- 2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-propyl-1*H*-benzo[*d*]imidazole (105);
- 25 4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-5,6,7,8-tetrahydrocinnoline (106);
- 1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-5-carbonitrile (Ex. 107);
- 1-Cyclobutyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (108);
- 30 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazol-6-ol (109);
- 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid (110);

- 1-Cyclopropyl-7-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (111);  
 5-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (112);  
 4-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (113);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(methoxymethyl)pyridazin-4-yl)-1*H*-  
 5 benzo[*d*]imidazole (114);  
 Methyl 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate  
 (115);  
 5-(6-Cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid  
 (116);  
 10 1-Cyclopropyl-2-(6-(cyclopropylmethoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (117);  
 1-Cyclopropyl-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-  
 carbonitrile (118);  
 6-Chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-  
 15 benzo[*d*]imidazole (119);  
 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-benzo[*d*]imidazole-  
 6-carbonitrile (120);  
 4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-6,7-dihydro-5*H*-  
 cyclopenta[*c*]pyridazine (121);  
 20 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole  
 (122);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole  
 (123);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(isopropylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole  
 25 (124);  
 1-Cyclopropyl-2-(6-((difluoromethyl)thio)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (125);  
 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-ol (126);  
 1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 30 benzo[*d*]imidazole (127);  
 1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-ol  
 (128);

1-Cyclopropyl-5,6-difluoro-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (129);

1-Cyclopropyl-5,6-difluoro-2-(6-((trifluoromethyl)thio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (130)

5 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (131);

2-(6-(Difluoromethyl)pyridazin-4-yl)-1-propyl-1*H*-benzo[*d*]imidazole (132);

1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (133);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (134);

10 2-(6-(Difluoromethyl)pyridazin-4-yl)-1-methyl-1*H*-indole-3-carbonitrile (135);

1-Cyclopropyl-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-

carbonitrile (136); pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically enriched derivatives, and prodrugs thereof.

15 In another aspect, provided is 2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (103), or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof.

In one aspect, the compound of Formula **I** is that wherein the compound inhibits (or is identified to inhibit) aldosterone synthase (CYP11B2).

The compounds herein include those wherein the compound is identified as attaining affinity, at least in part, for a metalloenzyme by formation of one or more of the following types of chemical interactions or bonds to a metal: sigma bonds, covalent bonds, coordinate-covalent bonds, ionic bonds, pi bonds, delta bonds, or backbonding interactions. The compounds can also attain affinity through weaker interactions with the metal such as van der Waals interactions, pi cation interactions, pi-anion interactions, dipole-dipole interactions, ion-dipole interactions. In one aspect, the compound is identified as having a bonding interaction with the metal via the pyridazine moiety.

Methods for assessing metal-ligand binding interactions are known in the art as exemplified in references including, for example, “Principles of Bioinorganic Chemistry” by Lippard and Berg, University Science Books, (1994); “Mechanisms of Inorganic Reactions” by Basolo and Pearson John Wiley & Sons Inc; 2nd edition (September 1967); “Biological

Inorganic Chemistry” by Ivano Bertini, Harry Gray, Ed Stiefel, Joan Valentine, University Science Books (2007); Xue et al. “Nature Chemical Biology”, vol. 4, no. 2, 107-109 (2008).

In another aspect, provided are pharmaceutical compositions comprising the compound of Formula I and a pharmaceutically acceptable carrier.

5 In another aspect, provided are methods of modulating metalloenzyme activity in a subject, comprising contacting the subject with a compound of Formula I, in an amount and under conditions sufficient to modulate metalloenzyme activity.

In another aspect, provided are methods of treating a subject suffering from or susceptible to a disorder or disease, wherein the subject has been identified as in need of  
10 treatment for the disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of Formula I, such that said subject is treated for said disorder.

In another aspect the subject is an animal other than a human.

In another aspect, provided are methods of treating a subject suffering from or  
15 susceptible to a metalloenzyme-related disorder or disease, comprising administering to the subject an effective amount of a compound or pharmaceutical composition of Formula I.

In another aspect, provided are methods of treating a subject suffering from or susceptible to a metalloenzyme-related disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-related disorder or disease, comprising  
20 administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of Formula I, such that said subject is treated for said disorder.

In another aspect, provided are methods of treating a subject suffering from or susceptible to a metalloenzyme-mediated disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-mediated disorder or disease,  
25 comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of Formula I, such that metalloenzyme activity in said subject is modulated (e.g., down regulated, inhibited).

The methods herein include those wherein the disease or disorder is mediated by any of aromatase (CYP19), a member of the cyclooxygenase family, lanosterol demethylase  
30 (CYP51), a member of the nitric oxide synthase family, thromboxane synthase (CYP5a), thyroid peroxidase, 17-alpha hydroxylase/17,20-lyase (CYP17), cytochrome P450 2A6 (CYP2A6), heme oxygenase, indoleamine 2,3-dioxygenase, retinoic acid hydroxylase

(CYP26), vitamin D hydroxylase (CYP24), sterol 27-hydroxylase (CYP27), cytochrome P450 3A5 (CYP3A5), cholesterol 24-hydroxylase (CYP46), cytochrome P450 4F2 (CYP4F2), myeloperoxidase, or 11-beta-hydroxylase (CYP11B1).

The methods herein include those wherein the disease or disorder is cancer,  
 5 cardiovascular disease, inflammatory disease, infectious disease, metabolic disease, ophthalmologic disease, central nervous system (CNS) disease, urologic disease, or gastrointestinal disease.

The methods herein include those wherein the disease or disorder is hypertension, resistant hypertension, morbidities associated with primary or secondary hyperaldosteronism  
 10 and adrenal hyperplasia, pulmonary arterial hypertension, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, systolic heart failure, hypokalemia, renal failure, chronic renal failure, restenosis, nephropathy, post-myocardial infarction, coronary heart disease, fibrosis, diseases characterized by increased collagen formation, fibrosis and matrix remodeling following hypertension, fibrosis and  
 15 matrix remodeling following endothelial cell dysfunction, cardiovascular diseases such as atherosclerosis, atrial fibrillation, renal dysfunction, liver diseases, non-alcoholic steatohepatitis, vascular diseases, retinopathy, neuropathy, insulinopathy, endothelial dysfunction, myocardial fibrosis, vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, vascular wall hypertrophy,  
 20 endothelial thickening, fibrinoid necrosis of the arteries, kidney diseases, diabetic nephropathy, glomerulosclerosis, glomerulonephritis, nephritic syndrome, polycystic kidney disease, diabetes mellitus, metabolic syndrome, insulin resistance, sleep apnea, obstructive sleep apnea, muscular dystrophy, liver cirrhosis, non-alcoholic fatty liver disease, renal disorders, diabetic renal disorders, or stroke.

25 Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).

## 30 DETAILED DESCRIPTION

### Definitions

In order that the invention may be more readily understood, certain terms are first defined here for convenience.

As used herein, the term "treating" a disorder encompasses preventing, ameliorating, mitigating and/or managing the disorder and/or conditions that may cause the disorder. The terms "treating" and "treatment" refer to a method of alleviating or abating a disease and/or its attendant symptoms. In accordance with the present disclosure "treating" includes preventing, blocking, inhibiting, attenuating, protecting against, modulating, reversing the effects of and reducing the occurrence of e.g., the harmful effects of a disorder.

As used herein, "inhibiting" encompasses preventing, reducing and halting progression. Note that "enzyme inhibition" (e.g., metalloenzyme inhibition) is distinguished and described below.

The term "modulate" refers to increases or decreases in the activity of an enzyme in response to exposure to a compound of the present disclosure.

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. Particularly, in embodiments the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

The term "administration" or "administering" includes routes of introducing the compound(s) to a subject to perform their intended function. Examples of routes of administration which can be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), topical, oral, inhalation, rectal and transdermal.

The term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result. An effective amount of compound may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the inhibitor compound are outweighed by the therapeutically beneficial effects.

The phrases "systemic administration," "administered systemically", "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.

5           The term "therapeutically effective amount" refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.

          A therapeutically effective amount of compound (*i.e.*, an effective dosage) may range from about 0.005 µg/kg to about 200 mg/kg, preferably about 0.01 mg/kg to about 200 mg/kg, 10 more preferably about 0.015 mg/kg to about 30 mg/kg of body weight. In other embodiments, the therapeutically effect amount may range from about 1.0 pM to about 10 µM. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, 15 treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound in the range of between about 0.005 µg/kg to about 200 mg/kg of body weight, one time per day for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, 20 or 6 weeks. In another example, a subject may be treated daily for several years in the setting of a chronic condition or illness. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.

          The term "chiral" refers to molecules which have the property of non- 25 superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

          The term "diastereomers" refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.

          The term "enantiomers" refers to two stereoisomers of a compound which are non- 30 superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a "racemic mixture" or a "racemate."

The term "isomers" or "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

5 The term "prodrug" includes compounds with moieties which can be metabolized *in vivo*. Generally, the prodrugs are metabolized *in vivo* by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, *e.g.*, Berge *et al.* (1977) "Pharmaceutical Salts", *J. Pharm. Sci.* 66:1-19). The prodrugs can be prepared *in situ* during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent.

10 Hydroxyl groups can be converted into esters *via* treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branched or unbranched lower alkyl ester moieties, (*e.g.*, propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (*e.g.*, dimethylaminoethyl ester), acylamino lower alkyl esters (*e.g.*, acetyloxymethyl ester), acyloxy lower alkyl esters (*e.g.*, pivaloyloxymethyl ester), aryl esters

15 (phenyl ester), aryl-lower alkyl esters (*e.g.*, benzyl ester), substituted (*e.g.*, with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionic acid esters and acyl esters. Prodrugs which are converted to active forms through other mechanisms *in vivo* are also included. In aspects, the compounds of the present disclosure are

20 prodrugs of any of the formulae herein.

The term "subject" refers to animals such as mammals, including, but not limited to, primates (*e.g.*, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human.

25 The terms "a," "an," and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "a sample" includes a plurality of samples, unless the context clearly is to the contrary (*e.g.*, a plurality of samples), and so forth.

Throughout this specification and the claims, the words "comprise," "comprises," and "comprising" are used in a non-exclusive sense, except where the context requires otherwise.

30 As used herein, the term "about," when referring to a value is meant to encompass variations of, in some embodiments  $\pm 20\%$ , in some embodiments  $\pm 10\%$ , in some embodiments  $\pm 5\%$ , in some embodiments  $\pm 1\%$ , in some embodiments  $\pm 0.5\%$ , and in some

embodiments  $\pm 0.1\%$  from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.

Use of the word “inhibitor” herein is meant to mean a molecule that exhibits activity for inhibiting a metalloenzyme. By “inhibit” herein is meant to decrease the activity of metalloenzyme, as compared to the activity of metalloenzyme in the absence of the inhibitor. In some embodiments, the term “inhibit” means a decrease in metalloenzyme activity of at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%. In other embodiments, inhibit means a decrease in metalloenzyme activity of about 5% to about 25%, about 25% to about 50%, about 50% to about 75%, or about 75% to 100%. In some embodiments, inhibit means a decrease in metalloenzyme activity of about 95% to 100%, e.g., a decrease in activity of 95%, 96%, 97%, 98%, 99%, or 100%. Such decreases can be measured using a variety of techniques that would be recognizable by one of skill in the art. Particular assays for measuring individual activity are described below.

Furthermore, the compounds of the present disclosure include olefins having either geometry: “Z” refers to what is referred to as a “cis” (same side) configuration whereas “E” refers to what is referred to as a “trans” (opposite side) configuration. With respect to the nomenclature of a chiral center, the terms “d” and “l” configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate, epimer and enantiomer, these will be used in their normal context to describe the stereochemistry of preparations.

As used herein, the term “alkyl” refers to a straight-chained or branched hydrocarbon group containing 1 to 12 carbon atoms. The term “lower alkyl” refers to a C1-C6 alkyl chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, *tert*-butyl, and n-pentyl. Alkyl groups may be optionally substituted with one or more substituents.

The term “haloalkyl” refers to an alkyl group that is substituted by one or more halo substituents. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, and 2,2,2-trifluoroethyl.

The term “alkenyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups may be optionally substituted with one or more substituents.

The term “arylalkenyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond wherein one or more of the  $sp^2$  hybridized carbons of the alkenyl unit attaches to an aryl moiety. Alkenyl groups may be optionally substituted with one or more substituents.

The term “alkynyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing the 2 to 12 carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups may be optionally substituted with one or more substituents.

The term “arylalkynyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond wherein one or more of the  $sp$  hybridized carbons of the alkynyl unit attaches to an aryl moiety. Alkynyl groups may be optionally substituted with one or more substituents.

The  $sp^2$  or  $sp$  carbons of an alkenyl group and an alkynyl group, respectively, may optionally be the point of attachment of the alkenyl or alkynyl groups.

The term “alkoxy” refers to an -O-alkyl substituent.

As used herein, the term “halogen”, “hal” or “halo” means -F, -Cl, -Br or -I.

The term “alkylthio” refers to an -S-alkyl substituent.

The term “alkoxyalkyl” refers to an -alkyl-O-alkyl substituent.

The term “haloalkoxy” refers to an -O-alkyl that is substituted by one or more halo substituents. Examples of haloalkoxy groups include trifluoromethoxy, and 2,2,2-trifluoroethoxy.

The term “haloalkoxyalkyl” refers to an -alkyl-O-alkyl’ where the alkyl’ is substituted by one or more halo substituents.

The term “haloalkylaminocarbonyl” refers to a -C(O)-amino-alkyl where the alkyl is substituted by one or more halo substituents.

The term “haloalkylthio” refers to an -S-alkyl that is substituted by one or more halo substituents. Examples of haloalkylthio groups include trifluoromethylthio, and 2,2,2-trifluoroethylthio.

The term “haloalkylcarbonyl” refers to an -C(O)-alkyl that is substituted by one or more halo substituents. An example of a haloalkylcarbonyl group includes trifluoroacetyl.

The term “cycloalkyl” refers to a hydrocarbon 3-8 membered monocyclic or 7-14 membered bicyclic ring system having at least one saturated ring or having at least one non-aromatic ring, wherein the non-aromatic ring may have some degree of unsaturation.

Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent. Representative examples of cycloalkyl group include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.

The term “cycloalkoxy” refers to an -O-cycloalkyl substituent.

The term “cycloalkoxyalkyl” refers to an -alkyl-O-cycloalkyl substituent.

The term “cycloalkylalkoxy” refers to an -O-alkyl-cycloalkyl substituent.

The term “cycloalkylaminocarbonyl” refers to an -C(O)-NH-cycloalkyl substituent.

The term “aryl” refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system. Aryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.

The term “aryloxy” refers to an -O-aryl substituent.

The term “arylalkoxy” refers to an -O-alkyl-aryl substituent.

The term “arylalkylthio” refers to an -S-alkyl-aryl substituent.

The term “arylthioalkyl” refers to an -alkyl-S -aryl substituent.

The term “arylalkylaminocarbonyl” refers to a -C(O)-amino-alkyl-aryl substituent.

The term “arylalkylsulfonyl” refers to an -S(O)<sub>2</sub>-alkyl-aryl substituent.

The term “arylalkylsulfinyl” refers to an -S(O)-alkyl-aryl substituent.

The term “aryloxyalkyl” refers to an -alkyl-O-aryl substituent.

The term “alkylaryl” refers to an -aryl-alkyl substituent.

The term “arylalkyl” refers to an -alkyl-aryl substituent.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-4 ring heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated). Heteroaryl groups may be optionally substituted

with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like.

The term “heteroarylalkyl” refers to an –alkyl-heteroaryl substituent.

The term “heteroaryloxy” refers to an -O-heteroaryl substituent.

The term “heteroarylalkoxy” refers to an -O-alkyl-heteroaryl substituent.

The term “heteroaryloxyalkyl” refers to an –alkyl-O-heteroaryl substituent.

The term “nitrogen-containing heteroaryl” refers to a heteroaryl group having 1-4 ring nitrogen heteroatoms if monocyclic, 1-6 ring nitrogen heteroatoms if bicyclic, or 1-9 ring nitrogen heteroatoms if tricyclic.

The term “heterocycloalkyl” refers to a nonaromatic 3-8 membered monocyclic, 7-12 membered bicyclic, or 10-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, S, B, P or Si, wherein the nonaromatic ring system is completely saturated. Heterocycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heterocycloalkyl group may be substituted by a substituent. Representative heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thiirenyl, and the like.

The term “heterocycloalkylalkyl” refers to an –alkyl-heterocycloalkyl substituent.

The term “alkylamino” refers to an amino substituent which is further substituted with one or two alkyl groups. The term “aminoalkyl” refers to an alkyl substituent which is further substituted with one or more amino groups. The term “hydroxyalkyl” or “hydroxylalkyl” refers to an alkyl substituent which is further substituted with one or more hydroxyl groups. The alkyl or aryl portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl, mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl, and alkylcarbonylalkyl may be optionally substituted with one or more substituents.

Acids and bases useful in the methods herein are known in the art. Acid catalysts are any acidic chemical, which can be inorganic (e.g., hydrochloric, sulfuric, nitric acids, aluminum trichloride) or organic (e.g., camphorsulfonic acid, p-toluenesulfonic acid, acetic

acid, ytterbium triflate) in nature. Acids are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions. Bases are any basic chemical, which can be inorganic (e.g., sodium bicarbonate, potassium hydroxide) or organic (e.g., triethylamine, pyridine) in nature. Bases are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.

Alkylating agents are any reagent that is capable of effecting the alkylation of the functional group at issue (e.g., oxygen atom of an alcohol, nitrogen atom of an amino group). Alkylating agents are known in the art, including in the references cited herein, and include alkyl halides (e.g., methyl iodide, benzyl bromide or chloride), alkyl sulfates (e.g., methyl sulfate), or other alkyl group-leaving group combinations known in the art. Leaving groups are any stable species that can detach from a molecule during a reaction (e.g., elimination reaction, substitution reaction) and are known in the art, including in the references cited herein, and include halides (e.g., I-, Cl-, Br-, F-), hydroxy, alkoxy (e.g., -OMe, -O-t-Bu), acyloxy anions (e.g., -OAc, -OC(O)CF<sub>3</sub>), sulfonates (e.g., mesyl, tosyl), acetamides (e.g., -NHC(O)Me), carbamates (e.g., N(Me)C(O)Ot-Bu), phosphonates (e.g., -OP(O)(OEt)<sub>2</sub>), water or alcohols (protic conditions), and the like.

In certain embodiments, substituents on any group (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl) can be at any atom of that group, wherein any group that can be substituted (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl) can be optionally substituted with one or more substituents (which may be the same or different), each replacing a hydrogen atom. Examples of suitable substituents include, but are not limited to alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (i.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino, diarylamino, alkylcarbonyl, or arylamino-substituted aryl; arylalkylamino, aralkylaminocarbonyl, amido, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, imino, carboxamido, carbamido, carbamyl, thioureido, thiocyanato,

sulfoamido, sulfonylalkyl, sulfonylaryl, mercaptoalkoxy, N-hydroxyamidinyl, or N'-aryl, N''-hydroxyamidinyl.

Compounds of the present disclosure can be made by means known in the art of organic synthesis. Methods for optimizing reaction conditions, if necessary minimizing competing by-products, are known in the art. Reaction optimization and scale-up may advantageously utilize high-speed parallel synthesis equipment and computer-controlled microreactors (e.g. *Design And Optimization in Organic Synthesis*, 2<sup>nd</sup> Edition, Carlson R, Ed, 2005; Elsevier Science Ltd.; Jähnisch, K et al, *Angew. Chem. Int. Ed. Engl.* 2004 43: 406; and references therein). Additional reaction schemes and protocols may be determined by the skilled artisan by use of commercially available structure-searchable database software, for instance, SciFinder® (CAS division of the American Chemical Society) and CrossFire Beilstein® (Elsevier MDL), or by appropriate keyword searching using an internet search engine such as Google® or keyword databases such as the US Patent and Trademark Office text database.

As can be appreciated by the skilled artisan, methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art, including in the schemes and examples herein. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. In addition, the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired compounds of the present disclosure.

The compounds herein may also contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all *cis/trans* and *E/Z* isomers are expressly included in the present disclosure. The compounds herein may also be represented in multiple tautomeric forms, in such instances, the present disclosure expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds herein are expressly included in the present disclosure. All crystal forms and polymorphs of the compounds described herein are expressly included in the present disclosure. Also embodied are extracts and fractions comprising compounds of the present disclosure. The term isomers is intended to include diastereoisomers, enantiomers, regioisomers, structural isomers, rotational isomers, tautomers,

and the like. For compounds which contain one or more stereogenic centers, e.g., chiral compounds, the methods of the present disclosure may be carried out with an enantiomerically enriched compound, a racemate, or a mixture of diastereomers.

Preferred enantiomerically enriched compounds have an enantiomeric excess of 50% or more, more preferably the compound has an enantiomeric excess of 60%, 70%, 80%, 90%, 95%, 98%, or 99% or more. In preferred embodiments, only one enantiomer or diastereomer of a chiral compound of the present disclosure is administered to cells or a subject.

### Methods of Treatment

10 In one aspect, provided are methods of treating a subject suffering from or susceptible to a disorder or disease, comprising administering to the subject an effective amount of a compound or pharmaceutical composition of Formula I.

In other aspects, provided are methods of treating a subject suffering from or susceptible to a disorder or disease, wherein the subject has been identified as in need of  
15 treatment for a metalloenzyme-mediated disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of Formula I, such that said subject is treated for said disorder.

In one aspect, provided are methods of modulating the metalloenzyme activity of a cell in a subject, comprising contacting the subject with a compound of Formula I, in an amount  
20 and under conditions sufficient to modulate metalloenzyme activity.

In one embodiment, the modulation is inhibition.

In another aspect, provided are methods of treating a subject suffering from or susceptible to a metalloenzyme-mediated disorder or disease, comprising administering to the subject an effective amount of a compound or pharmaceutical composition of Formula I.

25 In other aspects, provided are methods of treating a subject suffering from or susceptible to a metalloenzyme-mediated disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-mediated disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of Formula I, such that said subject is treated for said disorder.

30 In certain embodiments, provided are methods of treating a disease, disorder or symptom thereof, wherein the disorder is cancer, cardiovascular disease, endocrinologic disease, inflammatory disease, infectious disease, gynecologic disease, metabolic disease,

ophthalmologic disease, central nervous system (CNS) disease, urologic disease, or gastrointestinal disease. In certain embodiments the disease is hypertension, resistant hypertension, morbidities associated with primary or secondary hyperaldosteronism and adrenal hyperplasia, pulmonary arterial hypertension, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, systolic heart failure, hypokalemia, renal failure, chronic renal failure, restenosis, nephropathy, post-myocardial infarction, coronary heart disease, fibrosis, diseases characterized by increased collagen formation, fibrosis and matrix remodeling following hypertension, fibrosis and matrix remodeling following endothelial cell dysfunction, cardiovascular diseases such as atherosclerosis, atrial fibrillation, renal dysfunction, liver diseases, non-alcoholic steatohepatitis, vascular diseases, retinopathy, neuropathy, insulinopathy, endothelial dysfunction, myocardial fibrosis, vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, vascular wall hypertrophy, endothelial thickening, fibrinoid necrosis of the arteries, kidney diseases, diabetic nephropathy, glomerulosclerosis, glomerulonephritis, nephritic syndrome, polycystic kidney disease, diabetes mellitus, metabolic syndrome, insulin resistance, sleep apnea, obstructive sleep apnea, muscular dystrophy, liver cirrhosis, non-alcoholic fatty liver disease, renal disorders, diabetic renal disorders, or stroke.

In certain embodiments, the subject is a mammal, preferably a primate or human.

In another embodiment, provided are methods as described above, wherein the effective amount of the compound of Formula **I** is as described above.

In another embodiment, provided are methods as described above, wherein the compound of Formula **I** is administered intravenously, intramuscularly, subcutaneously, intracerebroventricularly, orally or topically.

In another embodiment, provided are methods as described herein wherein the compound of Formula **I** demonstrates selectivity for an activity range against a target enzyme (e.g., aldosterone synthase (CYP11B2)  $IC_{50} < 1.0 \mu M$ ).

In other embodiments, provided are methods as described above, wherein the compound of Formula **I** is administered alone or in combination with one or more other therapeutics. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, antifungal agent, cardiovascular agent, anti-inflammatory agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent, metabolic disease agent,

ophthalmologic disease agent, central nervous system (CNS) disease agent, urologic disease agent, or gastrointestinal disease agent.

In certain embodiments, the additional therapeutic agent is an agent for the treatment of hypertension, agent for the treatment of primary aldosteronism, agent for the treatment of kidney disease, agent for the treatment of congestive heart failure, agent for the treatment of atherosclerotic conditions, agent for the treatment of diabetes, agent for the treatment of obesity, or agent for the treatment of metabolic disease.

Exemplary additional therapeutic agents include, but are not limited to, renin inhibitors, angiotensin converting enzyme (ACE) inhibitors, dual inhibitors of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), angiotensin II receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), neutral endopeptidase inhibitors (NEP), neprilysin inhibitors, calcium channel blockers, alpha-adrenergic blockers, beta-adrenergic blockers, diuretics (including loop diuretics), potassium channel activators, endothelin receptor antagonists, endothelin 1 receptor agonists, soluble guanylate cyclase stimulators, vasodilators, HMG-CoA reductase inhibitors, niacin and niacin receptor agonists, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, insulin or insulin analogs, biguanides (e.g., metformin), sulfonylureas, peroxisome proliferator-activated receptor (PPAR) agonists and partial agonists including PPAR $\gamma$  agonists and other PPAR ligands, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP-1), GLP-1 receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Another object of the present disclosure is the use of a compound as described herein (e.g., a compound of Formula I) in the manufacture of a medicament for use in the treatment of a metalloenzyme-mediated disorder or disease. Another object of the present disclosure is the use of a compound as described herein (e.g., a compound of Formula I) for use in the treatment of a metalloenzyme-mediated disorder or disease. Another object of the present disclosure is the use of a compound as described herein (e.g., a compound of Formula I) in the manufacture of an agricultural composition for use in the treatment or prevention of a metalloenzyme-mediated disorder or disease in agricultural or agrarian settings.

### Pharmaceutical Compositions

In one aspect, provided are pharmaceutical compositions comprising the compound of Formula I and a pharmaceutically acceptable carrier.

In another embodiment, provided are pharmaceutical compositions further comprising an additional therapeutic agent. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, antifungal agent, cardiovascular agent, anti-inflammatory agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent, metabolic disease agent, ophthalmologic disease agent, central nervous system (CNS) disease agent, urologic disease agent, or gastrointestinal disease agent.

In certain embodiments, the additional therapeutic agent is an agent for the treatment of hypertension, agent for the treatment of primary aldosteronism, agent for the treatment of kidney disease, agent for the treatment of congestive heart failure, agent for the treatment of atherosclerotic conditions, agent for the treatment of diabetes, agent for the treatment of obesity, or agent for the treatment of metabolic disease.

Exemplary additional therapeutic agents include, but are not limited to, renin inhibitors, angiotensin converting enzyme (ACE) inhibitors, dual inhibitors of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), angiotensin II receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), neutral endopeptidase inhibitors (NEP), neprilysin inhibitors, calcium channel blockers, alpha-adrenergic blockers, beta-adrenergic blockers, diuretics (including loop diuretics), potassium channel activators, endothelin receptor antagonists, endothelin 1 receptor agonists, soluble guanylate cyclase stimulators, vasodilators, HMG-CoA reductase inhibitors, niacin and niacin receptor agonists, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, insulin or insulin analogs, biguanides (e.g., metformin), sulfonylureas, peroxisome proliferator-activated receptor (PPAR) agonists and partial agonists including PPAR $\gamma$  agonists and other PPAR ligands, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP-1), GLP-1 receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

In one aspect, provided are kits comprising an effective amount of a compound of Formula I, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a metalloenzyme-mediated disease or disorder, including cancer, cardiovascular disease, endocrinologic disease, inflammatory disease, infectious disease, gynecologic disease, metabolic disease, ophthalmologic disease, central nervous system (CNS) disease, urologic disease, or gastrointestinal disease. In other embodiments, the disease, disorder or symptom thereof is hypertension, resistant hypertension, morbidities associated with primary or secondary hyperaldosteronism and

adrenal hyperplasia, pulmonary arterial hypertension, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, systolic heart failure, hypokalemia, renal failure, chronic renal failure, restenosis, nephropathy, post-myocardial infarction, coronary heart disease, fibrosis, diseases characterized by increased collagen formation, fibrosis and matrix remodeling following hypertension, fibrosis and matrix remodeling following endothelial cell dysfunction, cardiovascular diseases such as atherosclerosis, atrial fibrillation, renal dysfunction, liver diseases, non-alcoholic steatohepatitis, vascular diseases, retinopathy, neuropathy, insulinopathy, endothelial dysfunction, myocardial fibrosis, vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, vascular wall hypertrophy, endothelial thickening, fibrinoid necrosis of the arteries, kidney diseases, diabetic nephropathy, glomerulosclerosis, glomerulonephritis, nephritic syndrome, polycystic kidney disease, diabetes mellitus, metabolic syndrome, insulin resistance, sleep apnea, obstructive sleep apnea, muscular dystrophy, liver cirrhosis, non-alcoholic fatty liver disease, renal disorders, diabetic renal disorders, or stroke.

The term "pharmaceutically acceptable salts" or "pharmaceutically acceptable carrier" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also

included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present disclosure.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

In addition to salt forms, the present disclosure provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.

The present disclosure also provides a pharmaceutical composition, comprising an effective amount a compound described herein and a pharmaceutically acceptable carrier. In an embodiment, a compound of Formula I is administered to a subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.

Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic (or unacceptably toxic) to the patient.

In use, at least one compound according to the present disclosure is administered in a pharmaceutically effective amount to a subject in need thereof in a pharmaceutical carrier by intravenous, intramuscular, subcutaneous, or intracerebroventricular injection or by oral administration or topical application. In accordance with the present disclosure, a compound of the disclosure may be administered alone or in conjunction with a second, different therapeutic. By "in conjunction with" is meant together, substantially simultaneously or sequentially. In one embodiment, a compound of the disclosure is administered acutely. The compound of the disclosure may therefore be administered for a short course of treatment, such as for about 1 day to about 1 week. In another embodiment, the compound of the disclosure may be administered over a longer period of time to ameliorate chronic disorders, such as, for example, for about one week to several months depending upon the condition to be treated.

By "pharmaceutically effective amount" as used herein is meant an amount of a compound of the disclosure, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A pharmaceutically effective amount of a compound of the disclosure will vary with the particular goal to be achieved, the age and physical condition of the patient being treated, the severity of the underlying disease, the duration of treatment, the nature of concurrent therapy and the specific compound employed. For example, a therapeutically effective amount of a compound of the disclosure administered to a child or a neonate will be reduced proportionately in accordance with sound medical judgment. The effective amount of a compound of the disclosure will thus be the minimum amount which will provide the desired effect.

A decided practical advantage of the present disclosure is that the compound may be administered in a convenient manner such as by intravenous, intramuscular, subcutaneous, oral or intra-cerebroventricular injection routes or by topical application, such as in creams or gels. Depending on the route of administration, the active ingredients which comprise a

compound of the disclosure may be required to be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. In order to administer a compound of the disclosure by other than parenteral administration, the compound can be coated by, or administered with, a material to prevent inactivation.

The compound may be administered parenterally or intraperitoneally. Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.

Some examples of substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetates; powdered tragacanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives, can also be present. Solubilizing agents, including for example, cremaphore and beta-cyclodextrins can also be used in the pharmaceutical compositions herein.

Pharmaceutical compositions comprising the active compounds of the present disclosure (or prodrugs thereof) can be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes. The compositions can be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.

Pharmaceutical compositions of the present disclosure subject matter can take a form suitable for virtually any mode of administration, including, for example, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, and the like, or a form suitable for administration by inhalation or insufflation.

For topical administration, the active compound(s) or prodrug(s) can be formulated as solutions, gels, ointments, creams, suspensions, and the like.

Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral, or pulmonary administration.

Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles. The compositions also can contain formulating agents, such as suspending, stabilizing and/or dispersing agent. The formulations for injection can be presented in unit dosage form (e.g., in ampules or in multidose containers) and can contain added preservatives.

Alternatively, the injectable formulation can be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, and the like, before use. To this end, the active compound(s) can be dried by any art-known technique, such as lyophilization, and reconstituted prior to use.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.

For oral administration, the pharmaceutical compositions can take the form of, for example, lozenges, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets can be coated by methods well known in the art with, for example, sugars or enteric coatings.

Liquid preparations for oral administration can take the form of, for example, elixirs, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or

sorbic acid). The preparations also can contain buffer salts, preservatives, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration can be suitably formulated to give controlled release of the active compound or prodrug, as is well known.

5 For buccal administration, the compositions can take the form of tablets or lozenges formulated in a conventional manner.

For rectal and vaginal routes of administration, the active compound(s) can be formulated as solutions (for retention enemas), suppositories, or ointments containing conventional suppository bases, such as cocoa butter or other glycerides.

10 For nasal administration or administration by inhalation or insufflation, the active compound(s) or prodrug(s) can be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, fluorocarbons, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can  
15 be determined by providing a valve to deliver a metered amount. Capsules and cartridges for use in an inhaler or insufflator (for example capsules and cartridges comprised of gelatin) can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

A specific example of an aqueous suspension formulation suitable for nasal  
20 administration using commercially-available nasal spray devices includes the following ingredients: active compound or prodrug (0.5-20 mg/ml); benzalkonium chloride (0.1-0.2 mg/mL); polysorbate 80 (TWEEN<sup>®</sup> 80; 0.5-5 mg/ml); carboxymethylcellulose sodium or microcrystalline cellulose (1-15 mg/ml); phenylethanol (1-4 mg/ml); and dextrose (20-50 mg/ml). The pH of the final suspension can be adjusted to range from about pH5 to pH7, with  
25 a pH of about pH 5.5 being typical.

For ocular administration, the active compound(s) or prodrug(s) can be formulated as a solution, emulsion, suspension, and the like, suitable for administration to the eye. A variety of vehicles suitable for administering compounds to the eye are known in the art. Specific non-limiting examples are described in U.S. Patent No. 6,261,547; U.S. Patent No. 6,197,934;  
30 U.S. Patent No. 6,056,950; U.S. Patent No. 5,800,807; U.S. Patent No. 5,776,445; U.S. Patent No. 5,698,219; U.S. Patent No. 5,521,222; U.S. Patent No. 5,403,841; U.S. Patent No.

5,077,033; U.S. Patent No. 4,882,150; and U.S. Patent No. 4,738,851, each of which is incorporated herein by reference in its entirety.

For prolonged delivery, the active compound(s) or prodrug(s) can be formulated as a depot preparation for administration by implantation or intramuscular injection. The active  
5 ingredient can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., as a sparingly soluble salt. Alternatively, transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the active compound(s) for percutaneous absorption can be used. To this end, permeation enhancers can be used to facilitate  
10 transdermal penetration of the active compound(s). Suitable transdermal patches are described in for example, U.S. Patent No. 5,407,713; U.S. Patent No. 5,352,456; U.S. Patent No. 5,332,213; U.S. Patent No. 5,336,168; U.S. Patent No. 5,290,561; U.S. Patent No. 5,254,346; U.S. Patent No. 5,164,189; U.S. Patent No. 5,163,899; U.S. Patent No. 5,088,977; U.S. Patent No. 5,087,240; U.S. Patent No. 5,008,110; and U.S. Patent No. 4,921,475, each of  
15 which is incorporated herein by reference in its entirety.

Alternatively, other pharmaceutical delivery systems can be employed. Liposomes and emulsions are well-known examples of delivery vehicles that can be used to deliver active compound(s) or prodrug(s). Certain organic solvents such as dimethylsulfoxide (DMSO) also can be employed.

20 The pharmaceutical compositions can, if desired, be presented in a pack or dispenser device which can contain one or more unit dosage forms containing the active compound(s). The pack can, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.

The active compound(s) or prodrug(s) of the present disclosure, or compositions  
25 thereof, will generally be used in an amount effective to achieve the intended result, for example in an amount effective to treat or prevent the particular disease being treated. The compound(s) can be administered therapeutically to achieve therapeutic benefit or prophylactically to achieve prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of  
30 one or more of the symptoms associated with the underlying disorder such that the patient reports an improvement in feeling or condition, notwithstanding that the patient can still be afflicted with the underlying disorder. For example, administration of a compound to a patient

suffering from an allergy provides therapeutic benefit not only when the underlying allergic response is eradicated or ameliorated, but also when the patient reports a decrease in the severity or duration of the symptoms associated with the allergy following exposure to the allergen. As another example, therapeutic benefit in the context of asthma includes an improvement in respiration following the onset of an asthmatic attack, or a reduction in the frequency or severity of asthmatic episodes. Therapeutic benefit also includes halting or slowing the progression of the disease, regardless of whether improvement is realized.

For prophylactic administration, the compound can be administered to a patient at risk of developing one of the previously described diseases. A patient at risk of developing a disease can be a patient having characteristics placing the patient in a designated group of at risk patients, as defined by an appropriate medical professional or group. A patient at risk may also be a patient that is commonly or routinely in a setting where development of the underlying disease that may be treated by administration of a metalloenzyme inhibitor according to the present disclosure could occur. In other words, the at risk patient is one who is commonly or routinely exposed to the disease or illness causing conditions or may be acutely exposed for a limited time. Alternatively, prophylactic administration can be applied to avoid the onset of symptoms in a patient diagnosed with the underlying disorder.

The amount of compound administered will depend upon a variety of factors, including, for example, the particular indication being treated, the mode of administration, whether the desired benefit is prophylactic or therapeutic, the severity of the indication being treated and the age and weight of the patient, the bioavailability of the particular active compound, and the like. Determination of an effective dosage is well within the capabilities of those skilled in the art.

Effective dosages can be estimated initially from *in vitro* assays. For example, an initial dosage for use in animals can be formulated to achieve a circulating blood or serum concentration of active compound that is at or above an IC<sub>50</sub> of the particular compound as measured in as *in vitro* assay, such as the *in vitro* fungal MIC or MFC and other *in vitro* assays described in the Examples section. Calculating dosages to achieve such circulating blood or serum concentrations taking into account the bioavailability of the particular compound is well within the capabilities of skilled artisans. For guidance, see Fingl & Woodbury, "General Principles," In: *Goodman and Gilman's The Pharmaceutical Basis of Therapeutics*, Chapter 1,

pp. 1-46, latest edition, Pagamonon Press, and the references cited therein, which are incorporated herein by reference.

Initial dosages also can be estimated from *in vivo* data, such as animal models. Animal models useful for testing the efficacy of compounds to treat or prevent the various diseases described above are well-known in the art.

Dosage amounts will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, but can be higher or lower, depending upon, among other factors, the activity of the compound, its bioavailability, the mode of administration, and various factors discussed above. Dosage amount and interval can be adjusted individually to provide plasma levels of the compound(s) which are sufficient to maintain therapeutic or prophylactic effect. In cases of local administration or selective uptake, such as local topical administration, the effective local concentration of active compound(s) cannot be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation.

The compound(s) can be administered once per day, a few or several times per day, or even multiple times per day, depending upon, among other things, the indication being treated and the judgment of the prescribing physician.

Preferably, the compound(s) will provide therapeutic or prophylactic benefit without causing substantial toxicity. Toxicity of the compound(s) can be determined using standard pharmaceutical procedures. The dose ratio between toxic and therapeutic (or prophylactic) effect is the therapeutic index. Compounds(s) that exhibit high therapeutic indices are preferred.

The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

### Examples

In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope.

General Experimental Procedures

Definitions of variables in the structures in schemes herein are commensurate with those of corresponding positions in the formulae delineated herein. The example compounds listed in Table 2 were characterized by the HPLC and LCMS methods described in Table 1.

Table 1. HPLC and LCMS methods

|   | HPLC                                                                                                    | LCMS                                                                                                                                                   |
|---|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| a | Column: ZORBAX-SCB-C18 (150 X 4.6 mm, 3.5 μ); ACN: 0.05% Aq TFA; 1.0 mL/min                             | Column: X-Select CSH C-18 (50 × 3.0 mm, 2.5 μm); 2.5mM NH <sub>4</sub> OOCH in water: 5% ACN; ACN: 5% 2.5mM NH <sub>4</sub> OOCH in water: 0.80 mL/min |
| b | Column: X-Select-CSH-C18 (150 X 4.6 mm, 3.5 μm); 0.05% TFA+5%ACN: ACN+5% 0.05% TFA; 1.0 mL/min          | Column: Kinotex EVO C-18 (50 × 3.0 mm, 2.6 μm); 2.5mM NH <sub>4</sub> OOCH in water: 5% ACN; ACN: 5% 2.5mM NH <sub>4</sub> OOCH in water: 0.80 mL/min  |
| c | Column: X-Select-CSH-C18 (150 X 4.6 mm, 3.5 μm); 5mM NH <sub>4</sub> OAc: ACN; 1.0 mL/min.              | Column: Ascentis Express C-18 (50 × 3.0 mm, 2.7 μm); 0.025% Aq TFA+5%ACN: ACN: 5% 0.025% Aq TFA: 1.2 mL/min                                            |
| d | Column: X-Select-CSH-C18 (150 X 4.6 mm, 3.5 μm); 5mM NH <sub>4</sub> CO <sub>3</sub> : ACN; 1.0 mL/min. | Column: X-Select CSH C-18 (50 × 3.0 mm, 2.5 μm); 2.5mM Aq NH <sub>4</sub> OAc: ACN; 0.80 mL/min                                                        |
| e | Column: Atlantis-T3 (150 X 4.6 mm, 3.0 μm); 5mM NH <sub>4</sub> OAc: ACN; 1.0 mL/min.                   | Column: Kinotex EVO C-18 (50 × 3.0 mm, 2.6 μm); 2.5mM Aq NH <sub>4</sub> OAc: ACN: 0.80 mL/m                                                           |

Common abbreviations:


|       |                                             |
|-------|---------------------------------------------|
| ACN   | acetonitrile                                |
| br    | broad                                       |
| d     | doublet                                     |
| dd    | doublet of doublets                         |
| dba   | dibenzylideneacetone                        |
| DIPEA | diisopropylethylamine                       |
| dppf  | 1,1'-ferrocenediyl-bis(diphenylphosphine)   |
| h     | hour(s)                                     |
| HRMS  | high resolution mass spectrometry           |
| HPLC  | high performance liquid chromatography      |
| LCMS  | liquid chromatography and mass spectrometry |
| MS    | mass spectrometry                           |
| MW    | microwave                                   |
| m     | multiplet                                   |
| min   | minutes                                     |

|            |                            |
|------------|----------------------------|
| mL         | milliliter(s)              |
| m/z        | mass to charge ratio       |
| NMR        | nuclear magnetic resonance |
| ppm        | parts per million          |
| 5 rt or RT | room temperature           |
| s          | singlet                    |
| t          | triplet                    |
| TLC        | thin layer chromatography  |

10

### Preparation of Int-1

#### Scheme:



#### ***N*-Cyclopropyl-5-fluoro-2-nitroaniline**

15 To a stirred solution of 2,4-difluoro-1-nitrobenzene (25 g, 157.23 mmol) in potassium fluoride (9.12 g, 157.23 mmol) under an inert atmosphere was added potassium carbonate (21.7 g, 157.23 mmol) followed by cyclopropanamine (10.75 g, 188.68 mmol) drop wise at room temperature. The reaction mixture was stirred at room temperature for 2 h. After consumption of starting material was demonstrated by thin layer chromatography (TLC), the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (EtOAc) (2 x 200 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to afford *N*-cyclopropyl-5-fluoro-2-nitroaniline (26 g, 132.65 mmol, 84%) as yellow solid.

25 <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>): δ 8.20 (dd, *J* = 9.3, 6.1 Hz, 1H), 6.95 (dd, *J* = 11.4, 2.7 Hz, 1H), 6.45-6.39 (m, 1H), 2.59-2.53 (m, 1H), 0.97-0.92 (m, 2H), 0.71-0.65 (m, 2H).

#### ***N*<sup>1</sup>-Cyclopropyl-5-fluorobenzene-1, 2-diamine (Int-1)**

30 To a stirred solution of *N*-cyclopropyl-5-fluoro-2-nitroaniline (24 g, 122.45 mmol) in methanol (MeOH) (300 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 2.4 g) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 8 h. After consumption of starting material (by TLC), the


reaction mixture was filtered through a pad of celite and washed with methanol (100 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclopropyl-5-fluorobenzene-1,2-diamine **Int-1** (18 g, 108.43 mmol, 88%) as brown syrup.

<sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>): δ 6.52 (dd, *J* = 11.6, 2.8 Hz, 1H), 6.45 (dd, *J* = 8.4, 6.0 Hz, 1H), 6.18 (td, *J* = 8.5, 2.9 Hz, 1H), 5.28 (s, 1H), 4.30 (br s, 2H), 2.36-2.28 (m, 1H), 0.74-0.68 (m, 2H), 0.42-0.37 (m, 2H).

LC-MS: *m/z* 166.8 [M+H]<sup>+</sup> at 1.64 RT (72.46% purity).

### Preparation of Int-2

#### 10 Scheme:



#### (5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanol

To a stirred solution of methyl 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (250 mg, 0.8 mmol) in a mixture of methanol/tetrahydrofuran (THF) (2:1, 15 mL) under an inert atmosphere was added sodium borohydride (152 mg, 4.01 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was concentrated under reduced pressure. The residue was diluted with water (25 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl) methanol (130 mg, 0.46 mmol, 57%) as brown solid used in the next step without further purification.

LC-MS: *m/z* 284.9 [M+H]<sup>+</sup> at 1.94 RT (72.20% purity).

#### 25 **5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde (Int-2)**

To a stirred solution of (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methanol (130 mg, 0.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added Dess-Martin periodinane (DMP) (291 mg, 0.69 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by


TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-2** (50 mg, 0.18 mmol, 39%) as brown solid.

<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>): δ 10.50 (s, 1H), 10.06 (d, *J* = 2.0 Hz, 1H), 8.64 (d, *J* = 2.3 Hz, 1H), 7.80 (dd, *J* = 8.8, 4.8 Hz, 1H), 7.34 (dd, *J* = 8.4, 2.3 Hz, 1H), 7.13 (td, *J* = 9.3, 2.3 Hz, 1H), 3.73-3.69 (m, 1H), 1.37-1.31 (m, 2H), 0.90-0.85 (m, 2H).

LC-MS: *m/z* 282.9 [M+H]<sup>+</sup> at 1.85 RT (90.42% purity).

### Preparation of Int-3

#### Scheme:



**(*E*)-5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbaldehyde oxime**

To a stirred solution of 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-2** (100 mg, 0.35 mmol) in ethanol (EtOH) (2 mL) under an inert atmosphere was added hydroxylamine hydrochloride (49 mg, 0.71 mmol) and potassium carbonate (98 mg, 0.71 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was concentrated under reduced pressure. The residue was diluted with water (40 mL) and stirred for 10 min. The precipitated solid was filtered, washed with water (10 mL) and dried under vacuum to afford (*E*)-5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde oxime (70 mg, 0.23 mmol, 67%) as an off white solid.

<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>): δ 12.25 (s, 1H), 9.81 (s, 1H), 8.56 (s, 1H), 8.48 (s, 1H), 7.80 (dd, *J* = 8.7, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.0, 1.7 Hz, 1H), 7.20 (td, *J* = 9.8, 2.3 Hz, 1H), 3.95-3.89 (m, 1H), 1.20-1.16 (m, 2H), 0.84-0.79 (m, 2H).

LC-MS: *m/z* 297.9 [M+H]<sup>+</sup> at 1.95 RT (99.11% purity).

**(5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanamine (Int-3)**


To a stirred solution of (*E*)-5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbaldehyde oxime (70 mg, 0.23 mmol) in ethanol (5 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 25 mg) at room temperature. The reaction mixture was evacuated and stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with MeOH/CH<sub>2</sub>Cl<sub>2</sub> (10:1, 20 mL). The filtrate was concentrated under reduced pressure to obtain (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanamine **Int-3** (50 mg, crude) as an off white solid used in the next step without further purification.

**LC-MS:** *m/z* 283.9 [M+H]<sup>+</sup> at 1.62 RT (64.40% purity).

15

**Preparation of Int-4**

**Scheme:**



**3-(Ethylamino)-4-nitrobenzonitrile**

To a stirred solution of 3-fluoro-4-nitrobenzonitrile (2 g, 12.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) under an inert atmosphere was added potassium carbonate (3.32 g, 24.09 mmol) and ethylamine (Aq. 70%, 2.17 g, 48.19 mmol) at room temperature. The reaction mixture was stirred at room temperature for 6 h. After consumption of starting material (by TLC), the reaction mixture was quenched with water (60 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 3-(ethylamino)-4-nitrobenzonitrile (1.9 g, crude) as yellow solid used in next step without further purification.


**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 8.22-8.10 (m, 2H), 7.58 (br s, 1H), 7.00 (br d, *J* = 8.7 Hz, 1H), 3.48-3.38 (m, 2H), 1.21 (br t, *J* = 6.9 Hz, 3H).

**LC-MS:** *m/z* 192.1 [M+H]<sup>+</sup> at 4.10 RT (98.96% purity).

**4-Amino-3-(ethylamino) benzonitrile (Int-4)**

To a stirred solution of 3-(ethylamino)-4-nitrobenzonitrile (1.9 g, crude) in ethanol (20 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 190 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with methanol (50 mL) and EtOAc (30 mL). The filtrate was concentrated under reduced pressure to obtain 4-amino-3-(ethylamino) benzonitrile **Int-4** (1.5 g, crude) as an off white solid used in next step without further purification.

**LC-MS:**  $m/z$  161.9  $[M+H]^+$  at 2.11 RT (60.88% purity).

**Preparation of Int-5****Scheme:*****N*-Cyclopropyl-4, 5-difluoro-2-nitroaniline**

To 1, 2, 4-trifluoro-5-nitrobenzene (500 mg, 2.82 mmol) in potassium fluoride (164 mg, 2.82 mmol) under an inert atmosphere was added potassium carbonate (390 mg, 2.82 mmol) and cyclopropanamine (0.23 mL, 3.39 mmol) drop wise at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-cyclopropyl-4, 5-difluoro-2-nitroaniline **2** (320 mg, crude) as pale yellow solid used in next step without further purification.

**LC-MS:**  $m/z$  215.4  $[M+H]^+$  at 4.43 RT (69.03% purity).

***N*<sup>1</sup>-Cyclopropyl-4, 5-difluorobenzene-1, 2-diamine (Int-5)**


To a stirred solution of *N*-cyclopropyl-4, 5-difluoro-2-nitroaniline (300 mg, 1.4 mmol) in EtOAc (10 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 30 mg) at room

temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 4 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with methanol (15 mL) and EtOAc (10 mL). The filtrate was concentrated under reduced pressure to obtain *N*<sup>1</sup>-cyclopropyl-4, 5-difluorobenzene-1, 2-diamine **Int-5** (100 mg, crude) as brown viscous syrup used in next step without further purification.

**LC-MS:** *m/z* 184.9 [M+H]<sup>+</sup> at 2.12 RT (83.53% purity).

### Preparation of Int-6 & Int-7

#### Scheme:



#### **3-(Cyclopropylamino)-4-nitrobenzonitrile**

To a stirred solution of 3-fluoro-4-nitrobenzonitrile (1 g, 6.02 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under an inert atmosphere was added potassium carbonate (1.66 g, 12.05 mmol) and cyclopropanamine (3.33 mL, 48.19 mmol) drop wise at room temperature. The reaction mixture was stirred at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 3-(cyclopropylamino)-4-nitrobenzonitrile (900 mg, crude) as yellow solid used in next step without further purification.

**<sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>):** δ 8.24 (d, *J* = 8.7 Hz, 1H), 8.07 (br s, 1H), 7.64 (d, *J* = 1.7 Hz, 1H), 6.93 (dd, *J* = 8.7, 1.7 Hz, 1H), 2.62-2.57 (m, 1H), 1.03-0.97 (m, 2H), 0.72-0.67 (m, 2H).

**LC-MS:** *m/z* 201.9 [M-H]<sup>+</sup> at 3.25 RT (99.61% purity).

#### **4-Amino-3-(cyclopropylamino) benzonitrile (Int-6)**

To a stirred of solution of 3-(cyclopropylamino)-4-nitrobenzonitrile (900 mg, 4.43 mmol) in ethanol (10 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 500 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the

reaction mixture was filtered through a pad of celite and washed with EtOAc (30 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 4-amino-3-(cyclopropylamino) benzonitrile **Int-6** (500 mg, 2.89 mmol, 65%) as an off white solid.

- 5 <sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>): δ 6.93 (d, *J* = 1.9 Hz, 1H), 6.87 (dd, *J* = 8.0, 1.9 Hz, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 5.49 (s, 2H), 5.43 (s, 1H), 2.40-2.34 (m, 1H), 0.77-0.71 (m, 2H), 0.42-0.37 (m, 2H).

### 1-Cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (**Int-7**)


- 10 A solution of 4-amino-3-(cyclopropylamino) benzonitrile **Int-6** (500 mg, 2.89 mmol) in formic acid (5 mL) under an inert atmosphere was heated to reflux temperature and stirred for 5 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with water (10 mL), neutralized with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined  
15 organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile **Int-7** (250 mg, 1.37 mmol, 56%) as an off white solid.

- <sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>): δ 8.50 (s, 1H), 8.21 (d, *J* = 0.9 Hz, 1H), 7.82 (d, *J* = 8.1 Hz, 1H), 7.62 (dd, *J* = 8.4, 1.4 Hz, 1H), 3.59-3.54 (m, 1H), 1.15-1.05 (m, 4H).

LC-MS: *m/z* 184.0 [M+H]<sup>+</sup> at 2.46 RT (87.33% purity).

### Preparation of Int-8

#### Scheme:



25

### 6-Chloro-*N*-cyclopropyl-3-nitropyridin-2-amine

To a stirred solution of 2, 6-dichloro-3-nitropyridine (5 g, 26.04 mmol) in Toluene (25 mL) under an inert atmosphere was added cyclopropyl amine (3.7 mL, 52.08 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was warmed to room

temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/Hexane) to afford 6-chloro-*N*-cyclopropyl-3-nitropyridin-2-amine (4 g, 18.77 mmol, 72%) as a pale yellow solid.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.34 (d, *J* = 8.7 Hz, 2H), 6.66 (d, *J* = 8.7 Hz, 1H), 3.10-3.05 (m, 1H), 0.97-0.93 (m, 2H), 0.67-0.64 (m, 2H)

#### 10 **6-Chloro-*N*2-cyclopropylpyridine-2, 3-diamine (Int-8)**


To a stirred solution of 6-chloro-*N*-cyclopropyl-3-nitropyridin-2-amine (1 g, 4.69 mmol) in EtOH: water (1: 1, 10 mL) under an inert atmosphere was added iron (1.3 g, 23.47 mmol) and ammonium chloride (1.2 g, 23.47 mmol) at room temperature. The reaction mixture was heated to 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 6-chloro-*N*2-cyclopropylpyridine-2, 3-diamine **Int-8** (700 mg, crude) as a pale yellow solid used in the next step without further purification.

**LC-MS:** *m/z* 183.9 [M+H]<sup>+</sup> at 2.07 RT (58.13% purity).

20

#### **Preparation of Int-9**

##### **Scheme:**



#### ***N*-Cyclopropyl-6-methoxy-3-nitropyridin-2-amine**

25 To a stirred solution of 2-chloro-6-methoxy-3-nitropyridine (5 g, 26.5 mmol) in toluene (50 mL) under an inert atmosphere was added cyclopropyl amine (3.69 mL, 53 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and warmed to room temperature and stirred for 6 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were

washed with brine (20 mL), dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was triturated with *n*-pentane to afford *N*-cyclopropyl-6-methoxy-3-nitropyridin-2-amine (800 mg, 3.82 mmol, 83%) as a yellow solid.

### 5 ***N*<sup>2</sup>-Cyclopropyl-6-methoxypyridine-2,3-diamine (Int-9)**


To a stirred solution of *N*-cyclopropyl-6-methoxy-3-nitropyridin-2-amine (1 g, 4.78 mmol) in ethanol/water (1: 1, 10 mL) was added iron powder (1.3 g, 24 mmol) and ammonium chloride (1.29 g, 23.9 mmol) at room temperature. The reaction mixture was heated to 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a  
 10 pad of *celite* and the *celite* bed was washed with EtOAc (50 mL). The filtrate was concentrated under reduced pressure to obtain *N*<sup>2</sup>-cyclopropyl-6-methoxypyridine-2,3-diamine **Int-9** (150 mg) as black liquid. The crude material was used in next step without further purification.

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 6.71 (d, *J* = 7.9 Hz, 1H), 5.78 (d, *J* = 7.9 Hz, 1H), 4.09-  
 15 4.06 (m, 2H), 3.84-3.81 (m, 1H), 3.70 (s, 3H), 2.77-2.68 (m, 1H), 0.69-0.61 (m, 2H), 0.43-0.37 (m, 2H)

LC-MS: *m/z* 180.1 [M+H]<sup>+</sup> at 2.11 RT (75.36% purity)

### **Preparation of Int-10**

#### 20 **Scheme:**



#### ***N*-Ethyl-4,5-difluoro-2-nitroaniline**

To a stirred solution of 1,2,4-trifluoro-5-nitrobenzene (2 g, 11.29 mmol) in  $\text{CH}_2\text{Cl}_2$  (10 mL) was added potassium carbonate (3.1 g, 22.59 mmol) and ethanamine (559 mg, 12.42 mmol) at  
 25 room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  (2 x 100 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified

by silica gel column chromatography (eluent: 10% EtOAc/hexane) to afford *N*-ethyl-4,5-difluoro-2-nitroaniline (800 mg, 3.96 mmol, 35%) as yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 8.19 (brs, 1H), 8.13 (dd, *J* = 11.0, 8.7 Hz, 1H), 7.14 (dd, *J* = 13.9, 7.0 Hz, 1H), 3.40-3.33 (m, 2H), 1.20 (t, *J* = 7.2 Hz, 3H)

5 **LC-MS:** *m/z* 203.1 [M+H]<sup>+</sup> at 3.53 RT (98.40% purity)

### ***N*<sup>1</sup>-Ethyl-4,5-difluorobenzene-1,2-diamine (Int-10)**

To a stirred solution of *N*-ethyl-4,5-difluoro-2-nitroaniline (800 mg, 3.96 mmol) in ethylacetate (5 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 500 mg) at  
10 room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with EtOAc (50 mL). The filtrate was concentrated under reduced pressure to obtain *N*<sup>1</sup>-ethyl-4,5-difluorobenzene-1,2-diamine **Int-10** (500 mg, 2.90 mmol, 73%) as a black liquid which was  
15 used in the next step without further purification.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.47 (dd, *J* = 12.8, 8.1 Hz, 1H), 6.30 (dd, *J* = 13.3, 8.1 Hz, 1H), 4.64 (br s, 2H), 4.44 (t, *J* = 5.2 Hz, 1H), 3.00-2.94 (m, 2H), 1.17 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 173.2 [M+H]<sup>+</sup> at 3.16 RT (64.65% purity)

20

### **Preparation of Int-11**

#### **Scheme:**



### **6-Chloro-*N*-ethyl-3-nitropyridin-2-amine**

To a stirred solution of 2,6-dichloro-3-nitropyridine (2 g, 10.40 mmol) in toluene (8.5 mL)  
25 under an inert atmosphere was added ethylamine (1.35 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column

chromatography (eluent: 2% EtOAc/hexane) to afford 6-chloro-*N*-ethyl-3-nitropyridin-2-amine (800 mg, 3.98 mmol, 38%) as yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 8.70 (brs, 1H), 8.40 (d, *J* = 7.5 Hz, 1H), 6.75 (d, *J* = 8.1 Hz, 1H), 3.55-3.50 (m, 2H), 1.18 (t, *J* = 7.0 Hz, 3H)

5 **LC-MS:** *m/z* 202 [M+H]<sup>+</sup> at 2.63 RT (99.85% purity)

### 6-Chloro-*N*<sup>2</sup>-ethylpyridine-2,3-diamine (Int-11)

To a stirred solution of 6-chloro-*N*-ethyl-3-nitropyridin-2-amine (550 mg, 2.73 mmol) in ethanol/water (1: 1, 20 mL) was added iron powder (763.4 g, 13.68 mmol) and ammonium chloride (738.7 mg, 13.68 mmol) at room temperature. The reaction mixture was heated to 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 6-chloro-*N*<sup>2</sup>-ethylpyridine-2,3-diamine **Int-11** (452 mg) as a black solid. The crude material was used in the next step without further purification.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.67 (d, *J* = 7.5 Hz, 1H), 6.33 (d, *J* = 8.1 Hz, 1H), 5.85 (brs, 1H), 4.88 (br s, 2H), 3.37-3.25 (m, 2H), 1.15 (t, *J* = 7.0 Hz, 3H)

**LC-MS:** *m/z* 172 [M+H]<sup>+</sup> at 1.72 RT (85.88% purity)

20

### Preparation of Int-12

#### Scheme:



### 4,5-Difluoro-2-nitroaniline

To a stirred solution of 1,2,4-trifluoro-5-nitrobenzene (5 g, 28.24 mmol) in methanol (5 mL) under an inert atmosphere was added methanolic ammonia (15 mL) at 0 °C. The reaction mixture was heated to 90 °C and stirred for 2 h in a sealed tube. After consumption of starting material (by TLC), the reaction mixture was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% EtOAc/hexane) to afford 4,5-difluoro-2-nitroaniline (800 mg, 4.59 mmol, 16%) as pale yellow solid.

25

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 8.00 (dd, *J* = 10.4, 8.7 Hz, 1H), 6.60 (dd, *J* = 11.0, 6.4 Hz, 1H), 6.09 (brs, 2H)

**LC-MS:** *m/z* 172.8 [M-H]<sup>-</sup> at 2.49 RT (88.25% purity)

#### 5 **4,5-Difluorobenzene-1,2-diamine (Int-12)**


To a stirred solution of 4,5-difluoro-2-nitroaniline (800 mg, 4.59 mmol) in methanol (15 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 200 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was  
 10 filtered through a pad of celite and washed with methanol (15 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The filtrate was concentrated under reduced pressure. The crude material was washed with *n*-hexane (15 mL) to afford 4,5-difluorobenzene-1,2-diamine **Int-12** (500 mg, 3.47 mmol, 80%) as a black solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.47-6.41 (m, 2H), 4.55 (brs, 4H)

15 **LC-MS:** *m/z* 145 [M+H]<sup>+</sup> at 1.59 RT (75.16% purity)

### **Preparation of Int-13**

#### **Scheme:**



#### 20 **5-Chloro-N-cyclopropyl-3-nitropyridin-2-amine**

To a stirred solution of 2,5-dichloro-3-nitropyridine (1 g, 5.23 mmol) in toluene (10 mL) under an inert atmosphere was added cyclopropylamine (0.73 mL, 10.47 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 48 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (40 mL) and extracted with  
 25 EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 5-chloro-N-cyclopropyl-3-nitropyridin-2-amine (700 mg, 3.28 mmol, 63%) as an orange solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 8.45 (d, *J* = 2.5 Hz, 1H), 8.41 (d, *J* = 2.4 Hz, 1H), 8.18 (br s, 1H), 3.05-2.97 (m, 1H), 0.98-0.91 (m, 2H), 0.68-0.62 (m, 2H)

**LC-MS:**  $m/z$  214  $[M+H]^+$  at 3.03 RT (98.66% purity)

### 5-Chloro- $N^2$ -cyclopropylpyridine-2,3-diamine (Int-13)


To a stirred solution of 5-chloro- $N$ -cyclopropyl-3-nitropyridin-2-amine (200 mg, 0.938 mmol) in ethanol/water (1: 1, 20 mL) was added iron powder (262 mg, 4.69 mmol) and ammonium chloride (253 mg, 4.69 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and washed with EtOAc. The filtrate was diluted with water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to obtain 5-chloro- $N^2$ -cyclopropylpyridine-2,3-diamine **Int-13** (120 mg) as a black solid. The crude material was used in the next step without further purification.

**$^1H$  NMR (500 MHz, DMSO- $d_6$ ):**  $\delta$  7.35 (d,  $J$  = 1.7 Hz, 1H), 6.67 (d,  $J$  = 2.3 Hz, 1H), 6.00 (br s, 1H), 5.02 (br s, 2H), 2.72-2.63 (m, 1H), 0.68-0.63 (m, 2H), 0.41-0.37 (m, 2H)

**LC-MS:**  $m/z$  183.9  $[M+H]^+$  at 1.87 RT (88.05% purity)

### Preparation of Int-14

#### Scheme:



### 20 **$N$ -Cyclopropyl-2-fluoro-6-nitroaniline**

To a stirred solution of 1,2-difluoro-3-nitrobenzene (200 mg, 1.26 mmol) in ethanol (2 mL) was added cyclopropanamine (0.13 mL, 1.89 mmol) at room temperature under an inert atmosphere and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to afford  $N$ -cyclopropyl-2-fluoro-6-nitroaniline (200 mg, 1.02 mmol, 81%) as a yellow viscous syrup.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 7.93 (dt, *J* = 8.8, 1.5 Hz, 1H), 7.82 (brs, 1H), 7.24-7.19 (m, 1H), 6.63-6.58 (m, 1H), 3.12-3.07 (m, 1H), 0.87-0.79 (m, 2H), 0.67-0.61 (m, 2H)

**LC-MS:** *m/z* 197.0 [M+H]<sup>+</sup> at 3.28 RT (99.89% purity)


#### 5 ***N*<sup>1</sup>-Cyclopropyl-6-fluorobenzene-1,2-diamine (Int-14)**

To a stirred solution of *N*-cyclopropyl-2-fluoro-6-nitroaniline (200 mg, 1.02 mmol) in ethylacetate (5 mL) was added 10% Pd/C (50% wet, 30 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 4 h. After consumption of starting material (by TLC), the  
10 reaction mixture was filtered through a pad of *celite* and the bed was washed with EtOAc (15 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclopropyl-6-fluorobenzene-1,2-diamine **Int-14** (160 mg) as colorless viscous syrup. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.61-6.51 (m, 1H), 6.40-6.24 (m, 3H), 4.89 (br s, 2H),  
15 2.62-2.58 (m, 1H), 0.49-0.38 (m, 4H)

### **Preparation of Int-15**

#### **Scheme:**



#### 20 **4,5-Difluoro-*N*-methyl-2-nitroaniline**

To a stirred solution of 1,2,4-trifluoro-5-nitrobenzene (5 g, 28.25 mmol) in THF (50 mL) was added methanamine (2 M in THF, 28.25 mL, 56.5 mmol) dropwise at -20 °C under an inert atmosphere and allowed to stir at the same temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with brine (50 mL) and extracted with  
25 EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% EtOAc/hexane) to afford 4,5-difluoro-*N*-methyl-2-nitroaniline (1.1 g, 5.85 mmol, 20%) as pale yellow solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 8.06 (dd, *J* = 10.7, 8.4 Hz, 2H), 6.61 (dd, *J* = 12.5, 6.7 Hz,  
30 1H), 3.01 (d, *J* = 5.1 Hz, 3H)

**4,5-Difluoro-*N*<sup>1</sup>-methylbenzene-1,2-diamine (Int-15)**

To a stirred solution of 4,5-difluoro-*N*-methyl-2-nitroaniline (1 g, 5.32 mmol) in ethylacetate (15 mL) was added 10% Pd/C (50% wet, 250 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (30 mL). The filtrate was concentrated under reduced pressure to afford 4,5-difluoro-*N*<sup>1</sup>-methylbenzene-1,2-diamine **Int-15** (700 mg) as a brown syrup. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.48 (dd, *J* = 12.5, 8.4 Hz, 1H), 6.28 (dd, *J* = 13.3, 8.1 Hz, 1H), 4.71 (s, 1H), 4.59 (br s, 2H), 2.66 (d, *J* = 5.2 Hz, 3H)

**LC-MS:** *m/z* 158.8 [M+H]<sup>+</sup> at 2.20 RT (99.55% purity)

**Preparation of Int-16****Scheme:****4,5-Difluoro-2-nitro-*N*-propylaniline**

To a stirred solution of 1,2,4-trifluoro-5-nitrobenzene (5 g, 28.25 mmol) in THF (150 mL) were added potassium carbonate (5.07 g, 36.72 mmol) and propan-1-amine (3.48 mL, 42.37 mmol) dropwise at room temperature under an inert atmosphere and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% EtOAc/hexane) to afford 4,5-difluoro-2-nitro-*N*-propylaniline (600 mg, 2.77 mmol, 10%) as a yellow solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 8.25 (br s, 1H), 8.14 (dd, *J* = 11.3, 8.7 Hz, 1H), 7.17 (dd, *J* = 13.7, 7.2 Hz, 1H), 3.35-3.26 (m, 2H), 1.68-1.56 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H)

**4,5-Difluoro-*N*<sup>1</sup>-propylbenzene-1,2-diamine (Int-16)**

To a stirred solution of 4,5-difluoro-2-nitro-*N*-propylaniline (500 mg, 2.31 mmol) in ethylacetate (10 mL) was added 10% Pd/C (50% wet, 150 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 4 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (20 mL). The filtrate was concentrated under reduced pressure to afford 4,5-difluoro-*N*<sup>1</sup>-propylbenzene-1,2-diamine **Int-16** (350 mg) as a brown syrup. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.48 (dd, *J* = 12.8, 8.1 Hz, 1H), 6.30 (dd, *J* = 13.3, 8.1 Hz, 1H), 4.66 (s, 2H), 4.47 (br t, *J* = 4.6 Hz, 1H), 2.96-2.88 (m, 2H), 1.62-1.54 (m, 2H), 0.95 (t, *J* = 7.5 Hz, 3H)

**LC-MS:** *m/z* 186.9 [M+H]<sup>+</sup> at 2.88 RT (89.94% purity)

**Preparation of Int-17****Scheme:****3-(Cyclopropylamino)-4-nitrophenol**

To a stirred solution of 3-fluoro-4-nitrophenol (1 g, 6.37 mmol) in THF (20 mL) was added cyclopropanamine (726 mg, 12.74 mmol) in a sealed tube at room temperature under an inert atmosphere. The reaction mixture was heated to 80 °C and stirred for 6 h. After consumption of starting material (by TLC), the reaction mixture was poured into ice cold water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 3-(cyclopropylamino)-4-nitrophenol (1.2 g, 6.18 mmol, 75%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.86 (br s, 1H), 8.15 (br s, 1H), 7.97 (d, *J* = 9.3 Hz, 1H), 6.61 (d, *J* = 1.7 Hz, 1H), 6.22 (dd, *J* = 9.3, 2.3 Hz, 1H), 2.57-2.55 (m, 1H), 0.91-0.82 (m, 2H), 0.67-0.57 (m, 2H)

**LC-MS:**  $m/z$  194.9  $[M+H]^+$  at 2.51 RT (99.35% purity)

#### 4-Amino-3-(cyclopropylamino)phenol (**Int-17**)


To a stirred solution of 3-(cyclopropylamino)-4-nitrophenol (1 g, 5.15 mmol) in ethylacetate (10 mL) was added 10% Pd/C (50% wet, 250 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 4 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (30 mL). The filtrate was concentrated under reduced pressure to afford 4-amino-3-(cyclopropylamino)phenol **Int-17** (600 mg) as brown syrup. The crude material was taken to the next step without further purification.

**$^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ ):**  $\delta$  8.18 (brs, 1H), 6.37-6.29 (m, 2H), 5.86 (dd,  $J$  = 8.1, 2.3 Hz, 1H), 4.92 (s, 1H), 3.81 (brs, 2H), 2.27-2.25 (m, 1H), 0.69-0.62 (m, 2H), 0.41-0.35 (m, 2H)

**LC-MS:**  $m/z$  164.8  $[M+H]^+$  at 1.09 RT (74.22% purity)

#### Preparation of Int-18

##### Scheme:



#### **N-Cyclopropyl-5-methyl-2-nitroaniline**

To a stirred solution of 2-fluoro-4-methyl-1-nitrobenzene (500 mg, 3.22 mmol) in THF (5 mL) was added triethylamine (1.35 mL, 9.68 mmol) followed by cyclopropanamine (919 mg, 16.13 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 60 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to afford *N*-cyclopropyl-5-methyl-2-nitroaniline (500 mg, 2.6 mmol, 80%) as yellow solid.

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 8.10 (brs, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 7.07 (s, 1H), 6.50 (d, *J* = 8.8 Hz, 1H), 2.58-2.55 (m, 1H), 2.37 (s, 3H), 0.94-0.88 (m, 2H), 0.67-0.62 (m, 2H).

**LC-MS:** *m/z* 192.9 [M+H]<sup>+</sup> at 3.35 RT (99.53% purity).

## 5 ***N*<sup>1</sup>-Cyclopropyl-5-methylbenzene-1,2-diamine (Int-18)**


To a stirred solution of *N*-cyclopropyl-5-methyl-2-nitroaniline (150 mg, 0.78 mmol) in ethylacetate (1 mL) was added 10% Pd/C (50% wet, 50 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the  
10 reaction mixture was filtered through a pad of *celite* and the bed was washed with ethylacetate (15 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclopropyl-5-methylbenzene-1,2-diamine **Int-18** (120 mg) as black solid. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.60 (s, 1H), 6.41 (d, *J* = 8.1 Hz, 1H), 6.24 (br d, *J* = 7.5  
15 Hz, 1H), 4.91 (s, 1H), 4.21 (br s, 2H), 2.32-2.30 (m, 1H), 2.14 (s, 3H), 0.71-0.64 (m, 2H), 0.41-0.35 (m, 2H)

**LC-MS:** *m/z* 162.9 [M+H]<sup>+</sup> at 2.49 RT (81.92% purity)

## **Preparation of Int-19**

### 20 **Scheme:**



### ***N*-Cyclopropyl-2-nitro-5-(trifluoromethyl)aniline**

To a stirred solution of 2-fluoro-1-nitro-4-(trifluoromethyl)benzene (1 g, 4.78 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added potassium carbonate (1.32 g, 9.57 mmol) and cyclopropanamine  
25 (1.09 g, 19.14 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column

chromatography (eluent: 5% EtOAc/hexane) to afford *N*-cyclopropyl-2-nitro-5-(trifluoromethyl)aniline (1 g, 4.06 mmol, 85%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 8.25 (d, *J* = 8.9 Hz, 1H), 8.13 (brs, 1H), 7.62 (d, *J* = 1.0 Hz, 1H), 7.04 (dd, *J* = 8.8, 1.8 Hz, 1H), 2.76-2.69 (m, 1H), 0.95-0.87 (m, 2H), 0.69-0.63 (m, 2H)


**LC-MS:** *m/z* 245.0 [M-H]<sup>-</sup> at 4.33 RT (78.90% purity)

### *N*<sup>1</sup>-Cyclopropyl-5-(trifluoromethyl)benzene-1,2-diamine (Int-19)

To a stirred solution of *N*-cyclopropyl-2-nitro-5-(trifluoromethyl)aniline (1 g, 4.06 mmol) in methanol (20 mL) was added 10% Pd/C (50% wet, 100 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (20 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclopropyl-5-(trifluoromethyl)benzene-1,2-diamine **Int-19** (700 mg) as brown syrup. The crude material was taken to the next step without further purification.

### Preparation of Int-20

#### Scheme:



### *N*-Cyclopropyl-2,3-difluoro-6-nitroaniline

To a stirred solution of 1,2,3-trifluoro-4-nitrobenzene (1 g, 28.25 mmol) in ethanol (100 mL) was added cyclopropanamine (1.61 g, 28.25 mmol) at room temperature under an inert atmosphere and the reaction was stirred for 48 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (50 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to afford *N*-cyclopropyl-2,3-difluoro-6-nitroaniline (3 g, 14.0 mmol, 50%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 7.95-7.91 (m, 1H), 7.75 (brs, 1H), 6.85-6.80 (m, 1H), 3.02-2.98 (m, 1H), 0.79-0.72 (m, 2H), 0.67-0.65 (m, 2H)

**LC-MS:** *m/z* 213.4 [M-H]<sup>+</sup> at 4.06 RT (99.81% purity)

## 5 ***N*<sup>1</sup>-Cyclopropyl-5,6-difluorobenzene-1,2-diamine (Int-20)**


To a stirred solution of *N*-cyclopropyl-2,3-difluoro-6-nitroaniline (1 g, 4.67 mmol) in ethylacetate (10 mL) was added 10% Pd/C (50% wet, 100 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 2 h. After consumption of starting material (by TLC), the  
10 reaction mixture was filtered through a pad of *celite* and the bed was washed with ethylacetate (20 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclopropyl-5,6-difluorobenzene-1,2-diamine **Int-20** (700 mg) as a black solid. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.55-6.47 (m, 1H), 6.33-6.27 (m, 1H), 4.70 (br s, 2H),  
15 4.54 (br s, 1H), 2.74-2.66 (m, 1H), 0.59-0.52 (m, 2H), 0.48-0.43 (m, 2H)

**LC-MS:** *m/z* 185.0 [M+H]<sup>+</sup> at 2.60 RT (67.33% purity)

## **Preparation of Int-21**

### **Scheme:**



20

### ***N*-Cyclobutyl-4,5-difluoro-2-nitroaniline**

To a stirred solution of 1,2,4-trifluoro-5-nitrobenzene (1 g, 5.65 mmol) in THF (20 mL) were added potassium carbonate (1.17 g, 8.47 mmol) followed by cyclobutanamine (0.58 mL, 6.78 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room  
25 temperature and stirred for 6 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (50 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5%

EtOAc/hexane) to afford *N*-cyclobutyl-4,5-difluoro-2-nitroaniline (450 mg, 1.97 mmol, 35%) as yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 8.18-8.08 (m, 2H), 7.00 (dd, *J* = 13.4, 7.0 Hz, 1H), 4.16-4.07 (m, 1H), 2.48-2.39 (m, 2H), 2.06-1.94 (m, 2H), 1.83-1.69 (m, 2H)

5 **LC-MS:** *m/z* 229.0 [M+H]<sup>+</sup> at 2.90 RT (97.77% purity)

### ***N*<sup>1</sup>-Cyclobutyl-4,5-difluorobenzene-1,2-diamine (Int-21)**

To a stirred solution of *N*-cyclobutyl-4,5-difluoro-2-nitroaniline (450 mg, 1.97 mmol) in ethylacetate (10 mL) was added 10% Pd/C (50% wet, 45 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with ethylacetate (15 mL). The filtrate was concentrated under reduced pressure to afford *N*<sup>1</sup>-cyclobutyl-4,5-difluorobenzene-1,2-diamine **Int-21** (350 mg) as a black solid. This crude material was taken to next step without further purification.


**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 6.52 (dd, *J* = 11.3, 8.0 Hz, 1H), 6.33 (dd, *J* = 12.1, 7.1 Hz, 1H), 3.86-3.76 (m, 1H), 3.40-3.18 (m, 3H), 2.52-2.39 (m, 2H), 1.91-1.78 (m, 4H)

**LC-MS:** *m/z* 199.0 [M+H]<sup>+</sup> at 2.92 RT (83.44% purity)

20

### **Preparation of Int-22**

#### **Scheme:**



### **4-(Cyclopropylamino)-3-nitrobenzonitrile**

To a stirred solution of 4-fluoro-3-nitrobenzonitrile (1 g, 6.02 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added potassium carbonate (1.66 g, 12.05 mmol) followed by cyclopropanamine (3.33 mL, 48.19 mmol) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was poured into water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated

under reduced pressure to afford 4-(cyclopropylamino)-3-nitrobenzonitrile (1.1 g) as a yellow solid. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 8.49 (d, *J* = 1.9 Hz, 1H), 8.41 (brs, 1H), 7.66-7.63 (m, 1H), 7.40 (d, *J* = 9.0 Hz, 1H), 2.68-2.61 (m, 1H), 1.04-0.98 (m, 2H), 0.75-0.70 (m, 2H)

5 **LC-MS:** *m/z* 202.0 [M-H]<sup>-</sup> at 2.88 RT (99.48% purity)

### 3-Amino-4-(cyclopropylamino)benzonitrile (Int-22)

To a stirred solution of 4-(cyclopropylamino)-3-nitrobenzonitrile (1.1 g, crude) in ethanol (40 mL) was added 10% Pd/C (50% wet, 350 mg) at room temperature under an inert atmosphere.

10 The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with ethylacetate (20 mL). The filtrate was concentrated under reduced pressure to afford 3-amino-4-(cyclopropylamino) benzonitrile **Int-22** (900 mg) as a yellow solid. The crude material was taken to next step without further  
15 purification.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 7.18 (dd, *J* = 8.2, 1.8 Hz, 1H), 7.00 (d, *J* = 8.3 Hz, 1H), 6.92 (d, *J* = 1.9 Hz, 1H), 4.41 (br s, 1H), 3.24 (br s, 2H), 2.51-2.43 (m, 1H), 0.85-0.78 (m, 2H), 0.59-0.53 (m, 2H)

**LC-MS:** *m/z* 173.9 [M+H]<sup>+</sup> at 2.40 RT (84.82% purity)

20

### Preparation of Int-23

#### Scheme:



#### 1-Chloro-2,5-difluoro-4-nitrobenzene

25 To a stirred solution of 1-chloro-2,5-difluoro-4-nitrobenzene (500 mg, 2.59 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added potassium carbonate (715 mg, 5.18 mmol) and cyclopropanamine (305 mg, 5.18 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 24 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined

organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to obtain 1-chloro-2,5-difluoro-4-nitrobenzene (400 mg, 1.73 mmol, 67%) as a yellow solid.

**$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):**  $\delta$  7.97 (d,  $J$  = 9.3 Hz, 2H), 7.37 (d,  $J$  = 6.4 Hz, 1H), 2.57-2.54 (m, 1H), 1.00-0.91 (m, 2H), 0.71-0.59 (m, 2H)

5


### 5-Chloro- $N^1$ -cyclopropyl-4-fluorobenzene-1,2-diamine (Int-23)

To a stirred solution of 1-chloro-2,5-difluoro-4-nitrobenzene (400 mg, 1.74 mmol) in EtOAc (10 mL) under an inert atmosphere was added 10% Pd/C (50% wet, 100 mg) at room temperature. The reaction mixture was evacuated and stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with EtOAc (40 mL). The filtrate was concentrated under reduced pressure to obtain 5-chloro- $N^1$ -cyclopropyl-4-fluorobenzene-1,2-diamine **Int-23** (280 mg, 1.40 mmol, 81%) as an off white solid.

**$^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ ):**  $\delta$  6.68 (d,  $J$  = 7.5 Hz, 1H), 6.47 (d,  $J$  = 11.6 Hz, 1H), 5.16 (br s, 1H), 4.96 (br s, 2H), 2.34-2.27 (m, 1H), 0.74-0.67 (m, 2H), 0.42-0.28 (m, 2H)

### Preparation of Int-24

#### Scheme:



20

### 4-Chloro- $N$ -cyclopropyl-2-nitroaniline

To 4-chloro-1-fluoro-2-nitrobenzene (2 g, 11.43 mmol) was added cyclopropanamine (2.6 g, 45.71 mmol) dropwise at 10 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3-5% EtOAc/hexane) to afford 4-chloro- $N$ -cyclopropyl-2-nitroaniline (2.08 g, 0.98 mmol, 83%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 8.16 (d, *J* = 2.2 Hz, 1H), 8.04 (br s, 1H), 7.42 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.29 (d, *J* = 9.3 Hz, 1H), 2.61-2.55 (m, 1H), 0.96-0.90 (m, 2H), 0.69-0.63 (m, 2H)

**LC-MS:** *m/z* 213.1 [M+H]<sup>+</sup> at 2.85 RT (99.81% purity)

#### 5 **4-Chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine (Int-24)**


To a stirred solution of 4-chloro-*N*-cyclopropyl-2-nitroaniline (1 g, 4.72 mmol) in methanolic ammonia (2 M, 50 mL) was added Raney Nickel (500 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 4 h. After consumption of starting material (by TLC), the  
10 reaction mixture was filtered through a pad of *celite* and the bed was washed with ethylacetate (30 mL). The filtrate was concentrated under reduced pressure to afford 4-chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine **Int-24** (700 mg) as brown liquid. The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 6.70 (d, *J* = 8.3 Hz, 1H), 6.55-6.45 (m, 2H), 5.10 (s, 1H),  
15 4.77 (br s, 2H), 2.31-2.29 (m, 1H), 0.72-0.65 (m, 2H), 0.41-0.34 (m, 2H)

**LC-MS:** *m/z* 183.1 [M+H]<sup>+</sup> at 2.15 RT (87.51% purity)

### **Preparation of Int-25**

#### **Scheme:**



20

#### **3-Chloro-*N*-cyclopropyl-2-nitroaniline**

To 1-chloro-3-fluoro-2-nitrobenzene (500 mg, 2.85 mmol) was added cyclopropanamine (0.78 mL, 11.4 mmol) dropwise at room temperature under an inert atmosphere and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water  
25 (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 3-chloro-*N*-cyclopropyl-2-nitroaniline (500 mg) as a yellow solid. The crude material was taken to next step without further purification.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):**  $\delta$  7.28-7.22 (m, 1H), 7.15 (dd,  $J$  = 8.5, 1.3 Hz, 1H), 6.80 (dd,  $J$  = 7.8, 1.3 Hz, 1H), 6.01 (br s, 1H), 2.54-2.46 (m, 1H), 0.88-0.82 (m, 2H), 0.60-0.55 (m, 2H).

**LC-MS:**  $m/z$  213.1 [M+H]<sup>+</sup> at 2.74 RT (98.57% purity)


### 5 3-Chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine (Int-25)

To a stirred solution of 3-chloro-*N*-cyclopropyl-2-nitroaniline (200 mg, crude) in acetic acid (2 mL) was added Iron powder (157 mg, 2.83 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 80 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated NaHCO<sub>3</sub> solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 3-chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine **Int-25** (200 mg) as a brown syrup. The crude material was taken to the next step without further purification.

**LC-MS:**  $m/z$  183.0 [M+H]<sup>+</sup> at 2.47 RT (43.71% purity)

### Preparation of Int-26

#### Scheme:



### 4-Isopropyl-2-(trifluoromethyl)oxazol-5(2*H*)-one

To DL-Valine (30 g, 256.41 mmol) was added trifluoroacetic anhydride (72 mL) dropwise at room temperature. The reaction mixture was heated to reflux and stirred for 8 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (100 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (250 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 4-isopropyl-2-

(trifluoromethyl)oxazol-5(2*H*)-one **2** (45 g) as a pale yellow liquid. The crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 6.11-6.05 (m, 1H), 3.12-3.02 (m, 1H), 1.34 (d, *J* = 3.0 Hz, 3H), 1.32 (d, *J* = 3.0 Hz, 3H)

5 **LC-MS:** *m/z* 193.9 [M-H]<sup>-</sup> at 2.94 RT (75.69% purity)

**Diethyl 2-((4-isopropyl-5-oxo-2-(trifluoromethyl)-2,5-dihydrooxazol-2-yl)methyl) malonate**

To a stirred solution of 4-isopropyl-2-(trifluoromethyl)oxazol-5 (2*H*)-one (45 g, crude) in  
10 CH<sub>2</sub>Cl<sub>2</sub> (450 mL) under an inert atmosphere were added diethyl 2-methylenemalonate (47.63 g, crude) and triethylamine (48.2 mL, 346.14 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (150 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 250 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated  
15 under reduced pressure to afford diethyl 2-((4-isopropyl-5-oxo-2-(trifluoromethyl)-2,5-dihydrooxazol-2-yl)methyl) malonate (50 g, crude) as pale yellow solid. The crude material was used in the next step without further purification.

**LC-MS:** *m/z* 368.1 [M+H]<sup>+</sup> at 3.70 RT (82.98% purity)

20 **Ethyl 3-oxo-6-(trifluoromethyl)-2,3,4,5-tetrahydropyridazine-4-carboxylate**

To a stirred solution of diethyl 2-((4-isopropyl-5-oxo-2-(trifluoromethyl)-2,5-dihydrooxazol-2-yl)methyl)malonate (25 g, crude) in acetic acid (200 mL) under an inert atmosphere was added hydrazine hydrochloride (23.16 g, 340.59 mmol) at room temperature. The reaction mixture was heated to reflux and stirred for 3 h. After consumption of starting material (by  
25 TLC), the reaction mixture was basified with saturated sodium bicarbonate solution and extracted with EtOAc (2 x 250 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) to afford ethyl 3-oxo-6-(trifluoromethyl)-2,3,4,5-tetrahydropyridazine-4-carboxylate (15 g, 63.55 mmol) as a pale  
30 yellow liquid.

**LC-MS:** *m/z* 237.0 [M-H]<sup>-</sup> at 2.19 RT (87.20% purity)

**Ethyl 3-hydroxy-6-(trifluoromethyl)pyridazine-4-carboxylate**

To a stirred solution of ethyl 3-oxo-6-(trifluoromethyl)-2,3,4,5-tetrahydropyridazine-4-carboxylate (7.5 g, 31.51 mmol) in acetic acid (40 mL) under an inert atmosphere was added a solution of bromine (5.03 g, 31.51 mmol) in acetic acid (35 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was basified with saturated sodium bicarbonate solution and extracted with EtOAc (2 x 200 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) to afford ethyl 3-hydroxy-6-(trifluoromethyl)pyridazine-4-carboxylate (2.5 g, 10.59 mmol, 34%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 14.16 (br s, 1H), 8.12 (s, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 235.0 [M-H]<sup>-</sup> at 2.03 RT (98.67% purity)

**Ethyl 3-chloro-6-(trifluoromethyl)pyridazine-4-carboxylate**

To a stirred solution of ethyl 3-hydroxy-6-(trifluoromethyl)pyridazine-4-carboxylate (5.0 g, 21.19 mmol) in 1, 4-dioxane (50 mL) under an inert atmosphere was added phosphoryl trichloride (19.6 mL, 211.86 mmol) at 0 °C. The reaction mixture was heated to 100 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was basified with sodium bicarbonate solution (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 15-20% EtOAc/hexane) to afford ethyl 3-chloro-6-(trifluoromethyl)pyridazine-4-carboxylate (3 g, 11.81 mmol, 55%) as pale yellow liquid.

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 8.15 (s, 1H), 4.53 (q, *J* = 7.0 Hz, 2H), 1.47 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 255.4 [M+H]<sup>+</sup> at 3.61 RT (98.51% purity)

**Ethyl 6-(trifluoromethyl)pyridazine-4-carboxylate**

To a stirred solution of ethyl 3-chloro-6-(trifluoromethyl)pyridazine-4-carboxylate (500 mg, 1.96 mmol) in ethanol (10 mL) under an inert atmosphere was added triethylamine (0.5 mL) and 10% Pd/C (50% wet, 100 mg) at room temperature. The reaction headspace was briefly

placed under vacuum and quickly recharged with hydrogen. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with EtOAc (50 mL). The filtrate was concentrated under reduced pressure.

5 The obtained crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford ethyl 6-(trifluoromethyl)pyridazine-4-carboxylate (300 mg, 1.36 mmol, 69%) as an off white solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.85 (d, *J* = 1.8 Hz, 1H), 8.32 (d, *J* = 1.9 Hz, 1H), 4.53 (q, *J* = 7.2 Hz, 2H), 1.47 (t, *J* = 7.2 Hz, 3H)

10 LC-MS: *m/z* 221.1 [M+H]<sup>+</sup> at 3.09 RT (92.69% purity)

### 6-(Trifluoromethyl)pyridazine-4-carboxylic acid (Int-26)

To a stirred solution of ethyl 6-(trifluoromethyl)pyridazine-4-carboxylate (300 mg, 1.36 mmol) in a mixture of THF: water (4:1, 5 mL) was added lithium hydroxide (171.6 g, 4.09 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. Then the residue was acidified using con HCl (pH 3-4) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The obtained solid was washed with *n*-pentane (10 mL) and dried *in vacuo* to afford 6-(trifluoromethyl)pyridazine-4-carboxylic acid **Int-26** (210 mg) as an off white solid. The crude material was used in the next step without further purification.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 14.08 (brs, 1H), 9.83 (brs, 1H), 8.43 (brs, 1H)

LC-MS: *m/z* 191.0 [M-H]<sup>-</sup> at 3.79 RT (94.51% purity)

25

### Preparation of Int-27

#### Scheme:



### 1-Cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 22** (150 mg, 0.50 mmol) in 1,4-dioxane (3 mL) and water (0.5 mL) under an inert atmosphere were added vinyl boronic acid pinacol ester (76 mg, 0.50 mmol) and potassium carbonate (203 mg, 1.47 mmol) at room temperature. The reaction mixture was degassed with argon for 10 min. Pd(dppf)Cl<sub>2</sub> (4 mg, 0.005 mmol) was added at room temperature and the mixture was degassed with argon for 10 min. The reaction mixture was heated to 80 °C and stirred for 5 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[d]imidazole (70 mg, 0.23 mmol, 48%) as an off-white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.69 (s, 1H), 8.45 (s, 1H), 7.90-7.83 (m, 2H), 7.18-7.11 (m, 1H), 6.53 (d, *J* = 17.7 Hz, 1H), 5.82 (d, *J* = 11.4 Hz, 1H), 3.99-3.97 (m, 1H), 1.22-1.13 (m, 2H), 0.82-0.60 (m, 2H)

#### 5-(1-Cyclopropyl-5, 6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde (Int-27)

To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[d]imidazole (300 mg, 1.00 mmol) in acetone: <sup>t</sup>BuOH: water (1:1:1, 18 mL) under an inert atmosphere was added sodium periodate (430 mg, 2.01 mmol) and osmium tetroxide (1 M solution, 6 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with EtOAc (100 mL). The organic layer was washed with water (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-27** (200 mg) as black solid. The crude material was used without further purification.

<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 10.36 (s, 1H), 10.03 (s, 1H), 8.58 (s, 1H), 7.93-7.81 (m, 2H), 4.00-3.94 (m, 1H), 1.21-1.13 (m, 2H), 0.81-0.72 (m, 2H)

#### Preparation of Int-28

**Scheme:**

**(E)-5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde oxime**

- 5 To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-27** (600 mg, 2 mmol) in ethanol (10 mL) under an inert atmosphere was added hydroxylamine hydrochloride (276 mg, 4 mmol) and potassium carbonate (552 mg, 4 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was concentrated under
- 10 reduced pressure. The residue was diluted with water (70 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-hexane (20 mL) and dried *in vacuo* to afford (E)-5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde oxime (500 mg, 1.58 mmol, 79%) as an off white solid.

- 15 <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 12.26 (s, 1H), 9.80 (d, *J* = 1.7 Hz, 1H), 8.56 (d, *J* = 2.3 Hz, 1H), 8.48 (s, 1H), 7.91-7.80 (m, 2H), 3.97-3.88 (m, 1H), 1.22-1.14 (m, 2H), 0.85-0.78 (m, 2H)

LC-MS: *m/z* 315.9 [M+H]<sup>+</sup> at 2.33 RT (97.99% purity)

- 20 **(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanamine (Int-28)**

- To a stirred solution of (E)-5-(1-cyclopropyl-56-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde oxime (500 mg, 1.58 mmol) in ethanol (10 mL) was added sodium hydroxide (190 mg, 4.76 mmol) and 10% Pd/C (50% wet, 150 mg) at room temperature under
- 25 an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (80 mL) and washed with water (50

mL). The organic layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to afford (5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanamine **Int-28** (400 mg, 1.32 mmol, 84%) as an off white solid. The crude material was taken to the next step without further purification.


- 5  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  9.68 (d,  $J = 1.7$  Hz, 1H), 8.35 (d,  $J = 1.7$  Hz, 1H), 7.89-7.81 (m, 2H), 4.12 (s, 2H), 3.95-3.89 (m, 1H), 2.13 (brs, 2H), 1.27-1.14 (m, 2H), 0.79-0.66 (m, 2H)

LC-MS:  $m/z$  301.9  $[\text{M}+\text{H}]^+$  at 1.91 RT (95.51% purity)

10

### Preparation of Int-29

#### Scheme:




**6-(Difluoromethyl)pyridazine-4-carboxylic acid (Int-29)** was prepared in a manner analogous to **Int-26** starting with alanine and difluoroacetic anhydride (DFAA).

15

### Preparation of Int-30

#### Scheme:



**1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one oxime**

20

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one **Ex. 64** (170 mg, 0.54 mmol) in EtOH (10 mL) under an inert atmosphere was added and hydroxylamine hydrochloride (75 mg, 1.08 mmol) and potassium carbonate (149 mg, 1.08 mmol) at 0 °C. The reaction mixture was heated to 80 °C and stirred for 3 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one oxime (100 mg) as an off white solid. The crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 12.07 (s, 1H), 9.81 (d, *J* = 1.7 Hz, 1H), 8.63 (d, *J* = 1.7 Hz, 1H), 7.91-7.80 (m, 2H), 3.94-3.87 (m, 1H), 2.41 (s, 3H), 1.21-1.14 (m, 2H), 0.85-0.76 (m, 2H)

**LC-MS:** *m/z* 329.9 [M+H]<sup>+</sup> at 2.52 RT (86.46% purity)


### **1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-amine (Int-30)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one oxime (100 mg, crude) in ethanol (10 mL) under an inert atmosphere was added sodium hydroxide (37 mg, 0.91 mmol) and 10% Pd/C (50% wet, 80 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 8 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with MeOH (20 mL). The filtrate was concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-amine **Int-30** (80 mg) as an off white solid. The crude material was used without further purification.

**LC-MS:** *m/z* 315.9 [M+H]<sup>+</sup> at 1.71 RT (85.70% purity)

## **Example 1**

### **Scheme:**



### ***N*-(2-(Cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide**

To a stirred solution of *N*1-cyclopropyl-5-fluorobenzene-1, 2-diamine **Int-1** (300 mg, 1.81 mmol) in *N,N*-dimethylformamide (DMF) (3 mL) under an inert atmosphere was added  
 5 pyridazine-4-carboxylic acid (224 mg, 1.81 mmol), *N*-[(Dimethylamino)-1*H*-1,2,3-triazolo-[4,5-*b*]pyridin-1-ylmethylene]-*N*-methylnmethanaminium hexafluorophosphate *N*-oxide (HATU) (824 mg, 2.17 mmol) and ethyldiisopropylamine (1.26 mL, 7.23 mmol) at room temperature. The reaction mixture was stirred at room temperature for 8 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and  
 10 extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide (220 mg, 0.81 mmol, 44%) as brown solid.

**<sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>):** δ 9.89 (s, 1H), 9.66 (dd, *J* = 2.2, 1.3 Hz, 1H), 9.47 (dd, *J* = 5.2, 1.1 Hz, 1H), 8.12 (dd, *J* = 5.3, 2.3 Hz, 1H), 7.13 (dd, *J* = 8.5, 6.4 Hz, 1H), 6.75 (dd, *J* = 11.9, 2.9 Hz, 1H), 6.43 (td, *J* = 8.5, 2.9 Hz, 1H), 6.12 (s, 1H), 2.38-2.32 (m, 1H), 0.77-0.71 (m, 2H), 0.47-0.40 (m, 2H).

**LC-MS:** *m/z* 272.9 [M+H]<sup>+</sup> at 2.66 RT (89.14% purity).

### **20 1-Cyclopropyl-6-fluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex 1)**

To *N*-(2-(cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide (150 mg, 0.55 mmol) in acetic acid (3 mL) under an inert atmosphere was heated to 100 °C and stirred for 8 h. After consumption of starting material (by TLC), the reaction mixture was neutralized with saturated Sodium bicarbonate solution (50 mL) and extracted with EtOAc (2 x 30 mL). The  
 25 combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-6-fluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex 1** (68 mg, 0.27 mmol, 48%) as an off white solid.


**<sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>):** δ 9.82 (dd, *J* = 2.2, 1.3 Hz, 1H), 9.45 (dd, *J* = 5.4, 1.1 Hz, 1H), 8.29 (dd, *J* = 5.4, 2.4 Hz, 1H), 7.79 (dd, *J* = 8.9, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.1, 2.4 Hz, 1H), 7.22-7.15 (m, 1H), 3.94-3.87 (m, 1H), 1.22-1.16 (m, 2H), 0.78-0.73 (m, 2H).

**LC-MS:** *m/z* 255.0 [M+H]<sup>+</sup> at 2.98 RT (97.13% purity).

5 **HPLC:** 98.24%.

### Examples 2 & 3

#### Scheme:



#### 10 **6-Chloro-N-(2-(cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide**

To a stirred solution of *N*1-cyclopropyl-5-fluorobenzene-1, 2-diamine **Int-1** (500 mg, 3.01 mmol) in DMF (3 mL) under an inert atmosphere was added 6-chloropyridazine-4-carboxylic acid (475 mg, 3.01 mmol), HATU (1.37 g, 3.61 mmol) and ethyldiisopropylamine (2.2 mL, 12.04 mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/Hexane) to afford 6-chloro-*N*-(2-(cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide (550 mg, 1.79 mmol, 60%) as brown solid.

**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 9.96 (s, 1H), 9.63 (d, *J* = 1.4 Hz, 1H), 8.36 (d, *J* = 1.2 Hz, 1H), 7.13 (dd, *J* = 8.4, 6.7 Hz, 1H), 6.75 (dd, *J* = 11.7, 2.7 Hz, 1H), 6.43 (td, *J* = 8.5, 2.7 Hz, 1H), 6.14 (s, 1H), 2.37-2.33 (m, 1H), 0.77-0.73 (m, 2H), 0.46-0.42 (m, 2H).

**LC-MS:** *m/z* 305.0 [M-H]<sup>+</sup> at 3.00 RT (83.53% purity).

**2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole (Ex. 3)**

To a stirred solution of 6-chloro-*N*-(2-(cyclopropylamino)-4-fluorophenyl) pyridazine-4-carboxamide (550 mg, 1.79 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added  
5 trifluoroacetic acid (0.6 mL) drop wise at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with EtOAc (50 mL) and washed with saturated sodium bicarbonate solution (20 mL). The organic layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material  
10 was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (200 mg, 0.69 mmol, 38%) as an off-white solid.

**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 9.82 (s, 1H), 8.46 (s, 1H), 7.81 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.58 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.21 (td, *J* = 9.3, 2.2 Hz, 1H), 3.97-3.93 (m, 1H), 1.22-1.17 (m,  
15 2H), 0.83-0.79 (m, 2H).

**LC-MS:** *m/z* 288.9 [M+H]<sup>+</sup> at 2.59 RT (98.16% purity).

**HPLC:** 98.76%.

**5-(1-Cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbonitrile (Ex. 2)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 2** (100 mg, 0.35 mmol) in DMF (1 mL) under an inert atmosphere was added Zn(CN)<sub>2</sub> (24 mg, 0.21 mmol) at room temperature. The reaction mixture was degassed under argon for 10 min. Pd<sub>2</sub>(dba)<sub>3</sub> (16 mg, 0.02 mmol) and Pd(dppf)Cl<sub>2</sub> (13 mg, 0.02 mmol) were added at room temperature and the reaction mixture was degassed under argon for 5 min.  
25 The reaction mixture was heated to 100 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with EtOAc (40 mL), filtered through a pad of celite and the celite bed was washed with EtOAc (15 mL). The organic layer was washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40%  
30 EtOAc/hexane) to afford 5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbonitrile **Ex. 2** (30 mg, 0.11 mmol, 31%) as an off white solid.


**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  10.06 (d, *J* = 1.7 Hz, 1H), 8.92 (d, *J* = 1.7 Hz, 1H), 7.83 (dd, *J* = 8.7, 4.9 Hz, 1H), 7.59 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.25-7.20 (m, 1H), 3.98-3.93 (m, 1H), 1.24-1.19 (m, 2H), 0.82-0.78 (m, 2H).

**LC-MS:** *m/z* 279.8 [M+H]<sup>+</sup> at 2.92 RT (99.44% purity).

5 **HPLC:** 99.21%.

### Example 4

#### Scheme:



#### 10 **1-Cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 4)**


To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (300 mg, 1.04 mmol) in a mixture of 1,4-dioxane (15 mL) and water (2 mL) under an inert atmosphere was added potassium carbonate (431 mg, 3.12 mmol) and 4, 4, 5, 5-tetramethyl-2-vinyl-1, 3, 2-dioxaborolane (160 mg, 1.04 mmol) at room temperature.

15 The reaction mixture was degassed under argon for 15 min. To this was added Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (8.5 mg, 0.01 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was diluted with EtOAc (60 mL), filtered through a pad of celite and the celite bed was washed with EtOAc (15 mL). The organic layer was washed with water (20  
20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford 1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 4** (150 mg, 0.53 mmol, 51%) as an off white solid.

25 **<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.68 (d, *J* = 1.7 Hz, 1H), 8.44 (d, *J* = 1.7 Hz, 1H), 7.78 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.0, 2.3 Hz, 1H), 7.21-7.09 (m, 2H), 6.52 (d, *J* = 17.6 Hz, 1H), 5.80 (d, *J* = 11.0 Hz, 1H), 3.97-3.93 (m, 1H), 1.20-1.14 (m, 2H), 0.77-0.72 (m, 2H).

**LC-MS:** *m/z* 280.9 [M+H]<sup>+</sup> at 2.43 RT (93.90% purity).

**HPLC:** 95.00%.

**Example 5****Scheme:**


**5 Methyl 5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carboxylate (Ex. 5)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (200 mg, 0.69 mmol) in MeOH (3 mL) was added sodium acetate (171 mg, 2.08 mmol), 1,1'-Ferrocenediyl-bis(diphenylphosphine) (19 mg, 0.03 mmol) and palladium(II) acetate (7.8 mg, 0.03 mmol) at room temperature in a steel bomb. The steel bomb was filled with CO gas (15 bar pressure). The resulting reaction mixture was stirred at 50 °C for 2 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with methanol (30 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford methyl 5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carboxylate **Ex. 5** (70 mg, 0.22 mmol, 32%) as an off white solid.

**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 10.04 (d, *J* = 2.0 Hz, 1H), 8.74 (d, *J* = 2.0 Hz, 1H), 7.82 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.57 (dd, *J* = 9.1, 2.5 Hz, 1H), 7.21 (td, *J* = 9.3, 2.3 Hz, 1H), 4.03 (s, 3H), 3.99-3.95 (m, 1H), 1.23-1.18 (m, 2H), 0.82-0.78 (m, 2H).

**LC-MS:** *m/z* 312.9 [M+H]<sup>+</sup> at 2.36 RT (95.19% purity).

**HPLC:** 99.01%.

**Example 6****Scheme:**


**1-Cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1H-benzo[d]imidazole (Ex. 6)**

To a stirred solution of 1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 4** (70 mg, 0.25 mmol) in ethyl acetate (8 mL) under an inert atmosphere was added triethylamine (cat.) and 10% Pd/C (50% wet, 20 mg) at room temperature. The reaction mixture was evacuated and stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with EtOAc (40 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1H-benzo[d]imidazole **Ex. 6** (50 mg, 0.18 mmol, 67%) as an off white solid.

<sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>): δ 9.66 (d, *J* = 2.1 Hz, 1H), 8.18 (d, *J* = 2.0 Hz, 1H), 7.78 (dd, *J* = 8.8, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.22-7.14 (m, 1H), 3.95-3.90 (m, 1H), 3.07 (q, *J* = 7.6 Hz, 2H), 1.37 (t, *J* = 7.7 Hz, 3H), 1.21-1.15 (m, 2H), 0.77-0.71 (m, 2H).

LC-MS: *m/z* 282.9 [M+H]<sup>+</sup> at 2.37 RT (98.84% purity).

HPLC: 98.29%.

**Example 7****Scheme:****1-(5-(1-Cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (Ex. 7)**

To a stirred solution of 5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-2** (50 mg, 0.18 mmol) in THF (3 mL) under an inert atmosphere was added trimethyl (trifluoromethyl) silane (0.05 mL, 0.35 mmol) at 0 °C. Cesium fluoride (81 mg, 0.53 mmol) was added and the reaction was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (15 mL) and extracted with EtOAc (2 x 15 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure.

The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl)-2, 2, 2-trifluoroethan-1-ol **Ex. 7** (15 mg, 0.04 mmol, 24%) as an off white solid.

**<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD):** δ 9.83 (d, *J* = 2.1 Hz, 1H), 8.57 (d, *J* = 2.1 Hz, 1H), 7.76 (dd, *J* = 8.9, 4.8 Hz, 1H), 7.52 (dd, *J* = 8.8, 2.3 Hz, 1H), 7.20-7.13 (m, 1H), 5.54 (q, *J* = 6.9 Hz, 1H), 3.90-3.85 (m, 1H), 1.33-1.20 (m, 2H), 0.87-0.79 (m, 2H).


**LC-MS:** *m/z* 352.9 [M+H]<sup>+</sup> at 2.59 RT (96.11% purity).

**HPLC:** 93.29%.

10

### Example 8

#### Scheme:




#### ***N*-((5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propionamide (Ex. 8)**

To a stirred solution of (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methanamine **Int-3** (140 mg, 0.49 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under an inert atmosphere was added propionyl chloride (0.05 mL, 0.59 mmol) and triethylamine (0.14 mL, 0.1 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative high performance liquid chromatography (HPLC) to afford *N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methyl) propionamide **Ex. 8** (40 mg, 0.12 mmol, 24%) as white solid.

**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 9.72 (d, *J* = 1.4 Hz, 1H), 8.60 (br t, *J* = 5.1 Hz, 1H), 8.13 (d, *J* = 1.4 Hz, 1H), 7.79 (dd, *J* = 8.7, 4.9 Hz, 1H), 7.54 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.18 (td, *J* = 9.8, 2.3 Hz, 1H), 4.67 (d, *J* = 6.1 Hz, 2H), 3.89-3.84 (m, 1H), 2.22 (q, *J* = 7.5 Hz, 2H), 1.25-1.16 (m, 2H), 1.04 (t, *J* = 7.7 Hz, 3H), 0.77-0.71 (m, 2H).

**LC-MS:** *m/z* 340.1 [M+H]<sup>+</sup> at 2.07 RT (99.22% purity).

**HPLC:** 99.08%.

**Example 9****Scheme:**

5 **Ethyl((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl) carbamate (Ex. 9)**

To a stirred solution of (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methanamine **Int-3** (125 mg, 0.44 mmol) in THF (6 mL) under an inert atmosphere was added ethyl chloroformate (0.05 mL, 0.53 mmol) and triethylamine (0.12 mL, 0.88 mmol) at 0 °C.

10 The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford ethyl ((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methyl) carbamate **Ex. 9** (40 mg, 0.11 mmol, 26%) as an off white solid.


15 <sup>1</sup>H NMR (400MHz, DMSO-*d*<sub>6</sub>): δ 9.75 (d, *J* = 2.1 Hz, 1H), 8.18 (d, *J* = 2.0 Hz, 1H), 7.93 (br t, *J* = 6.0 Hz, 1H), 7.79 (dd, *J* = 8.9, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.1, 2.4 Hz, 1H), 7.22-7.15 (m, 1H), 4.60 (d, *J* = 6.1 Hz, 2H), 4.03 (q, *J* = 7.1 Hz, 2H), 3.91-3.84 (m, 1H), 1.22-1.16 (m, 5H), 0.78-0.73 (m, 2H).

LC-MS: *m/z* 356.1 [M+H]<sup>+</sup> at 2.33 RT (98.62% purity).

HPLC: 99.15%.

**Example 10**

25 **Scheme:**



**4-(5-(1-Cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)morpholine (Ex. 10)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (150 mg, 0.52 mmol) in ethanol (0.9 mL) under an inert atmosphere was added triethylamine (0.11 mL, 0.78 mmol) and morpholine (0.07 mL, 0.78 mmol) at room temperature. The reaction mixture was heated to 90 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 100% EtOAc) to afford 4-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)morpholine **Ex. 10** (40 mg, 0.12 mmol, 23%) as an off white solid.


**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 9.14 (s, 1H), 7.81-7.71 (m, 2H), 7.53 (br d, *J* = 7.8 Hz, 1H), 7.16 (br t, *J* = 7.1 Hz, 1H), 3.93-3.91 (m, 1H), 3.83-3.61 (m, 8H), 1.18-1.16 (m, 2H), 0.75-0.73 (m, 2H).

**LC-MS:** *m/z* 340.0 [M+H]<sup>+</sup> at 2.33 RT (97.11% purity).

**HPLC:** 97.09%.

**Example 11**

**Scheme:**



**1-Cyclopropyl-6-fluoro-2-(6-(4-(4-fluorophenyl)piperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 11)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (50 mg, 0.17 mmol) in EtOH (0.3 mL) under an inert atmosphere was added triethylamine (0.036 mL, 0.26 mmol) and 1-(4-fluorophenyl) piperazine (47 mg, 0.26 mmol) at room temperature. The reaction mixture was stirred at 90 °C for 7 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 90% EtOAc/hexane) to afford 1-cyclopropyl-6-fluoro-2-(6-(4-(4-fluorophenyl)piperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 11** (40 mg, 0.09 mmol, 53%) as an off-white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.13 (d, *J* = 1.6 Hz, 1H), 7.80 (d, *J* = 1.5 Hz, 1H), 7.77 (dd, *J* = 8.9, 4.9 Hz, 1H), 7.54 (dd, *J* = 9.1, 2.4 Hz, 1H), 7.20-7.14 (m, 1H), 7.12-7.02 (m, 4H), 3.96-3.92 (m, 1H), 3.89-3.83 (m, 4H), 3.28-3.24 (m, 4H), 1.21-1.15 (m, 2H), 0.78-0.72 (m, 2H)

**LC-MS:** *m/z* 433.1 [M+H]<sup>+</sup> at 2.38 RT (99.63% purity).

**HPLC:** 96.82%.

**Example 12**

**Scheme:**



**5-(1-Cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbaldehyde (Int-2)**

To a stirred solution of 1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 4** (600 mg, 2.14 mmol) in Acetone: *tert*-butanol (*t*BuOH): water (1:1:1, 30 mL) under an inert atmosphere was added sodium periodate (912 mg, 4.28 mmol) and osmium tetroxide (2.5 wt% in toluene, 3 mL) at 0 °C. The reaction mixture was stirred at 0 °C

for 5 h. After consumption of starting material (by TLC), the reaction mixture was filtered, and the filter was washed with EtOAc (2 x 30 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 90% EtOAc/hexane) to afford 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-2** (400 mg, 1.41 mmol, 66%) as brown solid.

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):** δ 10.52 (s, 1H), 10.08 (s, 1H), 8.65 (s, 1H), 7.81 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.35 (dd, *J* = 8.4, 2.3 Hz, 1H), 7.17-7.12 (m, 1H), 3.78-3.67 (m, 1H), 1.39-1.30 (m, 2H), 0.94-0.82 (m, 2H)

#### 10 **1-[5-(1-Cyclopropyl-6-fluoro-1*H*-1,3-benzodiazol-2-yl)pyridazin-3-yl]ethan-1-ol**

To a stirred solution of 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-2** (200 mg, 0.70 mmol) in THF (6 mL) under an inert atmosphere was added methylmagnesium bromide (2 M in diethylether, 0.35 mL, 0.70 mmol) drop wise at -78 °C. The reaction mixture was stirred at -78 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2-3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-[5-(1-cyclopropyl-6-fluoro-1*H*-1,3-benzodiazol-2-yl)pyridazin-3-yl]ethan-1-ol (150 mg, 0.50 mmol, 71%) as brown solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.72 (s, 1H), 8.34 (s, 1H), 7.79 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.55 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.23-7.14 (m, 1H), 5.78 (d, *J* = 4.6 Hz, 1H), 5.16-5.05 (m, 1H), 3.95-3.90 (m, 1H), 1.52 (d, *J* = 6.7 Hz, 3H), 1.25-1.15 (m, 2H), 0.77-0.75 (m, 2H)

#### 25 **1-(5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one**

To a stirred solution of 1-[5-(1-cyclopropyl-6-fluoro-1*H*-1,3-benzodiazol-2-yl)pyridazin-3-yl]ethan-1-ol (100 mg, 0.33 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added Dess-Martin periodinane (213 mg, 0.51 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL). The organic layer was washed with saturated sodium bicarbonate solution (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced

pressure. The crude material was purified by silica gel column chromatography (eluent: 2-3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) ethan-1-one (80 mg, 0.27 mmol, 81%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.04 (s, 1H), 8.64 (s, 1H), 7.82 (dd, *J* = 9.0, 4.9 Hz, 1H), 7.57 (dd, *J* = 9.0, 2.0 Hz, 1H), 7.23-7.11 (m, 1H), 4.02-3.91 (m, 1H), 2.87 (s, 3H), 1.20-1.15 (m, 2H), 0.79-0.76 (m, 2H)

## 2-(5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) propan-2-ol (Ex. 12)

To a stirred solution of 1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) ethan-1-one (60 mg, 0.20 mmol) in THF (2 mL) under an inert atmosphere was added methylmagnesium bromide (2 M in diethylether, 0.1 mL, 0.20 mmol) drop wise at -78 °C. The reaction mixture was stirred at -78 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 2-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) propan-2-ol **Ex. 12** (15 mg, 0.05 mmol, 24%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.65 (s, 1H), 8.57 (s, 1H), 7.73 (dd, *J* = 8.9, 4.8 Hz, 1H), 7.50 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.21-7.08 (m, 1H), 3.91-3.76 (m, 1H), 1.71 (s, 6H), 1.30-1.18 (m, 2H), 0.83-0.76 (m, 2H)


**LC-MS:** *m/z* 313 [M+H]<sup>+</sup> at 2.19 RT (95.83% purity).

**HPLC:** 95.47%.

25

## Example 13

### Scheme:



**5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridazin-3-amine (Ex. 13)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole **Ex. 3** (150 mg, 0.52 mmol) in EtOH (1.5 mL) under an inert atmosphere was added triethylamine (0.2 mL, 1.56 mmol) and tetrahydro-2*H*-pyran-4-amine (105 mg, 1.04 mmol) at room temperature. The reaction mixture was stirred at reflux for 16 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: EtOAc) to afford 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridazin-3-amine **Ex. 13** (40 mg, 0.11 mmol, 22%) as an off-white solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.01 (s, 1H), 7.74 (dd, *J* = 8.7, 4.9 Hz, 1H), 7.51 (dd, *J* = 9.1, 2.5 Hz, 1H), 7.41 (s, 1H), 7.18-7.11 (m, 1H), 7.07 (d, *J* = 7.2 Hz, 1H), 4.17-4.07 (m, 1H), 3.93-3.86 (m, 2H), 3.80-3.75 (m, 1H), 3.49-3.44 (m, 2H), 2.05-1.95 (m, 2H), 1.59-1.42 (m, 2H), 1.30-1.02 (m, 2H), 0.87-0.74 (m, 2H)

**LC-MS:** *m/z* 354 [M+H]<sup>+</sup> at 1.74 RT (97.97% purity).

**HPLC:** 97.95%.

**Example 14**

**Scheme:**



***N*-(2-(Cyclopropylamino)-4-fluorophenyl) cinnoline-4-carboxamide**

To a stirred solution of *N*1-cyclopropyl-5-fluorobenzene-1,2-diamine **Int-1** (500 mg, 3.01 mmol) in DMF (5 mL) under an inert atmosphere was added cinnoline-4-carboxylic acid (524 mg, 3.01 mmol), HATU (1.71 g, 4.51 mmol) and diisopropylethylamine (1 mL, 6.02 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(2-

(cyclopropylamino)-4-fluorophenyl) cinnoline-4-carboxamide (500 mg, crude) as brown solid used in the next step without further purification.

**LC-MS:**  $m/z$  322.9  $[M+H]^+$  at 2.71 RT (38.30% purity).

#### 5 **4-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)cinnoline (Ex. 14)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4-fluorophenyl) cinnoline-4-carboxamide (400 mg, 1.24 mmol) in EtOH (5 mL) under an inert atmosphere was added 6N HCl (4 mL) at room temperature. The reaction mixture was stirred at 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 4-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) cinnoline **Ex. 14** (160 mg, 0.52 mmol, 43%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):**  $\delta$  9.69 (s, 1H), 8.65 (d,  $J$  = 8.2 Hz, 1H), 8.23 (d,  $J$  = 8.5 Hz, 1H), 8.12-8.07 (m, 1H), 8.01-7.97 (m, 1H), 7.82-7.79 (m, 1H), 7.58 (dd,  $J$  = 8.8, 2.3 Hz, 1H), 7.25-7.18 (m, 1H), 3.76-3.71 (m, 1H), 0.98-0.93 (m, 2H), 0.65-0.54 (m, 2H)


**LC-MS:**  $m/z$  304.9  $[M+H]^+$  at 2.59 RT (99.51% purity).

**HPLC:** 99.30%.

20

#### **Example 15**

##### **Scheme:**



#### ***N*-(2-(Cyclopropylamino)-4-fluorophenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of 6-methylpyridazine-4-carboxylic acid (174 mg, 1.0 mmol) in DMF (3 mL) under an inert atmosphere was added *N*1-cyclopropyl-5-fluorobenzene-1,2-diamine **Int-1** (166 mg, 1.0 mmol), HATU (570 mg, 1.5 mmol) and diisopropylethylamine (1.38 mL, 4

mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(2-(cyclopropylamino)-4-fluorophenyl)-6-methylpyridazine-4-carboxamide (250 mg, crude) as brown solid.

**LC-MS:** *m/z* 287.2 [M+H]<sup>+</sup> at 3.53 RT (54.60% purity).

### 1-Cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 15)

To a stirred solution of *N*-(2-(cyclopropylamino)-4-fluorophenyl)-6-methylpyridazine-4-carboxamide (250 g, 0.87 mmol) in EtOH (1.5 mL) under an inert atmosphere was added 6N HCl (3.5 mL) at room temperature. The reaction mixture was stirred at 80 °C for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 4-5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 15** (80 mg, 0.29 mmol, 34%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.64 (s, 1H), 8.21 (s, 1H), 7.74 (dd, *J* = 9.0, 4.6 Hz, 1H), 7.51 (dd, *J* = 8.8, 2.1 Hz, 1H), 7.19-7.13 (m, 1H), 3.89-3.83 (m, 1H), 2.84 (s, 3H), 1.31-1.23 (m, 2H), 0.86-0.79 (m, 2H)

**LC-MS:** *m/z* 268.9 [M+H]<sup>+</sup> at 2.19 RT (95.85% purity).

**HPLC:** 97.59%.

### Example 16

#### Scheme:



***N*-(5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethanesulfonamide (Ex. 16)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole **Ex. 3** (100 mg, 0.34 mmol) in 1,4-dioxane (4 mL) was added ethane sulfonamide (57 mg, 0.52 mmol) and cesium carbonate (283 mg, 0.86 mmol) and the mixture was purged under argon for 5 min. Pd(OAc)<sub>2</sub> (7.8 mg, 0.004 mmol) and Xanthphos (30 mg, 0.05 mmol) were then added to the reaction mixture. The reaction mixture was heated to 120 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with 10% MeOH: CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2-3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethanesulfonamide **Ex. 16** (30 mg, 0.08 mmol, 24%) as colorless syrup.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 8.96 (brs, 1H), 8.45 (brs, 1H), 7.76-7.73 (m, 1H), 7.50 (dd, *J* = 8.8, 2.3 Hz, 1H), 7.25-7.12 (m, 1H), 3.79-3.73 (m, 1H), 3.30-3.21 (m, 2H), 1.46-1.37 (m, 5H), 1.03-0.82 (m, 2H)


**LC-MS:** *m/z* 362 [M+H]<sup>+</sup> at 2.04 RT (95.41% purity).

**HPLC:** 94.11%.

20

**Example 17**

**Scheme:**



**6-Chloro-*N*-(4-cyano-2-(ethylamino)phenyl)pyridazine-4-carboxamide**

To a stirred solution of 4-amino-3-(ethylamino) benzonitrile **Int-4** (322 mg, 2 mmol) in DMF (6 mL) under an inert atmosphere was added 6-chloropyridazine-4-carboxylic acid (316 mg, 2 mmol), HATU (1.14 g, 3 mmol) and ethyldiisopropylamine (1.38 mL, 8 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 6-chloro-*N*-(4-cyano-2-(ethylamino)phenyl) pyridazine-4-carboxamide (350 mg, crude) as an off-white solid.

**LC-MS:** *m/z* 300.1 [M-H]<sup>-</sup> at 2.07 RT (18.03% purity).

**2-(6-Chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 17)**


To a stirred solution of 6-chloro-*N*-(4-cyano-2-(ethylamino) phenyl) pyridazine-4-carboxamide (350 mg, 1.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) under an inert atmosphere was added trifluoroacetic acid (TFA) (1 mL) at room temperature. The reaction mixture was stirred at room temperature for 6 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 17** (25 mg, 0.08 mmol, 7.5%) as an off-white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.63 (d, *J* = 1.9 Hz, 1H), 8.27 (d, *J* = 1.8 Hz, 2H), 7.93 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.69 (dd, *J* = 8.5, 1.4 Hz, 1H), 4.56-4.51 (m, 2H), 1.51 (t, *J* = 7.3 Hz, 3H)

**LC-MS:** *m/z* 284.2 [M+H]<sup>+</sup> at 3.50 RT (99.67% purity).

**HPLC:** 99.48%.

**Example 18****Scheme:**



**2-(4-(5-(1-Cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-N-isopropylacetamide (Ex. 18)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole **Ex. 3** (56 mg, 0.19 mmol) in EtOH (2 mL) under an inert atmosphere was added triethylamine (0.04 mL, 0.28 mmol) and *N*-isopropyl-2-(4-(2, 2, 2-trifluoroacetyl)-4,5-piperazin-1-yl) acetamide (60 mg, 0.27 mmol) at room temperature. The reaction mixture was stirred at reflux for 16 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by preparative HPLC to afford 2-(4-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-*N*-isopropylacetamide **Ex. 18** (12 mg, 0.02 mmol, 14%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):**  $\delta$  9.08 (s, 1H), 7.76 (s, 1H), 7.72 (dd,  $J$  = 8.9, 4.8 Hz, 1H), 7.50 (dd,  $J$  = 8.8, 2.5 Hz, 1H), 7.15 (dt,  $J$  = 9.3, 2.4 Hz, 1H), 4.13-4.02 (m, 1H), 3.87-3.81 (m, 4H), 3.34-3.31 (m, 1H), 3.10 (s, 2H), 2.73-2.69 (m, 4H), 1.28-1.23 (m, 2H), 1.20 (d,  $J$  = 6.7 Hz, 6H), 0.86-0.80 (m, 2H)

**LC-MS:**  $m/z$  438.4  $[M+H]^+$  at 3.76 RT (94.38% purity).

**HPLC:** 94.23%.

**Example 19**

**Scheme:**



***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of *N*-1-cyclopropyl-4, 5-difluorobenzene-1, 2-diamine **Int-5** (184 mg, 1.0 mmol) in DMF (3 mL) under an inert atmosphere was added 6-methylpyridazine-4-carboxylic acid (174 mg, 1.0 mmol), HATU (570 mg, 1.5 mmol) and diisopropylethylamine (1.38 mL, 4.0 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide (220 mg, crude) as brown syrup.

**LC-MS:** *m/z* 305.2 [M+H]<sup>+</sup> at 3.78 RT (44.76% purity).

### **1-Cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 19)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide (220 mg, 0.72 mmol) in EtOH (1.5 mL) under an inert atmosphere was added 6N HCl (3.5 mL) at room temperature. The reaction mixture was stirred at 80 °C for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3-5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 19** (60 mg, 0.20 mmol, 29%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.63 (d, *J* = 1.9 Hz, 1H), 8.20 (d, *J* = 2.1 Hz, 1H), 7.72 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.62 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.90-3.83 (m, 1H), 2.84 (s, 3H), 1.31-1.24 (m, 2H), 0.85-0.80 (m, 2H)

**LC-MS:** *m/z* 286.9 [M+H]<sup>+</sup> at 2.32 RT (99.57% purity).

**HPLC:** 99.70%.

### **Example 20**

#### **Scheme:**



### ***tert*-Butyl 4-(2-ethoxy-2-oxoethyl) piperazine-1-carboxylate**

To a stirred solution of *tert*-butyl piperazine-1-carboxylate (2 g, 10.7 mmol) in DMF (14 mL) under an inert atmosphere was added potassium carbonate (3.71 g, 26.8 mmol) and ethylbromoacetate (1.2 mL, 10.8 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *tert*-butyl 4-(2-ethoxy-2-oxoethyl) piperazine-1-carboxylate (2.8 g, 10.29 mmol, 95%) as a yellow oil.

**<sup>1</sup>H NMR (500MHz, DMSO-*d*<sub>6</sub>):** δ 4.12-4.00 (m, 2H), 3.30 (s, 4H), 3.23 (s, 2H), 2.45 (t, *J* = 4.6 Hz, 4H), 1.39 (s, 9H), 1.18 (t, *J* = 7.1 Hz, 3H)

### **2-(4-*tert*-Butoxycarbonyl) piperazin-1-yl)acetic acid**

To a stirred solution of *tert*-butyl 4-(2-ethoxy-2-oxoethyl) piperazine-1-carboxylate (2.8 g, 10.29 mmol) in a mixture of THF: MeOH: water (3:1:1, 30 mL) was added lithium hydroxide (1.29 g, 30.8 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. Then the residue was acidified to pH 4-5 with 5% citric acid solution and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 2-(4-(*tert*-

butoxycarbonyl) piperazin-1-yl) acetic acid (200 mg, crude) as yellow oil used in the next step without further purification.

**LC-MS:**  $m/z$  245.1  $[M-H]^+$  at 1.06 RT (71.81% purity).

5 ***tert*-Butyl 4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazine-1-carboxylate**

To a stirred solution of 2-(4-(*tert*-butoxycarbonyl) piperazin-1-yl) acetic acid (500 mg, 2.04 mmol) in  $CH_2Cl_2$  (15 mL) under an inert atmosphere was added pyrrolidine (0.2 mL, 2.45 mmol), HATU (1.1 g, 3.07 mmol) and ethyldiisopropylamine (1.5 mL, 8.19 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After  
10 consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with  $CH_2Cl_2$  (2 x 30 mL). The combined organic extracts were dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/ $CH_2Cl_2$ ) to afford *tert*-butyl 4-(2-oxo-2-(pyrrolidin-1-yl) ethyl) piperazine-1-carboxylate (100 mg, 0.33 mmol, 16%) as brown  
15 solid.

**$^1H$  NMR (500MHz, DMSO- $d_6$ ):**  $\delta$  3.43 (t,  $J$  = 6.7 Hz, 2H), 3.31 (s, 2H), 3.29-3.25 (m, 4H), 2.43 (brs, 4H), 1.87-1.82 (m, 2H), 1.78-1.71 (m, 2H), 1.39 (s, 9H), 1.29-1.23 (m, 2H)

**4-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl 2,2,2-trifluoroacetate salt**

20 To a stirred solution of *tert*-butyl 4-(2-oxo-2-(pyrrolidin-1-yl) ethyl) piperazine-1-carboxylate (100 mg, 0.33 mmol) in  $CH_2Cl_2$  (1 mL) under an inert atmosphere was added trifluoroacetic acid (0.5 mL) drop wise at room temperature. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The crude material was washed with ether (2 x 5 mL) to  
25 afford 4-(2-oxo-2-(pyrrolidin-1-yl) ethyl) piperazin-1-yl 2, 2, 2-trifluoroacetate salt (120 mg as TFA salt) as a white solid.

**$^1H$  NMR (500 MHz, DMSO- $d_6$ ):**  $\delta$  3.72 (brs, 1H), 3.40-3.37 (m, 4H), 3.33-3.30 (m, 4H), 3.24 (s, 2H), 3.08 (brs, 4H), 1.92-1.85 (m, 2H), 1.81-1.76 (m, 2H)

30 **2-(4-(5-(1-Cyclopropyl-6-fluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (Ex. 20)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole **Ex. 3** (100 mg, 0.34 mmol) in EtOH (2 mL) under an inert atmosphere was added triethylamine (0.14 mL, 1.04 mmol) and 4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl 2,2,2-trifluoroacetate salt (34 mg, 0.17 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 32 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by preparative HPLC to afford 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) piperazin-1-yl)-1-(pyrrolidin-1-yl) ethan-1-one **Ex. 20** (20 mg, 0.041 mmol, 13%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.16 (s, 1H), 7.75-7.71 (m, 1H), 7.47 (s, 1H), 7.30 (dd, *J* = 8.6, 2.4 Hz, 1H), 7.11-7.06 (m, 1H), 3.87-3.85 (m, 4H), 3.63-3.57 (m, 1H), 3.53-3.43 (m, 4H), 3.28 (s, 2H), 2.83 (brs, 4H), 2.03-1.93 (m, 2H), 1.89-1.84 (m, 2H), 1.30-1.22 (m, 2H), 0.88-0.80 (m, 2H)

**LC-MS:** *m/z* 450.2 [M+H]<sup>+</sup> at 1.74 RT (97.66% purity).

**HPLC:** 97.81%.

### Examples 21 & 22

#### Scheme:



#### 20 6-Chloro-*N*-(2-(cyclopropylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide

To a stirred solution of *N*1-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (1 g, 5.43 mmol) in DMF (10 mL) under an inert atmosphere was added 6-chloropyridazine-4-carboxylic acid (1.03 g, 6.52 mmol), HATU (2.48 g, 6.52 mmol) and diisopropylethylamine (3.9 mL, 21.72 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 0-2%

MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 6-chloro-*N*-(2-(cyclopropylamino)-4, 5-difluorophenyl) pyridazine-4-carboxamide (800 mg, 2.46 mmol, 45%) as a brown solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.50 (s, 1H), 7.95 (d, *J* = 1.6 Hz, 1H), 7.74 (brs, 1H), 7.37 (dd, *J* = 10.5, 8.5 Hz, 1H), 7.06 (dd, *J* = 12.4, 7.7 Hz, 1H), 4.16-4.03 (m, 1H), 2.51-2.40 (m, 1H), 0.83-0.75 (m, 2H), 0.56-0.47 (m, 2H)

**2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 22)**

To a stirred solution of 6-chloro-*N*-(2-(cyclopropylamino)-4, 5-difluorophenyl) pyridazine-4-carboxamide (700 mg, 2.16 mmol) in EtOH (7 mL) under an inert atmosphere was added 6N HCl (10.5 mL) at room temperature. The reaction mixture was stirred at 70 °C for 30 min. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20-30% EtOAc/Hexane) to afford 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (280 mg, 0.91 mmol, 42%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.78 (d, *J* = 1.9 Hz, 1H), 8.15 (d, *J* = 1.9 Hz, 1H), 7.60 (dd, *J* = 10.0, 7.2 Hz, 1H), 7.44 (dd, *J* = 9.5, 6.9 Hz, 1H), 3.70-3.62 (m, 1H), 1.41-1.33 (m, 2H), 0.93-0.84 (m, 2H)

**LC-MS:** *m/z* 306.9 [M+1]<sup>+</sup> at 2.52 RT (99.86% purity).

**HPLC:** 99.51%.

**5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-methylpyridazin-3-amine (Ex. 21)**

2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (600 mg, 1.96 mmol) was dissolved in 2 M methylamine solution (2 M in diethylether, 3 mL) and the reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2-3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-

benzo[*d*]imidazol-2-yl)-*N*-methypyridazin-3-amine **Ex. 21** (50 mg, 0.16 mmol, 8%) as pale green solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.13 (d, *J* = 1.8 Hz, 1H), 7.57 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.41 (dd, *J* = 9.7, 7.0 Hz, 1H), 7.20 (d, *J* = 1.8 Hz, 1H), 5.03 (d, *J* = 4.5 Hz, 1H), 3.59 (tt, *J* = 7.0, 3.6 Hz, 1H), 3.12 (d, *J* = 5.1 Hz, 3H), 1.32-1.24 (m, 2H), 0.87-0.80 (m, 2H)

**LC-MS:** *m/z* 301.9 [M+1]<sup>+</sup> at 1.76 RT (98.78% purity).

**HPLC:** 99.48%.

### Example 23

#### 10 Scheme:



#### **1-Cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1H-benzo[*d*]imidazole (Ex. 23)**


To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[*d*]imidazole **Ex. 22** (100 mg, 0.32 mmol) in MeOH (5 mL) under an inert atmosphere was added sodium methoxide (53 mg, 0.98 mmol) at room temperature. The reaction mixture was stirred at 70 °C for 2 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was diluted with water (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 10 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/Hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1H-benzo[*d*]imidazole **Ex. 23** (40 mg, 0.13 mmol, 41%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.45 (s, 1H), 7.89-7.80 (m, 2H), 7.77 (s, 1H), 4.13 (s, 3H), 3.93-3.89 (m, 1H), 1.23-1.12 (m, 2H), 0.82-0.70 (m, 2H)

**LC-MS:** *m/z* 302.9 [M+H]<sup>+</sup> at 2.30 RT (99.80% purity).

**HPLC:** 99.68%.

### Example 24

**Scheme:**

**1-Cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 24)**

- 5 To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (70 mg, 0.23 mmol) in DMF (0.5 mL) under an inert atmosphere was added sodium hydride (55% in mineral oil, 20 mg, 0.46 mmol) portion wise at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. To this reaction mixture was added propan-2-ol (27.5 mg, 0.46 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. After
- 10 consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (10 mL), brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/Hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-
- 15 4-yl)-1H-benzo[d]imidazole **Ex. 24** (30 mg, 0.09 mmol, 40%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.39 (s, 1H), 7.89-7.80 (m, 2H), 7.67 (s, 1H), 5.57-5.51 (m, 1H), 3.93-3.89 (m, 1H), 1.42 (d, *J* = 6.1 Hz, 6H), 1.20-1.11 (m, 2H), 0.86-0.68 (m, 2H)

**LC-MS:** *m/z* 330.9 [M+H]<sup>+</sup> at 2.88 RT (93.72% purity).

**HPLC:** 95.25%.

20

**Example 25**

**Scheme:**

**5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N,N*-dimethylpyridazin-3-amine (Ex. 25)**

2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (60 mg, 0.19 mmol) was dissolved in 2 M dimethylamine solution (2 M in THF, 3 mL) and the reaction mixture was stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2-3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N,N*-dimethylpyridazin-3-amine **Ex. 25** (16 mg, 0.05 mmol, 26%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08 (s, 1H), 7.58 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.41 (dd, *J* = 9.7, 7.0 Hz, 1H), 7.32 (s, 1H), 3.62-3.57 (m, 1H), 3.28 (s, 6H), 1.29-1.23 (m, 2H), 0.87-0.77 (m, 2H)

LC-MS: *m/z* 316.1 [M+1]<sup>+</sup> at 1.81 RT (98.32% purity).

HPLC: 95.98%.

**Example 26**

**Scheme:**



**2-Bromo-1-ethyl-6-fluoro-1*H*-indole**

To a stirred solution of 2-bromo-6-fluoro-1*H*-indole (250 mg, 1.16 mmol) in DMF (2 mL) under an inert atmosphere were added potassium carbonate (476 mg, 3.50 mmol) followed by iodoethane (364 mg, 2.33 mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 2-bromo-1-ethyl-6-fluoro-1*H*-indole (280 mg, crude) as yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 7.43 (dd, *J* = 8.6, 5.3 Hz, 1H), 6.98 (dd, *J* = 9.7, 2.3 Hz, 1H), 6.86-6.84 (m, 1H), 6.54 (d, *J* = 0.8 Hz, 1H), 4.21-4.16 (m, 2H), 1.34 (t, *J* = 7.2 Hz, 3H)

**1-Ethyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (Ex. 26)**

5 To a stirred solution of 2-bromo-1-ethyl-6-fluoro-1*H*-indole (200 mg, 0.83 mmol) in 1, 4-dioxane (2 mL) were added (6-methylpyridazin-4-yl) boronic acid (214 mg, 1.24 mmol), sodium carbonate solution (2M, 0.5 mL) and purged under argon for 10 min. Then Pd(dppf)Cl<sub>2</sub> (60 mg, 0.08 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80 °C for 16 h in a sealed tube. The progress of the reaction was monitored by  
10 TLC; the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-ethyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole **Ex. 26** (50 mg, 0.19 mmol, 20%) as a yellow solid.

15 **<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.25 (d, *J* = 2.0 Hz, 1H), 7.76 (d, *J* = 2.1 Hz, 1H), 7.61 (dd, *J* = 8.7, 5.3 Hz, 1H), 7.28 (dd, *J* = 10.1, 2.2 Hz, 1H), 6.96-6.90 (m, 2H), 4.35-4.30 (m, 2H), 2.77 (s, 3H), 1.29 (t, *J* = 7.2 Hz, 3H)


**LC-MS:** *m/z* 256 [M+H]<sup>+</sup> at 2.73 RT (98.24% purity)

**HPLC:** 97.70%

20

**Example 27**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 27)**

25

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (70 mg, 0.23 mmol) in DMF (0.5 mL) under an inert atmosphere was added sodium hydride (55% in mineral oil, 20 mg, 0.46 mmol) portion wise at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. To this reaction mixture was added 2, 2, 2-trifluoroethan-1-ol (46 mg, 0.46 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (10 mL), brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/Hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(2, 2, 2-trifluoroethoxy) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 27** (50 mg, 0.13 mmol, 62%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.55 (s, 1H), 7.97 (s, 1H), 7.89-7.85 (m, 2H), 5.39-5.27 (m, 2H), 3.96-3.93 (m, 1H), 1.21-1.13 (m, 2H), 0.82-0.69 (m, 2H)

LC-MS: *m/z* 370.9 [M+1]<sup>+</sup> at 3.18 RT (99.73% purity).

HPLC: 98.32%.

### Example 28

#### Scheme:



#### 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2-methoxyethyl)pyridazin-3-amine (Ex. 28)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (50 mg, 0.16 mmol) in THF (0.5 mL) under an inert atmosphere was added 2-methoxyethan-1-amine (0.5 mL, 75.11 mmol) and ethyldiisopropylamine (0.5 mL) at room temperature. The reaction mixture was stirred at 110 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over

anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with CH<sub>2</sub>Cl<sub>2</sub>: Hexane (1: 9, 10 mL) to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2-methoxyethyl) pyridazin-3-amine **Ex. 28** (40 mg, 0.13 mmol, 92%) as a pale yellow solid.

5 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.12 (s, 1H), 7.56 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.41 (dd, *J* = 9.7, 6.9 Hz, 1H), 7.22 (s, 1H), 5.21 (brs, 1H), 3.76-3.73 (m, 2H), 3.69-3.64 (m, 2H), 3.61-3.59 (m, 1H), 3.41 (s, 3H), 1.31-1.25 (m, 2H), 0.87-0.81 (m, 2H)


LC-MS: *m/z* 346 [M+H]<sup>+</sup> at 1.80 RT (97.27% purity).

HPLC: 97.05%.

10

### Example 29

#### Scheme:



#### *N*-(4-Cyano-2-(cyclopropylamino) phenyl)-6-methoxypyridazine-4-carboxamide

15 To a stirred solution of 4-amino-3-(cyclopropylamino) benzonitrile **Int-6** (300 mg, 1.72 mmol) in DMF (5 mL) under an inert atmosphere was added 6-methoxypyridazine-4-carboxylic acid (281 mg, 1.72 mmol), HATU (720 mg, 1.89 mmol) and ethyldiisopropylamine (0.8 mL, 5.17 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture

20 was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(4-cyano-2-(cyclopropylamino) phenyl)-6-methoxypyridazine-4-carboxamide (300 mg, crude) as yellow liquid used in the next step without further purification.

25 **1-Cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 29)**

To a stirred solution of *N*-(4-cyano-2-(cyclopropylamino) phenyl)-6-methoxypyridazine-4-carboxamide (300 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added trifluoroacetic acid (0.5 mL) drop wise at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with water (5 mL), basified with saturated sodium carbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 29** (40 mg, 0.13 mmol, 14% (over two steps)) as a pale yellow solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.48 (s, 1H), 8.32 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.82 (s, 1H), 7.71 (dd, *J* = 8.4, 1.5 Hz, 1H), 4.14 (s, 3H), 4.01-3.85 (m, 1H), 1.23-1.14 (m, 2H), 0.87-0.77 (m, 2H)

**LC-MS:** *m/z* 291.9 [M+H]<sup>+</sup> at 2.25 RT (95.84% purity).

**HPLC:** 97.16%.

### Example 30

#### Scheme:



#### **1-(2, 2-Dibromovinyl)-4-fluoro-2-nitrobenzene**

To a stirred solution of 4-fluoro-2-nitrobenzaldehyde (2 g, 11.83 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) were added carbon tetrabromide (5.8 g, 17.75 mmol) and triphenylphosphine (9.3 g, 35.50

mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at 5 °C for 2 h. The progress of the reaction was monitored by TLC; the reaction mixture was filtered, the filtrate was concentrated under reduced pressure to obtain 1-(2, 2-dibromovinyl)-4-fluoro-2-nitrobenzene (3.2 g, crude) as brown solid which was used in the next step without further purification.

### 2-(2, 2-Dibromovinyl)-5-fluoroaniline

To a stirred solution of 1-(2, 2-dibromovinyl)-4-fluoro-2-nitrobenzene (3.2 g, 9.87 mmol) in EtOH (20 mL) was added SnCl<sub>2</sub> · H<sub>2</sub>O (11.1 g, 46.29 mmol) at RT under inert atmosphere. The reaction mixture was stirred at reflux for 2 h. The progress of the reaction was monitored by TLC; the volatiles were concentrated under reduced pressure. The obtained residue was basified with potassium carbonate solution to pH~10 and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/Hexane) to afford 2-(2, 2-dibromovinyl)-5-fluoroaniline (2.1 g, 7.14 mmol, 72%) as brown solid.

**LC-MS:** *m/z* 295.6 [M+2H]<sup>+</sup> at 3.34 RT (96.98% purity)

### *N*-(2-(2, 2-Dibromovinyl)-5-fluorophenyl) methanesulfonamide

To a stirred solution of 2-(2, 2-dibromovinyl)-5-fluoroaniline (1 g, 3.40 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) were added pyridine (0.54 mL, 6.80 mmol) and mesyl chloride (0.38 mL, 5.10 mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at RT for 16 h. The progress of the reaction was monitored by TLC; the reaction mixture was quenched with NaHSO<sub>4</sub> solution and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/Hexane) to afford *N*-(2-(2, 2-dibromovinyl)-5-fluorophenyl) methanesulfonamide (1.1 g, 2.94 mmol, 87%) as brown solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.57 (s, 1H), 7.69 (s, 1H), 7.59 (dd, *J* = 8.7, 6.4 Hz, 1H), 7.23 (dd, *J* = 10.4, 2.3 Hz, 1H), 7.14 (dt, *J* = 8.4, 2.3 Hz, 1H), 3.06 (s, 3H)

### 2-Bromo-6-fluoro-1*H*-indole

To a stirred solution of *N*-(2-(2, 2-dibromovinyl)-5-fluorophenyl) methanesulfonamide (200 mg, 0.53 mmol) in THF (2 mL) was added TBAF 1M in THF (1 mL) at RT under inert atmosphere. The reaction mixture was stirred at 100 °C for 5 min in *microwave*. The progress of the reaction was monitored by TLC; the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 2-bromo-6-fluoro-1*H*-indole **5** (100 mg, crude) as brown solid which was used in the next step without further purification.

**LC-MS:** *m/z* 295.6 [M+2H]<sup>+</sup> at 3.34 RT (96.98% purity)

### 2-Bromo-1-cyclopropyl-6-fluoro-1*H*-indole

To a stirred solution of 2-bromo-6-fluoro-1*H*-indole **5** (400 mg, 1.86 mmol) in 1, 2-dichloroethane (5 mL) were added cyclopropylboronic acid (321 mg, 3.73 mmol), sodium carbonate (571 mg, 5.60 mmol), copper acetate (371 mg, 1.86 mmol) and bipyridyl (291 mg, 1.86 mmol) at RT under inert atmosphere. The reaction mixture was stirred at 80 °C for 16 h in a sealed tube. The progress of the reaction was monitored by TLC; the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/Hexane) to afford 2-bromo-1-cyclopropyl-6-fluoro-1*H*-indole (300 mg, 1.19 mmol, 63%) as brown solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 7.39 (dd, *J* = 8.6, 5.4 Hz, 1H), 7.23 (dd, *J* = 10.1, 2.3 Hz, 1H), 6.88-6.83 (m, 1H), 6.51 (s, 1H), 3.14-3.09 (m, 1H), 1.27-1.19 (m, 2H), 1.13-1.08 (m, 2H)

### 1-Cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (Ex. 30)

To a stirred solution of 2-bromo-1-cyclopropyl-6-fluoro-1*H*-indole (200 mg, 0.79 mmol) in 1, 4-dioxane (5 mL) were added 3-methyl-5-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridazine (261 mg, 1.19 mmol), sodium carbonate solution (2M, 0.5 mL) and purged under argon for 10 min. Then Pd(dppf)Cl<sub>2</sub> (58 mg, 0.08 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80 °C for 16 h in a sealed tube. The progress of the reaction was monitored by TLC; the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine

(20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole **Ex. 30** (36 mg, 0.13 mmol, 17%) as a pale yellow solid.

5 <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 9.42 (d, *J* = 2.1 Hz, 1H), 7.97 (d, *J* = 2.1 Hz, 1H), 7.60 (dd, *J* = 8.7, 5.3 Hz, 1H), 7.37 (dd, *J* = 10.0, 2.4 Hz, 1H), 6.98 (s, 1H), 6.96-6.91 (m, 1H), 3.83-3.68 (m, 1H), 2.80-2.79 (m, 3H), 1.25-1.09 (m, 2H), 0.78-0.63 (m, 2H)


LC-MS: *m/z* 267.9 [M+H]<sup>+</sup> at 2.78 RT (98.96% purity)

HPLC: 97.98%

10

### Example 31

#### Scheme:



*N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (**Ex. 31**)

15

To a stirred solution of (5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanamine **Int-3** (30 mg, 0.10 mmol) in THF (2 mL) under an inert atmosphere was added ethanesulfonyl chloride (16 mg, 0.12 mmol) and triethylamine (0.03 mL, 0.21 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford *N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide **Ex. 31** (15 mg, 0.04 mmol, 38%) as white solid.

20


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.73 (s, 1H), 8.52 (s, 1H), 7.78-7.74 (m, 1H), 7.53 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.20-7.14 (m, 1H), 4.71 (s, 2H), 3.87-3.82 (m, 1H), 3.24-3.19 (m, 2H), 1.47-1.31 (m, 5H), 0.89-0.80 (m, 2H)

**LC-MS:** *m/z* 376 [M+H]<sup>+</sup> at 2.21 RT (99.12% purity).

5 **HPLC:** 98.34%.

### Example 32

#### Scheme:




10 **5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N-(2,2,2-trifluoroethyl)pyridazin-3-amine (Ex. 32)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (80 mg, 0.26 mmol) in NMP (1.2 mL) under an inert atmosphere was added 2,2,2-trifluoroethan-1-amine (1.2 mL) at room temperature. The reaction mixture  
 15 was stirred at 130 °C for 6 h in microwave. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3%MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N-(2, 2, 2-trifluoroethyl) pyridazin-3-amine **Ex. 32** (15 mg, 0.04 mmol, 15%) as a pale  
 20 yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.28 (s, 1H), 7.59 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.44 (dd, *J* = 9.6, 7.0 Hz, 1H), 7.37 (s, 1H), 5.09 (t, *J* = 6.0 Hz, 1H), 4.43-4.30 (m, 2H), 3.66-3.60 (m, 1H), 1.36-1.29 (m, 2H), 0.91-0.84 (m, 2H)

25 **LC-MS:** *m/z* 370 [M+H]<sup>+</sup> at 2.21 RT (97.23% purity).

**HPLC:** 97.15%.

**Example 33****Scheme:****1-Cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole**

- 5 To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (150 mg, 0.50 mmol) in 1,4-dioxane (3 mL) and water (0.5 mL) under an inert atmosphere was added vinyl boronic acid pinacol ester (76 mg, 0.50 mmol) and potassium carbonate (203 mg, 1.47 mmol) at room temperature. The reaction mixture was degassed with argon for 10 min, Pd(dppf)Cl<sub>2</sub> (4 mg, 0.005 mmol) was added, and the reaction
- 10 mixture was degassed with argon for another 10 min. The reaction mixture was heated to 80 °C and stirred for 5 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/ Hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole (70 mg, 0.23 mmol, 48%) as an off-white solid.
- 15 <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.69 (s, 1H), 8.45 (s, 1H), 7.90-7.83 (m, 2H), 7.18-7.11 (m, 1H), 6.53 (d, *J* = 17.7 Hz, 1H), 5.82 (d, *J* = 11.4 Hz, 1H), 3.99-3.97 (m, 1H), 1.22-1.13 (m, 2H), 0.82-0.60 (m, 2H)

**1-Cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 33)**

- 20 To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole (70 mg, 0.23 mmol) in EtOAc (3 mL) under an inert atmosphere was added 10% Pd/C (20 mg) and triethylamine (catalytic amount) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the reaction mixture was

filtered through a pad of celite and washed the pad was washed with methanol (30 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 33** (35 mg, 0.11 mmol, 50%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.65 (s, 1H), 8.17 (s, 1H), 7.89-7.81 (m, 2H), 3.95-3.91 (m, 1H), 3.10-3.04 (m, 2H), 1.36 (t, *J* = 7.6 Hz, 3H), 1.24-1.12 (m, 2H), 0.79-0.64 (m, 2H)

**LC-MS:** *m/z* 300.9 [M+H]<sup>+</sup> at 2.51 RT (98.98% purity).

**HPLC:** 97.01%.

### Example 34

#### Scheme:



#### **2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 34)**


To a stirred solution of 1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 29** (60 mg, 0.20 mmol) in phosphoryl chloride (POCl<sub>3</sub>) (0.38 mL, 4.13 mmol) under an inert atmosphere at room temperature. The reaction mixture was heated to 100 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified with saturated sodium carbonate solution (30 mL) extracted with EtOAc (2 x 30 mL).

The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 34** (10 mg, 0.03 mmol, 16%) as white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.82 (s, 1H), 8.47 (s, 1H), 8.26 (s, 1H), 7.91 (d, *J* = 8.4 Hz, 1H), 7.68 (dd, *J* = 8.4, 1.5 Hz, 1H), 3.95-3.90 (m, 1H), 1.36-1.29 (m, 2H), 0.94-0.84 (m, 2H)

**LC-MS:** *m/z* 296.2 [M+H]<sup>+</sup> at 3.28 RT (96.40% purity).

**HPLC:** 96.31%.

**Example 35****Scheme:****3-Cyclopropyl-2-oxo-2, 3-dihydro-1H-benzo[d]imidazole-5-carbonitrile**

5 To a stirred solution of 4-amino-3-(cyclopropylamino) benzonitrile **Int-6** (500 mg, 2.89 mmol) in THF (10 mL) under an inert atmosphere was added 1,1'-carbonyldiimidazole (CDI) (702 mg, 4.33 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic

10 extracts were washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/Hexane) to afford 3-cyclopropyl-2-oxo-2, 3-dihydro-1H-benzo[d]imidazole-5-carbonitrile (200 mg, 1.00 mmol, 35%) as an off-white solid.

<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 11.29 (brs, 1H), 7.55 (s, 1H), 7.45 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 1H), 2.91-2.85 (m, 1H), 1.05-1.00 (m, 2H), 0.92-0.83 (m, 2H)

15

**2-Bromo-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile**

To a stirred solution of 2-bromo-3-cyclopropyl-2, 3-dihydro-1H-benzo[d]imidazole-5-carbonitrile (200 mg, 1.0 mmol) in 1,2-dichloroethane (DCE) (4 mL) under an inert

20 atmosphere was added phosphoryl bromide (1.2 g, 4.02 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL), basified with saturated sodium carbonate solution (30 mL) extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced

pressure to obtain 2-bromo-3-cyclopropyl-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carbonitrile (50 mg, 0.20 mmol, 19%) as white solid used in the next step without further purification.

**LC-MS:** *m/z* 261.8 [M+]<sup>+</sup> at 2.52 RT (96.21% purity).

#### 5 **1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 35)**

To a stirred solution of 2-bromo-3-cyclopropyl-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carbonitrile (100 mg, 0.38 mmol) in 1,4-dioxane (3 mL) under an inert atmosphere was added 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridazine (126.9 mg, 0.57 mmol) and 2M aqueous sodium carbonate solution (0.3 mL, 0.64 mmol) at room temperature.

10 The reaction mixture was degassed under argon for 10 min, Pd(dppf)Cl<sub>2</sub> (23 mg, 0.03 mmol) was added, and the mixture was degassed under argon for another 10 min. The reaction mixture was heated to 90 °C and stirred for 16 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/ Hexane) to afford 1-cyclopropyl-2-

15 (6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 35** (20 mg, 0.07 mmol, 12%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.68 (d, *J* = 1.8 Hz, 1H), 8.26 (s, 2H), 7.91 (d, *J* = 8.5 Hz, 1H), 7.68 (dd, *J* = 8.4, 1.4 Hz, 1H), 3.94-3.90 (m, 1H), 2.86 (s, 3H), 1.36-1.25 (m, 2H), 0.90-0.81 (m, 2H)

20 **LC-MS:** *m/z* 275.9 [M+H]<sup>+</sup> at 2.02 RT (99.65% purity).

**HPLC:** 99.26%.

### Example 36

#### Scheme:



**1-Cyclopropyl-5,6-difluoro-2-(6-(4-methylpiperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 36)**

A solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (50 mg, 0.16 mmol) in 1-methylpiperazine (0.5 mL) under an inert atmosphere was stirred at 130 °C for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(4-methylpiperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 36** (25 mg, 0.06 mmol, 41%) as a pale yellow solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.13 (s, 1H), 7.57 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.46 (s, 1H), 7.41 (dd, *J* = 9.6, 7.0 Hz, 1H), 3.86-3.74 (m, 4H), 3.63-3.57 (m, 1H), 2.64-2.52 (m, 4H), 2.37 (s, 3H), 1.30-1.25 (m, 2H), 0.85-0.81 (m, 2H)

LC-MS: *m/z* 371 [M+H]<sup>+</sup> at 1.71 RT (98.46% purity).

HPLC: 97.35%.

**Example 37**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(piperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole**

To a stirred solution of *tert*-butyl 4-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) piperazine-1-carboxylate **Ex. 39** (200 mg, 0.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) under an inert atmosphere was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was neutralized with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The

combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with ether: *n*-pentane (1: 1, 2 x 2 mL) to obtain 1-cyclopropyl-5,6-difluoro-2-(6-(piperazin-1-yl) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (90 mg, crude) as brown solid used in the next step without further purification.

5 **LC-MS:** *m/z* 357 [M+H]<sup>+</sup> at 1.78 RT (98.01% purity).

**1-(4-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl) ethan-1-one (Ex. 37)**

To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(6-(piperazin-1-yl) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (50 mg, 0.14 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) under an inert atmosphere was added triethylamine (0.05 mL, 0.42 mmol) and acetyl chloride (0.01 mL, 0.14 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-(4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)ethan-1-one **Ex. 37** (14 mg, 0.03 mmol, 25%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.20 (s, 1H), 7.57 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.49 (s, 1H), 7.42 (dd, *J* = 9.6, 6.9 Hz, 1H), 3.94-3.89 (m, 2H), 3.84-3.78 (m, 2H), 3.75-3.70 (m, 2H), 3.69-3.64 (m, 2H), 3.64-3.59 (m, 1H), 2.18 (s, 3H), 1.32-1.26 (m, 2H), 0.86-0.81 (m, 2H)


**LC-MS:** *m/z* 399.1 [M+H]<sup>+</sup> at 1.57 RT (93.31% purity).

**HPLC:** 92.89%.

25

**Example 38**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 38)**

To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(6-(piperazin-1-yl) pyridazin-4-yl)-1H-benzo[d]imidazole (50 mg, 0.14) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) under an inert atmosphere was added triethylamine (0.05 mL, 0.42 mmol) and mesyl chloride (0.01 mL, 0.14 mmol) at 0 °C. The reaction mixture was stirred for 10 min. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(4-(methylsulfonyl) piperazin-1-yl) pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 38** (14 mg, 0.03 mmol, 25%) as a pale yellow solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.22 (s, 1H), 7.57 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.51 (s, 1H), 7.42 (dd, *J* = 9.6, 6.9 Hz, 1H), 3.96-3.91 (m, 4H), 3.65-3.60 (m, 1H), 3.43-3.38 (m, 4H), 2.84 (s, 3H), 1.34-1.24 (m, 2H), 0.91-0.80 (m, 2H)

**LC-MS:** *m/z* 435.1 [M+H]<sup>+</sup> at 2.09 RT (98.86% purity).

**HPLC:** 97.10%.

**Example 39**

**Scheme:**



***tert*-Butyl 4-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)piperazine-1-carboxylate (Ex. 39)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (200 mg, 0.65 mmol) in dimethyl sulfoxide (DMSO) (4 mL) under an inert atmosphere was added *tert*-butyl piperazine-1-carboxylate (729 mg, 3.97 mmol) at room temperature. The reaction mixture was stirred at 130 °C for 3 h. After consumption of

starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL) dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5%MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford **Ex. 39** (230 mg, 0.50 mmol, 77%) as brown solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.17 (s, 1H), 7.57 (dd, *J* = 10.0, 7.2 Hz, 1H), 7.47 (s, 1H), 7.41 (dd, *J* = 9.7, 6.9 Hz, 1H), 3.78-3.75 (m, 4H), 3.64-3.58 (m, 5H), 1.50 (s, 9H), 1.31-1.26 (m, 2H), 0.86-0.81 (m, 2H)

**LC-MS:** *m/z* 457.1 [M+H]<sup>+</sup> at 2.52 RT (97.87% purity).

**HPLC:** 95.78%.

### Examples 40 & 41

#### Scheme:



#### 6-Chloro-*N*-(4-cyano-2-(ethylamino) phenyl) pyridazine-4-carboxamide

To a stirred solution of 6-chloropyridazine-4-carboxylic acid (100 mg, 0.64 mmol) in DMF (2 mL) under an inert atmosphere was added 4-amino-3-(ethylamino) benzonitrile **Int-4** (104 mg, 0.64 mmol), HATU (369.9 mg, 0.97 mmol) and ethyldiisopropylamine (0.45 mL, 2.59 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h.

After consumption of starting material (by TLC), the reaction mixture was diluted with aqueous ammonium chloride solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced

pressure to obtain 6-chloro-*N*-(4-cyano-2-(ethylamino) phenyl) pyridazine-4-carboxamide (90 mg, crude) as yellow solid.

**LC-MS:**  $m/z$  300.9  $[M]^+$  at 2.07 RT (36.25% purity).

5

**1-Ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 40)**

To a stirred solution of 6-chloro-*N*-(4-cyano-2-(ethylamino) phenyl) pyridazine-4-carboxamide (100 mg, 0.33 mmol) in  $\text{CH}_2\text{Cl}_2$  (1.6 mL) under an inert atmosphere was added  
10 trifluoroacetic acid (0.4 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 6 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was triturated with ether  
15 (2 x 10 mL) and *n*-pentane (2 x 10 mL) to afford 1-ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 40** (25 mg, 0.09 mmol, 26%) as an off white solid.

**$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):**  $\delta$  9.27 (d,  $J$  = 1.9 Hz, 1H), 8.24 (s, 1H), 7.91 (dd,  $J$  = 8.4, 0.6 Hz, 1H), 7.68 (dd,  $J$  = 8.5, 1.4 Hz, 1H), 7.59 (s, 1H), 4.53-4.49 (m, 2H), 4.22 (s, 3H), 1.48 (t,  $J$  = 7.3 Hz, 3H)

20 **LC-MS:**  $m/z$  279.8  $[M+H]^+$  at 2.15 RT (98.27% purity).

**HPLC:** 98.65%.

**2-(6-Chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 17)**

To a stirred solution of 1-ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 40** (85 mg, 0.30 mmol) in phosphoryl chloride (0.57 mL, 6.09 mmol) under an  
25 inert atmosphere at room temperature. The reaction mixture was heated to 100 °C for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified with aqueous sodium carbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (10 mL), dried over anhydrous  $\text{Na}_2\text{SO}_4$   
30 and concentrated under reduced pressure. The crude material was triturated with ether (2 x 5 mL) and *n*-pentane (2 x 5 mL) to afford 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-

benzo[*d*]imidazole-6-carbonitrile **Ex. 17** (100 mg, crude) as pale yellow syrup used in the next step without further purification.

**1-Ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile**


- 5 To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 17** (130 mg, 0.46 mmol) in 1, 4-dioxane (3 mL) and water (0.5 mL) under an inert atmosphere was added vinyl boronic acid pinacol (70 mg, 0.46 mmol) and potassium carbonate (190 mg, 1.37 mmol) at room temperature. The reaction mixture was degassed under argon for 10 min. To this was added Pd(dppf)Cl<sub>2</sub> (3.7 mg, 0.005 mmol) at room  
10 temperature and the mixture was degassed under argon for an additional 10 min. The reaction mixture was heated to 80 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was filtered. The filtrate concentrated under reduced pressure to obtain 1-ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (110 mg, crude) as brown syrup.
- 15 **LC-MS:** *m/z* 275.9 [M+H]<sup>+</sup> at 2.18 RT (78.16% purity).

**1-Ethyl-2-(6-ethylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 41)**

- To a stirred solution of 1-ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (110 mg, 0.40 mmol) in EtOAc (5 mL) under an inert atmosphere was added 10% Pd/C (50%  
20 wet, 20 mg) and triethylamine (0.005 mL, 0.04 mmol) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 2 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with EtOAc (20 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 1-ethyl-2-(6-ethylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 41** (4 mg, 14.44 mmol, 4%) as  
25 an off-white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.51 (d, *J* = 2.0 Hz, 1H), 8.26 (s, 1H), 8.06 (d, *J* = 2.1 Hz, 1H), 7.92 (d, *J* = 8.4 Hz, 1H), 7.69 (dd, *J* = 8.5, 1.4 Hz, 1H), 4.55-4.50 (m, 2H), 3.21-3.15 (m, 2H), 1.53-1.45 (m, 6H)

- 30 **LC-MS:** *m/z* 277.9 [M+H]<sup>+</sup> at 2.12 RT (96.23% purity).  
**HPLC:** 96.66%.


**Example 42****Scheme:****1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole****(Ex. 42)**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-27** (100 mg, 0.33 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under an inert atmosphere was added (diethylamino)sulfur trifluoride (DAST) (0.09 mL, 0.66 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/Hexane) to afford 1-cyclopropyl-2-(6-(difluoromethyl) pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole **Ex. 42** (40 mg, 0.12 mmol, 37%) as brown solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.99 (s, 1H), 8.55 (s, 1H), 7.93-7.85 (m, 2H), 7.42 (t, *J* = 54.5 Hz, 1H), 4.01-3.97 (m, 1H), 1.25-1.13 (m, 2H), 0.84-0.72 (m, 2H)

**LC-MS:** *m/z* 323.3 [M+H]<sup>+</sup> at 3.53 RT (98.91% purity).

**HPLC:** 99.33%.

**Example 43****Scheme:**

**2-(6-Cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole (Ex. 43)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (50 mg, 0.16 mmol) in DMF (2 mL) under an inert atmosphere was added sodium hydride (60% in mineral oil, 16.3 mg, 0.41 mmol) portion wise at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. Then cyclobutanol (141 mg, 0.20 mmol) was added to the reaction mixture at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 2-(6-cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 43** (45 mg, 0.13 mmol, 57%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.42 (s, 1H), 7.59 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.47 (s, 1H), 7.44-7.40 (m, 1H), 5.53-5.48 (m, 1H), 3.62-3.57 (m, 1H), 2.67-2.50 (m, 2H), 2.31-2.08 (m, 2H), 1.99-1.83 (m, 1H), 1.78-1.73 (m, 1H), 1.37-1.24 (m, 2H), 0.89-0.77 (m, 2H)

LC-MS: *m/z* 343 [M+H]<sup>+</sup> at 2.61 RT (95.30% purity).

HPLC: 95.28%.

**Example 44**

**Scheme:**



**1-Cyclopropyl-2-(6-(4,4-difluoropiperidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 44)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (100 mg, 0.32 mmol) in DMSO (2 mL) under an inert atmosphere

was added 4, 4-difluoropiperidine (59 mg, 0.49 mmol) at room temperature. The reaction mixture was heated to 120-130 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50-60% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(4, 4-difluoropiperidin-1-yl) pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 44** (40 mg, 0.10 mmol, 32%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.09 (s, 1H), 7.82 (s, 1H), 7.72-7.68 (m, 1H), 7.62-7.57 (m, 1H), 3.99-3.92 (m, 4H), 3.86-3.83 (m, 1H), 2.19-2.00 (m, 4H), 1.27-1.19 (m, 2H), 0.87-0.76 (m, 2H)

**LC-MS:** *m/z* 392.1 [M+H]<sup>+</sup> at 2.98 RT (93.89% purity).

**HPLC:** 92.05%.

### Example 45

#### Scheme:



#### 6-Methylpyridazine-4-carboxylic acid

To a stirred solution of 3-chloro-6-methylpyridazine-4-carboxylic acid **1** (500 mg, 2.90 mmol) in MeOH (50 mL) under an inert atmosphere was added sodium hydroxide (395 mg, 9.80 mmol) and 10% Pd/C (50% wet, 150 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure and 6N HCl was added up to

pH~6 and concentrated under reduced pressure to obtain 6-methylpyridazine-4-carboxylic acid (410 mg, crude) as yellow liquid used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.24 (s, 1H), 7.69 (s, 1H), 2.62 (s, 3H)

#### 5 ***N*-(6-Chloro-2-(cyclopropylamino) pyridin-3-yl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of 6-chloro-*N*2-cyclopropylpyridine-2, 3-diamine **Int-8** (400 mg, 2.18 mmol) in DMF (5 mL) under an inert atmosphere was added compound 6-methylpyridazine-4-carboxylic acid (362 mg, 2.62 mmol), HATU (996 mg, 2.62 mmol) and ethyldiisopropylamine (1.6 mL, 8.75 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(6-chloro-2-(cyclopropylamino) pyridin-3-yl)-6-methylpyridazine-4-carboxamide (200 mg, 0.66 mmol, 30%) as black solid used in the next step without further purification.

**LC-MS:** *m/z* 303.9 [M+H]<sup>+</sup> at RT 2.06 (93.73% purity).


#### **5-Chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (Ex. 45)**

To a stirred solution of *N*-(6-chloro-2-(cyclopropylamino) pyridin-3-yl)-6-methylpyridazine-4-carboxamide (100 mg, 0.33 mmol) in EtOH (2 mL) under an inert atmosphere was added 6N HCl (3 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated Sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 45** (12 mg, 0.04 mmol, 10%) as brown solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.67 (s, 1H), 8.26 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 3.83-3.78 (m, 1H), 2.84 (s, 3H), 1.29-1.25 (m, 2H), 0.94-0.92 (m, 2H)

**LC-MS:** *m/z* 285.9 [M+H]<sup>+</sup> at 2.03 RT (98.73% purity).

**HPLC:** 95.65%.

**Example 46****Scheme:**

**1-Cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 46)**


To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (100 mg, 0.32 mmol) in DMSO (2 mL) under an inert atmosphere was added 3, 3-difluoropyrrolidine hydrochloride (70 mg, 0.50 mmol) and triethylamine (0.06 mL, 0.49 mmol) at room temperature. The reaction mixture was heated to 130 °C and stirred for 48 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 1-cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl) pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole **Ex. 46** (15 mg, 0.04 mmol, 12%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.10 (s, 1H), 7.72-7.68 (m, 1H), 7.62-7.57 (m, 1H), 7.49 (d, *J* = 1.8 Hz, 1H), 4.03 (t, *J* = 12.9 Hz, 2H), 3.90-3.77 (m, 3H), 2.69-2.54 (m, 2H), 1.30-1.22 (m, 2H), 0.86-0.80 (m, 2H)

**LC-MS:** *m/z* 378.1 [M+H]<sup>+</sup> at 2.80 RT (97.60% purity).

**HPLC:** 99.55%.

**Example 47****Scheme:**



**1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (Ex. 47)**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-27** (50 mg, 0.16 mmol) in THF (1 mL) under an inert atmosphere was added trimethyl (trifluoromethyl) silane (47 mg, 0.33 mmol) at 0 °C. Cesium fluoride (76 mg, 0.50 mmol) was added to the reaction mixture at 0 °C. The reaction mixture was stirred at room temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with 1N HCl solution (5 mL) at 0 °C and extracted with EtOAc (2 x 15 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/Hexane) to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2, 2, 2-trifluoroethan-1-ol **Ex. 47** (10 mg, 0.03 mmol, 16%) as brown solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.83 (s, 1H), 8.58 (s, 1H), 7.75-7.71 (m, 1H), 7.67-7.63 (m, 1H), 5.60-5.52 (m, 1H), 3.94-3.81 (m, 1H), 1.35-1.21 (m, 2H), 0.93-0.78 (m, 2H)

**LC-MS:** *m/z* 371 [M+H]<sup>+</sup> at 2.69 RT (95.24% purity).

**HPLC:** 95.69%.

**Example 48**

**Scheme:**



**1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N,N*-dimethylpyrrolidin-3-amine (Ex. 48)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (115 mg, 0.37 mmol) in DMSO (2 mL) under an inert atmosphere was added triethylamine (0.116 mL, 0.84 mmol) and 1-(3-(dimethylamino)-1*H*-pyrrolidin-1-yl)-2,2,2-trifluoroethan-1-one (120 mg, 0.56 mmol) at 0 °C. The reaction mixture was stirred at 90 °C for 5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 5-10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N,N*-dimethylpyrrolidin-3-amine **Ex. 48** (10 mg, 0.02 mmol, 7%) as an off-white solid.

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 9.01 (s, 1H), 7.72-7.67 (m, 1H), 7.61-7.57 (m, 1H), 7.44 (s, 1H), 3.96-3.93 (m, 1H), 3.86-3.81 (m, 2H), 3.62-3.55 (m, 1H), 3.45-3.37 (m, 1H), 3.09-2.99 (m, 1H), 2.38 (s, 6H), 2.08-1.95 (m, 1H), 1.32-1.20 (m, 3H), 0.87-0.78 (m, 2H)


**LC-MS:** *m/z* 385.1 [M+H]<sup>+</sup> at 2.06 RT (97.17% purity).

**HPLC:** 98.58%.

20

**Example 49**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 49)**

Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (11.5 mg, 0.01 mmol) and sodium carbonate (86.4 mg, 0.81 mmol) in 1,4-dimethoxyethane (DME): water (4: 1, 1.25 mL) at room temperature were purged under argon for 5 min. 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (50 mg, 0.16 mmol) and (4-fluorophenyl) boronic acid (25.1 mg, 0.17 mmol) were added

to the reaction mixture at room temperature. The reaction mixture was stirred at 80 °C for 12 h in a sealed tube. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 49** (40 mg, 0.10 mmol, 48%) as an off-white solid.


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 9.75 (s, 1H), 8.68 (s, 1H), 8.32-8.18 (m, 2H), 7.76-7.72 (m, 1H), 7.67-7.62 (m, 1H), 7.35 (t, *J* = 8.8 Hz, 2H), 3.98-3.93 (m, 1H), 1.32-1.25 (m, 2H), 0.90-0.84 (m, 2H)

LC-MS: *m/z* 367 [M+H]<sup>+</sup> at 2.58 RT (98.75% purity).

HPLC: 98.72%.

### Example 50

#### Scheme:




#### 1-Cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl)ethynyl)pyridazin-4-yl)-1H-benzo[d]imidazole (**Ex. 50**)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (100 mg, 0.32 mmol) in *N,N*-dimethylacetamide (DMA) (3 mL) under an inert atmosphere was added 1-ethynyl-4-fluorobenzene (40 mg, 0.32 mmol) and potassium carbonate (90 mg, 0.65 mmol) at room temperature. The reaction mixture was degassed with argon for 10 min. Pd<sub>2</sub>(dba)<sub>3</sub> (14.8 mg, 0.01 mmol) and X-phos (8 mg, 0.01 mmol) were added at room temperature and the mixture was degassed with argon for an additional 5 min. The reaction mixture was heated to 80 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over

anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl)ethynyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 50** (50 mg, 0.13 mmol, 39%) as a brown solid.

- 5 **<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.81 (s, 1H), 8.49 (s, 1H), 7.91-7.84 (m, 2H), 7.84-7.76 (m, 2H), 7.38 (t, *J* = 9.0 Hz, 2H), 4.01-3.93 (m, 1H), 1.24-1.16 (m, 2H), 0.85-0.71 (m, 2H)  
**LC-MS:** *m/z* 391.3 [M+H]<sup>+</sup> at 4.58 RT (97.94% purity).  
**HPLC:** 96.14%.

10

**Example 51****Scheme:****1-Cyclopropyl-5,6-difluoro-2-(6-(prop-1-en-2-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole**

- To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (120 mg, 0.40 mmol) in 1,4-dioxane (3.2 mL) and water (0.8 mL) was added 4, 4, 5, 5-tetramethyl-2-(prop-1-en-2-yl)-1, 3, 2-dioxaborolane (219 mg, 1.17 mmol) and sodium carbonate (164.6 mg, 1.56 mmol) and the mixture was purged with argon for 10 min at room temperature. Pd(PPh<sub>3</sub>)<sub>4</sub> (23 mg, 0.02 mmol) was added to the reaction mixture. The reaction mixture was heated at 110 °C for 8 h. After consumption of starting material (by TLC), the reaction mixture was filtered. The filtrate was concentrated under reduced pressure. The crude material was triturated with *n*-pentane (2 x 5 mL) to obtain 1-cyclopropyl-5,6-difluoro-2-(6-(prop-1-en-2-yl) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (100 mg, crude) as an off-white solid that was used in the next step without further purification.

**LC-MS:** *m/z* 313.1 [M+H]<sup>+</sup> at 2.38 RT (94.08% purity).

25

**1-Cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 51)**

To a stirred solution of compound 1-cyclopropyl-5,6-difluoro-2-(6-(prop-1-en-2-yl) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (100 mg, 0.32 mmol) in ethyl acetate (5 mL) under an inert

atmosphere was added triethylamine (0.04 mL), sodium hydroxide (25 mg, 0.64 mmol) and 10% Pd/C (50% wet, 30 mg) at room temperature. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with EtOAc (20 mL). The filtrate was concentrated under reduced pressure. The crude material was washed with *n*-pentane (2 x 2 mL) and ether (2 x 2 mL) to afford 1-cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 51** (55 mg, 0.17 mmol, 55%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.63 (s, 1H), 8.22 (s, 1H), 7.73-7.69 (m, 1H), 7.64-7.60 (m, 1H), 3.91-3.86 (m, 1H), 3.49-3.31 (m, 1H), 1.47 (d, *J* = 7.0 Hz, 6H), 1.31-1.20 (m, 2H), 0.86-0.73 (m, 2H)

**LC-MS:** *m/z* 315.1 [M+H]<sup>+</sup> at 2.31 RT (97.95% purity).

**HPLC:** 99.16%.

### Example 52

#### Scheme:



#### *N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (**Ex. 52**)

To a stirred solution of (5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazin-3-yl) methanamine (140 mg, 0.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) under an inert atmosphere was added triethylamine (0.19 mL, 0.79 mmol) and ethane sulfonyl chloride (65.7 mg, 0.51 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified

by preparative HPLC to afford *N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl) ethanesulfonamide **Ex. 52** (18 mg, 0.04 mmol, 10%) as white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.72 (s, 1H), 8.52 (s, 1H), 7.76-7.70 (m, 1H), 7.66-7.61 (m, 1H), 4.71 (s, 2H), 3.88-3.82 (m, 1H), 3.24-3.19 (m, 2H), 1.43-1.33 (m, 5H), 0.86-0.79 (m, 2H)

5 **LC-MS:** *m/z* 394 [M+H]<sup>+</sup> at 2.32 RT (99.29% purity).

**HPLC:** 98.78%.

### Example 53

#### Scheme:



10

#### 1-Cyclopropyl-5,6-difluoro-2-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 53)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (75 mg, 0.24 mmol) in DMF (2.25 mL) under an inert atmosphere was added sodium hydride (60% in mineral oil, 24.5 mg, 0.61 mmol) portion wise at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. Then 1, 1, 1-trifluoropropan-2-ol (34 mg, 0.30 mmol) was added to the reaction mixture at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL).

15

The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(6-((1, 1, 1-trifluoropropan-2-yl) oxy) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 53** (60 mg, 0.15 mmol, 84%) as brown solid.

20

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.54 (s, 1H), 7.63 (s, 1H), 7.62-7.58 (m, 1H), 7.45-7.41 (m, 1H), 6.15-6.04 (m, 1H), 3.69-3.42 (m, 1H), 1.64 (d, *J* = 6.3 Hz, 3H), 1.36-1.24 (m, 2H), 0.92-0.81 (m, 2H)


25

**LC-MS:**  $m/z$  385.1  $[M+H]^+$  at 2.76 RT (97.88% purity).

**HPLC:** 97.83%.

### Example 54

#### 5 Scheme:



#### 3-Cyclopropyl-2-(6-methylpyridazin-4-yl)-3H-imidazo[4,5-*b*]pyridine-5-carbonitrile (Ex. 54)

To a stirred solution of 5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3H-imidazo [4, 5-*b*] pyridine **Ex. 45** (75 mg, 0.26 mmol) in DMF (0.8 mL) at room temperature was added zinc cyanide (61.5 mg, 0.52 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (30.3 mg, 0.02 mmol). The mixture purged with argon for 10 min and then heated to 170 °C for 4.5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3H-imidazo [4, 5-*b*] pyridine-5-carbonitrile **Ex. 54** (25 mg, 0.09 mmol, 35%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):**  $\delta$  9.75 (s, 1H), 8.19 (d,  $J$  = 8.2 Hz, 1H), 8.01 (s, 1H), 7.72 (d,  $J$  = 8.2 Hz, 1H), 3.70-3.64 (m, 1H), 2.90 (s, 3H), 1.41-1.36 (m, 2H), 1.06-0.81 (m, 2H)

**LC-MS:**  $m/z$  276.9  $[M+H]^+$  at 1.88 RT (98.98% purity).

**HPLC:** 95.03%.

### Example 55

#### Scheme:



### *N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide

To a stirred solution of *N*1-cyclopropyl-4, 5-difluorobenzene-1, 2-diamine **Int-5** (300 mg, 1.63 mmol) in DMF (3 mL) under an inert atmosphere was added pyridazine-4-carboxylic acid (202 mg, 1.63 mmol), HATU (743 mg, 1.95 mmol) and ethyldiisopropylamine (1.1 mL, 6.52 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain *N*-(2-(cyclopropylamino)-4, 5-difluorophenyl) pyridazine-4-carboxamide (250 mg, crude) as an off-white solid that was used in the next step without further purification.

**LC-MS:**  $m/z$  291[M+H]<sup>+</sup> at 2.34 RT (96.97% purity).


### 1-Cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 55)

To a stirred solution of *N*-(2-(cyclopropylamino)-4, 5-difluorophenyl) pyridazine-4-carboxamide (200 mg, 0.68 mmol) in EtOH (4 mL) under an inert atmosphere was added 6N HCl (2 mL) at room temperature. The reaction mixture was stirred at 70 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-pentane (2 x 5 mL) to afford 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 55** (120 mg, 0.44 mmol, 64%) as an off-white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.81 (s, 1H), 9.41 (dd, *J* = 5.4, 1.3 Hz, 1H), 8.33 (dd, *J* = 5.5, 2.3 Hz, 1H), 7.4-7.69 (m, 1H), 7.65-7.61 (m, 1H), 3.87-3.84 (m, 1H), 1.30-1.24 (m, 2H), 0.88-0.73 (m, 2H)

**LC-MS:**  $m/z$  272.9 [M+H]<sup>+</sup> at 2.21 RT (99.23% purity).

**HPLC:** 99.54%.

**Example 56****Scheme:**

5 **1-Cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-4-(trifluoromethyl)-1H-benzo[d]imidazole (Ex. 56)**


To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 55** (100 mg, 0.36 mmol) in DMSO (1.5 mL) under an inert atmosphere was added zinc trifluoromethanesulfinate (243 mg, 0.73 mmol) at room temperature. To this was added TBHP  
 10 (141 mg, 1.10 mmol) at 0 °C. The reaction mixture was stirred at 50 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was basified with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 1-cyclopropyl-5,6-difluoro-2-  
 15 (pyridazin-4-yl)-4-(trifluoromethyl)-1H-benzo[d]imidazole **Ex. 56** (19 mg, 0.05 mmol, 15%) as an off-white solid.

**<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD):** δ 9.85 (s, 1H), 9.44 (dd, *J* = 5.2, 1.2 Hz, 1H), 8.38 (dd, *J* = 5.2, 2.3 Hz, 1H), 8.06 (dd, *J* = 9.3, 7.0 Hz, 1H), 3.92-3.86 (m, 1H), 1.38-1.20 (m, 2H), 0.89-0.83 (m, 2H)

20 **LC-MS:** *m/z* 340.9 [M+H]<sup>+</sup> at 2.75 RT (91.67% purity)

**HPLC:** 91.79%

**Example 57****Scheme:**



**1-Cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 57)**

5 To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (50 mg, 0.16 mmol) in DMF (1.5 mL) was added sodium hydride (60% in mineral oil, 16.2 mg, 0.40 mmol) portion wise at 0 °C under an inert atmosphere and the mixture was stirred for 5 min. 2,2-Difluoropropan-1-ol (18.8 mg, 0.19 mmol) was added to the reaction mixture and stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and

10 extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with CH<sub>2</sub>Cl<sub>2</sub>: *n*-pentane (5: 95, 10 mL) to afford 1-cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole **Ex. 57** (45 mg, 0.12 mmol, 82%) as an

15 off-white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.53 (s, 1H), 7.65 (d, 1H), 7.60 (dd, *J* = 10.0, 7.3 Hz, 1H), 7.43 (dd, *J* = 9.7, 6.9 Hz, 1H), 4.80 (t, *J* = 12.1 Hz, 2H), 3.67-3.58 (m, 1H), 1.80 (t, *J* = 18.6 Hz, 3H), 1.39-1.27 (m, 2H), 0.92-0.76 (m, 2H)

**LC-MS:** *m/z* 367 [M+H]<sup>+</sup> at 3.08 RT (96.40% purity)

20 **HPLC:** 94.40%

**Example 58**

**Scheme:**




**1-Cyclopropyl-5,6-difluoro-2-(5-isopropylpyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 58)**

To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 55** (100 mg, 0.37 mmol) in DMSO (1 mL) was added zinc isopropylsulfinate (205 mg, 0.73 mmol) at room temperature under an inert atmosphere. Then *tert*-butyl hydroperoxide (70% in water, 142 mg, 1.1 mmol) was added at 0 °C. The reaction mixture was gradually warmed to room temperature, and then heated to 50 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was basified with saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) followed by triturations with *n*-pentane (2 x 4 mL) and dried under vacuum to afford 1-cyclopropyl-5,6-difluoro-2-(5-isopropylpyridazin-4-yl)-1H-benzo[d]imidazole **Ex. 58** (15 mg, 0.05 mmol, 13%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.48 (d, *J* = 0.8 Hz, 1H), 9.31 (d, *J* = 1.0 Hz, 1H), 7.71 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.61 (dd, *J* = 10.5, 7.3 Hz, 1H), 3.62-3.56 (m, 1H), 3.27-3.20 (m, 1H), 1.33 (d, *J* = 7.0 Hz, 6H), 1.08-1.03 (m, 2H), 0.73-0.68 (m, 2H)

**LC-MS:** *m/z* 315.0 [M+H]<sup>+</sup> at 2.70 RT (95.37% purity)

**HPLC:** 92.84%

**Example 59****Scheme:****1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 59)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (70 mg, 0.22 mmol) in toluene/water (3: 1, 2 mL) was added cyclopropylboronic acid (24 mg, 0.27 mmol) and cesium carbonate (186 mg, 0.57 mmol) in a sealed tube and the mixture was purged under argon for 10 min. Pd(dppf)Cl<sub>2</sub> (18.6 mg, 0.02

mmol) was added to the reaction mixture with further degassed for 5 min. The reaction was heated to 110 °C for 16 h and then cooled. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 59** (8 mg, 0.02 mmol, 11%) as a pale yellow solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.57 (s, 1H), 7.81 (s, 1H), 7.59 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.43 (dd, *J* = 9.7, 7.0 Hz, 1H), 3.67-3.60 (m, 1H), 2.32-2.24 (m, 1H), 1.35-1.27 (m, 4H), 1.25-1.19 (m, 2H), 0.86-0.80 (m, 2H)

**LC-MS:** *m/z* 313.1 [M+H]<sup>+</sup> at 2.22 RT (93.72% purity)

**HPLC:** 96.07%

### Example 60

#### Scheme:



#### 6-Chloro-*N*-(2-(cyclopropylamino)-6-methoxypyridin-3-yl)pyridazine-4-carboxamide

To a stirred solution of 6-chloropyridazine-4-carboxylic acid (500 mg, 3.16 mmol) in DMF (10 mL) was added *N*<sup>2</sup>-cyclopropyl-6-methoxypyridine-2,3-diamine **Int-9** (566 mg, 3.16 mmol), HATU (1.8 g, 4.74 mmol) and diisopropylethylamine (2.19 mL, 12.64 mmol) at 0 °C under an inert atmosphere. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) to afford 6-chloro-*N*-(2-(cyclopropylamino)-6-

methoxypyridin-3-yl) pyridazine-4-carboxamide (225 mg, 0.70 mmol, 22%) as an off-white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.91 (s, 1H), 9.62 (s, 1H), 8.35 (s, 1H), 7.33 (d, *J* = 8.2 Hz, 1H), 6.50 (d, *J* = 2.4 Hz, 1H), 6.00 (d, *J* = 8.0 Hz, 1H), 3.82 (s, 3H), 2.73-2.70 (m, 1H), 0.73-0.64 (m, 2H), 0.52-0.40 (m, 2H)

### 2-(6-Chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridine (Ex. 60)

To a stirred solution of 6-chloro-*N*-(2-(cyclopropylamino)-6-methoxypyridin-3-yl) pyridazine-4-carboxamide (150 mg, 0.47 mmol) in EtOH (3.5 mL) was added 6 *N* HCl (2 mL) at 0 °C under an inert atmosphere. The reaction mixture was stirred at 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 60-70% EtOAc/hexane) to afford 2-(6-chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridine **Ex. 60** (35 mg, 0.11 mmol, 22%) as a brown solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 8.28 (s, 1H), 7.42 (s, 1H), 7.33 (d, *J* = 8.3 Hz, 1H), 6.03 (d, *J* = 8.3 Hz, 1H), 3.90 (s, 3H), 2.79-2.74 (m, 1H), 0.77-0.68 (m, 2H), 0.53-0.47 (m, 2H)

**LC-MS:** *m/z* 302.1 [M+H]<sup>+</sup> at 1.85 RT (95.67% purity)

**HPLC:** 94.24%

## Example 61

### Scheme:



**1-Cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 61)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (70 mg, 0.22 mmol) in DME/ EtOH (2: 1, 0.9 mL) was added (4-fluoro-2-methylphenyl) boronic acid (42 mg, 0.27 mmol) and sodium carbonate (72.5 mg, 0.68 mmol) in a sealed tube and the mixture was purged under argon for 10 min. *Trans*-dichloro bis-(triphenyl phosphine)-II (8 mg, 0.01 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 61** (45 mg, 0.11 mmol, 51%) as an off-white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.81 (s, 1H), 8.14 (s, 1H), 7.60 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.49 (dd, *J* = 8.34, 5.83 Hz, 1H), 7.44 (dd, *J* = 9.6, 6.9 Hz, 1H), 7.11-7.03 (m, 2H), 3.71-3.63 (m, 1H), 2.46 (s, 3H), 1.37-1.30 (m, 2H), 0.93-0.87 (m, 2H)

LC-MS: *m/z* 381.1 [M+H]<sup>+</sup> at 2.60 RT (97.81% purity)

HPLC: 96.11%

### Example 62

#### Scheme:



#### 1-Cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (**Ex. 62**)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (70 mg, 0.22 mmol) in DME: EtOH (2: 1, 0.9 mL) was added (2,4-difluorophenyl) boronic acid (43 mg, 0.27 mmol) and sodium carbonate (75.5 mg, 0.68 mmol) and the mixture was purged under argon for 10 min. *Trans*-dichloro bis-(triphenyl phosphine)-II (8 mg, 0.01 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80 °C for 16 h in a sealed tube. After consumption of starting material (by TLC), the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude

material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford

1-cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 62** (45 mg, 0.11 mmol, 51%) as an off-white solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.79 (s, 1H), 8.51 (s, 1H), 8.36-8.29 (m, 1H), 7.62 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.44 (dd, *J* = 9.6, 7.0 Hz, 1H), 7.16-7.10 (m, 1H), 7.03-6.97 (m, 1H), 3.71-3.64 (m, 1H), 1.38-1.32 (m, 2H), 0.92-0.87 (m, 2H)


LC-MS: *m/z* 385.1 [M+H]<sup>+</sup> at 2.61 RT (96.45% purity)

HPLC: 96.95%

10

### Example 63

#### Scheme:



#### **1-Cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 63)**

15 To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (70 mg, 0.22 mmol) in DME/EtOH (2: 1, 0.9 mL) was added (3,4-difluorophenyl) boronic acid (43 mg, 0.27 mmol) and sodium carbonate (75.5 mg, 0.68 mmol) in a sealed tube and the mixture was purged under argon for 10 min. *Trans*-dichloro bis-(triphenyl phosphine)-II (8 mg, 0.01 mmol) was added to the reaction mixture and the reaction

20 mixture was stirred at 80 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford

1-cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 63** (45 mg, 0.11 mmol, 51%) as an off-white solid.


25 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.79 (s, 1H), 8.43 (s, 1H), 8.14-8.09 (m, 1H), 7.96-7.90 (m, 1H), 7.62 (dd, *J* = 10.0, 7.3 Hz, 1H), 7.46 (dd, *J* = 9.5, 6.9 Hz, 1H), 7.36 (dd, *J* = 17.9, 8.7 Hz, 1H), 3.79-3.66 (m, 1H), 1.39-1.29 (m, 2H), 0.93-0.82 (m, 2H)

**LC-MS:**  $m/z$  385  $[M+H]^+$  at 2.62 RT (98.32% purity)

**HPLC:** 98.68%

### Example 64 & Example 70

#### 5 Scheme:



#### **1-Cyclopropyl-2-(6-(1-ethoxyvinyl) pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole**

To stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (200 mg, 0.65 mmol) in DMF (4 mL) was added tributyl(1-ethoxyvinyl)stannane (0.26 mL, 0.78 mmol) and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (53 mg, 0.06 mmol) at room temperature and the mixture was degassed under argon for 10 min. The reaction mixture was stirred at 100 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(1-ethoxyvinyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (180 mg, 0.52 mmol, 81%) as a pale brown semi solid.

**LC-MS:**  $m/z$  343.1  $[M+H]^+$  at 3.10 RT (81.31% purity)

#### 20 **1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethan-1-one (Ex. 64)**

To a stirred solution of 1-cyclopropyl-2-(6-(1-ethoxyvinyl) pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (180 mg, 0.52 mmol) in acetone (3 mL) was added 2.5 N HCl (2 mL) at room temperature. The reaction mixture was stirred at room temperature for 6 h. After

consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and washed with saturated sodium bicarbonate solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one **Ex. 64** (110 mg, 0.35 mmol, 69%) as a pale brown solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.01 (d, *J* = 2.3 Hz, 1H), 8.62 (d, *J* = 2.3 Hz, 1H), 7.91-7.82 (m, 2H), 3.99-3.94 (m, 1H), 2.85 (s, 3H), 1.19-1.14 (m, 2H), 0.79-0.75 (m, 2H)

**LC-MS:** *m/z* 315.0 [M+H]<sup>+</sup> at 2.65 RT (95.59% purity)

**HPLC:** 93.77%

**1-Cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 70)**

A solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one **Ex. 70** (110 mg, 0.35 mmol) in DAST (3 mL) under an inert atmosphere was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) which was further purified by preparative HPLC to afford 1-cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 70** (45 mg, 0.13 mmol, 41%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.98 (d, *J* = 2.1 Hz, 1H), 8.53 (d, *J* = 2.0 Hz, 1H), 7.94-7.85 (m, 2H), 4.02-3.97 (m, 1H), 2.22 (t, *J* = 19.4 Hz, 3H), 1.21-1.14 (m, 2H), 0.83-0.77 (m, 2H)

**LC-MS:** *m/z* 337.0 [M+H]<sup>+</sup> at 2.99 RT (99.31% purity)

**HPLC:** 99.50%

**Example 65**

**Scheme:**



### 6-Chloro-*N*-(2-(ethylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide

To a stirred solution of *N*<sup>1</sup>-ethyl-4,5-difluorobenzene-1,2-diamine **Int-10** (500 mg, 2.9 mmol) in EtOAc (15 mL) under an inert atmosphere was added 6-chloropyridazine-4-carboxylic acid (505 mg, 3.19 mmol), triethylamine (0.8 mL, 5.81 mmol) and propylphosphonic anhydride (50% in EtOAc, 4.5 mL, 7.26 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 5 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (50 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were washed with water (70 mL), brine (70 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 15% EtOAc/hexane) to afford 6-chloro-*N*-(2-(ethylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide (500 mg, 1.60 mmol, 55%) as a yellow solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.1 (brs, 1H), 9.65 (s, 1H), 8.39 (s, 1H), 7.3 (dd, *J* = 11.7, 8.1 Hz, 1H), 6.69 (dd, *J* = 12.1, 7.9 Hz, 1H), 5.5 (brs, 1H), 3.12-3.02 (m, 2H), 1.17 (t, *J* = 7.2 Hz, 3H)

LC-MS: *m/z* 312.9 [M+H]<sup>+</sup> at 2.69 RT (96.47% purity)

### 2-(6-Chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 65)

To a stirred solution of 6-chloro-*N*-(2-(ethylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide (400 mg, 1.28 mmol) in ethanol (4 mL) under an inert atmosphere was added 6 *N* HCl (6 mL) at room temperature. The reaction mixture was stirred at 50 °C for 15 min. After consumption of starting material (by TLC), the reaction mixture was poured into saturated sodium bicarbonate solution (40 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude (100 mg) material was purified by preparative HPLC to afford 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 65** (30 mg, 0.10 mmol, 29%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.59 (d, *J* = 1.9 Hz, 1H), 8.20 (d, *J* = 1.9 Hz, 1H), 7.73 (dd, *J* = 10.2, 7.0 Hz, 1H), 7.65 (dd, *J* = 10.4, 7.3 Hz, 1H), 4.46 (q, *J* = 7.3 Hz, 2H), 1.48 (t, *J* = 7.3 Hz, 3H)

**LC-MS:** *m/z* 294.9 [M+H]<sup>+</sup> at 2.58 RT (98.60% purity)

5 **HPLC:** 99.85%

### Example 66

#### Scheme:



#### 10 **1-Cyclopropyl-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile **Ex. 34** (200 mg, 0.67 mmol) in 1, 4-dioxane (5 mL) and water (1.5 mL) was added vinyl boronic acid pinacol ester (313 mg, 2.03 mmol) and potassium carbonate (374 mg, 2.71 mmol) in a sealed tube at room temperature. The reaction mixture was degassed under argon for 10 min. To this was added Pd(dppf)Cl<sub>2</sub>. CH<sub>2</sub>Cl<sub>2</sub> (5.3 mg, 0.006 mmol) at room temperature and the mixture was further degassed under argon for 10 min. The reaction mixture was heated to 100 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 1-cyclopropyl-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (200 mg) as a brown thick syrup. The crude material was taken to next step without further purification.

**LC-MS:** *m/z* 288 [M+H]<sup>+</sup> at 2.27 RT (73.7% purity)

**1-Cyclopropyl-2-(6-formylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile**

To a stirred solution of 1-cyclopropyl-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (200 mg, crude) in a mixture of *tert*-butanol (0.5 mL), acetone (0.5 mL) and water (0.5 mL) was added sodium periodate (29.68 mg, 0.13 mmol) followed by osmium tetroxide (0.1 M in toluene, 4 mL) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 1-cyclopropyl-2-(6-formylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (200 mg, crude) as an orange solid. The crude material was taken to the next step without further purification.

**LC-MS:** *m/z* 308.1 [M+H<sub>2</sub>O]<sup>+</sup> at 1.78 RT (8.32% purity)

**1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile**  
**(Ex. 66)**


To a stirred solution of 1-cyclopropyl-2-(6-formylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (200 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added DAST (223 mg, 1.38 mmol) at 0 °C under an inert atmosphere. The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium carbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) which was further purified by preparative HPLC to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile **Ex. 66** (15 mg, 0.05 mmol, 7%) as a brown solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.99 (s, 1H), 8.64 (s, 1H), 8.26 (s, 1H), 7.93 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.68 (dd, *J* = 8.4, 1.5 Hz, 1H), 7.19 (t, *J* = 51.1 Hz, 1H), 4.00-3.94 (m, 1H), 1.35-1.30 (m, 2H), 0.91-0.86 (m, 2H)

**LC-MS:** *m/z* 312 [M+H]<sup>+</sup> at 2.52 RT (98.91% purity)

**HPLC:** 99.83%

**Example 67**

**Scheme:****1-Ethyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1H-benzo[d]imidazole  
 5 **Ex. 65** (400 mg, crude) in 1, 4-dioxane (12 mL) and water (4 mL) under an inert atmosphere  
 was added vinyl boronic acid pinacol ester (419 mg, 2.72 mmol) and potassium carbonate  
 (563 mg, 4.08 mmol) in a sealed tube at room temperature. The reaction mixture was degassed  
 under argon for 20 min. To this was added Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (11 mg, 0.013 mmol) at room  
 temperature and the mixture was further degassed under argon for 10 min. The reaction  
 10 mixture was heated to 80 °C and stirred for 5 h. After consumption of starting material (by  
 TLC), the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 60  
 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated  
 under reduced pressure. The crude material was purified by silica gel column chromatography  
 (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-ethyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-  
 15 benzo[d]imidazole (100 mg, crude) as an off-white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.52 (d, *J* = 1.7 Hz, 1H), 8.27 (d, *J* = 1.7 Hz, 1H), 8.02  
 (dd, *J* = 10.4, 7.5 Hz, 1H), 7.87 (dd, *J* = 11.0, 7.5 Hz, 1H), 7.14 (dd, *J* =, 18.0, 11.0 Hz, 1H),  
 6.54 (d, *J* = 17.4 Hz, 1H), 5.82 (d, *J* = 11.6 Hz, 1H), 4.45 (q, *J* = 7.5 Hz, 2H), 1.34 (t, *J* = 7.2  
 Hz, 3H)

20 **LC-MS:** *m/z* 287 [M+H]<sup>+</sup> at 2.47 RT (96.16% purity)

**5-(1-Ethyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde**

To a stirred solution of 1-ethyl-5,6-difluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole  
 (100 mg, crude) in Acetone: tBuOH: water (1:1:1, 6 mL) was added sodium periodate (149  
 25 mg, 0.69 mmol) and osmium tetroxide (1% in toluene, 2 mL) at 0 °C. The reaction mixture

was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the *celite* bed was washed with EtOAc (30 mL). The filtrate was concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 5-(1-ethyl-5, 6-difluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde (100 mg, crude) as a brown solid. This crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.37 (s, 1H), 9.88 (d, *J* = 2.3 Hz, 1H), 8.39 (d, *J* = 2.3 Hz, 1H), 8.04 (dd, *J* = 10.7, 7.2 Hz, 1H), 7.90 (dd, *J* = 10.4, 7.5 Hz, 1H), 4.46 (q, *J* = 7.3 Hz, 2H), 1.37 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 289 [M+H]<sup>+</sup> at 1.87 RT (70.81% purity)

#### **2-(6-(Difluoromethyl)pyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 67)**

To a stirred solution of 5-(1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl) pyridazine-3-carbaldehyde (100 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) under an inert atmosphere was added DAST (0.09 mL, 0.69 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were washed with saturated sodium bicarbonate solution (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 67** (30 mg, 0.09 mmol, 28%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.83 (d, *J* = 2.1 Hz, 1H), 8.35 (d, *J* = 2.1 Hz, 1H), 8.04 (dd, *J* = 10.8, 7.3 Hz, 1H), 7.89 (dd, *J* = 10.9, 7.5 Hz, 1H), 7.56-7.24 (m, 1H), 4.46 (q, *J* = 7.3 Hz, 2H), 1.36 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 311.0 [M+H]<sup>+</sup> at 2.69 RT (98.69% purity)

**HPLC:** 98.72%

### **Example 68 & Example 69**

#### **Scheme:**



### 6-Chloro-*N*-(4-cyano-2-(ethylamino)phenyl)pyridazine-4-carboxamide

To a stirred solution of 4-amino-3-(ethylamino)benzonitrile **Int-4** (200 mg, 1.24 mmol) in EtOAc (10 mL) under an inert atmosphere was added 6-chloropyridazine-4-carboxylic acid (210 mg, 1.32 mmol), triethylamine (0.34 mL, 2.48 mmol) and propylphosphonic anhydride (50% in EtOAc, 1.97 mL, 3.10 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 5 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (40 mL), brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 6-chloro-*N*-(4-cyano-2-(ethylamino)phenyl)pyridazine-4-carboxamide (250 mg, 0.83 mmol, 67%) as a yellow solid.

<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 10.23 (brs, 1H), 9.65 (d, *J* = 1.2 Hz, 1H), 8.39 (s, 1H), 7.40 (d, *J* = 8.1 Hz, 1H), 7.06-6.99 (m, 2H), 5.77 (br s, 1H), 3.20-3.15 (m, 2H), 1.17 (t, *J* = 7.0 Hz, 3H)

### 2-(6-Chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 68)

To a stirred solution of 6-chloro-*N*-(4-cyano-2-(ethylamino)phenyl)pyridazine-4-carboxamide (50 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) under an inert atmosphere was added trifluoroacetic acid (0.2 mL) at 0 °C. The reaction mixture was stirred at room temperature for 6 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was quenched with saturated sodium bicarbonate solution (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 2-(6-chloropyridazin-4-

yl)-1-ethyl-1*H*-benzo[d]imidazole-6-carbonitrile **Ex. 68** (35 mg, 0.12 mmol, 74%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.70 (d, *J* = 1.9 Hz, 1H), 8.50 (s, 1H), 8.35 (d, *J* = 1.9 Hz, 1H), 7.96 (dd, *J* = 8.4, 0.5 Hz, 1H), 7.72 (dd, *J* = 8.5, 1.4 Hz, 1H), 4.52 (q, *J* = 7.3 Hz, 2H), 1.37 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 284 [M+H]<sup>+</sup> at 2.34 RT (97.52% purity)

**HPLC:** 97.70%

### 1-Ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[d]imidazole-6-carbonitrile **Ex. 68** (170 mg, 0.60 mmol) in a mixture of 1, 4-dioxane (6 mL) and water (2 mL) under an inert atmosphere was added vinyl boronic acid pinacol ester (185 mg, 1.20 mmol) and potassium carbonate (248.69 mg, 1.80 mmol). The reaction mixture was degassed under argon for 20 min. To this was added Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (4.9 mg, 0.06 mmol) at room temperature. The reaction mixture was heated to 80 °C and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 1-2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile (100 mg, 0.36 mmol, 61%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.56 (d, *J* = 2.1 Hz, 1H), 8.50-8.48 (m, 1H), 8.32 (d, *J* = 2.1 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 1H), 7.72 (dd, *J* = 8.4, 1.5 Hz, 1H), 7.16 (dd, *J* = 17.8, 11.0 Hz, 1H), 6.56 (dd, *J* = 17.7, 0.6 Hz, 1H), 5.84 (d, *J* = 11.7 Hz, 1H), 4.51 (q, *J* = 7.2 Hz, 2H), 1.37 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 276.1 [M+H]<sup>+</sup> at 2.23 RT (95.18% purity)

### 1-Ethyl-2-(6-formylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile

To a stirred solution of 1-ethyl-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile (100 mg, 0.36 mmol) in Acetone: <sup>t</sup>BuOH: water (1:1:1, 6 mL) under an inert atmosphere was added sodium periodate (154.9 mg, 0.72 mmol) and osmium tetroxide (1% in toluene, 2 mL) at 0 °C. The reaction mixture was stirred at room temperature for 5 h. After consumption of

starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with EtOAc (20 mL). The filtrate was concentrated under reduced pressure. The residue was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> 2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 1-ethyl-2-(6-formylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile (100 mg, crude) as a thick syrup. The crude material was used in the next step without further purification.

**LC-MS:** *m/z* 278.1 [M+H]<sup>+</sup> at 1.65 RT (43.82% purity)

10 **2-(6-(Difluoromethyl)pyridazin-4-yl)-1-ethyl-1*H*-benzo[d]imidazole-6-carbonitrile (Ex. 69)**

To a stirred solution of 1-ethyl-2-(6-formylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile (100 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) under an inert atmosphere was added DAST (0.09 mL, 0.72 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was poured into ice cold water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-1*H*-benzo[d]imidazole-6-carbonitrile **Ex. 69** (30 mg, 0.10 mmol) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 9.81 (d, *J* = 2.0 Hz, 1H), 8.42 (d, *J* = 2.0 Hz, 1H), 8.28 (dd, *J* = 1.4, 0.8 Hz, 1H), 7.94 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.69 (dd, *J* = 8.4, 1.5 Hz, 1H), 7.13 (t, *J* = 54.6 Hz, 1H), 4.54 (q, *J* = 7.3 Hz, 2H), 1.52 (t, *J* = 7.3 Hz, 3H)

**LC-MS:** *m/z* 300.0 [M+H]<sup>+</sup> at 2.41 RT (99.41% purity)

25 **HPLC:** 99.68%

### Example 71

#### Scheme:



**1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl) pyridazine-3-carbaldehyde **Int-27** (400 mg, 1.33 mmol) in DME (5 mL) under an inert atmosphere was added cesium fluoride (202.6 mg, 1.33 mmol) at 0 °C and the mixture was stirred for 15 min. TMS-CF<sub>3</sub> (284 mg, 1.99 mmol) was added to the reaction mixture at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with 1 N HCl solution (20 mL), basified with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (160 mg, 0.43 mmol, 32%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD):** δ 9.84 (d, *J* = 2.3 Hz, 1H), 8.58 (d, *J* = 1.7 Hz, 1H), 7.73 (dd, *J* = 9.9, 7.0 Hz, 1H), 7.65 (dd, *J* = 10.4, 7.5 Hz, 1H), 5.55 (q, *J* = 6.8 Hz, 1H), 4.57 (s, 1H), 3.92-3.86 (m, 1H), 1.29-1.20 (m, 2H), 0.88-0.78 (m, 2H)

**LC-MS:** *m/z* 371.1 [M+H]<sup>+</sup> at 2.76 RT (75.32% purity)

**O-(1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethyl) S-methyl carbonodithioate**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (100 mg, 0.27 mmol) in THF (5 mL) under an inert atmosphere was added sodium hydride (60% in mineral oil, 21.6 mg, 0.54 mmol) portion wise

at 0 °C and the mixture was stirred for 30 min. Carbon disulfide (41 mg, 0.54 mmol) was added to the reaction mixture at 0 °C and stirred for 30 min, followed by addition of methyl iodide (76 mg, 0.54 mmol) at 0 °C and stirring was continued for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (15 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford O-(1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2, 2, 2-trifluoroethyl) S-methyl carbonodithioate (100 mg) as a black thick syrup. The crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.88 (d, *J* = 2.3 Hz, 1H), 8.56 (d, *J* = 1.7 Hz, 1H), 7.92 (dd, *J* = 11.0, 7.5 Hz, 1H), 7.86 (dd, *J* = 10.4, 7.5 Hz, 1H), 7.52 (q, *J* = 6.8 Hz, 1H), 3.95-3.88 (m, 1H), 2.67 (s, 3H), 1.20-1.15 (m, 2H), 0.79-0.73 (m, 2H)

**LC-MS:** *m/z* 461.1 [M+H]<sup>+</sup> at 3.63 RT (77.86% purity)


**15 1-Cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole (Ex. 71)**

To a stirred solution of O-(1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethyl) S-methyl carbonodithioate (100 mg, 0.21 mmol) in toluene (5 mL) under an inert atmosphere was added AIBN (5.3 mg, 0.032 mmol) and tributylstannane (95 mg, 0.32 mmol) at room temperature. The reaction mixture was heated to 60 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) which was further purified by preparative HPLC to afford 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 71** (15 mg, 0.04 mmol, 19%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.84 (d, *J* = 2.0 Hz, 1H), 8.16 (d, *J* = 1.6 Hz, 1H), 7.61 (dd, *J* = 10.0, 7.3 Hz, 1H), 7.44 (dd, *J* = 9.5, 6.9 Hz, 1H), 3.99 (q, *J* = 10.5 Hz, 2H), 3.68-3.62 (m, 1H), 1.36-1.29 (m, 2H), 0.88-0.83 (m, 2H)

**LC-MS:** *m/z* 355.1 [M+H]<sup>+</sup> at 2.86 RT (98.85% purity)

**HPLC:** 99.79%

**Example 72****Scheme:****5 2-(6-Cyclopropylpyridazin-4-yl)-1-ethyl-5,6-difluoro-1H-benzo[d]imidazole (Ex. 72)**


To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 65** (150 mg, 0.51 mmol) in toluene/water (3: 1, 12 mL) was added cyclopropylboronic acid (52.6 mg, 0.61 mmol) and cesium carbonate (416 mg, 1.27 mmol) in a sealed tube and purged under argon for 20 min.  $\text{Pd(dppf)Cl}_2 \cdot \text{CH}_2\text{Cl}_2$  (4 mg, 0.005 mmol) was added to the  
 10 reaction mixture and again purged under argon for 5 min at room temperature. The reaction mixture was stirred at 100 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20%  
 15 EtOAc/hexane) to afford 2-(6-cyclopropylpyridazin-4-yl)-1-ethyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 72** (40 mg, 0.133 mmol, 26%) as an off white solid.

**$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):**  $\delta$  9.35 (d,  $J = 2.0$  Hz, 1H), 7.85 (d,  $J = 2.1$  Hz, 1H), 7.71 (dd,  $J = 10.3, 7.0$  Hz, 1H), 7.63 (dd,  $J = 10.4, 7.3$  Hz, 1H), 4.43 (q,  $J = 7.3$  Hz, 2H), 2.44-2.36 (m, 1H), 1.46 (t,  $J = 7.2$  Hz, 3H), 1.30-1.24 (m, 4H)

20 **LC-MS:**  $m/z$  301.0  $[\text{M}+\text{H}]^+$  at 2.58 RT (99.14% purity)

**HPLC:** 99.64%

**Example 73 & Example 76****Scheme:**



### Methyl 6-chloropyridazine-4-carboxylate

To a stirring solution of 6-chloropyridazine-4-carboxylic acid (1.5 g, 9.49 mmol) in  $\text{CH}_2\text{Cl}_2$  (30 mL) under argon atmosphere was added diazomethane in diethyl ether (freshly prepared by addition of *N*-nitrosomethyl urea (3 g) to mixture of 50% KOH solution (25 mL) and diethyl ether (50 mL) at 0 °C; warmed to RT and stirred for 30 min). After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with  $\text{CH}_2\text{Cl}_2$  (30 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford methyl 6-chloropyridazine-4-carboxylate (1.4 g, 8.13 mmol, 86%) as an off-white solid.

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  9.58 (d,  $J$  = 1.6 Hz, 1H), 8.03 (d,  $J$  = 1.8 Hz, 1H), 4.04 (s, 3H)

### Methyl 6-vinylpyridazine-4-carboxylate

To a stirred solution of methyl 6-chloropyridazine-4-carboxylate (1.4 g, 8.13 mmol) in 1, 2-dimethoxyethane (20 mL) under an inert atmosphere were added potassium carbonate (3.36 g, 24.39 mmol) and vinyl boronic acid pinacol ester (2.56 mL, 16.2 mmol) in a sealed tube at

room temperature. The reaction mixture was degassed under argon for 5-10 min. Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (66 mg, 0.08 mmol) was added to the reaction mixture at room temperature and degassed under argon for 5-10 min. The reaction mixture was heated to 80-90 °C for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted  
 5 with EtOAc (50 mL), filtered through a pad of *celite* and the bed was washed with EtOAc (50 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) to afford methyl 6-vinylpyridazine-4-carboxylate (1.3 g, 7.92 mmol, 97%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.51 (d, *J* = 2.0 Hz, 1H), 8.08 (d, *J* = 2.0 Hz, 1H), 7.14 (dd, *J* = 17.8, 11.0 Hz, 1H), 6.38 (d, *J* = 17.7 Hz, 1H), 5.80 (d, *J* = 11.0 Hz, 1H), 4.03 (s, 3H)  
 10

### 6-Vinylpyridazine-4-carboxylic acid

To a stirred solution of methyl 6-vinylpyridazine-4-carboxylate (1.4 g, 8.53 mmol) in a mixture of THF: water (1:2, 12.75 mL) was added lithium hydroxide (716 mg, 17.07 mmol) at  
 15 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. The residue was acidified (pH ~1-2) using conc. HCl and stirred for 30 min at room temperature. The precipitated solid was filtered and dried under vacuum to afford 6-vinylpyridazine-4-carboxylic acid (500 mg, 3.33 mmol, 39%) as an off white solid, which was  
 20 used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 14.10 (br s, 1H), 9.42 (d, *J* = 1.7 Hz, 1H), 8.24 (d, *J* = 2.3 Hz, 1H), 7.12 (dd, *J* = 18.0, 11.0 Hz, 1H), 6.53 (d, *J* = 17.4 Hz, 1H), 5.79 (d, *J* = 11.0 Hz, 1H)

### *N*-(6-Chloro-2-(cyclopropylamino) pyridin-3-yl)-6-vinylpyridazine-4-carboxamide

To a stirred solution of 6-vinylpyridazine-4-carboxylic acid (40 mg, 0.27 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) under an inert atmosphere was added 6-chloro-*N*<sup>2</sup>-cyclopropylpyridine-2,3-diamine **Int-8** (50 mg, 0.27 mmol), benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (170 mg, 0.32 mmol) and diisopropylethylamine (0.18 mL, 1.08 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting  
 25 material (by TLC), the reaction mixture was quenched with aqueous ammonium chloride solution (30 mL) and extracted with EtOAc (40 mL). The organic layer was washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The  
 30

crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/Hexane) to afford *N*-(6-chloro-2-(cyclopropylamino)pyridin-3-yl)-6-vinylpyridazine-4-carboxamide (140 mg, crude) as a brown solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.01 (s, 1H), 9.51 (d, *J* = 2.1 Hz, 1H), 8.36 (d, *J* = 2.0 Hz, 1H), 7.50 (d, *J* = 7.9 Hz, 1H), 6.86 (d, *J* = 2.5 Hz, 1H), 6.70-6.65 (m, 1H), 6.47 (d, *J* = 17.7 Hz, 1H), 5.83 (d, *J* = 11.4 Hz, 2H), 2.73-2.69 (m, 1H), 0.73-0.68 (m, 2H), 0.49-0.45 (m, 2H)

**LC-MS:** *m/z* 316.1 [M+H]<sup>+</sup> at 2.36 RT (70.07% purity)

#### 10 **5-Chloro-3-cyclopropyl-2-(6-vinylpyridazin-4-yl)-3*H*-imidazo[4, 5-*b*]pyridine**

To a stirred solution of *N*-(6-chloro-2-(cyclopropylamino) pyridin-3-yl)-6-vinylpyridazine-4-carboxamide (140 mg, 0.44 mmol) in *tert*-butanol (10 mL) under an inert atmosphere was added tripotassium phosphate (222 mg, 1.1 mmol) at room temperature. The reaction mixture was heated to 90 °C and stirred for 2 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was diluted with water (30 mL) and extracted with EtOAc (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 60-70% EtOAc/hexane) to afford 5-chloro-3-cyclopropyl-2-(6-vinylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (125 mg, crude) as a brown syrup.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.01 (s, 1H), 9.51 (d, *J* = 1.7 Hz, 1H), 8.36 (d, *J* = 1.7 Hz, 1H), 7.50 (d, *J* = 8.1 Hz, 1H), 6.67 (d, *J* = 8.1 Hz, 1H), 6.48 (d, *J* = 17.4 Hz, 1H), 5.83 (d, *J* = 11.0 Hz, 1H), 2.72-2.68 (m, 1H), 0.72-0.68 (m, 2H), 0.49-0.44 (m, 2H)

**LC-MS:** *m/z* 297.9 [M+H]<sup>+</sup> at 2.35 RT (77.28% purity)

#### 25 **5-(5-Chloro-3-cyclopropyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyridazine-3-carbaldehyde**

To a stirred solution of 5-chloro-3-cyclopropyl-2-(6-vinylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (125 mg, 0.42 mmol) in Acetone: *t*BuOH: water (1:1:1, 7.5 mL) under an inert atmosphere was added sodium periodate (179 mg, 0.84 mmol) and osmium tetroxide (1% in toluene, 2.5 mL) at 0 °C. The reaction mixture was gradually warmed to RT and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The organic layer was washed with water (20 mL) dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to

afford 5-(5-chloro-3-cyclopropyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyridazine-3-carbaldehyde **8** (130 mg) as a brown solid, which was used in the next step without further purification.

**5-Chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine**

**5 (Ex. 73)**

To a stirred solution of 5-(5-chloro-3-cyclopropyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl) pyridazine-3-carbaldehyde (130 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added DAST (0.11 mL, 0.86 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice water (20 mL) and basified with aqueous sodium carbonate solution (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/Hexane) to afford 5-chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 73** (7.2 mg, 0.022 mmol, 5%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 10.00 (d, *J* = 2.0 Hz, 1H), 8.64 (d, *J* = 2.0 Hz, 1H), 8.15 (d, *J* = 8.4 Hz, 1H), 7.43 (d, *J* = 8.4 Hz, 1H), 7.33-7.05 (m, 1H), 3.90-3.82 (m, 1H), 1.28-1.25 (m, 2H), 0.99-0.93 (m, 2H)

**LC-MS:** *m/z* 321.9 [M+H]<sup>+</sup> at 2.56 RT (94.15% purity)

**HPLC:** 92.45%

**3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (Ex. 76)**

To a stirred solution of 5-chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 73** (50 mg, 0.15 mmol) in DMF (2 mL) was added zinc cyanide (36 mg, 0.31 mmol) at room temperature and the mixture was purged under argon for 5 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (17.94 mg, 0.01 mmol) was added and the mixture was purged under argon for 5 min. The reaction mixture was heated to 150 °C for 1.5 h under microwave. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) to afford 3-cyclopropyl-2-(6-

(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile **Ex. 76** (27 mg, 0.086 mmol, 56%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 10.05 (d, *J* = 2.0 Hz, 1H), 8.70 (d, *J* = 2.1 Hz, 1H), 8.33 (d, *J* = 8.3 Hz, 1H), 7.88 (d, *J* = 8.2 Hz, 1H), 7.36-7.08 (m, 1H), 3.94-3.89 (m, 1H), 1.35-1.29 (m, 2H), 1.03-0.97 (m, 2H)

**LC-MS:** *m/z* 312.9 [M+H]<sup>+</sup> at 2.11 RT (99.81% purity)

**HPLC:** 99.53%

### Example 74

#### 10 Scheme:



#### *N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-5-methylpyridazine-4-carboxamide

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (250 mg, 1.35 mmol) in EtOAc (8 mL) under an inert atmosphere was added 5-methylpyridazine-4-carboxylic acid (206 mg, 1.49 mmol), triethylamine (0.37 mL, 2.71 mmol) and propylphosphonic anhydride (50% in EtOAc, 2.1 mL, 3.39 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was diluted with EtOAc (30 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under pressure. The crude material was purified by silica gel column chromatography (eluent: 50-70% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5-methylpyridazine-4-carboxamide (210 mg, 0.69 mmol, 51%) as a pale yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.78 (s, 1H), 9.36 (s, 1H), 9.26 (s, 1H), 7.47 (dd, *J* = 12.1, 8.7 Hz, 1H), 6.94 (dd, *J* = 13.4, 8.1 Hz, 1H), 5.85 (s, 1H), 2.43 (s, 3H), 2.12-2.03 (m, 1H), 0.78-0.71 (m, 2H), 0.46-0.39 (m, 2H)

**LC-MS:** *m/z* 305.1 [M+H]<sup>+</sup> at 2.47 RT (72.24% purity)

#### 1-Cyclopropyl-5,6-difluoro-2-(5-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 74)

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5-methylpyridazine-4-carboxamide (150 mg, 0.49 mmol) in ethanol (3 mL) was added 6 *N* HCl (3 mL) at room temperature. The reaction mixture was stirred at 50 °C for 1 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was

5 basified with saturated sodium bicarbonate solution (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (40 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with diethyl ether (5 mL) to afford 1-cyclopropyl-5,6-difluoro-2-(5-methylpyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 74** (65 mg, 0.21 mmol, 46%) as an off white solid.

10 **<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.47 (s, 1H), 9.36 (s, 1H), 7.87-7.81 (m, 2H), 3.75-3.69 (m, 1H), 2.44 (s, 3H), 0.99-0.94 (m, 2H), 0.63-0.58 (m, 2H)


**LC-MS:** *m/z* 287.0 [M+H]<sup>+</sup> at 2.26 RT (98.32% purity)

**HPLC:** 99.05%

15

### Example 75

#### Scheme:



#### **6-Chloro-*N*-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide**

To a stirred solution of 6-chloropyridazine-4-carboxylic acid (458 mg, 2.89 mmol) in EtOAc

20 (30 mL) under an inert atmosphere were added 4-amino-3-(cyclopropylamino)benzonitrile **Int-6** (500 mg, 2.89 mmol), triethylamine (0.8 mL, 5.78 mmol) and propylphosphonic anhydride (50% in EtOAc, 4.6 mL, 7.22 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was poured into saturated sodium bicarbonate solution (70 mL) and extracted with

25 EtOAc (2 x 100 mL). The combined organic extracts were washed with water (120 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was

purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) to afford 6-chloro-*N*-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide (650 mg, 2.07 mmol, 72%) as pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.17 (s, 1H), 9.63 (d, *J* = 1.8 Hz, 1H), 8.38 (d, *J* = 1.8 Hz, 1H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 1.8 Hz, 1H), 7.10 (dd, *J* = 8.0, 1.9 Hz, 1H), 6.31 (s, 1H), 2.45-2.38 (m, 1H), 0.82-0.77 (m, 2H), 0.48-0.43 (m, 2H)

**LC-MS:** *m/z* 312.1 [M-H]<sup>-</sup> at 2.57 RT (80.47% purity)

### 2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile

To a stirred solution of 6-chloro-*N*-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide (600 mg, 1.91 mmol) in ethanol (6 mL) under an inert atmosphere was added 6 *N* HCl (9 mL) at room temperature. The reaction mixture was stirred at 55 - 60 °C for 10 min. After consumption of starting material (by TLC), the reaction mixture was poured into saturated sodium bicarbonate solution (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (450 mg, 1.52 mmol, 80%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.82 (d, *J* = 1.9 Hz, 1H), 8.20 (d, *J* = 1.8 Hz, 1H), 8.02 (dd, *J* = 1.4, 0.7 Hz, 1H), 7.91 (dd, *J* = 8.5, 0.7 Hz, 1H), 7.63 (dd, *J* = 8.4, 1.5 Hz, 1H), 3.75-3.69 (m, 1H), 1.45-1.39 (m, 2H), 0.94-0.89 (m, 2H)

**LC-MS:** *m/z* 295.9 [M+H]<sup>+</sup> at 2.40 RT (95.15% purity)

### 1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 75)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (100 mg, 0.33 mmol) in toluene: water (3: 1, 3.2 mL) under an inert atmosphere was added cyclopropylboronic acid (35 mg, 0.40 mmol) and cesium carbonate (275.5 mg, 0.84 mmol) at room temperature and the mixture was purged under argon for 5 min. Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (27.6 mg, 0.03 mmol) was added to the reaction mixture at room temperature and the mixture was degassed under argon for 5 min. The reaction mixture was stirred at 100 °C for 5 h. After consumption of starting material (by TLC), the reaction mixture

was poured into water (40 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile

5 **Ex. 75** (40 mg, 0.13 mmol, 39%) as an off-white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.61 (d, *J* = 2.1 Hz, 1H), 8.00 (s, 1H), 7.89 (dd, *J* = 8.4, 0.5 Hz, 1H), 7.86 (d, *J* = 2.0 Hz, 1H), 7.61 (dd, *J* = 8.3, 1.4 Hz, 1H), 3.72-3.66 (m, 1H), 2.32-2.26 (m, 1H), 1.37-1.32 (m, 4H), 1.27-1.21 (m, 2H), 0.89-0.85 (m, 2H)

**LC-MS:** *m/z* 302 [M+H]<sup>+</sup> at 2.06 RT (96.07% purity)

10 **HPLC:**95.17%

### Example 77

#### Scheme:



15 **N-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl)methane sulfonamide (Ex. 77)**

To a stirred solution of (5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanamine **Int-28** (200 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (13 mL) under an inert atmosphere was added triethylamine (0.18 mL, 1.32 mmol) and mesyl chloride (0.08 mL, 0.74 mmol) at 0 °C.

20 The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and washed with water (30 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford

25 **N-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl)methane sulfonamide Ex. 77** (11 mg, 0.029 mmol, 4% overall yield) as a pale brown solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.72 (d, *J* = 2.0 Hz, 1H), 8.50 (d, *J* = 2.0 Hz, 1H), 7.73 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.64 (dd, *J* = 10.4, 7.3 Hz, 1H), 4.73 (s, 2H), 3.88-3.81 (m, 1H), 3.09 (s, 3H), 1.37-1.32 (m, 2H), 0.86-0.81 (m, 2H)

**LC-MS:** *m/z* 380.1 [M+H]<sup>+</sup> at 1.99 RT (96.14% purity)

5 **HPLC:** 98.32%

### Example 78

#### Scheme:



#### 10 **1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N*-methylemethanamine**

To a stirred solution of 5-(1-cyclopropyl-5, 6-difluoro-1*H*-benzo [*d*] imidazol-2-yl)pyridazine-3-carbaldehyde **Int-27** (200 mg, 0.66 mmol) in THF (10 mL) under an inert atmosphere was added methylamine solution (2 M in THF, 0.66 mL, 1.33 mmol) dropwise at  
 15 0 °C. The reaction was warmed to room temperature and stirred for 15 min, then recooled to 0 °C. Sodium triacetoxyborohydride was added and the reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and washed with saturated sodium bicarbonate solution (30 mL) and water (30 mL). The  
 20 organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N*-methylemethanamine (180 mg) as an off white solid. The crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.69 (d, *J* = 2.1 Hz, 1H), 8.30 (d, *J* = 2.1 Hz, 1H), 7.90-  
 25 7.80 (m, 2H), 4.07 (s, 2H), 3.95-3.87 (m, 1H), 2.90 (br s, 1H), 2.34 (s, 3H), 1.22-1.16 (m, 2H), 0.78-0.73 (m, 2H)

**LC-MS:** *m/z* 315.9 [M+H]<sup>+</sup> at 1.65 RT (90.51% purity)

***N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)-*N*-methylethanesulfonamide (Ex. 78)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N*-methylethylamine (200 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (13 mL) under an inert atmosphere were added triethylamine (0.17 mL, 1.26 mmol) and mesyl chloride (0.08 mL, 0.95 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by LCMS), the reaction mixture was diluted with water (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 80% EtOAc/hexane) to afford *N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)-*N*-methylethanesulfonamide **Ex. 78** (35 mg, 0.089 mmol, 14%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.80 (d, *J* = 2.1 Hz, 1H), 8.27 (d, *J* = 2.0 Hz, 1H), 7.90 (dd, *J* = 10.9, 7.5 Hz, 1H), 7.84 (dd, *J* = 10.4, 7.3, Hz, 1H), 4.73 (s, 2H), 3.93-3.87 (m, 1H), 3.08 (s, 3H), 2.87 (s, 3H), 1.23-1.18 (m, 2H), 0.82-0.77 (m, 2H)

LC-MS: *m/z* 394.1 [M+H]<sup>+</sup> at 2.43 RT (99.69% purity)

HPLC: 99.74%

**Example 79**

**Scheme:**



***N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-2-sulfonamide (Ex. 79)**

To a stirred solution of (5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl) methanamine **Int-28** (150 mg, 0.49) in CH<sub>2</sub>Cl<sub>2</sub> (7 mL) under an inert atmosphere were added triethylamine (0.13 mL, 0.99 mmol) and propane-2-sulfonyl chloride (106 mg, 0.74

mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) which was further purified by preparative HPLC to afford *N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-2-sulfonamide **Ex. 79** (40 mg, 0.09 mmol, 20%) as an off white solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.78 (d, *J* = 1.7 Hz, 1H), 8.34 (d, *J* = 1.7 Hz, 1H), 7.96-7.81 (m, 3H), 4.62 (d, *J* = 5.8 Hz, 2H), 3.91-3.85 (m, 1H), 3.30-3.27 (m, 1H), 1.28-1.21 (m, 8H), 0.79-0.74 (m, 2H)

**LC-MS:** *m/z* 408.0 [M+H]<sup>+</sup> at 2.49 RT (98.74% purity)

**HPLC:** 95.26%

### Example 80

#### Scheme:



#### 1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (100 mg, 0.32) in DMF (1 mL) under an inert atmosphere was added sodium methanethiolate (15% in water, 23 mg, 0.32 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC & LC-MS), the reaction mixture was diluted with brine solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-pentane (5 mL) and dried *in vacuo* to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methylthio) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (80 mg, 0.25 mmol, 77%) as pale brown solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.79-9.49 (m, 1H), 8.15-7.88 (m, 1H), 7.59 (dd, *J* = 10.1, 7.3 Hz, 1H), 7.42 (dd, *J* = 9.7, 6.9 Hz, 1H), 3.65-3.58 (m, 1H), 2.80 (s, 3H), 1.33-1.28 (m, 2H), 0.87-0.82 (m, 2H)

**LC-MS:** *m/z* 318.9 [M+H]<sup>+</sup> at 2.32 RT (97.39% purity)

5

**1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 80)**

To a stirred solution of 1-cyclopropyl-5, 6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (60 mg, 0.18 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) under an inert atmosphere was added *m*-chloroperoxybenzoic acid (81 mg, 0.47 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC & LC-MS), the reaction mixture was quenched with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl) pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 80** (30 mg, 0.085 mmol, 45%) as a pale brown solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 10.09 (d, *J* = 2.0 Hz, 1H), 8.79 (d, *J* = 2.1 Hz, 1H), 7.64 (dd, *J* = 9.9, 7.3 Hz, 1H), 7.46 (dd, *J* = 9.5, 6.9 Hz, 1H), 3.74-3.68 (m, 1H), 3.52 (s, 3H), 1.44-1.37 (m, 2H), 0.94-0.87 (m, 2H)

**LC-MS:** *m/z* 351.0 [M+H]<sup>+</sup> at 2.64 RT (95.45% purity)

**HPLC:** 96.64%

**Example 81 & Example 83**

**Scheme:**



**1-Cyclopropyl-2-(6-(ethylthio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (300 mg, 0.98) in DMF (7 mL) under an inert atmosphere was

added sodium ethane thiolate (15% in water, 90 mg, 1.07 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-pentane (5 mL) and dried *in vacuo* to afford 1-cyclopropyl-2-(6-(ethylthio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole (240 mg, 0.72 mmol, 74%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.49 (d, *J* = 2.0 Hz, 1H), 7.86 (d, *J* = 2.0 Hz, 1H), 7.58 (dd, *J* = 10.2, 7.3 Hz, 1H), 7.42 (dd, *J* = 9.7, 6.9 Hz, 1H), 3.65-3.57 (m, 1H), 3.44 (q, *J* = 7.4 Hz, 2H), 1.49 (t, *J* = 7.3 Hz, 3H), 1.33-1.29 (m, 2H), 0.88-0.83 (m, 2H)

**1-Cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole (Ex. 81) & 1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole (Ex. 83)**

To a stirred solution of 1-cyclopropyl-2-(6-(ethylthio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole (260 mg, 0.78) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) under an inert atmosphere was added *m*-chloroperoxybenzoic acid (296 mg, 1.56 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed water (60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50-70% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 81** (22 mg, 0.060 mmol) as an off white solid & 1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 83** (60 mg, 0.17 mmol) as an off white solid.

**Analytical data for Ex. 81:**

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 10.08 (d, *J* = 2.0 Hz, 1H), 8.89 (d, *J* = 2.0 Hz, 1H), 7.74 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.67 (dd, *J* = 10.3, 7.3 Hz, 1H), 3.96-3.89 (m, 1H), 3.69 (q, *J* = 7.4 Hz, 2H), 1.39 (t, *J* = 7.4 Hz, 3H), 1.33-1.27 (m, 2H), 0.93-0.86 (m, 2H)

**LC-MS:** *m/z* 365.0 [M+H]<sup>+</sup> at 2.72 RT (99.37% purity)


**HPLC:** 95.47%

**Analytical data for Ex. 83:**

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.93 (d, *J* = 2.1 Hz, 1H), 8.76 (d, *J* = 2.1 Hz, 1H), 7.75 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.67 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.94-3.89 (m, 1H), 3.49-3.42 (m, 1H), 3.27-3.19 (m, 1H), 1.35-1.31 (m, 2H), 1.29 (t, *J* = 7.3 Hz, 3H), 0.92-0.88 (m, 2H).

5 **LC-MS:** *m/z* 348.9 [M+H]<sup>+</sup> at 2.09 RT (95.88% purity)

**HPLC:** 95.47%

**Example 82****Scheme:**

10

**1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio pyridazin-4-yl)-1H-benzo[d]imidazole**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (100 mg, 0.32 mmol) in DMF (1 mL) under an inert atmosphere was added sodium methanethiolate (15% in water, 23 mg, 0.32 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC & LC-MS), the reaction mixture was diluted with brine solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-pentane (5 mL), dried *in vacuo* to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1H-benzo[d]imidazole (80 mg, 0.25 mmol, 77%) as a pale brown solid.

15

20

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.79-9.49 (m, 1H), 8.15-7.88 (m, 1H), 7.59 (dd, *J* = 10.1, 7.3 Hz, 1H), 7.42 (dd, *J* = 9.7, 6.9 Hz, 1H), 3.65-3.58 (m, 1H), 2.80 (s, 3H), 1.33-1.28 (m, 2H), 0.87-0.82 (m, 2H)

25

**LC-MS:** *m/z* 318.9 [M+H]<sup>+</sup> at 2.32 RT (97.39% purity)

**1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 82)**

To a stirred solution of 1-cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[d]imidazole (100 mg, 0.31 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) under an inert atmosphere was added *m*-chloroperoxybenzoic acid (59 mg, 0.34 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. After consumption of starting material (by

5 TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed water (60 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 60-70% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole

10 **Ex. 82** (15 mg, 0.04 mmol, 14%) as an off white solid


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.95 (d, *J* = 2.1 Hz, 1H), 8.78 (d, *J* = 2.1 Hz, 1H), 7.63 (dd, *J* = 10.0, 7.3 Hz, 1H), 7.45 (dd, *J* = 9.5, 6.9 Hz, 1H), 3.76-3.68 (m, 1H), 3.08 (s, 3H), 1.39-1.34 (m, 2H), 0.92-0.87 (m, 2H)

**LC-MS:** *m/z* 335 [M+H]<sup>+</sup> at 2.23 RT (95.79% purity)

15 **HPLC:** 96.90%

### Example 84

#### Scheme:



#### **Methyl 6-chloropyridazine-4-carboxylate**

To a stirred solution of 6-chloropyridazine-4-carboxylic acid (1.5 g, 9.49 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) under argon atmosphere was added diazomethane in diethyl ether (freshly prepared by addition of *N*-nitrosomethyl urea (3 g) to mixture of 50% KOH solution (25 mL) and diethyl ether (50 mL) at 0 °C) at 0 °C. The reaction was warmed to RT and stirred for 30 min. After

25 consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and washed with CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The filtrate was concentrated under reduced pressure.

The crude material was purified by silica gel column chromatography (eluent: 20-30% EtOAc/hexane) to afford methyl 6-chloropyridazine-4-carboxylate (1.4 g, 8.13 mmol, 86%) as an off-white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.58 (d, *J* = 1.6 Hz, 1H), 8.03 (d, *J* = 1.8 Hz, 1H), 4.04 (s, 3H)

#### **Methyl 6-cyclopropylpyridazine-4-carboxylate**

To a stirred solution of methyl 6-chloropyridazine-4-carboxylate (1 g, 5.81 mmol) in toluene (60 mL) was added cyclopropylboronic acid (874 mg, 10.17 mmol) and cesium carbonate (2.84 g, 8.72 mmol) in a sealed tube and the mixture was purged under argon for 20 min. Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (237 mg, 0.290 mmol) was added and the mixture was purged with argon for 5 min at room temperature. The reaction mixture was heated to 100 °C and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with EtOAc (40 mL), filtered through a pad of *celite* and the bed was washed with EtOAc (25 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford methyl 6-cyclopropylpyridazine-4-carboxylate (600 mg, 3.37 mmol, 58%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.42 (d, *J* = 2.0 Hz, 1H), 7.72 (d, *J* = 2.0 Hz, 1H), 4.00 (s, 3H), 2.30-2.22 (m, 1H), 1.30-1.24 (m, 2H), 1.24-1.18 (m, 2H)

**LC-MS:** *m/z* 178.9 [M+H]<sup>+</sup> at 1.70 RT (96.83% purity)

#### **6-Cyclopropylpyridazine-4-carboxylic acid**

To a stirred solution of methyl 6-cyclopropylpyridazine-4-carboxylate (400 mg, 2.24 mmol) in THF (0.6 mL) was added a solution of lithium hydroxide (283 g, 6.74 mmol) in water (1 M, 6.7 mL) at room temperature and stirred for 16 h. After consumption of starting material (by TLC), the volatiles were concentrated under reduced pressure. Then the residue was acidified using conc. HCl (pH 3-4) diluted with water (30 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford 6-cyclopropylpyridazine-4-carboxylic acid (300 mg, crude) as an off white solid. The crude material was used in the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 14.06 (br s, 1H), 9.31 (d, *J* = 1.7 Hz, 1H), 7.88 (d, *J* = 2.3 Hz, 1H), 2.43-2.37 (m, 1H), 1.16-1.11 (m, 4H)

**LC-MS:**  $m/z$  165.2  $[M+H]^+$  at 2.83 RT (95.00% purity)

***N*-(6-Chloro-2-(cyclopropylamino)pyridin-3-yl)-6-cyclopropylpyridazine-4-carboxamide**

To a stirred solution of 6-cyclopropylpyridazine-4-carboxylic acid (300 mg, crude) in THF (15 mL) under an inert atmosphere were added TBTU (1.03 g, 2.74 mmol) and HOBt (259 mg, 1.92 mmol) at room temperature and the reaction was stirred for 10 min. 6-Chloro-*N*<sup>2</sup>-cyclopropylpyridine-2, 3-diamine **Int-8** (334 mg, 1.82 mmol) and triethylamine (0.38 mL, 2.74 mmol) were added to the reaction mixture at room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-(6-chloro-2-(cyclopropylamino)pyridin-3-yl)-6-cyclopropylpyridazine-4-carboxamide (400 mg, 1.21 mmol, 54% , over two steps) as a thick syrup.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.93 (s, 1H), 9.40 (d,  $J$  = 1.7 Hz, 1H), 7.89 (d,  $J$  = 1.7 Hz, 1H), 7.49 (d,  $J$  = 8.1 Hz, 1H), 6.83 (d,  $J$  = 2.3 Hz, 1H), 6.66 (d,  $J$  = 8.1 Hz, 1H), 2.64-2.62 (m, 1H), 2.41-2.33 (m, 1H), 1.20-1.14 (m, 2H), 1.14-1.09 (m, 2H), 0.73-0.67 (m, 2H), 0.49-0.44 (m, 2H)

**LC-MS:**  $m/z$  329.9  $[M+H]^+$  at 2.54 RT (89.91% purity)

**5-Chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (Ex. 84)**

To a stirred solution of *N*-(6-chloro-2-(cyclopropylamino)pyridin-3-yl)-6-cyclopropylpyridazine-4-carboxamide (350 mg, 1.06 mmol) in *t*BuOH (4 mL) under an inert atmosphere was added potassium phosphate (676 mg, 3.19 mmol) in a sealed tube at room temperature. The reaction mixture was heated to 110 °C and stirred for 36 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The residue was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 90% EtOAc/Hexane) to afford 5-chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 84** (65 mg, 0.20 mmol, 19%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.59 (d, *J* = 2.0 Hz, 1H), 8.13-8.08 (m, 2H), 7.42 (d, *J* = 8.4 Hz, 1H), 3.85-3.77 (m, 1H), 2.46-2.37 (m, 1H), 1.30-1.22 (m, 6H), 0.96-0.89 (m, 2H).


**LC-MS:** *m/z* 311.9 [M+H]<sup>+</sup> at 2.44 RT (98.03% purity)

**HPLC:** 99.62%

5

### Example 85

#### Scheme:



#### ***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide**

10

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (200 mg, 1.08 mmol) in EtOAc (12 mL) under an inert atmosphere was added 6-(trifluoromethyl)pyridazine-4-carboxylic acid **Int-26** (208 mg, 1.08 mmol), triethylamine (0.3 mL, 2.17 mmol) and propylphosphonic anhydride (50% in EtOAc, 1.72 g, 2.71 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide (300 mg, 0.83 mmol, 77%) as an off white solid.

15

20

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.18 (s, 1H), 9.91 (d, *J* = 1.7 Hz, 1H), 8.67 (d, *J* = 1.7 Hz, 1H), 7.30 (dd, *J* = 11.0, 8.7 Hz, 1H), 6.93 (dd, *J* = 13.6, 7.8 Hz, 1H), 6.07 (s, 1H), 2.37-2.34 (m, 1H), 0.78-0.72 (m, 2H), 0.45-0.39 (m, 2H)

25

**LC-MS:** *m/z* 357.0 [M-H]<sup>-</sup> at 3.17 RT (95.02% purity)

**1-Cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 85)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide (200 mg, 0.55 mmol) in ethanol (2 mL) under an inert atmosphere was added 6*N* HCl (2.3 mL) at room temperature. The reaction mixture was heated to 70 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was basified to pH 8 using saturated sodium bicarbonate solution and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20-30% EtOAc/hexane) which was further washed with *n*-pentane (10 mL) and dried *in vacuo* to afford 1-cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 85** (100 mg, 0.29 mmol, 53%) as an off white solid.

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 10.07 (d, *J* = 2.0 Hz, 1H), 8.69 (d, *J* = 2.0 Hz, 1H), 7.74 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.66 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.94-3.89 (m, 1H), 1.32-1.26 (m, 2H), 0.90-0.84 (m, 2H)


**LC-MS:** *m/z* 340.9 [M+H]<sup>+</sup> at 3.12 RT (97.31% purity)

**HPLC:** 96.06%

20

**Example 86**

**Scheme:**



***N*-(4-Cyano-2-(cyclopropylamino)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 4-amino-3-(cyclopropylamino)benzonitrile **Int-6** (200 mg, 1.15 mmol) in EtOAc (12 mL) under an inert atmosphere was added 6-(trifluoromethyl) pyridazine-4-carboxylic acid **Int-26** (221 mg, 1.15 mmol) and triethylamine (0.3 mL, 2.31 mmol) at room temperature. The mixture was cooled to 0 °C and propylphosphonic anhydride (T3P, 50% in EtOAc, 1.8 mL, 2.89 mmol) was added. The reaction mixture was warmed to room

temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated sodium bicarbonate solution and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford *N*-(4-cyano-2-(cyclopropylamino) phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide (200 mg) as an off white solid. The crude material was used in the next step without further purification.

**LC-MS:** *m/z* 346.1 [M-H]<sup>-</sup> at 2.94 RT (67.16% purity)

**1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile (Ex. 86)**

To a stirred solution of *N*-(4-cyano-2-(cyclopropylamino)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide (200 mg, crude) in EtOH (2 mL) under an inert atmosphere was added 6 *N* HCl (2 mL) at room temperature. The reaction mixture was heated to 70 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to room temperature, basified with saturated sodium bicarbonate solution and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford a residue which was further purified by preparative HPLC to afford 1-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole-6-carbonitrile **Ex. 86** (40 mg, 0.066 mmol, 21%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 10.10 (d, *J* = 2.0 Hz, 1H), 8.52 (d, *J* = 2.0 Hz, 1H), 8.04 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.64 (dd, *J* = 8.5, 1.3 Hz, 1H), 3.81-3.74 (m, 1H), 1.46-1.40 (m, 2H), 0.95-0.89 (m, 2H)

**LC-MS:** *m/z* 329.9 [M+H]<sup>+</sup> at 2.80 RT (99.16% purity)

**HPLC:** 99.42%

**Example 87**

**Scheme:**



### 3-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3H-imidazo[4,5-*b*]pyridine-5-carbonitrile (Ex. 87)

To a stirred solution of 5-chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3H-imidazo[4, 5-*b*]pyridine **Ex. 84** (50 mg, 0.16 mmol) in DMF (1 mL) was added zinc cyanide (37 mg, 0.32 mmol) and  $\text{Pd(PPh}_3)_4$  (18.5 mg, 0.01 mmol) at room temperature in a sealed tube and the mixture was purged under argon for 20 min. The reaction mixture was heated to 170 °C and stirred for 9 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/ $\text{CH}_2\text{Cl}_2$ ) to afford 3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3H-imidazo[4, 5-*b*] pyridine-5-carbonitrile **Ex. 87** (40 mg, 0.13 mmol, 82%) as an off-white solid.

**$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ):**  $\delta$  9.63 (d,  $J$  = 2.0 Hz, 1H), 8.29 (d,  $J$  = 8.3 Hz, 1H), 8.16 (d,  $J$  = 2.0 Hz, 1H), 7.86 (d,  $J$  = 8.3 Hz, 1H), 3.90-3.83 (m, 1H), 2.48-2.41 (m, 1H), 1.32-1.25 (m, 6H), 1.00 - 0.94 (m, 2H)


**LC-MS:**  $m/z$  303  $[\text{M}+\text{H}]^+$  at 2.27 RT (93.10% purity)

**HPLC:** 96.03%

20

### Example 88

#### Scheme:



### 3-Chloro-*N*-((5-(1-cyclopropyl-5,6-difluoro-1H-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-1-sulfonamide

To a stirred solution of (5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanamine **Int-28** (300 mg, 0.99 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) under an inert atmosphere was added triethylamine (0.2 mL, 1.49 mmol) and 3-chloropropane-1-sulfonyl chloride (170 mg, 0.99 mmol) at 0 to 5 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (60 mL) and washed with water (40 mL) and brine (40 mL). The organic layer was separated dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 80% EtOAc/hexane) to afford 3-chloro-*N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-1-sulfonamide (280 mg) as colorless viscous syrup. The crude material was used in the next step without purification.

**LC-MS:** *m/z* 442.1 [M+H]<sup>+</sup> at 2.68 RT (90.03% purity)

**2-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)isothiazolidine 1,1-dioxide (Ex. 88)**

To a stirred solution of 3-chloro-*N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propane-1-sulfonamide (200 mg, crude) in DMF (10 mL) under an inert atmosphere was added potassium carbonate (125 mg, 0.90 mmol) at room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford 2-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)isothiazolidine 1,1-dioxide **Ex. 88** (80 mg, 0.20 mmol, 44%) as an off white solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.77 (d, *J* = 1.7 Hz, 1H), 8.28 (d, *J* = 1.7 Hz, 1H), 7.92-7.82 (m, 2H), 4.59 (s, 2H), 3.92-3.86 (m, 1H), 3.35-3.31 (m, 4H), 2.29 (m, 2H), 1.23-1.17 (m, 2H), 0.79-0.74 (m, 2H)

**LC-MS:** *m/z* 406.0 [M+H]<sup>+</sup> at 2.39 RT (99.55% purity)

**HPLC:** 97.80%

**Example 90**

**Scheme:**



### ***N*-(2-(Cyclopropylamino)-4-(trifluoromethyl)phenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-5-(trifluoromethyl)benzene-1,2-diamine **Int-19** (300 mg, crude) and 6-methylpyridazine-4-carboxylic acid (266 mg, 1.53 mmol) in ethylacetate (6 mL) was added triethylamine (0.39 mL, 2.78 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 2.21 mL, 3.47 mmol) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4-(trifluoromethyl)phenyl)-6-methylpyridazine-4-carboxamide (200 mg, 0.59 mmol, 42%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.03 (s, 1H), 9.51 (s, 1H), 8.02 (s, 1H), 7.41 (d, *J* = 8.1 Hz, 1H), 7.23 (s, 1H), 6.98 (br d, *J* = 8.1 Hz, 1H), 6.24 (s, 1H), 2.74 (s, 3H), 2.43-2.41 (m, 1H), 0.81-0.74 (m, 2H), 0.47-0.45 (m, 2H)

**LC-MS:** *m/z* 337.1 [M+H]<sup>+</sup> at 2.36 RT (96.19% purity)

### **1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1H-benzo[*d*]imidazole (Ex. 90)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4-(trifluoromethyl)phenyl)-6-methylpyridazine-4-carboxamide (100 mg, 0.3 mmol) in ethanol (1 mL) was added 6 *N* HCl (1.5 mL) dropwise at room temperature under an inert atmosphere. The mixture was warmed to 60 °C for 15 min in a pre-heated oil bath. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain the crude. The crude

material was washed with *n*-pentane (2 x 5 mL) and dried under vacuum to afford 1-cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1*H*-benzo[d]imidazole **Ex. 90** (40 mg, 0.12 mmol, 42%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.69 (d, *J* = 1.9 Hz, 1H), 8.21 (d, *J* = 2.0 Hz, 1H), 8.06 (s, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.64 (dd, *J* = 8.5, 1.4 Hz, 1H), 4.01-3.96 (m, 1H), 2.78 (s, 3H), 1.27-1.21 (m, 2H), 0.81-0.75 (m, 2H)


**LC-MS:** *m/z* 319.0 [M+H]<sup>+</sup> at 2.61 RT (97.98% purity)

**HPLC:** 97.37%

10

### Example 91

#### Scheme:



***N*-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethyl) methanesulfonamide (Ex. 91)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethan-1-amine **Int-30** (70 mg, crude) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) under an inert atmosphere was added triethylamine (0.07 mL, 0.55 mmol) and methanesulfonyl chloride (0.02 mL, 0.33 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 6 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (15 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethyl)methanesulfonamide **Ex. 91** (36 mg, 0.09 mmol, 17%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.74 (d, *J* = 2.1 Hz, 1H), 8.38 (d, *J* = 2.0 Hz, 1H), 8.02 (d, *J* = 7.5 Hz, 1H), 7.93-7.82 (m, 2H), 5.00-4.95 (m, 1H), 3.94-3.86 (m, 1H), 2.92 (s, 3H), 1.57 (d, *J* = 7.0 Hz, 3H), 1.25-1.20 (m, 2H), 0.78-0.75 (m, 2H)

**LC-MS:**  $m/z$  394.0  $[M+H]^+$  at 2.33 RT (92.93% purity)

**HPLC:** 97.92%

### Example 92 & Example 94

#### 5 Scheme:



**(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanol (Ex. 94)**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-27** (100 mg, 0.33 mmol) in methanol (5 mL) under an inert atmosphere was added sodium borohydride (6.3 mg, 0.16 mmol) at 0 °C. The reaction mixture was stirred at same temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with brine solution (10 mL). The volatiles were removed under reduced pressure. The residue was diluted with water (15 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) to afford (5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanol **Ex. 94** (30 mg, 0.099 mmol, 30%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.71 (d, *J* = 2.3 Hz, 1H), 8.28 (d, *J* = 1.7 Hz, 1H), 7.88-7.79 (m, 2H), 5.77 (t, *J* = 5.8 Hz, 1H), 4.88 (d, *J* = 5.8 Hz, 2H), 3.93-3.88 (m, 1H), 1.21-1.15 (m, 2H), 0.77-0.73 (m, 2H)

**LC-MS:**  $m/z$  302.9  $[M+H]^+$  at 2.39 RT (95.96% purity)

**HPLC:** 96.82%

#### 25 **1-Cyclopropyl-5,6-difluoro-2-(6-(fluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 92)**


To a stirred solution of (5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanol **Ex. 94** (130 mg, 0.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) under an inert atmosphere was added DAST (0.16 mL 210 mg, 1.29 mmol) at 0 °C. The reaction mixture was warmed to

5 gel column chromatography (eluent: 50% EtOAc/hexane) which was further purified by preparative HPLC to afford 1-cyclopropyl-5,6-difluoro-2-(6-(fluoromethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 92** (10 mg, 0.03 mmol, 8%) as an off white solid.

10 1H), 1.31-1.24 (m, 2H), 0.87-0.81 (m, 2H)

**HPLC: 99.73%.**

15     **Scheme:**



20 stirred for 16 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by silica gel column

chromatography (eluent: 1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford ethyl 3-hydrazinyl-3-oxopropanoate (6 g, 41.09 mmol, 13%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.16 (brs, 1 H), 4.28 (brs, 2 H), 4.07 (q, *J* = 7.1 Hz, 2 H), 3.40 (s, 2H), 1.20-1.16 (m, 3H)

5 **LC-MS:** *m/z* 147.2 [M+H]<sup>+</sup> at 3.53 RT (89.08% purity)

**Ethyl (*E*)-3-oxo-3-(2-(3-oxobutan-2-ylidene)hydrazinyl)propanoate**

To a stirred solution of ethyl 3-hydrazinyl-3-oxopropanoate (6 g, 41.09 mmol) in ethanol (120 mL) under an inert atmosphere was added diacetyl (3.5 g, 41.09 mmol) at room temperature  
10 and stirred for 16 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford ethyl (*E*)-3-oxo-3-(2-(3-oxobutan-2-ylidene) hydrazinyl) propanoate (6 g, 28.03 mmol, 69%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 11.18 (brs, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.71 (s, 2H),  
15 2.27 (s, 3H), 1.90 (s, 3H), 1.16 (t, *J* = 7.1 Hz, 3H)

**LC-MS:** *m/z* 215 [M+H]<sup>+</sup> at 1.69 RT (93.82% purity)

**Ethyl 5,6-dimethyl-3-oxo-2,3-dihydropyridazine-4-carboxylate**

To a stirred solution of ethyl (*E*)-3-oxo-3-(2-(3-oxobutan-2-ylidene) hydrazinyl) propanoate (3  
20 g, 14.01 mmol) in 1,4-dioxane (30 mL) under an inert atmosphere was added 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) (2.08 mL, 14.01 mmol) at room temperature. The reaction mixture was heated to 100 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (80 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts  
25 were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford ethyl 5,6-dimethyl-3-oxo-2,3-dihydropyridazine-4-carboxylate (1.5 g, crude) as colorless viscous syrup. The crude material was used in the next step without purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 12.97 (brs, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 2.23 (s, 3H), 2.09 (s, 3H), 1.27 (t, *J* = 7.0 Hz, 3H)

30 **LC-MS:** *m/z* 196.9 [M+H]<sup>+</sup> at 1.50 RT (46.75% purity)

**Ethyl 3-chloro-5,6-dimethylpyridazine-4-carboxylate**

To a stirred solution of ethyl 5,6-dimethyl-3-oxo-2,3-dihydropyridazine-4-carboxylate (1.5 g, crude) in 1,4-dioxane (25 mL) under an inert atmosphere was added phosphoryl trichloride (7.3 mL, 76.53 mmol) at 0 °C in a sealed tube. The reaction mixture was heated to 100 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was

5 quenched with saturated sodium bicarbonate solution (50 mL) and extracted with EtOAc (2 x 70 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford ethyl 3-chloro-5,6-dimethylpyridazine-4-carboxylate (250 mg, 1.16 mmol, 8%, over two steps) as a colorless viscous syrup.

10 **<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 4.46 (q, *J* = 7.2 Hz, 2H), 2.63 (s, 3H), 2.28 (s, 3H), 1.34 (t, *J* = 7.1 Hz, 3H)

**LC-MS:** *m/z* 214.9 [M+H]<sup>+</sup> at 2.19 RT (97.49% purity)

#### **Ethyl 5,6-dimethylpyridazine-4-carboxylate**

15 To a stirred solution of ethyl 3-chloro-5,6-dimethylpyridazine-4-carboxylate (250 mg, 1.16 mmol) in ethanol (12 mL) under an inert atmosphere was added triethylamine (catalytic) and 10% Pd/C (50% wet, 120 mg) at room temperature. The reaction was evacuated and a hydrogen atmosphere (balloon pressure) was established and the reaction was stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a

20 pad of *celite* and the bed was washed with ethanol (20 mL). The filtrate was concentrated under reduced pressure. The obtained crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford ethyl 5,6-dimethylpyridazine-4-carboxylate (100 mg, 0.55 mmol, 48%) as a colorless syrup.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.14 (s, 1H), 4.36 (q, *J* = 7.1 Hz, 2H), 2.66 (s, 3H), 2.44

25 (s, 3H), 1.33 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 180.9 [M+H]<sup>+</sup> at 1.76 RT (98.17% purity)

#### **5,6-Dimethylpyridazine-4-carboxylic acid**

To a stirred solution of ethyl 5,6-dimethylpyridazine-4-carboxylate (100 mg, 0.55 mmol) in a

30 mixture of THF: water (2:1, 2 mL) was added lithium hydroxide monohydrate (47 mg, 1.11 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the volatiles were concentrated

under reduced pressure. Then the residue was diluted with water (5 mL) and acidified using conc. HCl solution (~ pH 3-4). The aqueous layer was lyophilized to afford 5,6-dimethylpyridazine-4-carboxylic acid (110 mg, salt) as a white solid. The crude material was used in the next step without further purification.

5 **<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.17 (s, 1H), 2.69 (s, 3H), 2.48 (s, 3H)

**LC-MS:** *m/z* 153.2 [M+H]<sup>+</sup> at 1.79 RT (99.78% purity)

***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-5,6-dimethylpyridazine-4-carboxamide**

To a stirred solution of 5,6-dimethylpyridazine-4-carboxylic acid (67 mg, crude) in EtOAc (5 mL) under an inert atmosphere was added *N*<sup>1</sup>-cyclopropyl-4, 5-difluorobenzene-1,2-diamine **Int-5** (80 mg, 0.43 mmol), triethylamine (0.24 mL, 1.75 mmol) and propylphosphonic anhydride (50% in EtOAc, 0.7 mL, 1.09 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and  
15 extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 60% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5,6-dimethylpyridazine-4-carboxamide (40 mg, 0.12 mmol, 29%) as brown solid.

20 **<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.76 (s, 1H), 9.18 (s, 1H), 7.51 (dd, *J* = 11.9, 8.4 Hz, 1H), 6.67 (dd, *J* = 10.7, 7.2 Hz, 1H), 5.78 (s, 1H), 2.66 (s, 3H), 2.60-2.55 (m, 1H), 2.34 (s, 3H), 1.43-1.34 (m, 2H), 0.44-0.40 (m, 2H)

**LC-MS:** *m/z* 318.9 [M+H]<sup>+</sup> at 2.90 RT (49.24% purity).

25 **1-Cyclopropyl-2-(5,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 93)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5,6-dimethylpyridazine-4-carboxamide (40 mg, 0.125 mmol) in *t*BuOH (0.5 mL) under an inert atmosphere was added tri potassium phosphate (66 mg, 0.31 mmol) at room temperature in a sealed tube. The  
30 reaction mixture was heated to 120 °C and stirred for 6 h. After consumption of starting material (by TLC), the volatiles were evaporated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-

cyclopropyl-2-(5,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 93** (18 mg, 0.06 mmol, 48%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.18 (s, 1H), 7.71 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.61 (dd, *J* = 10.5, 7.2 Hz, 1H), 3.63-3.55 (m, 1H), 2.80 (s, 3H), 2.39 (s, 3H), 1.06-1.00 (m, 2H), 0.72-0.66 (m, 2H)

**LC-MS:** *m/z* 300.9 [M+H]<sup>+</sup> at 2.34 RT (99.49% purity)

**HPLC:** 99.17%

### Example 95 & Example 89

#### Scheme:



#### ***N*-(6-Chloro-2-(cyclopropylamino)pyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 6-chloro-*N*<sup>2</sup>-cyclopropylpyridine-2,3-diamine **Int-8** (300 mg, 1.63 mmol) in EtOAc (10 mL) under an inert atmosphere was added 6-(trifluoromethyl)pyridazine-4-carboxylic acid **Int-26** (314 mg, 1.63 mmol), triethylamine (0.43 mL, 3.27 mmol) and propylphosphonic anhydride (50% in EtOAc, 2.6 mL, 4.09 mmol) at 0 to 5 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated sodium bicarbonate solution (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-

(6-chloro-2-(cyclopropylamino)pyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide (250 mg, 0.70 mmol, 43%) as a brown solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.24 (s, 1H), 9.92 (s, 1H), 8.67 (d, *J* = 1.7 Hz, 1H), 7.49 (d, *J* = 8.1 Hz, 1H), 6.87 (d, *J* = 1.7 Hz, 1H), 6.68 (d, *J* = 8.1 Hz, 1H), 2.72-2.67 (m, 1H), 0.74-0.69 (m, 2H), 0.49-0.44 (m, 2H)

**LC-MS:** *m/z* 357.9 [M+H]<sup>+</sup> at 2.87 RT (96.94% purity)

**5-Chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (Ex. 95)**

To a stirred solution of *N*-(6-chloro-2-(cyclopropylamino)pyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide (200 mg, 0.56 mmol) in <sup>t</sup>BuOH (6 mL) under an inert atmosphere was added tripotassium phosphate (400 mg) at room temperature in a sealed tube. The reaction mixture was stirred at 130 °C for 24 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 25% EtOAc/hexane) to afford 5-chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 95** (150 mg, 0.44 mmol, 79%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 10.13 (d, *J* = 2.0 Hz, 1H), 8.76 (d, *J* = 2.0 Hz, 1H), 8.16 (d, *J* = 8.4 Hz, 1H), 7.44 (d, *J* = 8.5 Hz, 1H), 3.91-3.84 (m, 1H), 1.32-1.26 (m, 2H), 1.00-0.95 (m, 2H)

**LC-MS:** *m/z* 339.9 [M+H]<sup>+</sup> at 2.86 RT (97.81% purity)

**HPLC:** 98.06%

**3-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (Ex. 89)**

To a stirred solution of 5-chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine **Ex. 95** (90 mg, 0.26 mmol) in DMF (1.5 mL) was added zinc cyanide (62 mg, 0.53 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (30 mg, 0.02 mmol) at room temperature in a sealed tube and the mixture was purged under argon for 10 min. The reaction mixture was heated to 170 °C for 8 h. After consumption of starting material (by TLC), the reaction mixture was diluted

with water (20 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with diethyl ether (2 x 10 mL) dried *in vacuo*. The obtained solid was further purified by preparative HPLC to afford 3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile **Ex. 89** (13 mg, 0.039 mmol, 15%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 10.16 (d, *J* = 2.0 Hz, 1H), 8.81 (d, *J* = 2.0 Hz, 1H), 8.34 (d, *J* = 8.3 Hz, 1H), 7.87 (d, *J* = 8.2 Hz, 1H), 3.96-3.88 (m, 1H), 1.35-1.28 (m, 2H), 1.03-0.97 (m, 2H)

LC-MS: *m/z* 331.2 [M+H]<sup>+</sup> at 3.41 RT (99.80% purity)

HPLC: 99.55%

### Example 96

#### Scheme:



**N-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl)ethanesulfonamide (Ex. 96)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-amine **Int-30** (70 mg, 0.22 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under an inert atmosphere was added triethylamine (0.07 mL, 0.55 mmol) and ethanesulfonyl chloride (43 mg, 0.33 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by preparative HPLC to afford *N*-(1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl)ethanesulfonamide (**Ex. 96**) (40 mg, 0.09 mmol, 44%) as an off-white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.74 (d, *J* = 2.0 Hz, 1H), 8.39 (d, *J* = 2.1 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.92-7.81 (m, 2H), 4.92 (p, *J* = 7.3 Hz, 1H), 3.93-3.86 (m, 1H), 3.11-2.90 (m, 2H), 1.57 (d, *J* = 7.0 Hz, 3H), 1.27-1.20 (m, 2H), 1.16 (t, *J* = 7.3 Hz, 3H), 0.80-0.72 (m, 2H)

5 **LC-MS:** *m/z* 408.0 [M+H]<sup>+</sup> at 2.42 RT (98.97% purity)

**HPLC:** 99.61%

### Example 97

#### Scheme:



#### 2-(6-Butylpyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole (Ex. 97)

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (300 mg, 0.98 mmol) in toluene (5 mL) was added X-phos (47 mg, 0.1 mmol), tripotassium phosphate (623 mg, 2.94 mmol) and butylboronic acid (148 mg, 1.47 mmol) in a sealed tube at room temperature under an inert atmosphere. The reaction mixture was purged under argon for 15 min. Pd<sub>2</sub>(dba)<sub>3</sub> (90 mg, 0.1 mmol) was added at room temperature and the reaction mixture was heated to 100 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford a residue which was purified by normal phase preparative HPLC purification to afford 2-(6-butylpyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 97** (20 mg, 0.06 mmol, 6%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.63 (d, *J* = 2.1 Hz, 1H), 8.20 (d, *J* = 2.1 Hz, 1H), 7.71 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.62 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.90-3.84 (m, 1H), 3.15-3.09 (m, 2H),

1.90-1.81 (m, 2H), 1.52-1.43 (m, 2H), 1.29-1.23 (m, 2H), 1.01 (t,  $J = 7.3$  Hz, 3H), 0.85-0.79 (m, 2H)


**LC-MS:**  $m/z$  329.0  $[M+H]^+$  at 2.99 RT (99.92% purity)

**HPLC:** 99.82%

5

### Example 98

#### Scheme:



#### *N*-(2-(Cyclopropylamino)-4-methylphenyl)-6-methylpyridazine-4-carboxamide

- 10 To a stirred solution of *N*<sup>1</sup>-cyclopropyl-5-methylbenzene-1,2-diamine **Int-18** (120 mg, crude) and 6-methylpyridazine-4-carboxylic acid (129 mg, 0.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added HATU (310 mg, 0.81 mmol) and HOBt (110 mg, 0.81 mmol) followed by ethyldiisopropylamine (0.52 mL, 2.96 mmol) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 16 h. After
- 15 consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-(cyclopropylamino)-4-methylphenyl)-6-methylpyridazine-4-carboxamide (120 mg, 0.42
- 20 mmol, 57%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.80 (s, 1H), 9.48 (s, 1H), 7.99 (s, 1H), 7.02 (br d,  $J = 7.7$  Hz, 1H), 6.86 (s, 1H), 6.47 (d,  $J = 7.7$  Hz, 1H), 5.63 (brs, 1H), 2.72 (s, 3H), 2.36-2.32 (m, 1H), 2.28 (s, 3H), 0.72-0.69 (m, 2H), 0.43-0.39 (brs, 2H)

**LC-MS:**  $m/z$  282.9  $[M+H]^+$  at 2.36 RT (94.69% purity)

25

#### **1-Cyclopropyl-6-methyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 98)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4-methylphenyl)-6-methylpyridazine-4-carboxamide (120 mg, 0.42 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added trifluoroacetic acid (0.2 mL) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (5 mL), basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) followed by preparative HPLC to afford 1-cyclopropyl-6-methyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 98** (25 mg, 0.09 mmol, 22%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.68 (d, *J* = 1.9 Hz, 1H), 7.97 (d, *J* = 1.9 Hz, 1H), 7.70 (d, *J* = 8.3 Hz, 1H), 7.44-7.41 (m, 1H), 7.18 (dd, *J* = 8.3, 1.1 Hz, 1H), 3.66-3.61 (m, 1H), 2.84 (s, 3H), 2.56 (s, 3H), 1.31-1.25 (m, 2H), 0.86-0.81 (m, 2H)

LC-MS: *m/z* 264.9 [M+H]<sup>+</sup> at 2.26 RT (99.85% purity)

HPLC: 99.84%

### Example 99

#### Scheme:



#### 20 *N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-3-methylpyridazine-4-carboxamide

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (100 mg, 0.72 mmol) in ethylacetate (6 mL) was added 3-methylpyridazine-4-carboxylic acid (132 mg, 0.72 mmol) and triethylamine (0.2 mL, 1.45 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.15 mL, 1.81 mmol) dropwise at 0 °C under an inert atmosphere and the reaction was allowed to stir at room temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica

gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-3-methylpyridazine-4-carboxamide (100 mg, 0.33 mmol, 45%) as a brown solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.74 (s, 1H), 9.28 (d, *J* = 5.0 Hz, 1H), 7.86 (d, *J* = 5.0 Hz, 1H), 7.48 (dd, *J* = 11.9, 8.7 Hz, 1H), 6.94 (dd, *J* = 13.6, 8.0 Hz, 1H), 5.83 (s, 1H), 2.72 (s, 3H), 2.41-2.33 (m, 1H), 0.80-0.71 (m, 2H), 0.46-0.37 (m, 2H)

**LC-MS:** *m/z* 305.1[M+H]<sup>+</sup> at 2.43 RT (96.65% purity)

### 1-Cyclopropyl-5,6-difluoro-2-(3-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 99)

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-3-methylpyridazine-4-carboxamide (80 mg, 0.26 mmol) in ethanol (0.8 mL) was added 6 *N* HCl (0.4 mL) dropwise at room temperature under an inert atmosphere. Then the reaction mixture was heated to 60 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified with saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-5,6-difluoro-2-(3-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 99** (40 mg, 0.14 mmol, 53%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.26 (d, *J* = 5.1 Hz, 1H), 7.63-7.55 (m, 2H), 7.42 (dd, *J* = 9.6, 7.0 Hz, 1H), 3.41-3.36 (m, 1H), 2.82 (s, 3H), 1.10-1.01 (m, 2H), 0.72-0.62 (m, 2H).

**LC-MS:** *m/z* 287.2 [M+H]<sup>+</sup> at 3.10 RT (98.57% purity)

**HPLC:** 98.53%

### Example 100

#### 25 Scheme:



***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-3,6-dimethylpyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (200 mg, 1.09 mmol) in ethylacetate (10 mL) was added 3,6-dimethylpyridazine-4-carboxylic acid (165 mg, 1.09 mmol) and triethylamine (0.3 mL, 2.17 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.73 mL, 2.71 mmol) dropwise at 0-5 °C under an inert atmosphere and the mixture was allowed to stir at room temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. The material was combined with another lot (100 mg, crude) and purified by silica gel column chromatography (eluent: 2% MeOH/EtOAc) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-3,6-dimethylpyridazine-4-carboxamide (260 mg, 0.82 mmol, 51%) as a brown solid.

**LC-MS:** *m/z* 319.1[M+H]<sup>+</sup> at 2.51 RT (98.54% purity)


**15 1-Cyclopropyl-2-(3,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (Ex. 100)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-3,6-dimethylpyridazine-4-carboxamide (200 mg, 0.63 mmol) in ethanol (3 mL) was added 6 *N* HCl (3 mL) dropwise at room temperature under an inert atmosphere. Then the reaction mixture was heated to 60 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified with saturated NaHCO<sub>3</sub> (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. The material was combined with another lot (50 mg, crude) and purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford a solid which was triturated with EtOAc (5 mL) and dried under vacuum to afford 1-cyclopropyl-2-(3,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 100** (110 mg, 0.37 mmol, 48%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 7.87 (s, 1H), 7.71 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.60 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.63-3.57 (m, 1H), 2.77 (s, 3H), 2.69 (s, 3H), 1.09-1.02 (m, 2H), 0.73-0.67 (m, 2H)

**LC-MS:** *m/z* 300.9 [M+H]<sup>+</sup> at 2.35 RT (98.70% purity)

**HPLC:** 99.50%

**Example 101****Scheme:**

5 ***N*-(2-(Cyclopropylamino)-3,4-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-5,6-difluorobenzene-1,2-diamine **Int-20** (250 mg, crude) and 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (260 mg, 1.49 mmol) in ethylacetate (5 mL) was added triethylamine (0.38 mL, 2.72 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 2.16 mL, 3.4 mmol) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-(cyclopropylamino)-3,4-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (300 mg, 0.88 mmol, 65%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.24 (s, 1H), 9.79 (s, 1H), 8.45 (d, *J* = 1.2 Hz, 1H), 7.56-7.28 (m, 1H), 6.95 (t, *J* = 6.7 Hz, 1H), 6.68 (q, *J* = 8.7 Hz, 1H), 5.60 (br s, 1H), 2.82-2.75 (m, 1H), 0.63-0.48 (m, 4H)

**LC-MS:** *m/z* 340.9 [M+H]<sup>+</sup> at 2.79 RT (92.05% purity)

**1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6,7-difluoro-1H-benzo[*d*]imidazole (Ex. 101)**

To a stirred solution of *N*-(2-(cyclopropylamino)-3,4-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (150 mg, 0.44 mmol) in ethanol (1.5 mL) was

added 6 N HCl (2.25 mL) dropwise at room temperature under an inert atmosphere. The reaction mixture was stirred in a pre-heated oil bath at 60 °C for 15 min. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic  
 5 extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6,7-difluoro-1H-benzo[d]imidazole **Ex. 101** (70 mg, 0.22 mmol, 49%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.97 (d, *J* = 2.0 Hz, 1H), 8.53 (d, *J* = 2.0 Hz, 1H), 7.65-  
 10 7.62 (m, 1H), 7.57-7.29 (m, 2H), 4.20-4.15 (m, 1H), 1.16-1.09 (m, 2H), 0.88-0.84 (m, 2H)

LC-MS: *m/z* 323.0 [M+H]<sup>+</sup> at 2.83 RT (98.57% purity)

HPLC: 98.76%

### Example 102

#### 15 Scheme:



#### **5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-thiol (Ex. 102)**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (100 mg, 0.33 mmol) in ethanol (5 mL) was added thiourea (35 mg,  
 20 0.49 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to reflux temperature for 4 h and cooled. Saturated sodium hydroxide solution (2 mL) was added at room temperature and heated to reflux temperature for 1 h. The reaction mixture was cooled and neutralized to pH ~7 using 6 N HCl. The precipitated solid was filtered and the solid was again washed successively with water (5 mL), MeOH (5 mL), CH<sub>2</sub>Cl<sub>2</sub> (5 mL),  
 25 EtOAc (5 mL), Et<sub>2</sub>O (5 mL) and dried under vacuum to afford 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-thiol **Ex. 102** (50 mg, 0.16 mmol, 50%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 14.94 (br s, 1H), 8.79 (d, *J* = 1.8 Hz, 1H), 8.19 (s, 1H), 7.89-7.80 (m, 2H), 3.93-3.83 (m, 1H), 1.22-1.19 (m, 2H), 0.91-0.89 (m, 2H)


**LC-MS:** *m/z* 304.9 [M+H]<sup>+</sup> at 2.56 RT (94.69% purity)

**HPLC:** 93.13%

5

### Example 103

#### Scheme:



#### 10 ***N*-(2-Amino-4,5-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 4, 5-difluorobenzene-1,2-diamine **Int-12** (199 mg, 1.37 mmol) in EtOAc (12 mL) under an inert atmosphere was added 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (200 mg, 1.14 mmol), triethylamine (0.32 mL, 2.29 mmol) and propylphosphonic anhydride (50% in EtOAc, 1.83 mL, 2.87 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC & LC-MS), the reaction mixture was quenched with saturated sodium bicarbonate solution (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (70 mL) and brine (70 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-(2-amino-4,5-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (70 mg, 0.23 mmol, 13%) as a yellow solid.

**LC-MS:** *m/z* 300.9 [M+H]<sup>+</sup> at 2.2 RT (85.12% purity)

#### **2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 103)**

To a stirred solution of *N*-(2-amino-4,5-difluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (50 mg, 0.16 mmol) in EtOH (0.75 mL) under an inert atmosphere was added 6 *N* HCl (0.5 mL) at room temperature. The reaction mixture was heated to 90 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was basified with sodium bicarbonate solution (40 mL) and extracted with EtOAc (2 x 50 mL). The combined

organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 103** (15 mg, 0.05 mmol, 23%) as a pink solid.

5 <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 13.88 (brs, 1H), 10.03 (d, *J* = 2.0 Hz, 1H), 8.58 (d, *J* = 2.1 Hz, 1H), 7.87-7.81 (m, 2H), 7.55-7.25 (m, 1H)


LC-MS: *m/z* 283.1 [M+H]<sup>+</sup> at 2.12 RT (97.58% purity)

HPLC: 98.71%

10

### Example 104

#### Scheme:



#### *N*-(4,5-Difluoro-2-(methylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide

15 To a stirred solution of 4,5-difluoro-*N*<sup>1</sup>-methylbenzene-1,2-diamine **Int-15** (200 mg, crude) and 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (220 mg, 1.26 mmol) in ethylacetate (20 mL) was added triethylamine (0.36 mL, 2.53 mmol) and propylphosphonic anhydride (50% in EtOAc, 2 mL, 3.16 mmol) dropwise at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-(4,5-difluoro-2-(methylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (210 mg, 0.67 mmol, 53%) as a pale yellow solid.

25 <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 10.23 (s, 1H), 9.81 (d, *J* = 1.7 Hz, 1H), 8.48 (d, *J* = 1.7 Hz, 1H), 7.55-7.25 (m, 2H), 6.60 (dd, *J* = 13.6, 7.8 Hz, 1H), 5.68 (br s, 1H), 2.69 (d, *J* = 4.6 Hz, 3H)

**LC-MS:**  $m/z$  314.9  $[M+H]^+$  at 2.53 RT (93.02% purity)

**2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole (Ex. 104)**

To a stirred solution of *N*-(4,5-difluoro-2-(methylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (150 mg, 0.48 mmol) in ethanol (1.5 mL) was added 6 *N* HCl (1.5 mL) at 0 °C under an inert atmosphere. Then the reaction mixture was stirred in a pre-heated oil bath at 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-methyl-1H-benzo[d]imidazole **Ex. 104** (98 mg, 0.33 mmol, 69%) as a pale yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.89 (s, 1H), 8.44 (d,  $J$  = 1.7 Hz, 1H), 7.99 (dd,  $J$  = 10.4, 7.5 Hz, 1H), 7.89 (dd,  $J$  = 11.0, 7.5 Hz, 1H), 7.54-7.29 (m, 1H), 4.04 (s, 3H)


**LC-MS:**  $m/z$  296.9  $[M+H]^+$  at 2.46 RT (97.61% purity)

**HPLC:** 97.08%

20

**Example 105**

**Scheme:**



***N*-(4,5-Difluoro-2-(propylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 4,5-difluoro-*N*<sup>1</sup>-propylbenzene-1,2-diamine **Int-16** (200 mg, crude) and 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (187 mg, 1.07 mmol) in ethylacetate (20 mL) was added triethylamine (0.3 mL, 2.15 mmol) and propylphosphonic anhydride (50% in EtOAc, 1.71 mL, 2.69 mmol) dropwise at 0 °C under an inert atmosphere.

The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-(4,5-difluoro-2-(propylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (200 mg, 0.58 mmol, 55%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.19 (brs, 1H), 9.82 (d, *J* = 1.2 Hz, 1H), 8.47 (d, *J* = 1.7 Hz, 1H), 7.55-7.23 (m, 2H), 6.66 (dd, *J* = 13.9, 7.5 Hz, 1H), 5.52 (brs, 1H), 3.02 (q, *J* = 6.6 Hz, 2H), 1.60-1.50 (m, 2H), 0.91 (t, *J* = 7.5 Hz, 3H)

**LC-MS:** *m/z* 342.9 [M+H]<sup>+</sup> at 3.00 RT (95.46% purity)

**2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-propyl-1*H*-benzo[*d*]imidazole (Ex. 105)**

To a stirred solution of *N*-(4,5-difluoro-2-(propylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (150 mg, 0.44 mmol) in ethanol (1.5 mL) was added 6 *N* HCl (1.5 mL) at 0 °C under an inert atmosphere. Then the reaction mixture was stirred in a pre-heated oil bath at 80 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-propyl-1*H*-benzo[*d*]imidazole **Ex. 105** (110 mg, 0.34 mmol, 77%) as a yellow solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.85 (d, *J* = 1.7 Hz, 1H), 8.38 (d, *J* = 1.7 Hz, 1H), 8.07 (dd, *J* = 10.7, 7.2 Hz, 1H), 7.89 (dd, *J* = 11.0, 7.5 Hz, 1H), 7.53-7.28 (m, 1H), 4.42 (t, *J* = 7.2 Hz, 2H), 1.75-1.68 (m, 2H), 0.77 (t, *J* = 7.2 Hz, 3H)

**LC-MS:** *m/z* 324.9 [M+H]<sup>+</sup> at 2.90 RT (97.45% purity)

**HPLC:** 96.79%

**Example 106**

**Scheme:**



### Diethyl 2-hydroxy-2-(2-oxocyclohexyl)malonate

A solution of diethyl 2-oxomalonate (500 mg, 2.87 mmol) and cyclohexanone (282 mg, 2.87 mmol) in a sealed tube was heated to 100 °C and stirred for 16 h and cooled. The reaction mixture (brown syrup) containing diethyl 2-hydroxy-2-(2-oxocyclohexyl) malonate (500 mg) was taken to the next step without further purification.

**LC-MS:**  $m/z$  273.3  $[M+H]^+$  at 2.83 RT (82.91% purity)

### Ethyl 3-hydroxy-5,6,7,8-tetrahydrocinnoline-4-carboxylate

To a stirred solution of diethyl 2-hydroxy-2-(2-oxocyclohexyl) malonate (5 g, crude) in acetic acid (35 mL) was added hydrazine monohydrochloride (6.25 g, 91.91 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 100 °C and stirred for 3 h. The progress of the reaction was monitored by TLC, the reaction mixture was quenched using saturated  $\text{NaHCO}_3$  solution (100 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/ $\text{CH}_2\text{Cl}_2$ ) to afford ethyl 3-hydroxy-5,6,7,8-tetrahydrocinnoline-4-carboxylate (4 g, 18.0 mmol, 98%) as an off white solid.

**$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):**  $\delta$  4.48 (q,  $J$  = 7.1 Hz, 2H), 3.18 (t,  $J$  = 6.4 Hz, 2H), 2.81 (t,  $J$  = 6.4 Hz, 2H), 1.99-1.92 (m, 2H), 1.89-1.82 (m, 2H), 1.44 (t,  $J$  = 7.2 Hz, 3H)

**LC-MS:**  $m/z$  223.0  $[M+H]^+$  at 1.87 RT (83.82% purity)

**Ethyl 3-chloro-5,6,7,8-tetrahydrocinnoline-4-carboxylate**

To a stirred solution of ethyl 3-hydroxy-5,6,7,8-tetrahydrocinnoline-4-carboxylate (4 g, 18.0 mmol) in 1,4-dioxane (40 mL) was added phosphoryl chloride (16.79 mL, 179.98 mmol) in a sealed tube at room temperature under an inert atmosphere. The reaction mixture was heated to 100 °C and stirred for 2 h. The progress of the reaction was monitored by TLC, the reaction mixture was quenched using saturated  $\text{NaHCO}_3$  solution (100 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford ethyl 3-chloro-5,6,7,8-tetrahydrocinnoline-4-carboxylate (3.5 g, 14.54 mmol, 81%) as a brown solid.

**$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):**  $\delta$  4.48 (q,  $J = 7.0$  Hz, 2H), 3.17 (t,  $J = 6.4$  Hz, 2H), 2.80 (t,  $J = 6.7$  Hz, 2H), 1.98-1.92 (m, 2H), 1.88-1.82 (m, 2H), 1.43 (t,  $J = 7.0$  Hz, 3H)

**LC-MS:**  $m/z$  241.0  $[M+H]^+$  at 2.57 RT (99.53% purity)

**Ethyl 5,6,7,8-tetrahydrocinnoline-4-carboxylate**

To a stirred solution of ethyl 3-chloro-5,6,7,8-tetrahydrocinnoline-4-carboxylate (500 mg, 2.08 mmol) in ethylacetate (10 mL) was added 10% Pd/C (50% wet, 150 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 1 h. The progress of the reaction was monitored by TLC, the reaction mixture was filtered through a pad of *celite* and the bed was washed with EtOAc (15 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford ethyl 5,6,7,8-tetrahydrocinnoline-4-carboxylate (100 mg, 0.48 mmol, 23%) as a brown syrup.

**$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.26 (s, 1H), 4.41 (q,  $J = 7.2$  Hz, 2H), 3.22 (t,  $J = 6.5$  Hz, 2H), 3.15 (t,  $J = 6.5$  Hz, 2H), 1.98-1.89 (m, 2H), 1.89-1.80 (m, 2H), 1.41 (t,  $J = 7.2$  Hz, 3H)

**LC-MS:**  $m/z$  206.9  $[M+H]^+$  at 2.12 RT (98.29% purity)

**5,6,7,8-Tetrahydrocinnoline-4-carboxylic acid**

To a stirred solution of ethyl 5,6,7,8-tetrahydrocinnoline-4-carboxylate (20 mg, 0.1 mmol) in a mixture of THF/water (4:1, 1 mL) was added lithium hydroxide monohydrate (12 mg, 0.29 mmol) at room temperature and stirred for 2 h. Then the reaction mixture was lyophilized to afford 5,6,7,8-tetrahydrocinnoline-4-carboxylic acid (25 mg, 0.14 mmol) as an off white solid.

5 The crude material was taken to the next step without further purification.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.24 (s, 1H), 3.14 (t, *J* = 6.4 Hz, 2H), 3.09 (t, *J* = 6.4 Hz, 2H), 1.89-1.81 (m, 2H), 1.80-1.72 (m, 2H)

**LC-MS:** *m/z* 179.0 [M+H]<sup>+</sup> at 2.73 RT (70.16% purity)

10 ***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-5,6,7,8-tetrahydrocinnoline-4-carboxamide**

To a stirred solution of 5,6,7,8-tetrahydrocinnoline-4-carboxylic acid (86 mg, crude) in ethylacetate (5 mL) was added *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (88 mg, 0.48 mmol), triethylamine (0.27 mL, 1.93 mmol) and propylphosphonic anhydride (50% in  
15 EtOAc, 0.77 mL, 1.21 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. The progress of the reaction was monitored by TLC, the reaction mixture was quenched using saturated NaHCO<sub>3</sub> solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified  
20 by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5,6,7,8-tetrahydrocinnoline-4-carboxamide (50 mg, 0.14 mmol, 30%) as a brown solid.

**LC-MS:** *m/z* 343.1 [M-H]<sup>-</sup> at 2.74 RT (66.07% purity)

25 **4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-5,6,7,8-tetrahydrocinnoline (Ex. 106)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-5,6,7,8-tetrahydrocinnoline-4-carboxamide (50 mg, 0.14 mmol) in ethanol (0.5 mL) was added 6 *N* HCl (0.2 mL) dropwise at room temperature under an inert atmosphere. Then the reaction  
30 mixture was heated to 60 °C and stirred for 2 h. The reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under

reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 4-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-5,6,7,8-tetrahydrocinnoline **Ex. 106** (20 mg, 0.06 mmol, 42%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.20 (s, 1H), 7.71 (dd, *J* = 10.1, 7.1 Hz, 1H), 7.60 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.65-3.60 (m, 1H), 3.24 (t, *J* = 6.6 Hz, 2H), 2.90 (t, *J* = 6.4 Hz, 2H), 2.07-1.99 (m, 2H), 1.90-1.82 (m, 2H), 1.08-1.02 (m, 2H), 0.73-0.67 (m, 2H)


**LC-MS:** *m/z* 327.2 [M+H]<sup>+</sup> at 2.22 RT (95.90% purity)

**HPLC:** 96.28%

10

### Example 107

#### Scheme:



#### ***N*-(5-Cyano-2-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of 3-amino-4-(cyclopropylamino)benzonitrile **Int-22** (198 mg, crude) and 6-methylpyridazine-4-carboxylic acid hydrochloride (200 mg, 1.15 mmol) in ethylacetate (12 mL) was added triethylamine (0.32 mL, 2.29 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.82 mL, 2.86 mmol) dropwise at 0 °C under an inert atmosphere. The reaction was warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated NaHCO<sub>3</sub> (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 60% EtOAc/hexane) to afford *N*-(5-cyano-2-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (400 mg, 1.34 mmol, 79%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.12 (s, 1H), 9.60 (d, *J* = 2.0 Hz, 1H), 8.11 (d, *J* = 2.0 Hz, 1H), 7.71-7.63 (m, 2H), 7.19 (d, *J* = 8.5 Hz, 1H), 6.83 (s, 1H), 2.84 (s, 3H), 2.57-2.50 (m, 1H), 0.92-0.85 (m, 2H), 0.60-0.55 (m, 2H)

**LC-MS:** *m/z* 293.9 [M+H]<sup>+</sup> at 2.14 RT (88.98% purity)

25


**1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-5-carbonitrile (Ex. 107)**

To a stirred solution of *N*-(5-cyano-2-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (200 mg, 0.68 mmol) in ethanol (2 mL) was added 6 *N* HCl (3 mL) drop wise at room temperature under an inert atmosphere. Then the reaction mixture was stirred in a pre-heated oil bath at 70 °C for 25 min. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution to pH ~8 and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 1-2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-5-carbonitrile **Ex. 107** (120 mg, 0.43 mmol, 64%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.69 (s, 1H), 8.16 (dd, *J* = 1.4, 0.6 Hz, 1H), 7.98 (d, *J* = 1.9 Hz, 1H), 7.75 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.65 (dd, *J* = 8.4, 1.5 Hz, 1H), 3.74-3.69 (m, 1H), 2.88 (s, 3H), 1.38-1.32 (m, 2H), 0.89-0.83 (m, 2H)

**LC-MS:** *m/z* 275.9 [M+H]<sup>+</sup> at 2.07 RT (99.17% purity)

**HPLC:** 99.01%

**Example 108****Scheme:*****N*-(2-(Cyclobutylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclobutyl-4,5-difluorobenzene-1,2-diamine **Int-21** (200 mg, crude) and 6-methylpyridazine-4-carboxylic acid hydrochloride (176 mg, 1.01 mmol) in ethylacetate (10 mL) was added triethylamine (0.56 mL, 4.04mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.61 mL, 2.52 mmol) dropwise at 0 °C under an

inert atmosphere. The reaction was warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-(cyclobutylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide (250 mg, 0.78 mmol, 78%) as yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.95 (s, 1H), 9.51 (s, 1H), 8.01 (s, 1H), 7.31 (dd, *J* = 11.5, 8.8 Hz, 1H), 6.54 (dd, *J* = 13.7, 7.7 Hz, 1H), 5.58 (d, *J* = 6.6 Hz, 1H), 3.91-3.79 (m, 1H), 2.74 (s, 3H), 2.40-2.31 (m, 2H), 1.93-1.83 (m, 2H), 1.76-1.66 (m, 2H)

**LC-MS:** *m/z* 318.9 [M+H]<sup>+</sup> at 2.64 RT (97.50% purity)

### **1-Cyclobutyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 108)**

To a stirred solution of *N*-(2-(cyclobutylamino)-4,5-difluorophenyl)-6-methylpyridazine-4-carboxamide (150 mg, 0.47 mmol) in ethanol (1.5 mL) was added 6 *N* HCl (2.2 mL) dropwise at room temperature under an inert atmosphere. The reaction mixture was heated to 60 °C in a pre-heated oil bath for 15 min and cooled. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclobutyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 108** (100 mg, 0.33 mmol, 70%) as an off white solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.36 (d, *J* = 1.1 Hz, 1H), 7.98 (dd, *J* = 11.0, 7.7 Hz, 1H), 7.88-7.80 (m, 2H), 5.19-5.12 (m, 1H), 2.74 (s, 3H), 2.44-2.42 (m, 4H), 1.89-1.70 (m, 2H).

**LC-MS:** *m/z* 300.9 [M+H]<sup>+</sup> at 2.51 RT (98.06% purity)

**HPLC:** 98.42%

### **Example 109**

#### **Scheme:**



***N*-(2-(Cyclopropylamino)-4-hydroxyphenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 4-amino-3-(cyclopropylamino)phenol **Int-17** (50 mg, crude) and 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (53 mg, 0.3 mmol) in ethylacetate (10 mL) was added triethylamine (0.08 mL, 0.61 mmol) and propylphosphonic anhydride (50% in EtOAc, 0.48 mL, 0.76 mmol) dropwise at 0 °C under an inert atmosphere. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution to pH ~8 and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4-hydroxyphenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (50 mg, 0.16 mmol, 51%) as a pale yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.88 (s, 1H), 9.80 (s, 1H), 9.16 (br s, 1H), 8.44 (s, 1H), 7.55-7.26 (m, 1H), 6.89 (d, *J* = 8.1 Hz, 1H), 6.48 (d, *J* = 1.7 Hz, 1H), 6.07 (dd, *J* = 8.4, 2.0 Hz, 1H), 5.71 (s, 1H), 2.30-2.28 (m, 1H), 0.71-0.68 (m, 2H), 0.43-0.39 (m, 2H)

**LC-MS:** *m/z* 321.2 [M+H]<sup>+</sup> at 1.84 RT (99.05% purity)

**1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazol-6-ol (Ex. 109)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4-hydroxyphenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (50 mg, 0.16 mmol) in ethanol (1 mL) was added 6 N HCl (1 mL) dropwise at 0 °C under an inert atmosphere. The reaction mixture was heated to 70 °C in a pre-heated oil bath for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-

(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazol-6-ol **Ex. 109** (40 mg, 0.13 mmol, 85%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.93 (d, *J* = 2.1 Hz, 1H), 8.54 (d, *J* = 2.1 Hz, 1H), 7.57 (d, *J* = 8.8 Hz, 1H), 7.29-7.00 (m, 2H), 6.90 (dd, *J* = 8.8, 2.3 Hz, 1H), 3.88-3.82 (m, 1H), 1.31-1.22 (m, 2H), 0.86-0.79 (m, 2H)

**LC-MS:** *m/z* 302.9 [M+H]<sup>+</sup> at 2.01 RT (99.11% purity)

**HPLC:** 98.91%

### Example 110

#### 10 **Scheme:**



#### **Methyl 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate**

To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole **Ex. 22** (1 g, 2.9 mmol) in methanol (50 mL) was added sodium acetate (713 mg, 8.69 mmol) and dppf (80 mg, 0.14 mmol) followed by Pd(OAc)<sub>2</sub> (97 mg, 0.14 mmol) in a steel bomb at room temperature. The steel bomb was filled with CO gas (200 psi) and the reaction mixture was heated to 100 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (30 mL). The filtrate was concentrated under reduced pressure.

The residue was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford methyl 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (200 mg, 0.6 mmol, 21%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.03 (d, *J* = 2.1 Hz, 1H), 8.73 (d, *J* = 2.1 Hz, 1H), 7.93-7.84 (m, 2H), 4.03 (s, 3H), 4.00-3.96 (m, 1H), 1.23-1.16 (m, 2H), 0.84-0.78 (m, 2H)

**LC-MS:** *m/z* 330.9 [M+H]<sup>+</sup> at 2.49 RT (94.38% purity)

**5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid (Ex. 110)**

To a stirred solution of methyl 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (100 mg, 0.3 mmol) in a mixture of THF/water (3:1, 3 mL) was added lithium hydroxide monohydrate (38 mg, 0.91 mmol) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. The reaction mixture was washed with ether (10 mL) and the organic layer was separated. The aqueous layer was acidified using conc. HCl (pH ~2) which resulted in a precipitate forming. The precipitated solid was filtered, washed with diethylether (2 x 5 mL) and dried under vacuum to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid **Ex. 110** (40 mg, 0.13 mmol, 42%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 14.15 (brs, 1H), 10.00 (d, *J* = 2.1 Hz, 1H), 8.72 (d, *J* = 2.1 Hz, 1H), 7.93-7.84 (m, 2H), 4.00-3.95 (m, 1H), 1.22-1.16 (m, 2H), 0.83-0.78 (m, 2H)

**LC-MS:** *m/z* 316.9 [M+H]<sup>+</sup> at 1.55 RT (99.76% purity)

**HPLC:** 99.88%

**Example 111**

**Scheme:**



**20 N-(2-(Cyclopropylamino)-3-fluorophenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-6-fluorobenzene-1,2-diamine **Int-14** (100 mg, crude) and 6-methylpyridazine-4-carboxylic acid hydrochloride (83 mg, 0.6 mmol) in ethylacetate (4 mL) was added triethylamine (0.34 mL, 2.41 mmol) and propylphosphonic anhydride (50% in EtOAc, 0.95 mL, 1.51 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was quenched using saturated NaHCO<sub>3</sub> solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified

by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-3-fluorophenyl)-6-methylpyridazine-4-carboxamide (200 mg, 0.7 mmol, 72%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.06 (br s, 1H), 9.47 (s, 1H), 7.98 (s, 1H), 7.05-6.97 (m, 2H), 6.73-6.66 (m, 1H), 5.09 (br s, 1H), 2.72-2.70 (m, 4H), 0.55-0.42 (m, 4H)

**LC-MS:** *m/z* 286.9 [M+H]<sup>+</sup> at 2.15 RT (91.92% purity)

### 1-Cyclopropyl-7-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 111)

To a stirred solution of *N*-(2-(cyclopropylamino)-3-fluorophenyl)-6-methylpyridazine-4-carboxamide (200 mg, 0.7 mmol) in ethanol (3 mL) was added 6 *N* HCl (2 mL) at room temperature under an inert atmosphere. Then the reaction mixture was stirred in a pre-heated oil bath at 65 °C for 15 min. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated NaHCO<sub>3</sub> solution (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) followed by washing with *n*-pentane (2 x 5 mL) and dried under vacuum to afford 1-cyclopropyl-7-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 111** (110 mg, 0.41 mmol, 59%) as an off white solid.


**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.64 (d, *J* = 1.7 Hz, 1H), 8.14 (d, *J* = 2.0 Hz, 1H), 7.58 (d, *J* = 7.8 Hz, 1H), 7.30-7.17 (m, 2H), 4.11-4.07 (m, 1H), 2.77 (s, 3H), 1.15-1.10 (m, 2H), 0.77-0.75 (m, 2H)

**LC-MS:** *m/z* 269.2 [M+H]<sup>+</sup> at 2.05 RT (98.96% purity)

**HPLC:** 98.50%

### Example 112

#### Scheme:



***N*-(5-Chloro-2-(cyclopropylamino) phenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of 4-chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine **Int-24** (200 mg, crude) in ethylacetate (8 mL) was added 6-methylpyridazine-4-carboxylic acid hydrochloride (191 mg, 1.1 mmol) and triethylamine (0.61 mL, 4.37 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.74 mL, 2.73 mmol) dropwise at 0 °C under an inert atmosphere.

5 The reaction was allowed to stir at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. This lot was combined with another lot (90 mg crude) and purified by silica gel column  
10 chromatography (eluent: 40% EtOAc/hexane) to afford *N*-(5-chloro-2-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (200 mg, 0.66 mmol, 40%) as a brown solid.

<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 9.94 (s, 1H), 9.49 (d, *J* = 1.7 Hz, 1H), 8.00 (d, *J* = 1.9 Hz, 1H), 7.26 (d, *J* = 2.3 Hz, 1H), 7.19 (dd, *J* = 8.7, 2.5 Hz, 1H), 7.03 (d, *J* = 8.7 Hz, 1H), 5.93 (s, 1H), 2.73 (s, 3H), 2.38-2.32 (m, 1H), 0.75-0.70 (m, 2H), 0.45-0.40 (m, 2H)  
15

LC-MS: *m/z* 302.9 [M+H]<sup>+</sup> at 2.55 RT (88.67% purity)


### 5-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 112)

To a stirred solution of *N*-(5-chloro-2-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (100 mg, 0.33 mmol) in ethanol (1 mL) was added 6 *N* HCl (1 mL) dropwise at  
20 room temperature under an inert atmosphere. The reaction mixture was heated to 50 °C with a pre-heated oil bath for 1 h, cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. This lot  
25 was combined with another lot (90 mg, crude) and purified by silica gel column chromatography (eluent: 70-80% EtOAc/hexane) to afford 5-chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 112** (100 mg, 0.35 mmol, 53%) as an off white solid.

<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 9.66 (d, *J* = 2.0 Hz, 1H), 8.17 (d, *J* = 1.9 Hz, 1H), 7.84 (d, *J* = 1.9 Hz, 1H), 7.75 (d, *J* = 8.7 Hz, 1H), 7.42 (dd, *J* = 8.6, 2.0 Hz, 1H), 3.96-3.92 (m, 1H), 2.77 (s, 3H), 1.22-1.17 (m, 2H), 0.77-0.72 (m, 2H)  
30

LC-MS: *m/z* 284.9 [M+H]<sup>+</sup> at 2.42 RT (96.67% purity)

HPLC: 96.19%

**Example 113****Scheme:*****N*-(2-Chloro-6-(cyclopropylamino) phenyl)-6-methylpyridazine-4-carboxamide**

To a stirred solution of 3-chloro-*N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine **Int-25** (200 mg, crude) in ethylacetate (10 mL) was added 6-methylpyridazine-4-carboxylic acid hydrochloride (191 mg, 1.1 mmol) and triethylamine (0.31 mL, 2.2 mmol) followed by propylphosphonic anhydride (50% in EtOAc, 1.75 mL, 2.75 mmol) dropwise at 0 °C under an inert atmosphere and the reaction was allowed to stir at room temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford *N*-(2-chloro-6-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (50 mg, 0.16 mmol, 15%) as an off white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.98 (s, 1H), 9.51 (d, *J* = 1.9 Hz, 1H), 8.01 (d, *J* = 2.0 Hz, 1H), 7.19 (t, *J* = 8.1 Hz, 1H), 6.97 (dd, *J* = 8.3, 0.9 Hz, 1H), 6.75 (dd, *J* = 8.0, 1.0 Hz, 1H), 6.16 (s, 1H), 2.74 (s, 3H), 2.35-2.31 (m, 1H), 0.75-0.70 (m, 2H), 0.44-0.40 (m, 2H)

**LC-MS:** *m/z* 302.9 [M+H]<sup>+</sup> at 2.38 RT (88.61% purity)

**4-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 113)**

To a stirred solution of *N*-(2-chloro-6-(cyclopropylamino)phenyl)-6-methylpyridazine-4-carboxamide (50 mg, 0.16 mmol) in ethanol (0.7 mL) was added 6 N HCl (0.3 mL) dropwise at room temperature under an inert atmosphere. Then the reaction mixture was heated to 60 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified with saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2

x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70-80% EtOAc/hexane) to afford 4-chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 113** (30 mg, 0.1 mmol, 64%) as an off white solid.

5 **<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.67 (d, *J* = 2.0 Hz, 1H), 8.24 (d, *J* = 2.1 Hz, 1H), 7.75-7.71 (m, 1H), 7.39 (dd, *J* = 4.6, 0.8 Hz, 2H), 3.91-3.86 (m, 1H), 2.84 (s, 3H), 1.29-1.23 (m, 2H), 0.84-0.79 (m, 2H)


**LC-MS:** *m/z* 285.1 [M+H]<sup>+</sup> at 2.07 RT (95.04% purity)

**HPLC:** 95.53%

10

### Example 114

#### Scheme:



#### **(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl)methanol**

15 To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazine-3-carbaldehyde **Int-27** (400 mg, crude) in methanol (20 mL) was added sodium borohydride (25 mg, 0.67 mmol) at 0 °C under an inert atmosphere and the reaction stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were

20 dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with 5% CH<sub>2</sub>Cl<sub>2</sub>/*n*-pentane (10 mL) to afford 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazin-3-yl) methanol (300 mg, 1.0 mmol, 75%) as an off white solid.

**LC-MS:** *m/z* 302.9 [M+H]<sup>+</sup> at 2.10 RT (90.22% purity)


25

#### **1-Cyclopropyl-5,6-difluoro-2-(6-(methoxymethyl)pyridazin-4-yl)-1*H*-benzo[d]imidazole (Ex. 114)**

- To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanol (150 mg, 0.5 mmol) in DMF (5 mL) was added sodium hydride (55% in mineral oil, 32 mg, 0.74 mmol) at 0 °C under an inert atmosphere and the mixture was stirred for 15 min. Iodomethane (0.05 mL, 0.74 mmol) was added at 0 °C and the reaction was stirred at room temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methoxymethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 114** (70 mg, 0.22 mmol, 49%) as an off white solid.
- <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.77 (d, *J* = 1.7 Hz, 1H), 8.25 (d, *J* = 1.7 Hz, 1H), 7.91-7.81 (m, 2H), 4.84 (s, 2H), 3.96-3.92 (m, 1H), 3.44 (s, 3H), 1.21-1.16 (m, 2H), 0.80-0.75 (m, 2H)
- LC-MS:** *m/z* 316.9 [M+H]<sup>+</sup> at 2.41 RT (96.55% purity)
- HPLC:** 97.19%

### Example 115

#### Scheme:



- Methyl 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (Ex. 115)**

- To a stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 34** (200 mg, 0.68 mmol) in methanol (10 mL) was added triethylamine (0.19 mL, 1.35 mmol) and Pd(dppf)Cl<sub>2</sub> (99 mg, 0.13 mmol) in a steel bomb at room temperature.
- The steel bomb was filled with CO gas (50 psi) and the reaction mixture was heated to 60 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with methanol (10 mL). The filtrate was concentrated under reduced pressure to obtain crude material which was purified by silica

gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) followed by triturations with CH<sub>2</sub>Cl<sub>2</sub> (1 mL), Et<sub>2</sub>O (1 mL), and *n*-pentane (2 x 5 mL) and finally dried under vacuum to afford methyl 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate **Ex. 115** (140 mg, 0.44 mmol, 65%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.07 (d, *J* = 2.1 Hz, 1H), 8.78 (d, *J* = 2.1 Hz, 1H), 8.36-8.34 (m, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.73 (dd, *J* = 8.4, 1.5 Hz, 1H), 4.05-3.99 (m, 4H), 1.24-1.20 (m, 2H), 0.87-0.82 (m, 2H)


**LC-MS:** *m/z* 320.2 [M+H]<sup>+</sup> at 1.98 RT (95.55% purity)

**HPLC:** 95.69%

10

### Example 116

#### Scheme:



**5-(6-Cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid (Ex. 116)**

15

To a stirred solution of methyl 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate **Ex. 115** (80 mg, 0.25 mmol) in a mixture of THF/water (3:1, 3 mL) was added lithium hydroxide monohydrate (31 mg, 0.75 mmol) at 0 °C. The reaction mixture turned into a clear solution. After 15-20 min., the reaction mixture turned turbid and was stirred at 0 °C for 1 h. The reaction mixture was washed with ether (10 mL) and the organic layer was separated. The aqueous layer was acidified with 6 *N* HCl (pH ~2) at 0 °C which afforded a precipitated solid that was filtered, washed successively with diethylether (2 x 5 mL) and *n*-pentane (2 x 5 mL) and dried under vacuum to afford 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid **Ex. 116** (29 mg, 0.09 mmol, 38%) as an off white solid.

20

25


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 14.18 (br s, 1H), 10.04 (d, *J* = 2.1 Hz, 1H), 8.77 (d, *J* = 2.1 Hz, 1H), 8.35-8.33 (m, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.73 (dd, *J* = 8.4, 1.5 Hz, 1H), 4.05-3.98 (m, 1H), 1.25-1.18 (m, 2H), 0.87-0.82 (m, 2H)

**LC-MS:**  $m/z$  306.2  $[M+H]^+$  at 1.75 RT (99.32% purity)

**HPLC:** 98.53%

### Example 117

#### 5 Scheme:



#### **1-Cyclopropyl-2-(6-(cyclopropylmethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 117)**

To a stirred solution of cyclopropylmethanol (0.11 mL, 0.98 mmol) in DMF (3 mL) was added sodium hydride (60% in mineral oil, 59 mg, 1.47 mmol) at 0 °C under an inert atmosphere and the mixture was stirred for 30 min. 2-(6-Chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole **Ex. 22** (300 mg, 0.98 mmol) was added at 0 °C and the reaction was stirred at the same temperature for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) followed by trituration with *n*-pentane (2 x 10 mL) and dried under vacuum to afford 1-cyclopropyl-2-(6-(cyclopropylmethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole **Ex. 117** (200 mg, 0.58 mmol, 60%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.41 (d,  $J$  = 1.7 Hz, 1H), 7.89-7.81 (m, 2H), 7.77 (d,  $J$  = 1.8 Hz, 1H), 4.37 (d,  $J$  = 7.2 Hz, 2H), 3.95-3.90 (m, 1H), 1.42-1.30 (m, 1H), 1.21-1.13 (m, 2H), 0.80-0.73 (m, 2H), 0.65-0.59 (m, 2H), 0.44-0.39 (m, 2H)

**LC-MS:**  $m/z$  343.0  $[M+H]^+$  at 3.07 RT (96.81% purity)

**HPLC:** 97.26%

### Example 118

#### Scheme:



**1-Cyclopropyl-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (Ex. 118)**

To a stirred solution of 2,2,2-trifluoroethan-1-ol (66 mg, 0.68 mmol) in DMF (2 mL) was added sodium hydride (60% in mineral oil, 41 mg, 1.02 mmol) at 0 °C under an inert atmosphere and the mixture was stirred at the same temperature for 20 min. A solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile **Ex. 34** (200 mg, 0.68 mmol) in DMF (1 mL) was added at 0 °C and the reaction was stirred at room temperature for 4 h. After consumption of starting material (by TLC), the reaction mixture was quenched with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile **Ex. 118** (180 mg, 0.5 mmol, 74%) as a white solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.58 (d, *J* = 1.7 Hz, 1H), 8.34 (s, 1H), 8.02 (d, *J* = 1.7 Hz, 1H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.72 (dd, *J* = 8.4, 1.4 Hz, 1H), 5.31 (q, *J* = 9.0 Hz, 2H), 4.01-3.97 (m, 1H), 1.22-1.17 (m, 2H), 0.85-0.81 (m, 2H)


**LC-MS:** *m/z* 360.0 [M+H]<sup>+</sup> at 2.86 RT (95.88% purity)

**HPLC:** 96.79%

20

**Example 119**

**Scheme:**



***N*-(5-Chloro-2-(cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 5-chloro-*N*<sup>1</sup>-cyclopropyl-4-fluorobenzene-1,2-diamine **Int-23** (400 mg, 2.0 mmol) in ethylacetate (10 mL) was added 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (350 mg, 2.0 mmol), triethylamine (1.11 mL, 8.0 mmol) and propylphosphonic anhydride (50% in EtOAc, 3.18 mL, 5.0 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was quenched using saturated NaHCO<sub>3</sub> solution (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. This lot was combined with another lot (100 mg crude) and was purified by silica gel column chromatography (eluent: 70% EtOAc/hexane) to afford *N*-(5-chloro-2-(cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (300 mg, 0.84 mmol, 34%) as a yellow solid.

**LC-MS:** *m/z* 357.0 [M+H]<sup>+</sup> at 3.08 RT (60.71% purity)


**6-Chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-benzo[*d*]imidazole (Ex. 119)**

To a stirred solution of *N*-(5-chloro-2-(cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (200 mg, 0.56 mmol) in ethanol (2 mL) was added 6 *N* HCl (2 mL) at room temperature under an inert atmosphere. The reaction mixture was stirred in a pre-heated oil bath at 50 °C for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched using saturated NaHCO<sub>3</sub> solution (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 6-chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-benzo[*d*]imidazole **Ex. 119** (100 mg, 0.29 mmol, 53%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.00 (d, *J* = 2.0 Hz, 1H), 8.56 (d, *J* = 2.1 Hz, 1H), 8.00 (d, *J* = 6.7 Hz, 1H), 7.89 (d, *J* = 9.8 Hz, 1H), 7.58-7.28 (m, 1H), 4.02-3.96 (m, 1H), 1.23-1.16 (m, 2H), 0.84-0.78 (m, 2H)

**LC-MS:** *m/z* 339.2 [M+H]<sup>+</sup> at 3.72 RT (94.81% purity)

HPLC: 95.18%

**Example 120****Scheme:**

**1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1H-benzo[d]imidazole-6-carbonitrile (Ex. 120)**


To a stirred solution of 6-chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1H-benzo[d]imidazole **Ex. 119** (150 mg, 0.44 mmol) in DMF (1 mL) was added zinc cyanide (104 mg, 0.89 mmol) in a microwave vessel at room temperature and the mixture was purged under argon for 20 min.  $\text{Pd}_2(\text{dba})_3$  (41 mg, 0.04 mmol) and  $\text{Pd}(\text{dppf})\text{Cl}_2$  (33 mg, 0.04 mmol) were added and the mixture was purged with argon for 5 min. The reaction mixture was heated to 150 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *celite* and the bed was washed with EtOAc (30 mL). The filtrate was concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1H-benzo[d]imidazole-6-carbonitrile **Ex. 120** (50 mg, 0.15 mmol, 34%) as an off white solid.

**$^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):**  $\delta$  10.02 (d,  $J = 2.0$  Hz, 1H), 8.59 (d,  $J = 2.0$  Hz, 1H), 8.47 (d,  $J = 5.6$  Hz, 1H), 7.98 (d,  $J = 10.0$  Hz, 1H), 7.60-7.31 (m, 1H), 4.05-4.00 (m, 1H), 1.23-1.16 (m, 2H), 0.87-0.82 (m, 2H)

**LC-MS:**  $m/z$  329.9  $[\text{M}+\text{H}]^+$  at 2.67 RT (99.00% purity)

HPLC: 98.49%

**Example 121****Scheme:**



### Diethyl 2-hydroxy-2-(2-oxocyclopentyl)malonate

A solution of diethyl 2-oxomalonate (5 g, 28.73 mmol) and cyclopentanone (2.54 mL, 28.73 mmol) in a sealed tube was heated to 100 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture (brown syrup) containing diethyl 2-hydroxy-2-(2-oxocyclopentyl) malonate (5 g) was taken to the next step without further purification.

**LC-MS:**  $m/z$  259.0  $[M+H]^+$  at 2.05 RT (47.02% purity)

### Ethyl 3-hydroxy-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate

To a stirred solution of diethyl 2-hydroxy-2-(2-oxocyclopentyl) malonate (5 g, crude) in acetic acid (35 mL) was added hydrazine monohydrochloride (6.59 g, 96.9 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 100 °C and stirred for 3 h. After consumption of starting material (by TLC), the reaction mixture was quenched using saturated  $\text{NaHCO}_3$  solution (100 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/ $\text{CH}_2\text{Cl}_2$ ) to afford ethyl 3-hydroxy-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate (800 mg, 3.84 mmol, 20%) as an off white solid.

**$^1\text{H}$  NMR (500 MHz,  $\text{DMSO}-d_6$ ):**  $\delta$  12.85 (brs, 1H), 4.26 (q,  $J = 7.1$  Hz, 2H), 2.86 (t,  $J = 7.4$  Hz, 2H), 2.72 (t,  $J = 7.5$  Hz, 2H), 2.05-1.96 (m, 2H), 1.26 (t,  $J = 7.1$  Hz, 3H)

**LC-MS:**  $m/z$  208.9  $[M+H]^+$  at 1.58 RT (39.74% purity)

**Ethyl 3-chloro-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate**

To a stirred solution of ethyl 3-hydroxy-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate (800 mg, 3.85 mmol) in 1,4-dioxane (8 mL) was added phosphoryl chloride (3.59 mL, 38.46 mmol) in a sealed tube at room temperature under an inert atmosphere. The reaction mixture was heated to 100 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched using saturated NaHCO<sub>3</sub> solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford ethyl 3-chloro-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate (300 mg, 1.32 mmol, 34%) as a brown solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):**  $\delta$  4.46 (q,  $J$  = 7.1 Hz, 2H), 3.25 (t,  $J$  = 7.8 Hz, 2H), 3.10 (t,  $J$  = 7.6 Hz, 2H), 2.28-2.20 (m, 2H), 1.42 (t,  $J$  = 7.2 Hz, 3H)

**LC-MS:**  $m/z$  227.0  $[M+H]^+$  at 2.25 RT (93.52% purity)

**Ethyl 6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate**

To a stirred solution of ethyl 3-chloro-6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate (300 mg, 1.33 mmol) in ethylacetate (8 mL) was added 10% Pd/C (50% wet, 120 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 1 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of celite and the celite bed was washed with methanol (15 mL). The filtrate was concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford ethyl 6,7-dihydro-5H-cyclopenta[c]pyridazine-4-carboxylate (100 mg, 0.52 mmol, 39%) as a brown syrup.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):**  $\delta$  9.21 (s, 1H), 4.37 (q,  $J$  = 7.0 Hz, 2H), 3.27 (t,  $J$  = 7.5 Hz, 2H), 3.18 (t,  $J$  = 7.8 Hz, 2H), 2.13-2.07 (m, 2H), 1.35 (t,  $J$  = 7.1 Hz, 3H)

**LC-MS:**  $m/z$  192.9  $[M+H]^+$  at 1.83 RT (92.05% purity)

**6,7-Dihydro-5H-cyclopenta[c]pyridazine-4-carboxylic acid**

To a stirred solution of ethyl 6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxylate (100 mg, 0.52 mmol) in a mixture of THF/water (4:1, 2 mL) was added lithium hydroxide monohydrate (66 mg, 1.56 mmol) at room temperature and the mixture was stirred for 4 h. The reaction mixture was lyophilized to afford 6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxylic acid (120 mg, 0.73 mmol) as an off white solid. The crude material was taken to the next step without further purification.

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.22 (s, 1H), 3.28 (t, *J* = 7.6 Hz, 2H), 3.19 (t, *J* = 7.8 Hz, 2H), 2.14-2.06 (m, 2H)

LC-MS: *m/z* 165.0 [M+H]<sup>+</sup> at 2.03 RT (89.57% purity)

#### ***N*-(2-(Cyclopropylamino)-4,5-difluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (111 mg, 0.61 mmol) in ethylacetate (6 mL) was added 6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxylic acid (100 mg, crude), triethylamine (0.34 mL, 2.44 mmol) and propylphosphonic anhydride (50% in EtOAc, 0.97 mL, 1.52 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was quenched with saturated NaHCO<sub>3</sub> solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxamide (100 mg, 0.3 mmol, 50%) as brown solid.

LC-MS: *m/z* 330.9 [M+H]<sup>+</sup> at 2.59 RT (38.96% purity)

#### **4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine (Ex. 121)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4,5-difluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*c*]pyridazine-4-carboxamide (75 mg, 0.23 mmol) in ethanol (0.75 mL) was added 6 *N* HCl (0.75 mL) dropwise at room temperature under an inert atmosphere. The reaction mixture was heated to 50 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH

~8) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude material. This lot was combined with another lot (20 mg, crude) and purified by preparative HPLC to afford 4-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-6,7-dihydro-5*H*-

5 cyclopenta[*c*]pyridazine **Ex. 121** (20 mg, 0.06 mmol, 28%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):** δ 9.36 (s, 1H), 7.70 (dd, *J* = 10.0, 7.2 Hz, 1H), 7.61 (dd, *J* = 10.4, 7.3 Hz, 1H), 3.80-3.75 (m, 1H), 3.36-3.32 (m, 2H), 3.30-3.27 (m, 2H), 2.28-2.21 (m, 2H), 1.18-1.12 (m, 2H), 0.75-0.69 (m, 2H)

**LC-MS:** *m/z* 313.0 [M+H]<sup>+</sup> at 2.47 RT (99.66% purity)

10 **HPLC:** 99.76%

### Example 122

#### Scheme:



15 ***N*-(2-(Cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl) pyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropyl-5-fluorobenzene-1,2-diamine **Int-1** (300 mg, crude) and 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (314 mg, 1.81 mmol) in ethylacetate (10 mL) was added triethylamine (0.51 mL, 3.61 mmol) and propylphosphonic anhydride (50% in EtOAc, 2.87 mL, 4.52 mmol) dropwise at 0 °C under an inert atmosphere and the reaction was allowed to stir at the same temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was washed with *n*-hexanes (2 x 20 mL) and dried under vacuum to afford *N*-(2-(cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (320 mg, 1.0 mmol, 55%) as a yellow solid. The material was taken to the next step without further purification.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.05 (br s, 1H), 9.79 (d, *J* = 1.7 Hz, 1H), 8.45 (d, *J* = 1.7 Hz, 1H), 7.52-7.28 (m, 1H), 7.12 (dd, *J* = 8.4, 6.4 Hz, 1H), 6.74 (dd, *J* = 11.9, 2.6 Hz, 1H), 6.41 (td, *J* = 8.4, 2.9 Hz, 1H), 6.15 (br s, 1H), 2.37-2.31 (m, 1H), 0.76-0.70 (m, 2H), 0.44-0.40 (m, 2H)

5 **LC-MS:** *m/z* 322.9 [M+H]<sup>+</sup> at 2.80 RT (99.46% purity)

**1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole (Ex. 122)**

To a stirred solution of *N*-(2-(cyclopropylamino)-4-fluorophenyl)-6-(difluoromethyl)pyridazine-4-carboxamide **2** (320 mg, 1.0 mmol) in ethanol (4 mL) was added 6 *N* HCl (4 mL) at 0 °C under an inert atmosphere. Then the reaction mixture was stirred in a pre-heated oil bath at 70 °C for 30 min. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C; basified using saturated NaHCO<sub>3</sub> solution (pH ~8) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole **B-680** (250 mg, 0.82 mmol, 82%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.00 (d, *J* = 2.1 Hz, 1H), 8.56 (d, *J* = 2.0 Hz, 1H), 7.82 (dd, *J* = 8.9, 4.9 Hz, 1H), 7.60-7.28 (m, 2H), 7.24-7.19 (m, 1H), 4.01-3.96 (m, 1H), 1.23-1.15 (m, 2H), 0.83-0.77 (m, 2H)


**LC-MS:** *m/z* 304.9 [M+H]<sup>+</sup> at 2.73 RT (99.60% purity)

**HPLC:** 99.62%

25

**Example 123**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 123)**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-thiol **Ex. 102** (100 mg, 0.33 mmol) in acetonitrile (3 mL) was added triethylamine (0.07 mL, 0.49 mmol) followed by iodomethane (0.02 mL, 0.39 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 24 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 123** (50 mg, 0.16 mmol, 48%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.52 (d, *J* = 1.9 Hz, 1H), 8.17 (d, *J* = 1.9 Hz, 1H), 7.89-7.82 (m, 2H), 3.95-3.90 (m, 1H), 2.72 (s, 3H), 1.21-1.14 (m, 2H), 0.80-0.74 (m, 2H)

LC-MS: *m/z* 318.9 [M+H]<sup>+</sup> at 2.75 RT (98.20% purity)

HPLC: 98.82%

### Example 124

#### Scheme:



#### 1-Cyclopropyl-5,6-difluoro-2-(6-(isopropylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 124)

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-thiol **Ex. 102** (100 mg, 0.33 mmol) in DMF (3 mL) was added triethylamine (0.14 mL, 0.98 mmol) and 2-bromopropane (61 mg, 0.49 mmol) at room temperature under an inert atmosphere and the reaction was stirred for 24 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) followed by preparative HPLC to afford 1-

cyclopropyl-5,6-difluoro-2-(6-(isopropylthio)pyridazin-4-yl)-1*H*-benzo[d]imidazole **Ex. 124** (40 mg, 0.11 mmol, 35%) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.52 (d, *J* = 2.0 Hz, 1H), 8.10 (d, *J* = 2.0 Hz, 1H), 7.89-7.81 (m, 2H), 4.23-4.16 (m, 1H), 3.94-3.89 (m, 1H), 1.45 (d, *J* = 6.8 Hz, 6H), 1.19-1.14 (m, 2H), 0.81-0.75 (m, 2H)

**LC-MS:** *m/z* 346.9 [M+H]<sup>+</sup> at 3.24 RT (98.03% purity)

**HPLC:** 99.28%

### Example 125

#### Scheme:




#### **1-Cyclopropyl-2-(6-((difluoromethyl)thio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole (Ex. 125)**

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[d]imidazol-2-yl)pyridazine-3-thiol **Ex. 102** (100 mg, 0.33 mmol) in DMF (3 mL) was added sodium 2-chloro-2,2-difluoroacetate (130 mg, 0.66 mmol) and potassium carbonate (68 mg, 0.49 mmol) in a sealed tube at room temperature under an inert atmosphere. The reaction mixture was heated to 80 °C and stirred for 18 h. After consumption of starting material (by TLC), the reaction mixture was diluted with ice cold water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-((difluoromethyl)thio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[d]imidazole **Ex. 125** (40 mg, 0.11 mmol, 34%) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.74 (d, *J* = 1.8 Hz, 1H), 8.43 (d, *J* = 1.8 Hz, 1H), 8.32-8.02 (m, 1H), 7.91-7.83 (m, 2H), 3.96-3.88 (m, 1H), 1.23-1.15 (m, 2H), 0.84-0.77 (m, 2H)

**LC-MS:** *m/z* 354.9 [M+H]<sup>+</sup> at 3.06 RT (98.26% purity)

**HPLC:** 99.31%

**Example 126****Scheme:****6-Chloro-N-(2-(cyclopropylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide**

- 5 To a stirred solution of 6-chloropyridazine-4-carboxylic acid (200 mg, 1.08 mmol) in DMF (4 mL) was added *N*<sup>1</sup>-cyclopropyl-4,5-difluorobenzene-1,2-diamine **Int-5** (172 mg, 1.08 mmol), HATU (495 mg, 1.30 mmol) and diisopropylethylamine (0.78 mL, 4.35 mmol) at 0 °C under an inert atmosphere. The reaction mixture was stirred at room temperature for 16 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 6-chloro-*N*-(2-(cyclopropylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide (100 mg, 0.30 mmol, 28%) as a yellow solid.
- 10
- 15 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.50 (s, 1H), 7.95 (d, *J* = 1.6 Hz, 1H), 7.74 (brs, 1H), 7.37 (dd, *J* = 10.5, 8.5 Hz, 1H), 7.06 (dd, *J* = 12.4, 7.7 Hz, 1H), 4.16-4.03 (m, 1H), 2.51-2.40 (m, 1H), 0.83-0.75 (m, 2H), 0.56-0.47 (m, 2H)

**5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-ol (Ex. 126)**

- 20 To a stirred solution of 6-chloro-*N*-(2-(cyclopropylamino)-4,5-difluorophenyl)pyridazine-4-carboxamide (500 mg, 1.54 mmol) in EtOH (5 mL) was added 6 *N* HCl (7.5 mL) at 0 °C under an inert atmosphere. The reaction mixture was stirred at 100 °C for 3 h. After consumption of starting material (by TLC), the reaction mixture was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were
- 25 dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-ol **Ex. 126** (300 mg, 1.04 mmol, 67%) as an off-white solid.

**<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>COOD):** δ 8.70 (s, 1H), 7.94 (s, 1H), 7.80 (dd, *J* = 10.1, 7.2 Hz, 1H), 7.65 (dd, *J* = 9.9, 7.0 Hz, 1H), 3.82-3.72 (m, 1H), 1.41-1.32 (m, 2H), 1.05-0.90 (m, 2H)


**LC-MS:** *m/z* 289.9 [M+H]<sup>+</sup> at 2.15 RT (91.69% purity)

**HPLC:** 91.55%

5

### Example 127

#### Scheme:



#### **1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (Ex. 127)**

10

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-ol **Ex. 126** (1 g, 3.47 mmol) in *N*-methyl-2-pyrrolidone (15 mL) was added sodium hydroxide (972 mg, 24.3 mmol) followed by sodium 2-chloro-2,2-difluoroacetate (1.06 g, 6.94 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 120 °C and stirred for 24 h. After consumption of starting material (by TLC & LCMS), the mixture was cooled and combined with a second lot (200 mg). The combined reaction mixtures were diluted with water (100 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole **Ex. 127** (80 mg, 0.24 mmol, 6% from two batches) as an off white solid.

15

20

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 9.69 (d, *J* = 1.4 Hz, 1H), 8.16-8.00 (m, 2H), 7.93-7.84 (m, 2H), 3.97-3.92 (m, 1H), 1.22-1.17 (m, 2H), 0.83-0.78 (m, 2H)


**LC-MS:** *m/z* 338.9 [M+H]<sup>+</sup> at 3.00 RT (96.39% purity)

25

**HPLC:** 96.85%

### Example 128

#### Scheme:



**1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethan-1-ol (Ex. 128)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethan-1-one **Ex. 64** (300 mg, 0.95 mmol) in methanol (12 mL) was added sodium borohydride (36 mg, 0.95 mmol) at 0 °C under an inert atmosphere and the mixture was stirred at the same temperature for 1 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with water (20 mL) and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) to afford 1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethan-1-ol **Ex. 128** (150 mg, 0.47 mmol, 50%) as a pale yellow solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.71 (d, *J* = 2.3 Hz, 1H), 8.34 (d, *J* = 2.1 Hz, 1H), 7.90-7.81 (m, 2H), 5.78 (d, *J* = 4.9 Hz, 1H), 5.15-5.07 (m, 1H), 3.96-3.91 (m, 1H), 1.52 (d, *J* = 6.5 Hz, 3H), 1.24-1.16 (m, 2H), 0.79-0.73 (m, 2H)

**LC-MS:** *m/z* 317.0 [M+H]<sup>+</sup> at 2.17 RT (99.24% purity)

**HPLC:** 98.70%

**Example 129**

**Scheme:**



**1-Cyclopropyl-5,6-difluoro-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (Ex. 129)**

To a stirred solution of 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-ol **Ex. 128** (100 mg, 0.32 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added diethylaminosulfur trifluoride (0.06 mL, 0.47 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (20 mL), neutralized using saturated sodium carbonate solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain the crude. The crude material was combined with another crude lot (25 mg) and the combined material was purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 129** (40 mg, 0.12 mmol, 32% for two batches) as an off white solid.


**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 9.82 (d, *J* = 2.1 Hz, 1H), 8.37 (d, *J* = 2.1 Hz, 1H), 7.91-7.83 (m, 2H), 6.22-6.02 (m, 1H), 4.00-3.94 (m, 1H), 1.84-1.75 (m, 3H), 1.21-1.15 (m, 2H), 0.80-0.75 (m, 2H)

**LC-MS:** *m/z* 318.9 [M+H]<sup>+</sup> at 2.69 RT (98.49% purity)

**HPLC:** 97.92%

### Example 130

#### Scheme:



#### 1-Cyclopropyl-5,6-difluoro-2-(6-((trifluoromethyl)thio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 130)

To a stirred solution of 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-thiol **Ex. 102** (200 mg, 0.66 mmol) in acetonitrile/water (1:1, 3 mL) was added sodium trifluoromethanesulfonate (205 mg, 1.31 mmol), potassium monopersulfate (355 mg, 1.31 mmol), and silver nitrate (11 mg, 0.06 mmol) at room temperature under an inert atmosphere. The reaction mixture was heated to 80 °C and stirred for 18 h. After consumption of starting material (by TLC), the reaction mixture was poured into water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and

concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 15% EtOAc/hexane) to afford 1-cyclopropyl-5,6-difluoro-2-(6-((trifluoromethyl)thio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole **Ex. 130** (75 mg, 0.2 mmol, 31%) as an off white solid.

- 5 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.85 (d, *J* = 2.0 Hz, 1H), 8.34 (d, *J* = 1.9 Hz, 1H), 7.62 (dd, *J* = 10.0, 7.3 Hz, 1H), 7.44 (dd, *J* = 9.5, 6.9 Hz, 1H), 3.69-3.63 (m, 1H), 1.40-1.33 (m, 2H), 0.92-0.86 (m, 2H)


LC-MS: *m/z* 373.0 [M+H]<sup>+</sup> at 3.21 RT (98.19% purity)


HPLC: 98.55%

10

### Example 131 & Example 132

#### Scheme:





### ***N*-Cyclopropyl-2-nitroaniline**

To 1-fluoro-2-nitrobenzene (1 g, 7.09 mmol) was added cyclopropanamine (1.47 mL, 21.28 mmol) drop wise at room temperature under an inert atmosphere and the mixture was stirred for 24 h. After consumption of starting material (by TLC), the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2% EtOAc/hexane) to afford *N*-cyclopropyl-2-nitroaniline (720 mg, 4.04 mmol, 60%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 8.15 (dd, *J* = 8.6, 1.4 Hz, 1H), 8.07 (brs, 1H), 7.50-7.44 (m, 1H), 7.32 (dd, *J* = 8.6, 1.2 Hz, 1H), 6.72-6.67 (m, 1H), 2.62-2.55 (m, 1H), 0.94-0.89 (m, 2H), 0.69-0.64 (m, 2H)

**LC-MS:** *m/z* 179.0 [M+H]<sup>+</sup> at 3.11 RT (99.64% purity)

### ***N*<sup>1</sup>-Cyclopropylbenzene-1,2-diamine & *N*<sup>1</sup>-propylbenzene-1,2-diamine**

To a stirred solution of *N*-cyclopropyl-2-nitroaniline (700 mg, 3.93 mmol) in methanol (10 mL) was added 10% Pd/C (50% wet, 300 mg) at room temperature under an inert atmosphere. The reaction mixture was stirred at room temperature under a hydrogen atmosphere (balloon pressure) for 5 h. After consumption of starting material (by TLC), the reaction mixture was

filtered through a pad of celite and the celite bed was washed with methanol (15 mL). The filtrate was concentrated under reduced pressure to obtain a mixture of *N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine & *N*<sup>1</sup>-propylbenzene-1,2-diamine (400 mg) as brown viscous syrup. The mixture was taken to next step without further purification.

5

***N*-(2-(Cyclopropylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide & 6-(difluoromethyl)-*N*-(2-(propylamino)phenyl)pyridazine-4-carboxamide**

To a stirred solution of *N*<sup>1</sup>-cyclopropylbenzene-1,2-diamine & *N*<sup>1</sup>-propylbenzene-1,2-diamine (400 mg, mixture) in ethylacetate (10 mL) was added 6-(difluoromethyl) pyridazine-4-carboxylic acid **Int-29** (470 mg, 2.7 mmol) and triethylamine (0.75 mL, 5.4 mmol) followed by dropwise addition of propylphosphonic anhydride (50% in EtOAc, 3.44 mL, 5.4 mmol) at 0 °C under inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 5 h. After consumption of starting material (by TLC), the reaction mixture was basified with saturated NaHCO<sub>3</sub> solution to pH ~8 and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 40-50% EtOAc/hexane) to afford a mixture of *N*-(2-(cyclopropylamino) phenyl)-6-(difluoromethyl) pyridazine-4-carboxamide **5** & 6-(difluoromethyl)-*N*-(2-(propylamino) phenyl) pyridazine-4-carboxamide **6** (300 mg, 37%) as a pale yellow solid. The mixture was taken to next step without further purification.

15  
20

**LC-MS:** *m/z* 305.0 [M+H]<sup>+</sup> at 2.63 RT (51.82% purity) & *m/z* 306.9 [M+H]<sup>+</sup> at 2.74 RT (41.52% purity)

**1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (Ex. 131) & 2-(6-(difluoromethyl)pyridazin-4-yl)-1-propyl-1*H*-benzo[*d*]imidazole (Ex. 132)**

25

To a stirred solution of mixture of *N*-(2-(cyclopropylamino)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide & 6-(difluoromethyl)-*N*-(2-(propylamino)phenyl)pyridazine-4-carboxamide (300 mg, mixture) in ethanol (10 mL) was added 6 N HCl (6 mL) drop wise at room temperature under inert atmosphere. The reaction mixture was heated to 50 °C and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was cooled to 0 °C, basified with saturated NaHCO<sub>3</sub> solution to pH ~8 and extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried over

30

anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain the crude. The crude material was purified by normal phase preparative HPLC to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (**Ex. 131**) (60 mg, 0.21 mmol) & 2-(6-(difluoromethyl)pyridazin-4-yl)-1-propyl-1*H*-benzo[*d*]imidazole (**Ex. 132**) (40 mg, 0.14 mmol) as a pale yellow solids respectively.

**Analytical data of Ex. 131:**

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 10.03 (d, *J* = 2.0 Hz, 1H), 8.57 (d, *J* = 2.0 Hz, 1H), 7.82-7.74 (m, 2H), 7.45-7.28 (m, 3H), 4.04-3.99 (m, 1H), 1.24-1.17 (m, 2H), 0.82-0.77 (m, 2H).

LC-MS: *m/z* 286.9 [M+H]<sup>+</sup> at 2.52 RT (98.41% purity)

HPLC: 99.92%

**Analytical data of Ex. 132:**


<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 9.88 (d, *J* = 2.1 Hz, 1H), 8.39 (d, *J* = 2.1 Hz, 1H), 7.82-7.77 (m, 2H), 7.43-7.27 (m, 3H), 4.44 (t, *J* = 7.5 Hz, 2H), 1.81-1.70 (m, 2H), 0.78 (t, *J* = 7.4 Hz, 3H)

LC-MS: *m/z* 288.9 [M+H]<sup>+</sup> at 2.61 RT (99.03% purity)

HPLC: 99.86%

**Example 133**

**Scheme:**



**6-Chloro-N-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide**

To a stirred solution of 6-chloropyridazine-4-carboxylic acid (458 mg, 2.89 mmol) in ethylacetate (30 mL) was added 4-amino-3-(cyclopropylamino)benzonitrile **Int-6** (500 mg,

2.89 mmol), triethylamine (0.8 mL, 5.78 mmol) and propylphosphonic anhydride (50% in EtOAc, 4.6 mL, 7.22 mmol) at 0 °C under an inert atmosphere. The reaction mixture was gradually warmed to room temperature and stirred for 1 h. After consumption of starting material (by TLC), the reaction mixture was poured into saturated sodium bicarbonate solution (70 mL) and extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with water (120 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) to afford 6-chloro-*N*-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide (650 mg, 2.07 mmol, 72%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 10.17 (s, 1H), 9.63 (d, *J* = 1.8 Hz, 1H), 8.38 (d, *J* = 1.8 Hz, 1H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 1.8 Hz, 1H), 7.10 (dd, *J* = 8.0, 1.9 Hz, 1H), 6.31 (s, 1H), 2.45-2.38 (m, 1H), 0.82-0.77 (m, 2H), 0.48-0.43 (m, 2H)

**LC-MS:** *m/z* 312.1 [M-H]<sup>-</sup> at 2.57 RT (80.47% purity)

**1-Cyclopropyl-2-(6-hydroxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile**

To a stirred solution of 6-chloro-*N*-(4-cyano-2-(cyclopropylamino)phenyl)pyridazine-4-carboxamide (1 g, 3.19 mmol) in ethanol (15 mL) was added 6 *N* HCl (22.5 mL) at room temperature under an inert atmosphere. The reaction mixture was heated to 60 °C and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified to pH ~8 using ice cold saturated sodium bicarbonate solution and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 2-5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-hydroxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (500 mg, 1.8 mmol, 56%) as a brown solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 13.36 (br s, 1H), 8.41 (d, *J* = 2.3 Hz, 1H), 8.29 (s, 1H), 7.92 (d, *J* = 8.7 Hz, 1H), 7.72-7.67 (m, 1H), 7.54 (s, 1H), 3.91-3.84 (m, 1H), 1.26-1.19 (m, 2H), 0.94-0.87 (m, 2H)

**LC-MS:** *m/z* 277.9 [M+H]<sup>+</sup> at 2.10 RT (91.16% purity)

**1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (Ex. 133)**

To a stirred solution of 1-cyclopropyl-2-(6-hydroxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (350 mg, 1.26 mmol) in DMF (3.5 mL) was added sodium 2-chloro-2,2-difluoroacetate (290 mg, 1.89 mmol) and potassium carbonate (349 mg, 2.53 mmol) in a sealed tube at room temperature under an inert atmosphere. The vessel was sealed and the reaction mixture was heated to 90 °C and stirred for 32 h. The reaction mixture was cooled, quenched with water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 30-40% EtOAc/hexane) followed by preparative HPLC to afford 1-cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 133** (5 mg, 0.01 mmol, 1%) as an off white solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.72 (d, *J* = 1.8 Hz, 1H), 8.03-8.01 (m, 1H), 7.98-7.77 (m, 3H), 7.64-7.61 (m, 1H), 3.73-3.68 (m, 1H), 1.45-1.38 (m, 2H), 0.95-0.89 (m, 2H)

LC-MS: *m/z* 328.2 [M+H]<sup>+</sup> at 2.33 RT (99.76% purity)

HPLC: 99.44%

### Example 134 & Example 135

#### Scheme:



**N-(2-(Cyanomethyl)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide**

To a stirred solution of 6-(difluoromethyl)pyridazine-4-carboxylic acid **Int-29** (1 g, 5.75 mmol) in ethylacetate (60 mL) was added 2-(2-aminophenyl)acetonitrile (759 mg, 5.75 mmol) and triethylamine (1.6 mL, 11.49 mmol) at room temperature under an inert atmosphere. To this was added propylphosphonic anhydride (50% in EtOAc, 9.14 mL, 14.37 mmol) drop wise at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 2 h. After consumption of starting material (by TLC), the reaction mixture was basified using saturated sodium bicarbonate solution to pH ~8 and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was triturated with *n*-pentane (2 x 25 mL) and dried under vacuum to afford *N*-(2-(cyanomethyl)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (1.4 g, 4.86 mmol, 85%) as a yellow solid.

**<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):** δ 10.77 (s, 1H), 9.80 (s, 1H), 8.45 (s, 1H), 7.54-7.49 (m, 1H), 7.45-7.30 (m, 4H), 4.02 (s, 2H)

**LC-MS:** *m/z* 288.9 [M+H]<sup>+</sup> at 2.25 RT (98.33% purity)

#### **2-(6-(Difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile**

To a stirred solution of *N*-(2-(cyanomethyl)phenyl)-6-(difluoromethyl)pyridazine-4-carboxamide (1 g, 3.47 mmol) in DMF (20 mL) was added sodium hydride (60% in mineral oil, 139 mg, 3.47 mmol) at 0 °C under an inert atmosphere. The reaction mixture was heated to 120 °C and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (80 mg, 0.3 mmol, 8%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):** δ 13.21 (brs, 1H), 9.96 (d, *J* = 2.3 Hz, 1H), 8.48 (d, *J* = 2.3 Hz, 1H), 7.80-7.74 (m, 1H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.50-7.32 (m, 3H)

**LC-MS:** *m/z* 270.9 [M+H]<sup>+</sup> at 2.71 RT (90.28% purity)

#### **1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (Ex. 134)**

To a stirred solution of 2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (100 mg, 0.37 mmol) and 1,2-dichloroethane (15 mL) in a sealed tube was added

cyclopropylboronic acid (64 mg, 0.74 mmol) and sodium carbonate (78 mg, 0.74 mmol) at room temperature under an inert atmosphere. The mixture purged under argon for 5 min. In a separate sealed, tube copper(II) acetate (67 mg, 0.37 mmol) and 2,2'-bipyridine (58 mg, 0.37 mmol) were dissolved in 1,2-dichloroethane (10 mL) at room temperature under an inert atmosphere and purged under argon for 5 min. The vessel was sealed and the reaction mixture was heated to 80 °C and stirred for 3 min. The resulting blue color solution was added to the above pre-mixed boronic acid and the resulting mixture purged under argon for 5 min. The vessel was sealed and the reaction mixture was heated to 80 °C and stirred for 4 h. After consumption of starting material (by TLC), the reaction mixture was acidified using 1 N HCl solution (25 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 15-20% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile **Ex. 134** (11 mg, 0.03 mmol, 9%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.71 (d, *J* = 2.0 Hz, 1H), 8.17 (d, *J* = 2.1 Hz, 1H), 7.82 (d, *J* = 7.9 Hz, 1H), 7.73 (d, *J* = 8.4 Hz, 1H), 7.49 (td, *J* = 7.7, 1.0 Hz, 1H), 7.43-7.37 (m, 1H), 7.21-6.91 (m, 1H), 3.67-3.59 (m, 1H), 1.25-1.17 (m, 2H), 0.75-0.68 (m, 2H)

**LC-MS:** *m/z* 310.9 [M+H]<sup>+</sup> at 3.08 RT (98.05% purity)

**HPLC:** 97.84%

#### **2-(6-(Difluoromethyl)pyridazin-4-yl)-1-methyl-1*H*-indole-3-carbonitrile (Ex. 135)**

To a stirred solution of 2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (35 mg, 0.13 mmol) in DMF (0.8 mL) was added sodium hydride (60% in mineral oil, 6 mg, 0.15 mmol) at 0 °C under an inert atmosphere and the mixture was stirred for 5 min. Iodomethane (0.01 mL, 0.15 mmol) was added at 0 °C and the mixture was stirred at room temperature for 1 h. After consumption of starting material (by TLC), the reaction mixture was quenched with ice cold water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) to afford 2-(6-(difluoromethyl)pyridazin-4-yl)-1-methyl-1*H*-indole-3-carbonitrile **Ex. 135** (10 mg, 0.03 mmol, 28%) as a pale yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.57 (d, *J* = 2.1 Hz, 1H), 8.05 (d, *J* = 2.1 Hz, 1H), 7.85 (dt, *J* = 7.9, 0.9 Hz, 1H), 7.53-7.50 (m, 2H), 7.45-7.39 (m, 1H), 7.23-6.92 (m, 1H), 3.88 (s, 3H)


**LC-MS:** *m/z* 284.9 [M+H]<sup>+</sup> at 2.81 RT (98.36% purity)

**HPLC:** 99.44%

5

### Example 136

#### Scheme:



#### 1-Cyclopropyl-2-(6-(1-ethoxyvinyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile

- 10 To stirred solution of 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile **Ex. 34** (750 mg, 2.54 mmol) in toluene (7.5 mL) was added tributyl(1-ethoxyvinyl) stannane (0.86 mL, 2.54 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (294 mg, 0.25 mmol) at room temperature under an inert atmosphere. The reaction mixture was purged under argon for 5 min and heated to reflux temperature and stirred for 16 h. After consumption of starting material (by TLC), the reaction mixture was filtered through a pad of *Celite* and the pad was washed with EtOAc (20 mL). The filtrate was washed with water (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 50-60% EtOAc/hexane) to afford 1-cyclopropyl-2-(6-(1-ethoxyvinyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (425 mg, 1.28 mmol, 50%) as a pale yellow solid.

**LC-MS:** *m/z* 331.9 [M+H]<sup>+</sup> at 2.80 RT (56.84% purity)

#### 2-(6-Acetylpyridazin-4-yl)-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile

To a stirred solution of 1-cyclopropyl-2-(6-(1-ethoxyvinyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (425 mg, 1.28 mmol) in acetone (2.2 mL) was added 2.5 N HCl (0.44 mL) at room temperature under an inert atmosphere and the mixture was stirred for 1 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and washed with saturated sodium bicarbonate solution (30 mL) and water (30 mL). The organic layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was triturated with *n*-pentane (2 x 10 mL) to afford 2-(6-acetylpyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (380 mg, 1.25 mmol, 97%) as an off white solid.

10 **LC-MS:** *m/z* 304.0 [M+H]<sup>+</sup> at 2.35 RT (53.18% purity).

**1-Cyclopropyl-2-(6-(1-hydroxyethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile**

To a stirred solution of 2-(6-acetylpyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (380 mg, 1.25 mmol) in methanol (4 mL) was added sodium borohydride (48 mg, 1.25 mmol) at 0 °C under an inert atmosphere and the mixture was stirred for 1 h. After consumption of starting material (by TLC), the volatiles were removed under reduced pressure. The residue was diluted with water (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 25 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (eluent: 4-5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 1-cyclopropyl-2-(6-(1-hydroxyethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (300 mg, 0.98 mmol, 78%) as an off white solid.

**LC-MS:** *m/z* 305.9 [M+H]<sup>+</sup> at 1.92 RT (56.55% purity)

**1-Cyclopropyl-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile**

25 **(Ex. 136)**

To a stirred solution of 1-cyclopropyl-2-(6-(1-hydroxyethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (300 mg, 0.98 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added diethylaminosulfur trifluoride (0.19 mL, 1.47 mmol) at 0 °C under an inert atmosphere and the reaction was stirred for 30 min. After consumption of starting material (by TLC), the reaction mixture was neutralized using saturated sodium carbonate solution and extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by silica gel column

30

chromatography (eluent: 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford the desired compound (35 mg). This material was combined with another lot (10 mg) and purified by preparative HPLC to afford 1-cyclopropyl-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile **Ex. 136** (21 mg, 0.07 mmol, 6% for two batches) as an off white solid.

**<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD):**  $\delta$  9.83 (d, *J* = 2.0 Hz, 1H), 8.50 (d, *J* = 2.1 Hz, 1H), 8.28-8.26 (m, 1H), 7.93 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.70 (dd, *J* = 8.4, 1.5 Hz, 1H), 6.19-6.01 (m, 1H), 3.99-3.94 (m, 1H), 1.93-1.81 (m, 3H), 1.37-1.28 (m, 2H), 0.93-0.86 (m, 2H)

**LC-MS:** *m/z* 308.0 [M+H]<sup>+</sup> at 2.55 RT (99.50% purity)

**HPLC:** 99.43%

10














### Example 137: Metalloenzyme activity

A. V79-4 cells expressing recombinant adrenodoxin and adrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according to methods previously described (LaSala et al 2009 Anal Bioch 394:56-61). An enzyme enriched microsomal fraction was prepared from cellular lysates and subsequently used as the enzyme source for determining inhibitor IC<sub>50</sub>s. The substrate Km values were experimentally determined for 11-deoxycorticosterone (CYP11B2 substrate) and 11-deoxycortisol (CYP11B1 substrate). Enzyme assays for inhibitor screening employed CYP11B2 and CYP11B1 enzyme enriched microsomes and were run at the Km of the respective substrates. Products of the enzyme reactions, aldosterone for CYP11B2 or cortisol for CYP11B1, were measured by LC-MS. Assays were run under conditions of less than 20% substrate turnover. Inhibitor IC<sub>50</sub>s were generated by determining the product formation in the absence or presence of inhibitor at various concentrations. In the absence of the test compound, the product formed (P<sub>t</sub>) in each data set was defined as 100% activity. In the absence of enzyme, the product formed (P<sub>b</sub>) in each data set was defined as 0% activity. The percent activity in the presence of each inhibitor was calculated according to the following equation: % activity = (P-P<sub>b</sub>)/(P<sub>t</sub>-P<sub>b</sub>), where P = the product formed in the presence of the inhibitor. The IC<sub>50</sub> value was defined as the inhibitor concentration causing a 50% decrease in activity relative to the no inhibitor control reaction.











30











Table 2. Results: CYP11B2 Activity











| Ex. No. | hCYP11B2 IC <sub>50</sub> Range <sup>f</sup> | hCYP11B1 IC <sub>50</sub> Range <sup>f</sup> | HPLC Retention Time (min) <sup>g</sup> | LCMS (M+1) <sup>g</sup> | Structure |
|---------|----------------------------------------------|----------------------------------------------|----------------------------------------|-------------------------|-----------|
|---------|----------------------------------------------|----------------------------------------------|----------------------------------------|-------------------------|-----------|

|    |      |     |                          |                             |                                                                                       |
|----|------|-----|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 1  | +++  | +   | 7.77 (min) <sup>a</sup>  | 255.0<br>[M+H] <sup>a</sup> |    |
| 2  | ++   | +   | 9.29 (min) <sup>b</sup>  | 279.8<br>[M+H] <sup>a</sup> |    |
| 3  | +++  | ++  | 8.98 (min) <sup>b</sup>  | 288.9<br>[M+H] <sup>b</sup> |    |
| 4  | ++++ | ++  | 7.70 (min) <sup>b</sup>  | 280.9<br>[M+H] <sup>b</sup> |    |
| 5  | +++  | +   | 8.04 (min) <sup>b</sup>  | 312.9<br>[M+H] <sup>b</sup> |   |
| 6  | ++++ | ++  | 7.76 (min) <sup>b</sup>  | 282.9<br>[M+H] <sup>b</sup> |  |
| 7  | ++++ | ++  | 8.73 (min) <sup>b</sup>  | 352.9<br>[M+H] <sup>b</sup> |  |
| 8  | ++   | +   | 8.40 (min) <sup>c</sup>  | 340.1<br>[M+H] <sup>b</sup> |  |
| 9  | +++  | +   | 7.67 (min) <sup>b</sup>  | 356.1<br>[M+H] <sup>b</sup> |  |
| 10 | ++++ | +++ | 6.03 (min) <sup>b</sup>  | 340.0<br>[M+H] <sup>b</sup> |  |
| 11 | ++++ | +++ | 11.17 (min) <sup>c</sup> | 433.1<br>[M+H] <sup>c</sup> |  |
| 12 | ++++ | ++  | 8.69 (min) <sup>c</sup>  | 313<br>[M+H] <sup>b</sup>   |  |
| 13 | ++   | +   | 5.76 (min) <sup>b</sup>  | 354<br>[M+H] <sup>c</sup>   |  |











|    |      |     |                         |                             |  |
|----|------|-----|-------------------------|-----------------------------|--|
| 14 | ++++ | +++ | 8.51 (min) <sup>b</sup> | 304.9<br>[M+H] <sup>b</sup> |  |
| 15 | ++++ | ++  | 6.97 (min) <sup>b</sup> | 268.9<br>[M+H] <sup>b</sup> |  |
| 16 | ++   | +   | 7.84 (min) <sup>b</sup> | 362<br>[M+H] <sup>c</sup>   |  |
| 17 | +++  | +   | 7.98 (min) <sup>b</sup> | 284.2<br>[M+H] <sup>d</sup> |  |
| 18 | ++++ | ++  | 9.27 (min) <sup>c</sup> | 438.4<br>[M+H] <sup>d</sup> |  |
| 19 | ++++ | ++  | 7.53 (min) <sup>b</sup> | 286.9<br>[M+H] <sup>b</sup> |  |
| 20 | +++  | ++  | 9.06 (min) <sup>c</sup> | 450.2<br>[M+H] <sup>c</sup> |  |
| 21 | ++++ | ++  | 9.05 (min) <sup>c</sup> | 301.9<br>[M+H] <sup>c</sup> |  |
| 22 | ++++ | ++  | 9.29 (min) <sup>b</sup> | 306.9<br>[M+H] <sup>c</sup> |  |
| 23 | ++++ | +++ | 8.35(min) <sup>b</sup>  | 302.9<br>[M+H] <sup>c</sup> |  |
| 24 | ++++ | ++  | 9.73 (min) <sup>b</sup> | 330.9<br>[M+H] <sup>b</sup> |  |

|    |      |     |                          |                             |                                                                                       |
|----|------|-----|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 25 | ++++ | +++ | 9.61 (min) <sup>c</sup>  | 316.1<br>[M+H] <sup>c</sup> |    |
| 26 | ++++ | +++ | 8.55 (min) <sup>b</sup>  | 256<br>[M+H] <sup>b</sup>   |    |
| 27 | ++++ | ++  | 10.40 (min) <sup>b</sup> | 370.9<br>[M+H] <sup>b</sup> |    |
| 28 | ++++ | ++  | 6.05 (min) <sup>b</sup>  | 346<br>[M+H] <sup>c</sup>   |   |
| 29 | ++++ | +++ | 7.43 (min) <sup>b</sup>  | 291.9<br>[M+H] <sup>b</sup> |  |
| 30 | ++++ | +++ | 7.83 (min) <sup>c</sup>  | 255<br>[M+H] <sup>b</sup>   |  |
| 31 | ++++ | +   | 7.35 (min) <sup>b</sup>  | 376<br>[M+H] <sup>b</sup>   |  |
| 32 | ++++ | ++  | 7.93 (min) <sup>b</sup>  | 370<br>[M+H] <sup>c</sup>   |  |
| 33 | ++++ | +++ | 8.26 (min) <sup>b</sup>  | 300.9<br>[M+H] <sup>b</sup> |  |
| 34 | ++++ | ++  | 8.32 (min) <sup>b</sup>  | 296.2<br>[M+H] <sup>e</sup> |  |
| 35 | ++++ | ++  | 8.78 (min) <sup>d</sup>  | 275.9<br>[M+H] <sup>b</sup> |  |









|    |      |      |                          |                             |                                                                                       |
|----|------|------|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 36 | ++++ | ++   | 5.47 (min) <sup>b</sup>  | 371<br>[M+H] <sup>c</sup>   |    |
| 37 | ++++ | ++   | 6.29 (min) <sup>b</sup>  | 399.1<br>[M+H] <sup>c</sup> |    |
| 38 | ++++ | +++  | 7.52 (min) <sup>b</sup>  | 435.1<br>[M+H] <sup>c</sup> |   |
| 39 | ++++ | ++++ | 8.69 (min) <sup>b</sup>  | 457.1<br>[M+H] <sup>c</sup> |  |
| 40 | ++++ | ++   | 7.57 (min) <sup>b</sup>  | 279.8<br>[M+H] <sup>b</sup> |  |
| 41 | ++++ | ++   | 7.24 (min) <sup>b</sup>  | 277.9<br>[M+H] <sup>b</sup> |  |
| 42 | ++++ | ++   | 9.40 (min) <sup>b</sup>  | 323.3<br>[M+H] <sup>c</sup> |  |
| 43 | ++++ | ++   | 10.41 (min) <sup>b</sup> | 343<br>[M+H] <sup>c</sup>   |  |
| 44 | ++++ | +++  | 8.63 (min) <sup>b</sup>  | 392.1<br>[M+H] <sup>b</sup> |  |
| 45 | ++++ | ++   | 8.31 (min) <sup>c</sup>  | 285.9<br>[M+H] <sup>b</sup> |  |









|    |      |     |                          |                             |                                                                                       |
|----|------|-----|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 46 | ++++ | ++  | 7.66 (min) <sup>b</sup>  | 378.1<br>[M+H] <sup>b</sup> |    |
| 47 | ++++ | ++  | 9.03 (min) <sup>b</sup>  | 371<br>[M+H] <sup>b</sup>   |    |
| 48 | ++   | ++  | 8.56 (min) <sup>e</sup>  | 385.1<br>[M+H] <sup>b</sup> |    |
| 49 | ++++ | +++ | 10.35 (min) <sup>b</sup> | 367<br>[M+H] <sup>c</sup>   |   |
| 50 | +++  | +   | 10.98 (min) <sup>b</sup> | 391.3<br>[M+H] <sup>c</sup> |  |
| 51 | ++++ | +++ | 8.85 (min) <sup>b</sup>  | 315.1<br>[M+H] <sup>c</sup> |  |
| 52 | +++  | ++  | 7.70 (min) <sup>b</sup>  | 394<br>[M+H] <sup>b</sup>   |  |
| 53 | ++++ | ++  | 10.66 (min) <sup>b</sup> | 385.1<br>[M+H] <sup>c</sup> |  |
| 54 | ++++ | ++  | 6.33 (min) <sup>b</sup>  | 276.9<br>[M+H] <sup>b</sup> |  |
| 55 | +++  | +   | 7.33 (min) <sup>b</sup>  | 272.9<br>[M+H] <sup>b</sup> |  |









|    |      |     |                          |                             |  |
|----|------|-----|--------------------------|-----------------------------|--|
| 56 | ++   | +   | 10.15 (min) <sup>c</sup> | 340.9<br>[M+H] <sup>b</sup> |  |
| 57 | ++++ | +++ | 9.95 (min) <sup>b</sup>  | 367<br>[M+H] <sup>b</sup>   |  |
| 58 | ++++ | ++  | 8.48 (min) <sup>b</sup>  | 315.0<br>[M+H] <sup>b</sup> |  |
| 59 | ++++ | +++ | 8.50 (min) <sup>b</sup>  | 313.1<br>[M+H] <sup>c</sup> |  |
| 60 | ++   | +   | 4.14 (min) <sup>b</sup>  | 302.1<br>[M+H] <sup>b</sup> |  |
| 61 | ++++ | ++  | 10.26 (min) <sup>b</sup> | 381.1<br>[M+H] <sup>c</sup> |  |
| 62 | ++++ | ++  | 10.23 (min) <sup>b</sup> | 385.1<br>[M+H] <sup>c</sup> |  |
| 63 | ++++ | ++  | 10.29 (min) <sup>b</sup> | 385<br>[M+H] <sup>c</sup>   |  |
| 64 | ++++ | ++  | 8.92 (min) <sup>b</sup>  | 315.0<br>[M+H] <sup>b</sup> |  |

|    |      |     |                         |                             |                                                                                       |
|----|------|-----|-------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 65 | +++  | +   | 8.70 (min) <sup>b</sup> | 294.9<br>[M+H] <sup>b</sup> |    |
| 66 | ++++ | ++  | 8.37 (min) <sup>b</sup> | 312<br>[M+H] <sup>b</sup>   |    |
| 67 | ++++ | ++  | 8.87 (min) <sup>b</sup> | 311.0<br>[M+H] <sup>b</sup> |    |
| 68 | +++  | +   | 7.82 (min) <sup>b</sup> | 284<br>[M+H] <sup>b</sup>   |   |
| 69 | ++++ | ++  | 8.02 (min) <sup>b</sup> | 300.0<br>[M+H] <sup>b</sup> |  |
| 70 | ++++ | +++ | 9.65 (min) <sup>b</sup> | 337.0<br>[M+H] <sup>b</sup> |  |
| 71 | ++++ | ++  | 9.40 (min) <sup>b</sup> | 355.1<br>[M+H] <sup>b</sup> |  |
| 72 | ++++ | +++ | 8.30 (min) <sup>b</sup> | 301.0<br>[M+H] <sup>b</sup> |  |
| 73 | +++  | +   | 8.70 (min) <sup>b</sup> | 321.9<br>[M+H] <sup>b</sup> |  |
| 74 | ++++ | +   | 7.47 (min) <sup>b</sup> | 287.0<br>[M+H] <sup>b</sup> |  |









|    |      |     |                         |                             |  |
|----|------|-----|-------------------------|-----------------------------|--|
| 75 | ++++ | +++ | 7.60 (min) <sup>b</sup> | 302<br>[M+H] <sup>c</sup>   |  |
| 76 | ++++ | ++  | 7.73 (min) <sup>b</sup> | 312.9<br>[M+H] <sup>c</sup> |  |
| 77 | +++  | ++  | 7.10 (min) <sup>b</sup> | 380.1<br>[M+H] <sup>c</sup> |  |
| 78 | +++  | ++  | 8.01 (min) <sup>b</sup> | 394.1<br>[M+H] <sup>b</sup> |  |
| 79 | +++  | ++  | 7.85 (min) <sup>b</sup> | 408.0<br>[M+H] <sup>b</sup> |  |
| 80 | +++  | +   | 9.60 (min) <sup>c</sup> | 351.0<br>[M+H] <sup>b</sup> |  |
| 81 | ++++ | +++ | 8.91 (min) <sup>b</sup> | 365.0<br>[M+H] <sup>b</sup> |  |
| 82 | +++  | ++  | 7.39 (min) <sup>b</sup> | 335<br>[M+H] <sup>b</sup>   |  |
| 83 | ++++ | ++  | 7.80 (min) <sup>b</sup> | 348.9<br>[M+H] <sup>c</sup> |  |









|    |       |       |                          |                             |                                                                                       |
|----|-------|-------|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 84 | +++++ | +++   | 7.80 (min) <sup>b</sup>  | 311.9<br>[M+H] <sup>b</sup> |    |
| 85 | +++++ | ++    | 10.70 (min) <sup>c</sup> | 340.9<br>[M+H] <sup>b</sup> |    |
| 86 | +++++ | ++    | 9.95 (min) <sup>d</sup>  | 329.9<br>[M+H] <sup>b</sup> |   |
| 87 | +++++ | +++++ | 7.50 (min) <sup>b</sup>  | 303<br>[M+H] <sup>b</sup>   |  |
| 88 | +++++ | +++   | 7.77 (min) <sup>b</sup>  | 406.0<br>[M+H] <sup>b</sup> |  |
| 89 | +++++ | ++    | 8.96 (min) <sup>b</sup>  | 331.2<br>[M+H] <sup>e</sup> |  |
| 90 | ++    | +     | 8.30 (min) <sup>b</sup>  | 319.0<br>[M+H] <sup>b</sup> |  |
| 91 | +++++ | +++   | 7.55 (min) <sup>b</sup>  | 394.0<br>[M+H] <sup>b</sup> |  |






|    |      |      |                         |                             |                                                                                       |
|----|------|------|-------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 92 | ++++ | ++   | 7.75 (min) <sup>b</sup> | 304.9<br>[M+H] <sup>b</sup> |    |
| 93 | ++++ | ++   | 7.31 (min) <sup>b</sup> | 300.9<br>[M+H] <sup>b</sup> |    |
| 94 | +++  | ++   | 6.74 (min) <sup>b</sup> | 302.9<br>[M+H] <sup>b</sup> |    |
| 95 | ++++ | ++   | 9.44 (min) <sup>b</sup> | 339.9<br>[M+H] <sup>b</sup> |  |
| 96 | +++  | ++   | 7.96 (min) <sup>b</sup> | 408.0<br>[M+H] <sup>b</sup> |  |
| 97 | ++++ | ++++ | 9.59 (min) <sup>b</sup> | 329.0<br>[M+H] <sup>b</sup> |  |
| 98 | +++  | +    | 8.19 (min) <sup>d</sup> | 264.9<br>[M+H] <sup>b</sup> |  |
| 99 | ++   | +    | 7.33 (min) <sup>b</sup> | 287.2<br>[M+H] <sup>e</sup> |  |

|     |      |     |                         |                             |                                                                                       |
|-----|------|-----|-------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 100 | +    | +   | 7.00 (min) <sup>b</sup> | 300.9<br>[M+H] <sup>b</sup> |    |
| 101 | ++++ | ++  | 9.10 (min) <sup>b</sup> | 323.0<br>[M+H] <sup>b</sup> |    |
| 102 | ++++ | ++  | 8.79 (min) <sup>b</sup> | 304.9<br>[M+H] <sup>b</sup> |   |
| 103 | ++   | +   | 8.12 (min) <sup>b</sup> | 283.1<br>[M+H] <sup>c</sup> |  |
| 104 | ++++ | ++  | 9.45 (min) <sup>c</sup> | 296.9<br>[M+H] <sup>b</sup> |  |
| 105 | ++   | +   | 9.58 (min) <sup>b</sup> | 324.9<br>[M+H] <sup>b</sup> |  |
| 106 | ++++ | +++ | 7.99 (min) <sup>b</sup> | 327.2<br>[M+H] <sup>c</sup> |  |
| 107 | +    | +   | 6.82 (min) <sup>b</sup> | 275.9<br>[M+H] <sup>b</sup> |  |

|     |      |    |                         |                             |  |
|-----|------|----|-------------------------|-----------------------------|--|
| 108 | ++   | +  | 8.02 (min) <sup>b</sup> | 300.9<br>[M+H] <sup>b</sup> |  |
| 109 | ++   | +  | 6.63 (min) <sup>b</sup> | 302.9<br>[M+H] <sup>b</sup> |  |
| 110 | ++   | +  | 7.91 (min) <sup>b</sup> | 316.9<br>[M+H] <sup>b</sup> |  |
| 111 | +++  | +  | 6.37 (min) <sup>b</sup> | 269.2<br>[M+H] <sup>c</sup> |  |
| 112 | ++   | +  | 7.69 (min) <sup>b</sup> | 284.9<br>[M+H] <sup>b</sup> |  |
| 113 | ++   | +  | 7.61 (min) <sup>b</sup> | 285.1<br>[M+H] <sup>c</sup> |  |
| 114 | ++++ | ++ | 8.08 (min) <sup>b</sup> | 316.9<br>[M+H] <sup>b</sup> |  |
| 115 | +++  | +  | 7.44 (min) <sup>b</sup> | 320.2<br>[M+H] <sup>c</sup> |  |

|     |      |      |                          |                             |                                                                                       |
|-----|------|------|--------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 116 | ++   | +    | 6.94 (min) <sup>b</sup>  | 306.2<br>[M+H] <sup>c</sup> |    |
| 117 | ++++ | ++++ | 10.12 (min) <sup>b</sup> | 343.0<br>[M+H] <sup>b</sup> |    |
| 118 | ++++ | +++  | 9.64 (min) <sup>b</sup>  | 360.0<br>[M+H] <sup>b</sup> |   |
| 119 | ++++ | ++   | 10.00 (min) <sup>b</sup> | 339.2<br>[M+H] <sup>e</sup> |  |
| 120 | ++++ | ++   | 9.01 (min) <sup>b</sup>  | 329.9<br>[M+H] <sup>b</sup> |  |
| 121 | ++++ | ++   | 7.77 (min) <sup>b</sup>  | 313.0<br>[M+H] <sup>b</sup> |  |
| 122 | ++++ | ++   | 8.85 (min) <sup>b</sup>  | 304.9<br>[M+H] <sup>b</sup> |  |
| 123 | ++++ | ++   | 8.95 (min) <sup>b</sup>  | 318.9<br>[M+H] <sup>b</sup> |  |

|     |      |     |                          |                              |                                                                                       |
|-----|------|-----|--------------------------|------------------------------|---------------------------------------------------------------------------------------|
| 124 | ++++ | +++ | 10.42 (min) <sup>b</sup> | 346.9<br>[M+H] <sup>b</sup>  |    |
| 125 | ++++ | ++  | 10.09 (min) <sup>b</sup> | 354.9<br>[M+H] <sup>b</sup>  |    |
| 126 | ++   | +   | 7.00 (min) <sup>b</sup>  | 288.9<br>[M+H] <sup>+b</sup> |   |
| 127 | ++++ | ++  | 9.84 (min) <sup>b</sup>  | 338.9<br>[M+H] <sup>b</sup>  |  |
| 128 | +++  | ++  | 6.92 (min) <sup>b</sup>  | 317.0<br>[M+H] <sup>b</sup>  |  |
| 129 | ++++ | ++  | 8.59 (min) <sup>b</sup>  | 318.9<br>[M+H] <sup>b</sup>  |  |
| 130 | +++  | ++  | 10.19 (min) <sup>b</sup> | 373.0<br>[M+H] <sup>b</sup>  |  |
| 131 | ++   | ++  | 7.45 (min) <sup>b</sup>  | 286.9<br>[M+H] <sup>b</sup>  |  |

|     |      |    |                         |                             |                                                                                       |
|-----|------|----|-------------------------|-----------------------------|---------------------------------------------------------------------------------------|
| 132 | +    | ++ | 7.42 (min) <sup>b</sup> | 288.9<br>[M+H] <sup>b</sup> |    |
| 133 | +++  | ++ | 9.82 (min) <sup>d</sup> | 328.2<br>[M+H] <sup>c</sup> |    |
| 134 | +++  | +  | 9.77 (min) <sup>b</sup> | 310.9<br>[M+H] <sup>b</sup> |   |
| 135 | +++  | +  | 9.54 (min) <sup>b</sup> | 284.9<br>[M+H] <sup>b</sup> |  |
| 136 | ++++ | ++ | 7.98 (min) <sup>b</sup> | 308.0<br>[M+H] <sup>b</sup> |  |

<sup>f</sup> See table 1 for HPLC and LCMS methods


<sup>g</sup> IC<sub>50</sub> ranges: + > 10 μM; ++ 1-10 μM; +++ 0.1-1 μM; ++++ 0.001-0.1 μM

The results in Table 2 demonstrate that compounds of Formula **I** have potent activity  
 5 against CYP11B2, and many compounds of Formula **I** have significant selectivity for  
 inhibiting CYP11B2 over CYP11B1.

Comparison Examples were also prepared. Tables 3 and 4 show that replacing the  
 pyridazine of compounds of Formula **I** with a pyridine results in compounds (*e.g.*, Examples  
 137-140) that show increased inhibition of CYP11B1 (7-54 fold increase) for each of the  
 10 comparisons. These structural changes also result in compounds that are less selective for  
 CYP11B2 over CYP11B1. Both of these features are undesirable in a CYP11B2 inhibitor  
 because, as described above, CYP11B1 activity is integral to cortisol production. In addition,  
 Examples 14 and 42 demonstrated decreased inhibition of CYP1A2 and CYP19 in comparison  
 to their respective comparison examples. Examples 42 and 19 also showed much greater

metabolic stability when exposed to cynomolgus monkey and rat liver microsomes than their pyridine counterparts, Examples 139 and 140. Likewise, Table 5 shows that known inhibitors of CYP11B2, such as Examples 141-143, also have undesirable activity against CYP11B1, limiting their effectiveness as therapeutic agents. However, analogous Examples 31 and 52 are much less potent inhibitors of CYP11B1. Examples 31 and 52 also possess greater metabolic stability than Example 141. Taken together, these results demonstrate that the pyridazine compounds of Formula I are potentially of greater therapeutic utility in humans than known compounds, due in part to their decreased inhibition of CYP11B1, increased selectivity for inhibition of CYP11B2 over other related metalloenzymes, and their metabolic stability.

Table 3. Comparison Results



| Ex. No.                             | 12    | 137 <sup>d,e</sup> | 14    | 138 <sup>e</sup> | 42    | 139   |
|-------------------------------------|-------|--------------------|-------|------------------|-------|-------|
| Ar                                  |       |                    |       |                  |       |       |
| R <sup>6</sup>                      | H     | H                  | H     | H                | F     | F     |
| pKa <sup>a</sup>                    | -9.82 | 3.30               | 1.84  | 3.89             | -0.59 | 3.05  |
| cLogP <sup>a</sup>                  | 1.64  | 2.57               | 2.98  | 3.91             | 2.18  | 3.22  |
| tPSA <sup>a</sup> (Å <sup>2</sup> ) | 63.83 | 50.94              | 43.60 | 30.71            | 43.60 | 30.71 |
| CYP11B2 IC <sub>50</sub> (μM)       | 0.031 | 0.008              | 0.004 | 0.003            | 0.021 | 0.003 |
| CYP11B1 IC <sub>50</sub> (μM)       | 1.124 | 0.150              | 0.582 | 0.038            | 5.183 | 0.347 |
| Selectivity <sup>b</sup>            | 36    | 19                 | 145   | 13               | 247   | 115   |
| CYP1A2 IC <sub>50</sub> (μM)        | 84    | 11                 | 67    | 24               | 21    | 2.0   |
| CYP19 IC <sub>50</sub> (μM)         | 30    | 14                 | 73    | 5.2              | > 100 | 30.6  |
| Cyno LM Stability <sup>c</sup>      | 93    | 71                 | 44    | 1                | 108   | 19    |
| Rat LM Stability <sup>c</sup>       | 71    | 76                 | 18    | 4                | 91    | 4     |

<sup>a</sup> pKa (of the N2 pyridazine atom or pyridine N), LogP (Chemaxon Method), and total polar surface area (tPSA) calculated with MarvinSketch 15.5.4.0




<sup>b</sup> Selectivity = CYP11B1 IC<sub>50</sub>/CYP11B2 IC<sub>50</sub>

5 <sup>c</sup> Percentage of compound remaining at 65 min in rat or cynomolgus monkey liver microsomes

<sup>d</sup> ACS Med. Chem. Lett. **2015**, 6, 573.

<sup>e</sup> WO 2012/012478

10 *Table 4. Comparison Results*






| Ex. No.                             | 54                                                                                | 19                                                                                 | 140                                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Ar                                  |  |  |  |
| pKa <sup>a</sup>                    | -9.27                                                                             | -9.32                                                                              | 4.10                                                                                |
| cLogP <sup>a</sup>                  | 0.94                                                                              | 1.89                                                                               | 3.52                                                                                |
| tPSA <sup>a</sup> (Å <sup>2</sup> ) | 80.28                                                                             | 43.60                                                                              | 30.71                                                                               |
| CYP11B2 IC <sub>50</sub> (μM)       | 0.052                                                                             | 0.030                                                                              | 0.002                                                                               |
| CYP11B1 IC <sub>50</sub> (μM)       | 8.201                                                                             | 4.767                                                                              | 0.088                                                                               |
| Selectivity <sup>b</sup>            | 157                                                                               | 159                                                                                | 36                                                                                  |
| CYP1A2 IC <sub>50</sub> (μM)        | > 200                                                                             | 62                                                                                 | 6.3                                                                                 |
| CYP19 IC <sub>50</sub> (μM)         | > 100                                                                             | > 100                                                                              | 24                                                                                  |
| Cyno LM Stability <sup>c</sup>      | 94                                                                                | 75                                                                                 | 0                                                                                   |
| Rat LM Stability <sup>c</sup>       | 102                                                                               | 60                                                                                 | 0                                                                                   |

<sup>a</sup> pKa (of the N2 pyridazine atom or pyridine N), LogP (Chemaxon Method), and total polar surface area (tPSA) calculated with MarvinSketch 15.5.4.0

<sup>b</sup> Selectivity = CYP11B1 IC<sub>50</sub>/CYP11B2 IC<sub>50</sub>

15 <sup>c</sup> Percentage of compound remaining at 65 min in rat or cynomolgus monkey liver microsomes

5 Table 5. Comparison Results

| Ex No.                              | 31                                                                                | 52                                                                                 | 141                                                                                 | 142 <sup>d</sup>                                                                    | 143 <sup>e</sup>                                                                    |
|-------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Structure                           |  |  |  |  |  |
| pKa <sup>a</sup>                    | -9.92                                                                             | -9.91                                                                              | 3.43                                                                                | 4.11                                                                                | 7.15                                                                                |
| cLogP <sup>a</sup>                  | 0.80                                                                              | 0.94                                                                               | 2.12                                                                                | 1.93                                                                                | 1.80                                                                                |
| tPSA <sup>a</sup> (Å <sup>2</sup> ) | 89.77                                                                             | 89.77                                                                              | 76.88                                                                               | 87.78                                                                               | 41.61                                                                               |
| CYP11B2 IC <sub>50</sub> (μM)       | 0.069                                                                             | 0.100                                                                              | 0.006                                                                               | 0.005                                                                               | 0.0007                                                                              |
| CYP11B1 IC <sub>50</sub> (μM)       | > 10.000                                                                          | 5.696                                                                              | 1.407                                                                               | 0.457                                                                               | 0.013                                                                               |
| Selectivity <sup>b</sup>            | > 145                                                                             | 57                                                                                 | 230                                                                                 | 91                                                                                  | 17                                                                                  |
| CYP1A2 IC <sub>50</sub> (μM)        | > 100                                                                             | > 200                                                                              | 93.741                                                                              | 7.100                                                                               | 1.600                                                                               |
| CYP19 IC <sub>50</sub> (μM)         | > 100                                                                             | > 100                                                                              | 82.477                                                                              | 0.457                                                                               | 0.023                                                                               |
| Cyno LM Stability <sup>c</sup>      | 71                                                                                | 83                                                                                 | 19                                                                                  |                                                                                     |                                                                                     |
| Rat LM Stability <sup>c</sup>       | 72                                                                                | 84                                                                                 | 2                                                                                   |                                                                                     |                                                                                     |

<sup>a</sup> pKa (of the N2 pyridazine atom or pyridine N) calculated with MarvinSketch 15.5.4.0

<sup>b</sup> Selectivity = CYP11B1 IC<sub>50</sub>/CYP11B2 IC<sub>50</sub>

<sup>c</sup> Percentage of compound remaining at 65 min in rat or cynomolgus monkey liver microsomes

10 <sup>d</sup> J. Med. Chem. **2015**, 58, 9382.

<sup>e</sup> ACS Med. Chem. Lett. **2013**, 4, 1203.

### Incorporation by Reference


15 The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference.

### Equivalents

20 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.

What is claimed:

1. A compound of Formula I:



5 or a pharmaceutically acceptable salt thereof; wherein

A is N or CR<sup>5</sup>;

W is N or CR<sup>6</sup>;

X is N or CR<sup>6</sup>;

Y is N or CR<sup>6</sup>;

10 Z is N or CR<sup>6</sup>;

provided that no more than two of W, X, Y, and Z are N;

R<sup>1</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NHSO<sub>2</sub>R<sup>d</sup>,  
15 CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, S(O)R<sup>d</sup>, S(O)<sub>2</sub>R<sup>d</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH, wherein any R<sup>1</sup> can be optionally substituted with 1-3 independent substituents R<sup>7</sup>;

R<sup>2</sup> is hydrogen, halogen, cyano, alkyl, or haloalkyl;

or R<sup>1</sup> and R<sup>2</sup> together with the atoms to which they are attached form an aryl, heterocycloalkyl, or cycloalkyl ring;

20 R<sup>3</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NHSO<sub>2</sub>R<sup>d</sup>, CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH;

R<sup>4</sup> is alkyl, cycloalkyl, haloalkyl, or heteroalkyl;

25 R<sup>5</sup> is hydrogen, alkyl, haloalkyl, heteroalkyl, or cycloalkyl;

each occurrence of R<sup>6</sup> is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, alkoxy, haloalkyl, or carboxyl;

each occurrence of R<sup>7</sup> is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl, aryl, aryl substituted with 1-3 independent halogen, -(CH<sub>2</sub>)<sub>n</sub>C(O)NR<sup>g</sup>R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>i</sup>, -CO<sub>2</sub>R<sup>j</sup>, or  
30 NR<sup>g</sup>R<sup>h</sup>,

each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

each occurrence of  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$ , and  $R^f$  is, independently, hydrogen, acyl, alkoxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $C(O)OC_{1-6}$  alkyl,  $C(O)C_{1-6}$  alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or  $R^a$  and  $R^b$  together with the atoms to which they are attached form a heterocycloalkyl ring; or  $R^e$  and  $R^f$  together with the atoms to which they are attached form a cycloalkyl ring; and

each occurrence of  $R^g$ ,  $R^h$ ,  $R^i$ , and  $R^j$  is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,  $C(O)OC_{1-6}$  alkyl,  $C(O)C_{1-6}$  alkyl, or  $R^g$  and  $R^h$  together with the atoms to which they are attached form a heterocycloalkyl ring.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl,  $NR^aR^b$ ,  $NHSO_2R^c$ ,  $CH_2NR^aR^b$ ,  $CH_2NHSO_2R^d$ ,  $COR^f$ , or  $CR^eR^fOH$ ; or  $R^1$  and  $R^2$  together with the atoms to which they are attached form an aryl ring.


3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is hydrogen, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, cycloalkoxy, aryl,  $NR^aR^b$ ,  $CH_2NHSO_2R^d$ , or  $CR^eR^fOH$ ; or  $R^1$  and  $R^2$  together with the atoms to which they are attached form an aryl ring.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:  
 $R^1$  is hydrogen, halogen, alkyl, haloalkyl,  $CH_2NHSO_2R^d$ , or  $NR^aR^b$ ; and  
 $R^a$ ,  $R^b$ , and  $R^d$  are, independently, hydrogen, alkyl, or haloalkyl.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is haloalkyl.

6. The compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein  $R^2$  is hydrogen or alkyl.


7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is hydrogen and R<sup>2</sup> is alkyl.
8. The compound of any of claims 1-7, or a pharmaceutically acceptable salt thereof,  
5 wherein R<sup>4</sup> is alkyl or cycloalkyl.
9. The compound of any of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is C<sub>1-4</sub> alkyl or C<sub>3-5</sub> cycloalkyl.
10. The compound of any of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein each R<sup>6</sup> is, independently, hydrogen, halogen, cyano, alkoxy, haloalkyl, or carboxyl.
11. The compound of any of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein each R<sup>6</sup> is, independently, hydrogen, halogen, or cyano.  
15
12. The compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein A is CR<sup>5</sup> and R<sup>5</sup> is hydrogen, C<sub>1-4</sub> alkyl, or C<sub>3-5</sub> cycloalkyl.
13. The compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof,  
20 wherein A is N.
14. The compound of any of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein no more than one of W, X, Y, and Z is N.
- 25 15. The compound of any of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein W, X, Y, and Z are each independently CR<sup>6</sup>.
16. The compound of any of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein Z is N.  
30
17. The compound of claim 1, wherein the compound is of Formula **I-a**:

**I-a,**

or a pharmaceutically acceptable salt thereof.


18. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein A is N.

19. The compound of claim 1, wherein the compound is of Formula **I-b**:

**I-b,**


or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1, wherein the compound is of Formula **I-c**:

**I-c,**


or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1, wherein the compound is of Formula **I-d**:

**I-d,**

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1, wherein the compound is of Formula **I-e**:




**I-e,**

or a pharmaceutically acceptable salt thereof.

5

23. The compound of claim 1, wherein the compound is of Formula **I-f**:



**I-f,**

or a pharmaceutically acceptable salt thereof.


10

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is haloalkyl.

25. The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein each  $R^6$  is independently halogen.

15

26. The compound of claim 1, wherein the compound is of Formula **I-g**:



**I-g,**

or a pharmaceutically acceptable salt thereof.

20

27. The compound of claim 1 selected from the group consisting of:

1-cyclopropyl-6-fluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (1);

25

- 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbonitrile (2);  
 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole (3);  
 1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (4);  
 methyl 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate  
 5 (5);  
 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole (6);  
 1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-  
 trifluoroethan-1-ol (7);  
*N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 10 yl)methyl)propionamide (8);  
 ethyl ((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)methyl)carbamate (9);  
 4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)morpholine  
 (10);  
 15 1-cyclopropyl-6-fluoro-2-(6-(4-(4-fluorophenyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (11);  
 2-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)propan-2-ol  
 (12);  
 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-  
 20 yl)pyridazin-3-amine (13);  
 4-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)cinnoline (14);  
 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (15);  
*N*-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)ethanesulfonamide (16);  
 25 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (17);  
 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-  
 yl)-*N*-isopropylacetamide (18);  
 1-cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (19);  
 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-  
 30 yl)-1-(pyrrolidin-1-yl)ethan-1-one (20);  
 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-methylpyridazin-3-amine  
 (21);

- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (22);  
 1-cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole (23);  
 1-cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole  
 (24);
- 5 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N,N*-dimethylpyridazin-3-  
 amine (25);  
 1-ethyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (26);  
 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (27);
- 10 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2-  
 methoxyethyl)pyridazin-3-amine (28);  
 1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (29);  
 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (30);  
*N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 15 yl)methyl)ethanesulfonamide (31);  
 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2,2,2-  
 trifluoroethyl)pyridazin-3-amine (32);  
 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (33);  
 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (34);
- 20 1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (35);  
 1-cyclopropyl-5,6-difluoro-2-(6-(4-methylpiperazin-1-yl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (36);  
 1-(4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)piperazin-1-yl)ethan-1-one (37);
- 25 1-cyclopropyl-5,6-difluoro-2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (38);  
 tert-butyl 4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)piperazine-1-carboxylate (39);  
 1-ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (40);
- 30 1-ethyl-2-(6-ethylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (41);  
 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (42);

- 2-(6-cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (43);
- 1-cyclopropyl-2-(6-(4,4-difluoropiperidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (44);
- 5 5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (45);
- 1-cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (46);
- 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (47);
- 10 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N,N*-dimethylpyrrolidin-3-amine (48);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (49);
- 1-cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl)ethynyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (50);
- 15 1-cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (51);
- N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (52);
- 1-cyclopropyl-5,6-difluoro-2-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (53);
- 20 3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (54);
- 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (55);
- 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-4-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (56);
- 25 1-cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (57);
- 1-cyclopropyl-5,6-difluoro-2-(5-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (58);
- 1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (59);
- 30 2-(6-chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridine (60);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1*H*-

- benzo[*d*]imidazole (61);  
 1-cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (62);  
 1-cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 5 benzo[*d*]imidazole (63);  
 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-  
 one (64);  
 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (65);  
 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-  
 10 carbonitrile (66);  
 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (67);  
 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (68);  
 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile  
 (69);  
 15 1-cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (70);  
 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (71);  
 2-(6-Cyclopropylpyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (72);  
 20 5-Chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-  
*b*]pyridine (73);  
 1-Cyclopropyl-5,6-difluoro-2-(5-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (74);  
 1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile  
 (75);  
 25 3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-  
 carbonitrile (76);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)methyl)methane sulfonamide (77);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)-  
 30 *N*-methylmethanesulfonamide (78);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)methyl)propane-2-sulfonamide (79);

1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (80);

1-Cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (81);

5 1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (82);

1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (83);

10 5-Chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (84);

1-Cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (85);

1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (86);

15 3-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (87);


2-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)isothiazolidine 1,1-dioxide (88);

20 3-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (89);

1-cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (90);

and pharmaceutically acceptable salts thereof.

25 28. A compound of Formula I:



I,

or a pharmaceutically acceptable salt thereof; wherein

A is N or CR<sup>5</sup>;

30 W is N or CR<sup>6</sup>;

X is N or CR<sup>6</sup>;

Y is N or CR<sup>6</sup>;

Z is N or CR<sup>6</sup>;

provided that no more than two of W, X, Y, and Z are N;

5 R<sup>1</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CR<sup>e</sup>R<sup>f</sup>NHSO<sub>2</sub>R<sup>d</sup>, OR<sup>f</sup>, SR<sup>f</sup>, CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, S(O)R<sup>d</sup>, S(O)<sub>2</sub>R<sup>d</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH, wherein any R<sup>1</sup> can be optionally substituted with 1-3 independent substituents R<sup>7</sup>;

10 R<sup>2</sup> is hydrogen, halogen, cyano, alkyl, or haloalkyl;  
or R<sup>1</sup> and R<sup>2</sup> together with the atoms to which they are attached form an aryl, heterocycloalkyl, or cycloalkyl ring;

R<sup>3</sup> is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl,  
15 heterocycloalkyl, heterocycloalkylalkyl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NHSO<sub>2</sub>R<sup>d</sup>, CO<sub>2</sub>R<sup>e</sup>, COR<sup>f</sup>, CH<sub>2</sub>OR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH;

R<sup>4</sup> is alkyl, cycloalkyl, haloalkyl, or heteroalkyl;

R<sup>5</sup> is hydrogen, cyano, alkyl, haloalkyl, heteroalkyl, or cycloalkyl;

each occurrence of R<sup>6</sup> is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl,  
20 cycloalkyl, alkoxy, haloalkyl, OR<sup>f</sup>, or carboxyl;

each occurrence of R<sup>7</sup> is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl, cycloalkyl, aryl, aryl substituted with 1-3 independent halogen, -(CH<sub>2</sub>)<sub>n</sub>C(O)NR<sup>g</sup>R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>i</sup>, -CO<sub>2</sub>R<sup>j</sup>, or NR<sup>g</sup>R<sup>h</sup>,

each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

25 each occurrence of R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, and R<sup>f</sup> is, independently, hydrogen, acyl, alkoxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C(O)OC<sub>1-6</sub> alkyl, C(O)C<sub>1-6</sub> alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or R<sup>a</sup> and R<sup>b</sup> together with the atoms to which they are attached form a heterocycloalkyl ring; or R<sup>e</sup> and R<sup>f</sup>  
30 together with the atoms to which they are attached form a cycloalkyl ring; and

each occurrence of R<sup>g</sup>, R<sup>h</sup>, R<sup>i</sup>, and R<sup>j</sup> is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C(O)OC<sub>1-6</sub> alkyl,

C(O)C<sub>1-6</sub> alkyl, or R<sup>g</sup> and R<sup>h</sup> together with the atoms to which they are attached form a heterocycloalkyl ring.

29. The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, NR<sup>a</sup>R<sup>b</sup>, NHSO<sub>2</sub>R<sup>c</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, CR<sup>e</sup>R<sup>f</sup>NHSO<sub>2</sub>R<sup>d</sup>, SR<sup>f</sup>, COR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH; or R<sup>1</sup> and R<sup>2</sup> together with the atoms to which they are attached form an aryl or cycloalkyl ring.
30. The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is hydrogen, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, cycloalkoxy, aryl, NR<sup>a</sup>R<sup>b</sup>, CR<sup>e</sup>R<sup>f</sup>NHSO<sub>2</sub>R<sup>d</sup>, SR<sup>f</sup>, or CR<sup>e</sup>R<sup>f</sup>OH; or R<sup>1</sup> and R<sup>2</sup> together with the atoms to which they are attached form an aryl or cycloalkyl ring.
31. The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein: R<sup>1</sup> is hydrogen, halogen, alkyl, haloalkyl, CR<sup>e</sup>R<sup>f</sup>NHSO<sub>2</sub>R<sup>d</sup>, SR<sup>f</sup>, or NR<sup>a</sup>R<sup>b</sup>; and R<sup>a</sup>, R<sup>b</sup>, R<sup>d</sup>, R<sup>e</sup>, and R<sup>f</sup> are, independently, hydrogen, alkyl, or haloalkyl.
32. The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is haloalkyl.
33. The compound of any of claims 28-32, or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is hydrogen or alkyl.
34. The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is hydrogen and R<sup>2</sup> is alkyl.
35. The compound of any of claims 28-34, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is alkyl or cycloalkyl.
36. The compound of any of claims 28-34, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is C<sub>1-4</sub> alkyl or C<sub>3-5</sub> cycloalkyl.

37. The compound of any of claims 28-36, or a pharmaceutically acceptable salt thereof, wherein each  $R^6$  is, independently, hydrogen, halogen, cyano, alkoxy, haloalkyl, or carboxyl.

5 38. The compound of any of claims 28-36, or a pharmaceutically acceptable salt thereof, wherein each  $R^6$  is, independently, hydrogen, halogen, or cyano.

39. The compound of any of claims 28-38, or a pharmaceutically acceptable salt thereof, wherein A is  $CR^5$  and  $R^5$  is hydrogen,  $C_{1-4}$  alkyl, or  $C_{3-5}$  cycloalkyl.

10


40. The compound of any of claims 28-38, or a pharmaceutically acceptable salt thereof, wherein A is N.

41. The compound of any of claims 28-40, or a pharmaceutically acceptable salt thereof,  
15 wherein no more than one of W, X, Y, and Z is N.

42. The compound of any of claims 28-41, or a pharmaceutically acceptable salt thereof, wherein W, X, Y, and Z are each independently  $CR^6$ .

20 43. The compound of any of claims 28-41, or a pharmaceutically acceptable salt thereof, wherein Z is N.

44. The compound of claim 28, wherein the compound is of Formula **I-a**:



25


**I-a,**

or a pharmaceutically acceptable salt thereof.

45. The compound of claim 44, or a pharmaceutically acceptable salt thereof, wherein A is N.

30

46. The compound of claim 28, wherein the compound is of Formula **I-b**:




**I-b,**

or a pharmaceutically acceptable salt thereof.

5

47. The compound of claim 28, wherein the compound is of Formula **I-c**:




**I-c,**

or a pharmaceutically acceptable salt thereof.

10

48. The compound of claim 28, wherein the compound is of Formula **I-d**:




**I-d,**

or a pharmaceutically acceptable salt thereof.

15

49. The compound of claim 28, wherein the compound is of Formula **I-e**:




**I-e,**

or a pharmaceutically acceptable salt thereof.

20

50. The compound of claim 28, wherein the compound is of Formula **I-f**:


**I-f,**

or a pharmaceutically acceptable salt thereof.

51. The compound of claim 50, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is haloalkyl.

52. The compound of claim 50, or a pharmaceutically acceptable salt thereof, wherein R<sup>6</sup> is independently halogen.

53. The compound of claim 28, wherein the compound is of Formula **I-g**:

**I-g,**

or a pharmaceutically acceptable salt thereof.

54. A compound selected from the group consisting of:

1-cyclopropyl-6-fluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (1);

5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carbonitrile (2);

2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazole (3);

1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (4);

methyl 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate (5);

1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole (6);

1-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-

trifluoroethan-1-ol (7);

*N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)propionamide (8);

- ethyl ((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)carbamate (9);
- 4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)morpholine (10);
- 5 1-cyclopropyl-6-fluoro-2-(6-(4-(4-fluorophenyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (11);
- 2-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)propan-2-ol (12);
- 10 5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridazin-3-amine (13);
- 4-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)cinnoline (14);
- 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (15);
- N*-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethanesulfonamide (16);
- 15 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (17);
- 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-*N*-isopropylacetamide (18);
- 1-cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (19);
- 2-(4-(5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (20);
- 20 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-methylpyridazin-3-amine (21);
- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (22);
- 1-cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole (23);
- 25 1-cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole (24);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N,N*-dimethylpyridazin-3-amine (25);
- 1-ethyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (26);
- 30 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (27);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2-

- methoxyethyl)pyridazin-3-amine (28);
- 1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (29);
- 1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-indole (30);
- N*-((5-(1-cyclopropyl-6-fluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (31);
- 5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-*N*-(2,2,2-trifluoroethyl)pyridazin-3-amine (32);
- 1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (33);
- 2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (34);
- 1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (35);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-methylpiperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (36);
- 1-(4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)ethan-1-one (37);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (38);
- tert-butyl 4-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)piperazine-1-carboxylate (39);
- 1-ethyl-2-(6-methoxypyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (40);
- 1-ethyl-2-(6-ethylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (41);
- 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (42);
- 2-(6-cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (43);
- 1-cyclopropyl-2-(6-(4,4-difluoropiperidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (44);
- 5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (45);
- 1-cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (46);
- 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (47);
- 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)-*N,N*-

- dimethylpyrrolidin-3-amine (48);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (49);
- 1-cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl)ethynyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (50);
- 1-cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (51);
- N*-((5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (52);
- 1-cyclopropyl-5,6-difluoro-2-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (53);
- 3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (54);
- 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (55);
- 1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-4-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (56);
- 1-cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (57);
- 1-cyclopropyl-5,6-difluoro-2-(5-isopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (58);
- 1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (59);
- 2-(6-chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridine (60);
- 1-cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (61);
- 1-cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (62);
- 1-cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (63);
- 1-(5-(1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-one (64);
- 2-(6-chloropyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (65);
- 1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (66);

- 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (67);  
 2-(6-chloropyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile (68);  
 2-(6-(difluoromethyl)pyridazin-4-yl)-1-ethyl-1*H*-benzo[*d*]imidazole-6-carbonitrile  
 (69);
- 5 1-cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (70);  
 1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (71);  
 2-(6-Cyclopropylpyridazin-4-yl)-1-ethyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (72);
- 10 5-Chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-  
*b*]pyridine (73);  
 1-Cyclopropyl-5,6-difluoro-2-(5-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (74);  
 1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile  
 (75);
- 15 3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-  
 carbonitrile (76);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)methyl)methane sulfonamide (77);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)-  
 20 *N*-methylmethanesulfonamide (78);  
*N*-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-  
 yl)methyl)propane-2-sulfonamide (79);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (80);
- 25 1-Cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole  
 (81);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (82);  
 1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole  
 30 (83);  
 5-Chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine  
 (84);

- 1-Cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (85);
- 1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (86);
- 5 3-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (87);
- 2-((5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methyl)isothiazolidine 1,1-dioxide (88);
- 10 3-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (89);
- 1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (90);
- N*-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl)methanesulfonamide (91);
- 15 1-Cyclopropyl-5,6-difluoro-2-(6-(fluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (92);
- 1-Cyclopropyl-2-(5,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (93);
- (5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)methanol (94);
- 20 5-Chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine (95);
- N*-(1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethyl)ethanesulfonamide (96);
- 25 2-(6-Butylpyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazole (97);
- 1-Cyclopropyl-6-methyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (98);
- 1-Cyclopropyl-5,6-difluoro-2-(3-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (99);
- 1-Cyclopropyl-2-(3,6-dimethylpyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (100);
- 30 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6,7-difluoro-1*H*-benzo[*d*]imidazole (101);
- 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-thiol (102);

- 2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (103);  
 2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-methyl-1*H*-benzo[*d*]imidazole  
 (104);  
 2-(6-(Difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1-propyl-1*H*-benzo[*d*]imidazole  
 5 (105);  
 4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-5,6,7,8-tetrahydrocinnoline  
 (106);  
 1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole-5-carbonitrile (Ex.  
 107);  
 10 1-Cyclobutyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (108);  
 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazol-6-ol (109);  
 5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid  
 (110);  
 1-Cyclopropyl-7-fluoro-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (111);  
 15 5-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (112);  
 4-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1*H*-benzo[*d*]imidazole (113);  
 1-Cyclopropyl-5,6-difluoro-2-(6-(methoxymethyl)pyridazin-4-yl)-1*H*-  
 benzo[*d*]imidazole (114);  
 Methyl 5-(6-cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylate  
 20 (115);  
 5-(6-Cyano-1-cyclopropyl-1*H*-benzo[*d*]imidazol-2-yl)pyridazine-3-carboxylic acid  
 (116);  
 1-Cyclopropyl-2-(6-(cyclopropylmethoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-  
 benzo[*d*]imidazole (117);  
 25 1-Cyclopropyl-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-  
 carbonitrile (118);  
 6-Chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-  
 benzo[*d*]imidazole (119);  
 1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1*H*-benzo[*d*]imidazole-  
 30 6-carbonitrile (120);  
 4-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)-6,7-dihydro-5*H*-  
 cyclopenta[*c*]pyridazine (121);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6-fluoro-1*H*-benzo[*d*]imidazole (122);

1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (123);

5 1-Cyclopropyl-5,6-difluoro-2-(6-(isopropylthio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (124);

1-Cyclopropyl-2-(6-((difluoromethyl)thio)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (125);

5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-ol (126);

10 1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-5,6-difluoro-1*H*-benzo[*d*]imidazole (127);

1-(5-(1-Cyclopropyl-5,6-difluoro-1*H*-benzo[*d*]imidazol-2-yl)pyridazin-3-yl)ethan-1-ol (128);

15 1-Cyclopropyl-5,6-difluoro-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (129);

1-Cyclopropyl-5,6-difluoro-2-(6-((trifluoromethyl)thio)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (130)

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole (131);

2-(6-(Difluoromethyl)pyridazin-4-yl)-1-propyl-1*H*-benzo[*d*]imidazole (132);

20 1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (133);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1*H*-indole-3-carbonitrile (134);

2-(6-(Difluoromethyl)pyridazin-4-yl)-1-methyl-1*H*-indole-3-carbonitrile (135);

25 1-Cyclopropyl-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (136);

and pharmaceutically acceptable salts thereof.

55. A compound selected from the group consisting of:

1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1*H*-

30 benzo[*d*]imidazole (42);

3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-5-carbonitrile (76);

1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1*H*-benzo[*d*]imidazole-6-carbonitrile (86);

and pharmaceutically acceptable salts thereof.

5 56. A method of inhibiting metalloenzyme activity comprising contacting a compound or pharmaceutical salt thereof of any one of claims 1-55 with a metalloenzyme.

57. The method of claim 56, wherein the contacting is in vivo.

10 58. The method of claim 56, wherein the contacting is in vitro.

59. The method of claim 56, wherein the metalloenzyme comprises a metal atom that is iron, zinc, heme iron, manganese, magnesium, iron sulfide cluster, nickel, molybdenum, or copper.

15

60. The method of claim 56, wherein the metalloenzyme is a member of an enzyme class selected from the cytochrome P450 family, the cyclooxygenases, and the nitric oxide synthases.

20 61. The method of claim 56, wherein the metalloenzyme is aldosterone synthase (CYP11B2).

62. The method of claim 56, wherein the metalloenzyme is aromatase (CYP19), a member of the cyclooxygenase family, lanosterol demethylase (CYP51), a member of the nitric oxide synthase family, thromboxane synthase (CYP5a), thyroid peroxidase, 17-alpha hydroxylase/17,20-lyase (CYP17), cytochrome P450 2A6 (CYP2A6), heme oxygenase, indoleamine 2,3-dioxygenase, retinoic acid hydroxylase (CYP26), vitamin D hydroxylase (CYP24), sterol 27-hydroxylase (CYP27), cytochrome P450 3A5 (CYP3A5), cholesterol 24-hydroxylase (CYP46), cytochrome P450 4F2 (CYP4F2), myeloperoxidase, and 11-beta-  
30 hydroxylase (CYP11B1).

63. The method of claim 56, further comprising administering the compound to a human

subject.

64. A method of modulating metalloenzyme activity in a subject, comprising contacting the subject with a compound or pharmaceutical salt thereof of any of claims 1-55, in an amount and under conditions sufficient to modulate metalloenzyme activity.

65. A method of treating a subject suffering from or susceptible to a disorder or disease, wherein the subject has been identified as in need of treatment for the disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical salt thereof of any of claims 1-55.

66. A method of treating a subject suffering from or susceptible to a metalloenzyme-related disorder or disease, comprising administering to the subject an effective amount of a compound or pharmaceutical salt thereof of any of claims 1-55.

67. A method of treating a subject suffering from or susceptible to a metalloenzyme-related disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-related disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound of any of claims 1-55, such that said subject is treated for said disorder or disease.

68. A method of treating a subject suffering from or susceptible to a metalloenzyme-mediated disorder or disease, wherein the subject has been identified as in need of treatment for a metalloenzyme-mediated disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound of any of claims 1-54, such that metalloenzyme activity in said subject is modulated (e.g., down regulated, inhibited).

69. The method of any of claims 65-68, wherein the disorder or disease is mediated by aromatase (CYP19), a member of the cyclooxygenase family, lanosterol demethylase (CYP51), a member of the nitric oxide synthase family, thromboxane synthase (CYP5a), thyroid peroxidase, 17-alpha hydroxylase/17,20-lyase (CYP17), cytochrome P450 2A6 (CYP2A6), heme oxygenase, indoleamine 2,3-dioxygenase, retinoic acid hydroxylase

(CYP26), vitamin D hydroxylase (CYP24), sterol 27-hydroxylase (CYP27), cytochrome P450 3A5 (CYP3A5), cholesterol 24-hydroxylase (CYP46), cytochrome P450 4F2 (CYP4F2), myeloperoxidase, or 11-beta-hydroxylase (CYP11B1).

5 70. The method of any of claims 65-69, wherein the disorder or disease is cancer, cardiovascular disease, endocrinologic disease, inflammatory disease, infectious disease, gynecologic disease, metabolic disease, ophthalmologic disease, central nervous system (CNS) disease, urologic disease, or gastrointestinal disease.

10 71. The method of any of claims 65-70, wherein the disorder or disease is hypertension, resistant hypertension, morbidities associated with primary or secondary hyperaldosteronism and adrenal hyperplasia, pulmonary arterial hypertension, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, systolic heart failure, hypokalemia, renal failure, chronic renal failure, restenosis, nephropathy, post-  
 15 myocardial infarction, coronary heart disease, fibrosis, diseases characterized by increased collagen formation, fibrosis and matrix remodeling following hypertension, fibrosis and matrix remodeling following endothelial cell dysfunction, cardiovascular diseases such as atherosclerosis, atrial fibrillation, renal dysfunction, liver diseases, non-alcoholic steatohepatitis, vascular diseases, retinopathy, neuropathy, insulinopathy, endothelial  
 20 dysfunction, myocardial fibrosis, vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, vascular wall hypertrophy, endothelial thickening, fibrinoid necrosis of the arteries, kidney diseases, diabetic nephropathy, glomerulosclerosis, glomerulonephritis, nephritic syndrome, polycystic kidney disease, diabetes mellitus, metabolic syndrome, insulin resistance, sleep apnea, obstructive  
 25 sleep apnea, muscular dystrophy, liver cirrhosis, non-alcoholic fatty liver disease, renal disorders, diabetic renal disorders, or stroke.

72. A pharmaceutical composition comprising a compound or pharmaceutical salt thereof of any of claims 1-55 and a pharmaceutically acceptable carrier.

30

73. The pharmaceutical composition of claim 72 further comprising an additional therapeutic agent.

74. The pharmaceutical composition of claim 72 further comprising an additional therapeutic agent that is an anti-cancer agent, antifungal agent, cardiovascular agent, anti-inflammatory agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an  
5 anti-proliferation agent, metabolic disease agent, ophthalmologic disease agent, central nervous system (CNS) disease agent, urologic disease agent, or gastrointestinal disease agent.
75. The method of claim 65, wherein the subject is an animal other than a human.